<SEC-DOCUMENT>0001144204-18-048915.txt : 20181022
<SEC-HEADER>0001144204-18-048915.hdr.sgml : 20181022
<ACCEPTANCE-DATETIME>20180911060537
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-18-048915
CONFORMED SUBMISSION TYPE:	DOS/A
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20180911
<PUBLIC-REL-DATE>20181022
DATE AS OF CHANGE:		20180921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Glucose Biosensor Systems (Greater China) Holdings, Inc.
		CENTRAL INDEX KEY:			0001725430
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				821512711
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		DOS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	367-00130
		FILM NUMBER:		181063967

	BUSINESS ADDRESS:	
		STREET 1:		733 THIRD AVENUE
		STREET 2:		FLOOR 15
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		646-790-5756

	MAIL ADDRESS:	
		STREET 1:		733 THIRD AVENUE
		STREET 2:		FLOOR 15
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>DOS/A
<SEQUENCE>1
<FILENAME>filename1.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/rega/oneafiler" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>DOS/A</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <filer>
        <issuerCredentials>
          <cik>0001725430</cik>
          <ccc>XXXXXXXX</ccc>
        </issuerCredentials>
      </filer>
      <flags>
        <returnCopyFlag>false</returnCopyFlag>
        <overrideInternetFlag>false</overrideInternetFlag>
        <sinceLastFiling>true</sinceLastFiling>
      </flags>
    </filerInfo>
  </headerData>
  <formData>
    <employeesInfo>
      <issuerName>Glucose Biosensor Systems (Greater China) Holdings, Inc.</issuerName>
      <jurisdictionOrganization>DE</jurisdictionOrganization>
      <yearIncorporation>2016</yearIncorporation>
      <cik>0001725430</cik>
      <sicCode>3829</sicCode>
      <irsNum>82-1512711</irsNum>
      <fullTimeEmployees>1</fullTimeEmployees>
      <partTimeEmployees>2</partTimeEmployees>
    </employeesInfo>
    <issuerInfo>
      <street1>733 Third Avenue</street1>
      <street2>Floor 15</street2>
      <city>New York</city>
      <stateOrCountry>NY</stateOrCountry>
      <zipCode>10017</zipCode>
      <phoneNumber>646-790-5756</phoneNumber>
      <connectionName>Gary Simon</connectionName>
      <industryGroup>Other</industryGroup>
      <cashEquivalents>1054650.00</cashEquivalents>
      <investmentSecurities>0.00</investmentSecurities>
      <accountsReceivable>0.00</accountsReceivable>
      <propertyPlantEquipment>0.00</propertyPlantEquipment>
      <totalAssets>2787590.00</totalAssets>
      <accountsPayable>5510638.00</accountsPayable>
      <longTermDebt>0.00</longTermDebt>
      <totalLiabilities>5510638.00</totalLiabilities>
      <totalStockholderEquity>-2723048.00</totalStockholderEquity>
      <totalLiabilitiesAndEquity>2787590.00</totalLiabilitiesAndEquity>
      <totalRevenues>278.00</totalRevenues>
      <costAndExpensesApplToRevenues>3166864.00</costAndExpensesApplToRevenues>
      <depreciationAndAmortization>0.00</depreciationAndAmortization>
      <netIncome>-3166586.00</netIncome>
      <earningsPerShareBasic>-0.38</earningsPerShareBasic>
      <earningsPerShareDiluted>-0.38</earningsPerShareDiluted>
      <nameAuditor>BDO East Coast Partnership</nameAuditor>
    </issuerInfo>
    <commonEquity>
      <commonEquityClassName>Common Stock</commonEquityClassName>
      <outstandingCommonEquity>8250000</outstandingCommonEquity>
      <commonCusipEquity>0000000NA</commonCusipEquity>
      <publiclyTradedCommonEquity>0000000NA</publiclyTradedCommonEquity>
    </commonEquity>
    <preferredEquity>
      <preferredEquityClassName>Series A Preferred</preferredEquityClassName>
      <outstandingPreferredEquity>1222506</outstandingPreferredEquity>
      <preferredCusipEquity>0000000NA</preferredCusipEquity>
      <publiclyTradedPreferredEquity>0000000NA</publiclyTradedPreferredEquity>
    </preferredEquity>
    <debtSecurities>
      <debtSecuritiesClassName>Convertible Notes</debtSecuritiesClassName>
      <outstandingDebtSecurities>7036075</outstandingDebtSecurities>
      <cusipDebtSecurities>0000000NA</cusipDebtSecurities>
      <publiclyTradedDebtSecurities>0000000NA</publiclyTradedDebtSecurities>
    </debtSecurities>
    <issuerEligibility>
      <certifyIfTrue>true</certifyIfTrue>
    </issuerEligibility>
    <applicationRule262>
      <certifyIfNotDisqualified>true</certifyIfNotDisqualified>
      <certifyIfBadActor>false</certifyIfBadActor>
    </applicationRule262>
    <summaryInfo>
      <indicateTier1Tier2Offering>Tier2</indicateTier1Tier2Offering>
      <financialStatementAuditStatus>Audited</financialStatementAuditStatus>
      <securitiesOfferedTypes>Equity (common or preferred stock)</securitiesOfferedTypes>
      <offerDelayedContinuousFlag>Y</offerDelayedContinuousFlag>
      <offeringYearFlag>N</offeringYearFlag>
      <offeringAfterQualifFlag>N</offeringAfterQualifFlag>
      <offeringBestEffortsFlag>Y</offeringBestEffortsFlag>
      <solicitationProposedOfferingFlag>N</solicitationProposedOfferingFlag>
      <resaleSecuritiesAffiliatesFlag>N</resaleSecuritiesAffiliatesFlag>
      <securitiesOffered>2083334</securitiesOffered>
      <outstandingSecurities>8250000</outstandingSecurities>
      <pricePerSecurity>12.0000</pricePerSecurity>
      <issuerAggregateOffering>25000000.00</issuerAggregateOffering>
      <securityHolderAggegate>0.00</securityHolderAggegate>
      <qualificationOfferingAggregate>0.00</qualificationOfferingAggregate>
      <concurrentOfferingAggregate>0.00</concurrentOfferingAggregate>
      <totalAggregateOffering>25000000.00</totalAggregateOffering>
      <underwritersServiceProviderName>Cuttone &amp; Co., LLC</underwritersServiceProviderName>
      <underwritersFees>1750000.00</underwritersFees>
      <auditorServiceProviderName>BDO East Coast Partnership</auditorServiceProviderName>
      <auditorFees>100000.00</auditorFees>
      <legalServiceProviderName>Hughes Hubbard &amp; Reed LLP</legalServiceProviderName>
      <legalFees>250000.00</legalFees>
      <brokerDealerCrdNumber>33038</brokerDealerCrdNumber>
      <estimatedNetAmount>22500000.00</estimatedNetAmount>
      <clarificationResponses>Based on maximum offering of $25,000,000 and includes sales commissions, audit, legal and miscellaneous other expenses totaling $2,500,000.</clarificationResponses>
    </summaryInfo>
    <juridictionSecuritiesOffered>
      <jurisdictionsOfSecOfferedNone>false</jurisdictionsOfSecOfferedNone>
      <jurisdictionsOfSecOfferedSame>true</jurisdictionsOfSecOfferedSame>
      <issueJuridicationSecuritiesOffering>AL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AZ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>FL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>GA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>HI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ID</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>LA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ME</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NJ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NM</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ND</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>RI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TX</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>UT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WY</issueJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AZ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>FL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>GA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>HI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ID</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>LA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ME</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NJ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NM</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ND</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>RI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TX</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>UT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WY</dealersJuridicationSecuritiesOffering>
    </juridictionSecuritiesOffered>
    <unregisteredSecurities>
      <ifUnregsiteredNone>false</ifUnregsiteredNone>
    </unregisteredSecurities>
    <securitiesIssued>
      <securitiesIssuerName>Glucose Biosensor Systems (Greater China) Holdings, Inc.</securitiesIssuerName>
      <securitiesIssuerTitle>Series A Convertible Preferred Stock $0.01 par value</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>1222506</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>$8,715,793</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <securitiesIssued>
      <securitiesIssuerName>Glucose Biosensor Systems (Greater China) Pty Ltd.</securitiesIssuerName>
      <securitiesIssuerTitle>Convertible Notes (Convertible into shares of common stock of Glucose Biosensor Systems (Greater China) Holdings, Inc.)</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>7036075</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>$5,277,056</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <unregisteredSecuritiesAct>
      <securitiesActExcemption>Regulation S</securitiesActExcemption>
    </unregisteredSecuritiesAct>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>PART II AND III
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II PRELIMINARY OFFERING CIRCULAR - FORM
1-A: TIER 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><B>An offering statement pursuant
to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission. Information
contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may
offers to buy be accepted before the offering statement filed with the United States Securities and Exchange Commission is qualified.
This Preliminary Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be
any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification
under the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering Circular by sending you a
notice within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular
or the offering statement in which such Final Offering Circular was filed may be obtained.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-size: 10pt; color: red"><B>Preliminary
                                         Offering Circular</B></FONT> </P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-size: 10pt; color: red"><B>(Subject
                                         to Completion)</B></FONT> </P></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt; color: red"><B>Dated: September
    11, 2018</B></FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>GLUCOSE BIOSENSOR
SYSTEMS<BR>
(GREATER CHINA) HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$9,000,000 MINIMUM OFFERING AMOUNT
(750,000 SHARES OF COMMON STOCK)&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$25,000,000 MAXIMUM OFFERING AMOUNT (2,083,334
SHARES OF COMMON STOCK)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is the initial public offering
of securities of Glucose Biosensor Systems (Greater China) Holdings, Inc., a Delaware corporation (the &ldquo;Company,&rdquo;
&ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo;). We are offering a minimum of 750,000 and a maximum of 2,083,334 shares
(the &ldquo;Shares&rdquo;) of our common stock, par value $0.01 (&ldquo;Common Stock&rdquo;), at an offering price of $12.00 per
share for a minimum offering amount of $9,000,000 and a maximum offering amount of $25,000,000 (the &ldquo;Offering&rdquo;). The
Offering will terminate on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, subject to extension by us for up to
thirty (30) days; provided that, if we have received and accepted subscriptions for the minimum number of Shares on or before
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, or the end of the thirty (30) day extension, if exercised, then
the Company will close on the minimum offering amount (the &ldquo;Initial Closing&rdquo;) and this offering will continue until
the earlier of (i) the date which is sixty (60) days after the Initial Closing, or (ii) the date on which the maximum offering
amount is sold (such earlier date, the &ldquo;Termination Date&rdquo;). If, on the Initial Closing date, we have sold less than
the maximum number of Shares, then we may hold one or more additional closings to sell additional Shares (each, an &ldquo;Additional
Closing&rdquo;), until the earlier of: (i) the sale of the maximum number of Shares or (ii) the Termination Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Until we achieve the minimum offering amount,
the proceeds for the Offering will be kept in a non-interest bearing escrow account. Upon achievement of the minimum offering amount
and the closing on such amount, the proceeds from the minimum offering amount will be distributed to the Company and the associated
Shares will be issued to the investors in the Initial Closing. If the Offering does not close on or before &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 for any
reason, the proceeds for the Offering will be promptly returned to investors, without deduction and without interest. Prime Trust,
LLC will serve as the escrow agent. Prime Trust is a &quot;bank&quot; under SEC Rule 15c2-4. The minimum purchase requirement per
investor is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;); however, we can waive the minimum purchase requirement on a case-by-case basis in our sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have engaged Cuttone &amp; Co., LLC
as our placement agent (the &ldquo;Placement Agent&rdquo;) to offer the Shares to prospective investors on a &ldquo;best efforts
basis, minimum-maximum&rdquo; basis, and our Placement Agent will have the right to engage such other Financial Industry Regulatory
Authority, Inc. (&ldquo;FINRA&rdquo;) member firms as it deems appropriate to assist in the offering. We expect to commence the
sale of the Shares as of the date on which the offering statement of which this Offering Circular is a part (the &ldquo;Offering
Statement&rdquo;), is qualified by the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Prior to this
offering, there has been no public market for our Common Stock. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have applied to list our Common Stock on
The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;GBSG&rdquo;. We expect our Common Stock to begin trading
on Nasdaq upon consummation of the Offering; provided that we have met the minimum listing criteria of Nasdaq. There is no assurance
that this application will be approved, or that a market for our Shares will develop. Our Common Stock will not commence trading
on Nasdaq, however, unless and until (i) this Offering is closed in an amount sufficient to meet the minimum listing criteria of
Nasdaq, including having a market value of shares sold in this Offering of at least $15 million in accordance with Nasdaq rules;
(ii) this Offering is terminated and (iii) we have filed a post-qualification amendment to the Offering Statement, and a registration
statement on Form 8-A (&ldquo;Form 8-A&rdquo;) under the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and
such post-qualification amendment is qualified by the SEC and the Form 8-A has become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 5, 2017, the Company effected
a stock split of one to 90,000 shares resulting in 9,000,000 issued and outstanding shares of common stock as of that date and
the date hereof. On August 9, 2018, the Company effected a reverse stock split of approximately one
to 0.9167 shares that resulted in the Company having 8,250,000 issued and outstanding shares of common stock. Share and per
share amounts set forth herein (except in any historical financial information) give effect to the reverse split, unless indicated
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Following this offering, we will be a &ldquo;controlled
company&rdquo; within the meaning of the corporate governance rules of Nasdaq. See &ldquo;Management.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, and, as such, may elect to comply with certain reduced
reporting requirements for this Offering Circular and future filings after this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investing in our Common Stock involves
a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 17 for a discussion of certain risks that you should carefully
consider in connection with an investment in our Common Stock. An investment in this company should only be made if you are capable
of evaluating the risks and merits of this investment and if you have sufficient resources to bear the entire loss of your investment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross Proceeds</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Placement Agent<BR>
    Commissions (1)(2)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proceeds to the<BR>
    Company (3)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-weight: bold; text-align: justify">Total Minimum(4)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: bold; text-align: right">9,000,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: bold; text-align: right">630,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: bold; text-align: right">7,620,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Total Maximum</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">25,000,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,750,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">22,500,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(1)&nbsp;Represents
placement agent commissions equal to 7.0% per share (or $0.84 per share) payable to the Placement Agent in connection with this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(2) Does
not include a non-accountable expense allowance equal to 0.75% of the gross proceeds of this offering, payable to the Placement
Agent, nor does it include the reimbursement of up to $150,000 in expenses incurred by the Placement Agent in connection with
this offering. We have agreed to issue to the Placement Agent warrants to purchase shares of common stock equal to 5% of the total
number of Shares sold in this offering, and to grant the Placement Agent certain indemnification and advancement rights. See &ldquo;Plan
of Distribution&rdquo; beginning on page  52 of this Offering Circular for additional information regarding total Placement
Agent compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(3) Includes estimated
total offering expenses, which are expected to be approximately $750,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(4) Sales of
Shares, if any, to affiliates of, and persons associated with, the Underwriter, the Dealers and the Company will be included
for purposes of satisfying the Minimum Offering Amount. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Generally, no sale may be made to you in
this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or your net worth.
Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does
not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing,
we encourage you to refer to investor.gov.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THE UNITED STATES SECURITIES AND EXCHANGE
COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES
IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SELLING LITERATURE. THESE SECURITIES ARE OFFERED PURSUANT
TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE
SECURITIES OFFERED HEREUNDER ARE EXEMPT FROM REGISTRATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">This Offering Circular follows the disclosure
format prescribed by Part I of Form S-1 pursuant to the general instructions of Part II(a)(1)(ii) of Form 1-A.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Cuttone &amp;
Co., LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this Offering Circular is&nbsp;_____,
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>AN OFFERING STATEMENT PURSUANT TO REGULATION
A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY
OFFERING CIRCULAR IS SUBJECT TO COMPLETION OR AMENDMENT. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED BEFORE
THE OFFERING STATEMENT FILED WITH THE COMMISSION IS QUALIFIED. THIS PRELIMINARY OFFERING CIRCULAR SHALL NOT CONSTITUTE AN OFFER
TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR MAY THERE BE ANY SALES OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER,
SOLICITATION OR SALE WOULD BE UNLAWFUL BEFORE REGISTRATION OR QUALIFICATION UNDER THE LAWS OF ANY SUCH STATE. WE MAY ELECT TO SATISFY
OUR OBLIGATION TO DELIVER A FINAL OFFERING CIRCULAR BY SENDING YOU A NOTICE WITHIN TWO BUSINESS DAYS AFTER THE COMPLETION OF OUR
SALE TO YOU THAT CONTAINS THE URL WHERE THE FINAL OFFERING CIRCULAR OR THE OFFERING STATEMENT IN WHICH SUCH FINAL OFFERING CIRCULAR
WAS FILED MAY BE OBTAINED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THIS OFFERING CIRCULAR DOES NOT CONSTITUTE
AN OFFER OR SOLICITATION IN ANY JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION WOULD BE UNLAWFUL. NO PERSON HAS BEEN AUTHORIZED
TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS CONCERNING THE COMPANY OTHER THAN THOSE CONTAINED IN THIS OFFERING CIRCULAR,
AND IF GIVEN OR MADE, SUCH OTHER INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>PROSPECTIVE INVESTORS ARE NOT TO CONSTRUE
THE CONTENTS OF THIS OFFERING CIRCULAR, OR OF ANY PRIOR OR SUBSEQUENT COMMUNICATIONS FROM THE COMPANY OR ANY OF ITS EMPLOYEES,
AGENTS OR AFFILIATES, AS INVESTMENT, LEGAL, FINANCIAL OR TAX ADVICE.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>BEFORE INVESTING IN THIS OFFERING, PLEASE
REVIEW ALL DOCUMENTS CAREFULLY, ASK ANY QUESTIONS OF THE COMPANY&rsquo;S MANAGEMENT THAT YOU WOULD LIKE ANSWERED AND CONSULT YOUR
OWN COUNSEL, ACCOUNTANT AND OTHER PROFESSIONAL ADVISORS AS TO LEGAL, TAX AND OTHER RELATED MATTERS CONCERNING THIS INVESTMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NASAA UNIFORM LEGEND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FOR RESIDENTS OF ALL STATES: THE PRESENCE
OF A LEGEND FOR ANY GIVEN STATE REFLECTS ONLY THAT A LEGEND MAY BE REQUIRED BY THAT STATE AND SHOULD NOT BE CONSTRUED TO MEAN AN
OFFER OR SALE MAY BE MADE IN A PARTICULAR STATE. IF YOU ARE UNCERTAIN AS TO WHETHER OR NOT OFFERS OR SALES MAY BE LAWFULLY MADE
IN ANY GIVEN STATE, YOU ARE HEREBY ADVISED TO CONTACT THE COMPANY. THE SECURITIES DESCRIBED IN THIS OFFERING CIRCULAR HAVE NOT
BEEN REGISTERED UNDER ANY STATE SECURITIES LAWS (COMMONLY CALLED &ldquo;BLUE SKY&rdquo; LAWS).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IN MAKING AN INVESTMENT DECISION INVESTORS
MUST RELY ON THEIR OWN EXAMINATION OF THE PERSON OR ENTITY CREATING THE SECURITIES AND THE TERMS OF THE OFFERING, INCLUDING THE
MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY
AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTICE TO FOREIGN INVESTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IF THE PURCHASER LIVES OUTSIDE THE UNITED
STATES, IT IS THE PURCHASER&rsquo;S RESPONSIBILITY TO FULLY OBSERVE THE LAWS OF ANY RELEVANT TERRITORY OR JURISDICTION OUTSIDE
THE UNITED STATES IN CONNECTION WITH ANY PURCHASE OF THE SECURITIES, INCLUDING OBTAINING REQUIRED GOVERNMENTAL OR OTHER CONSENTS
OR OBSERVING ANY OTHER REQUIRED LEGAL OR OTHER FORMALITIES. THE COMPANY RESERVES THE RIGHT TO DENY THE PURCHASE OF THE SECURITIES
BY ANY FOREIGN PURCHASER.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_009" TITLE="Forward Looking Statement"></A>Forward Looking Statement Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Form 1-A, Offering
Circular, and any documents incorporated by reference herein or therein contain forward-looking statements and are subject to risks
and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included
in this Form 1-A, Offering Circular, and any documents incorporated by reference are forward-looking statements. Forward-looking
statements give the Company&rsquo;s current reasonable expectations and projections relating to its financial condition, results
of operations, plans, objectives, future performance and business. You can identify forward- looking statements by the fact that
they do not relate strictly to historical or current facts. These statements may include words such as &lsquo;&lsquo;anticipate,&rdquo;
 &lsquo;&lsquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;can have,&rdquo; &ldquo;likely&rdquo; and other words and terms of similar meaning
in connection with any discussion of the timing or nature of future operating or financial performance or other events. The forward-looking
statements contained in this Form 1-A, Offering Circular, and any documents incorporated by reference herein or therein are based
on reasonable assumptions the Company has made in light of its industry experience, perceptions of historical trends, current conditions,
expected future developments and other factors it believes are appropriate under the circumstances. As you read and consider this
Form 1-A, Offering Circular, and any documents incorporated by reference, you should understand that these statements are not guarantees
of performance or results. They involve risks, uncertainties (many of which are beyond the Company&rsquo;s control) and assumptions.
Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that
many factors could affect its actual operating and financial performance and cause its performance to differ materially from the
performance anticipated in the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should
any of these assumptions prove incorrect or change, the Company&rsquo;s actual or uncertainties materialize, or should any of these
assumptions prove incorrect or change, the Company&rsquo;s actual operating and financial performance may vary in material respects
from the performance projected in these forward-looking statements. Any forward-looking statement made by the Company in this Form
1-A, Offering Circular or any documents incorporated by reference herein speaks only as of the date of this Form 1-A, Offering
Circular or any documents incorporated by reference herein. Factors or events that could cause our actual operating and financial
performance to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company
undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or
otherwise, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>About This Form 1-A and Offering Circular</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In making an investment
decision, you should rely only on the information contained in this Form 1-A and Offering Circular. The Company has not authorized
anyone to provide you with information different from that contained in this Form 1-A and Offering Circular. We are offering to
sell, and seeking offers to buy the Shares only in jurisdictions where offers and sales are permitted. You should assume that the
information contained in this Form 1-A and Offering Circular is accurate only as of the date of this Form 1-A and Offering Circular,
regardless of the time of delivery of this Form 1-A and Offering Circular. Our business, financial condition, results of operations,
and prospects may have changed since that date. Statements contained herein as to the content of any agreements or other documents
are summaries and, therefore, are necessarily selective and incomplete and are qualified in their entirety by the actual agreements
or other documents. The Company will provide the opportunity to ask questions of and receive answers from the Company&rsquo;s management
concerning terms and conditions of the Offering, the Company or any other relevant matters and any additional reasonable information
to any prospective investor prior to the consummation of the sale of the Shares. This Form 1-A and Offering Circular do not purport
to contain all of the information that may be required to evaluate the Offering and any recipient hereof should conduct its own
independent analysis. The statements of the Company contained herein are based on information believed to be reliable. No warranty
can be made as to the accuracy of such information or that circumstances have not changed since the date of this Form 1-A and Offering
Circular. The Company does not expect to update or otherwise revise this Form 1-A, Offering Circular or other materials supplied
herewith. The delivery of this Form 1-A and Offering Circular at any time does not imply that the information contained herein
is correct as of any time subsequent to the date of this Form 1- A and Offering Circular. This Form 1-A and Offering Circular are
submitted in connection with the Offering described herein and may not be reproduced or used for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are offering to sell,
and seeking offers to buy, the Shares only in jurisdictions where such offers and sales are permitted. You should rely only on
the information contained in this Offering Circular. We have not authorized anyone to provide you with any information other than
the information contained in this Offering Circular. The information contained in this Offering Circular is accurate only as of
its date, regardless of the time of its delivery or of any sale or delivery of our securities. Neither the delivery of this Offering
Circular nor any sale or delivery of our securities shall, under any circumstances, imply that there has been no change in our
affairs since the date of this Offering Circular. This Offering Circular will be updated and made available for delivery to the
extent required by the federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
data contained in this Offering Circular concerning the glucose monitoring market and the other markets relevant to our operations
are based on information from various public sources. Although we believe that this data is generally reliable, such information
is inherently imprecise, and our estimates and expectations based on these data involve a number of assumptions and limitations.
As a result, you are cautioned not to give undue weight to such data, estimates or expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 92%; text-align: right"> &nbsp; </TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD
    LOOKING STATEMENT DISCLOSURE</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#a_009">4</A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFERING
    SUMMARY AND RISK FACTORS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFERING
    SUMMARY</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
    OFFERING</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK
    FACTORS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_0022">CAPITALIZATION</A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_0022">49</A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN
    OF DISTRIBUTION</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#a_007">52</A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE
    OF PROCEEDS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION
    OF BUSINESS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY
    OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTEREST
    OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION
    OF OUR SECURITIES</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND
    POLICY</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHARES
    ELIGIBLE FOR FUTURE SALE</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISQUALIFYING
    EVENTS DISCLOSURE</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ERISA
    CONSIDERATIONS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR
    ELIGIBILITY STANDARDS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
    MATTERS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> <A HREF="#partii_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
    OF CONTENTS TO FINANCIAL STATEMENTS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> <A HREF="#partii_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></A> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: center; text-indent: -0.3in"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_001"></A>OFFERING
SUMMARY AND RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_002"></A>OFFERING
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>The following summary
is qualified in its entirety by the more detailed information appearing elsewhere in this Offering Circular and/or incorporated
by reference in this Offering Circular. For full offering details, please (1) thoroughly review this Form 1-A filed with the Securities
and Exchange Commission (2) thoroughly review this Offering Circular and (3) thoroughly review any attached documents to or documents
referenced in, this Form 1-A and Offering Circular.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <I>This summary highlights
information contained in other parts of this Offering Circular. Because it is a summary, it does not contain all of the information
that you should consider in making your investment decision. Before investing in our securities, you should read the entire Offering
Circular carefully, including our consolidated financial statements and the related notes included in this Offering Circular and
the information set forth under the headings &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations.&rdquo; When used herein, unless the context requires otherwise, references to
the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refer to Glucose Biosensor Systems (Greater
China) Holdings, Inc., a Delaware corporation, collectively with its subsidiaries, Glucose Biosensor Systems (Greater China),
Inc., a Delaware corporation and Glucose Biosensor Systems (Greater China) Pty Ltd, an Australian corporation.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>On November 5, 2017,
the Company effected a stock split of one to 90,000 shares resulting in 9,000,000 issued and outstanding shares of common stock
as of that date and the date hereof. On August 9, 2018, the Company effected a reverse
stock split of approximately one to 0.9167 shares that resulted in the Company having 8,250,000 issued and outstanding shares
of common stock. Share and per share amounts set forth herein (except in any historical financial information) give effect to
the reverse split, unless indicated otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv502124_img01.jpg" ALT="" STYLE="width: 657px; height: 197px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">For illustrative purposes only &ndash; not
Company products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a development stage
medical device company with licensed rights to commercialize a novel &ldquo;smart&rdquo; biosensor salivary glucose monitoring
system (the &ldquo;GBS System&rdquo;) in the greater China region (the &ldquo;China Region&rdquo;), comprised of Mainland China,
Hong Kong, Vietnam and Bangladesh. We were formed on December 5, 2016, as a Delaware corporation with headquarters in New York
City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a wholly-owned subsidiary
of Life Science Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;), an Australian company that acquired the worldwide intellectual
property rights to the biosensor platform from the University of Newcastle, Australia. LSBD has licensed to us that technology
for us to commercialize the GBS System in the China Region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>The GBS System</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The basic components of
the GBS System are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Biosensor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The technology in development
is a single-use organic biosensor that reacts with saliva and initiates an electrochemical reaction, producing a detectable electrical
signal that is proportional to the glucose present in the sample and converted by a smart device into a real-time saliva glucose
reading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Dedicated digital health care application</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our digital health care
application will be designed to enable user interaction, data interface, storage, analytics and patient support programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A major feature of the
GBS System will be its ability to detect glucose in saliva, obviating the need for patients or consumers to perform frequent finger
punctures as required by conventional blood glucose measurement techniques.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System is being
designed such that when the GBS System&rsquo;s single-use organic biosensor interacts with saliva it initiates an electrochemical
reaction, producing a measurable electrical signal directly correlated to the amount of glucose present in the saliva. This measurement
is then converted into a real-time saliva glucose reading, by a smartphone or a dedicated reading &ldquo;smart&rdquo; device.
This data set would then be securely stored, in analyzed and/or raw form, in a non-relational database in the cloud, for further
evaluation and processing. This digital platform, combined with the clinically-relevant data, is designed to enable diabetics
to achieve better glucose control, including through an accumulation of lifestyle data, thereby helping prevent or delay long
term medical complications. This is summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="tv502124_img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System is currently
in the development stage following feasibility work. The GBS System will require regulatory approval in the various jurisdictions
comprising the China Region. We believe that the GBS System&rsquo;s fabrication method will allow for printing at high volume
and low cost using existing technology. Certain proprietary components of the digital infrastructure required to support the GBS
System are in design and development planning stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We contemplate that
the use of saliva-based sampling will make glucose monitoring more accessible to patients, as no painful intervention is necessary.
The intuitive interface with smart devices would enable analytical capabilities accessed through the data generated. These attributes
would be designed to unlock a broader opportunity in the personalized medicine sector of the healthcare industry in the China
Region, as illustrated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv502124_img03.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe the methodology
of the GBS System will represent a breakthrough in glucose monitoring as it is a non-invasive, painless, scientifically valid
and cost-effective saliva-based method of measuring glucose levels. A number of reports over recent years have shown that there
is a direct relationship between blood glucose levels and the concentration of glucose in saliva. Glucose is present in saliva
at a concentration range of approximately 0.008 to 0.20 mM, which is considerably lower than the range of concentration for glucose
in blood, which is typically 3.3&ndash;8.3mM. The goal and our expectation for the GBS System is to use the technology to detect
those low concentrations of glucose, making it possible to measure the level of glucose and offer a path towards glucose monitoring
that is comparable to existing blood-based measurement. The biosensor exhibits linear glucose sensing at significantly greater
sensitivity than commercial blood glucose sensors, offering potential for the prospect of a saliva-based test for diabetic monitoring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to engage local
distributors in the China Region that will agree to stock, market, distribute and sell the GBS System across the region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Diabetes and The Importance of Glucose Monitoring</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Diabetes is the condition
in which the body does not properly process food for use as energy. Most of the food we eat is turned into glucose, or sugar, for
our bodies to use for energy. The pancreas, an organ that lies near the stomach, makes a hormone called insulin to help glucose
get into the cells of our bodies. When a person has diabetes, the body either does not make enough insulin or cannot use its own
insulin as well as it should. This causes sugars to build up in blood. Diabetes can cause serious health complications including
heart disease, blindness, kidney failure, and lower-extremity amputations. Self-monitoring of blood glucose is an important component
of modern therapy for diabetes and is recommended for people with diabetes by their health care professionals in order to achieve
normal levels of glycemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Self-monitoring should
be part of a regular management plan for patients with diabetes. Self-monitoring provides information regarding an individual&rsquo;s
dynamic blood glucose profile. This information can help with the appropriate scheduling of food, activity, and medication. It
is also required for understanding of the timing of blood glucose variations. Lack of regular self-monitoring predicts hospitalization
for diabetes-related complications. Self-monitoring of blood glucose is an essential tool for people with diabetes who are taking
insulin or for those who experience fluctuations in their blood glucose levels, especially hypoglycemia. For patients taking insulin
and adjusting their dose, self-monitoring is needed for self-management. For others receiving oral medication, profiling glucose
trends and the confirmation of high or low blood glucose can be a useful addendum to successful management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>The Diabetes Market</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The economic growth of
China has had a major impact on the incidence of diabetes. China accounts for the fastest growing global market segment and has,
by a significant number, the largest diabetic population. In 2015, China alone had a similar number of people with diabetes as
the next 3 largest diabetes markets combined (India, USA and Brazil). China alone had 1.3 million deaths due to diabetes in 2015
(26% of total global deaths), with 41% of those deaths occurring in people under 60. The Journal of the American Medical Association
identified that out of 99,000 people surveyed in China, half had pre-diabetes blood glucose levels &ndash; abnormally high but
not high enough for a diagnosis of diabetes. The projections suggest that there are 493 million people with pre-diabetes in China.
Diabetes related health expenditure in China was $51 billion in 2015 and is expected to reach $72 billion by 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The healthcare industry
in China is undergoing significant change, driven by ongoing healthcare reforms, the review of government policies and the introduction
and adoption of new technologies; in some cases even leading to the shift of screening for disease or symptoms of disease, from
health care providers to consumers, through wearable devices and software applications. Combined with China&rsquo;s aging population
and a healthcare infrastructure that has struggled to keep up with the pace of socioeconomic change, these changes create significant
opportunity in China to enhance efficiency through innovation. In the Chinese digital healthcare market alone, investment in 2020
in general disease management is expected to be $35 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Our Technology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>(Below &ndash; image of prototype)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv502124_img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The core innovation
of our business will be the ability to measure glucose in saliva non-invasively. The core technology is the biosensor that enables
the wider glucose management system. The biosensor technology is being built into a medical device that we expect to conform with
global medical device standards. The biosensor is based on a modified organic thin film transistor architecture incorporating
glucose oxidase as the recognition element. Through prototypes, the biosensor exhibits linear glucose sensing at concentrations
with greater sensitivity than commercial blood glucose sensors, offering potential for the prospect of a saliva-based test for
diabetic monitoring. It has been demonstrated that the biosensor exhibits sensitivity in the saliva glucose region of 8-200 uM.
The mechanism by which the glucose sensing occurs involves the diffusion of protons (generated by the enzymatic oxidation of glucose)
to, and subsequent doping of, the poly (3-hexythiophene) transistor channel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Through the deployment
of our digital ecosystem, we propose to enable an entire patient/user community providing educational resources, enabling patient
support groups and taking patient care beyond the health care provider&rsquo;s office. This would create a tool extending beyond
a simple stand-alone device, in essence a system that enables the patient to take greater control of their levels of glucose. This
would all be possible due to the following attributes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No more multiple daily routine finger prick testing.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Programmable notifications and reminders.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Insight and practical understanding of factors that affect patient/user glucose levels.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The non-invasive attributes
of our technology, including the ability for real-time measurement and remote monitoring, could make it easier for a patient to
monitor their glucose levels. This means that we would have the potential to collect a greater amount of information from a larger
proportion of patients. This increased data flow would enable significant disease management opportunities to improve the way diabetes
is controlled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>The License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2017, the
Company entered into the Technology License Agreement with LSBD, as amended by the Variation Agreement to Technology License Agreement,
dated as December 8, 2017, the Second Variation Agreement to Technology License Agreement, dated as of April 18, 2018, and the
Third Variation Agreement to Technology License Agreement dated July 10, 2018 (as so amended to date, cumulatively, the &ldquo;License
Agreement&rdquo;), setting forth our contractual rights in and responsibilities relating to the saliva glucose biosensor system
for the China Region. The License Agreement includes the following summary terms:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exclusive license is granted to the Company covering certain glucose sensor intellectual property scheduled in the License Agreement and other data owned by LSBD, but solely to (i) hold regulatory marketing authorizations in the China Region, (ii) promote, market and import specific licensed products in the China Region, (iii) provide customer support on the licensed products in the China Region, (iv) use the licensed products in the China Region, and &nbsp;(v) collect data for LSBD regarding the use of the licensed products in the China Region;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the licensed products covered by the License Agreement are only those products that are procured
by the Company from authorized suppliers in the China Region under rights owned by LSBD;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the licensed rights do not cover digital or online use to users not physically in the China Region;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the licensed rights are limited to those expressly set forth in the License Agreement and are non-transferable,
non-assignable and non-sub-licensable, except that LSBD will in good faith consider any Company request for any sub-license;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         Company is required to meet specified performance milestones, including conducting clinical
                                         studies; obtaining regulatory approvals in the China Region within two years after the
                                         commencement of trading of the Shares on Nasdaq and within two years thereof placing
                                         orders with LSBD for a minimum number of products based on market growth, with annual
                                         increases; annually agree with LSBD as to that market growth; achieve annually that market
                                         share growth plus a minimum fixed percentage and quarterly orders with LSBD for products
                                         in quantities at that quarterly market share growth plus a minimum fixed percentage;
                                         conduct minimum marketing on standards reasonably determined by LSBD; and convert all
                                         glucose monitoring sales by the Company into glucose monitoring sales of the biosensor
                                         strip within five years; provided that (i) LSBD must supply all licensed product in accordance
                                         with the License Agreement, (ii) such product must be of merchantable quality and in
                                         accordance with local law, and (iii) certain end user data must be accessible to the
                                         Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">upon failure of any of these requirements, LSBD may require the Company to make cash payment of
the value of any shortfall and the failure to pay this amount within 14 business days will subject it to monthly compounding interest
at a rate of LIBOR plus 4%;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must notify LSBD of infringements of any licensed intellectual property and cooperate
with and as instructed by LSBD, at LSBD&rsquo;s expense, in preventing such infringement, but may take no other action regarding
infringement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must market, sell and distribute the licensed products in accordance with law and distribution
requirements set forth in the License Agreement, including delivering licensed products without inclusion of any other product,
only as supplied by LSBD, without changing LSBD&rsquo;s packaging or branding thereof and only in quantities as directed by LSBD;
complying with all regulations; and keeping specified records and batch samples relating to its activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must file for and obtain all legal permits for marketing and selling the licensed products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must pay LSBD, subject to a monthly late charge, a one-time fixed license fee within
14 days of the obtaining of required regulatory approvals in China; fixed royalty percentages on the sale of specified licensed
products on sales of commercial units and certain other devices; application license fees and fees for patient education services,
all as determined from time to time by LSBD;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must obtain, retain and provide to LSBD certain end user and other data and notify
LSBD as to a variety of matters relating to the data, almost all of which data will be solely owned by LSBD, provided that the
Company will have rights to certain of the data during the term of the License Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">LSBD will own all of the right, title and interest in substantially all of the intellectual property
covered by the License Agreement and LSBD shall have the right to control the protection of that licensed intellectual property
as assisted by the Company, which shall have no rights to control or otherwise conduct protective activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the parties generally agree to keep confidential, subject to customary exceptions, all confidential
information of the other party, subject to express exceptions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">except with respect to LSBD&rsquo;s ownership of all intellectual property rights in respect of
the licensed property and the non-infringement by the Company&rsquo;s exercise of those rights, LSBD provides no, and disclaims
all, representations, warranties or covenants relating to the licensed intellectual property or any other matters under the License
Agreement and in particular disclaims any fitness of the property for any purpose;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">LSBD is indemnified by the Company for any losses that may be incurred relating to any conduct,
including any data collection or retention, by the Company under or relating to the License Agreement or the intellectual property
under it, or any negligent or willful misconduct or violation of law by the Company, with no reciprocal indemnity; provided that
LSBD indemnifies the Company for any losses arising that may be incurred related to (i) any third party claim that the exercise
by the Company of its rights in respect of a licensed product violates its property or rights, and (ii) any regulatory or quality
recall or any consumer or user claims or liability in relation to a licensed product (regardless of any contributory or comparative
negligence of any Licensee Indemnitee, subject to contributory negligence; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> the
                                         term of the License Agreement runs until the final date of protection afforded to the
                                         patent portfolio covered by the License Agreement, which is currently until 2033, provided
                                         that either party may terminate the License Agreement earlier following any uncured material
                                         breach by the other party of it, the discontinuation of the other party&rsquo;s operations
                                         or an actual or prospective change in control of the other party, where change in control
                                         means, among other things, (i) any change of 50% ownership of outstanding Common Stock
                                         or voting rights, (ii) a merger resulting in our pre-merger voting securities failing
                                         to represent at least 50% of all voting power immediately post-merger, (iii) a sale of
                                         substantially all assets, (iv) solely with respect to the Company, without LSBD&rsquo;s
                                         prior approval a majority change in the composition of our board of directors (unless
                                         such change was pre-approved by our board, a nominating or other independent committee
                                         thereof) or (v) the dissolution or liquidation of the other party. In the event of a
                                         change in control of LSBD, LSBD must pay the Company an amount equal to the greater of
                                         the five-year projected net sales  and five times the prior year&rsquo;s actual net sales
                                         of the Company, as adjusted depending on how much of the term of the License Agreement
                                         remains. No similar payment is required by the Company in the event of a change in control
                                         of the Company. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Upon
                                         the expiration, termination or cancellation of the License Agreement in any way, the following consequences are required (i) the cessation of substantially all
                                         of the Company&rsquo;s operations, (ii) the forfeiture to LSBD of substantially all of
                                         the Company&rsquo;s intellectual property, and (iii) the payment of due amounts, effectively
                                         threatening the Company&rsquo;s viability and otherwise having a material adverse effect
                                         on the Company and its business, assets and prospects. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preceding summary and
all other references to the License Agreement in this Offering Circular is subject to and you are encouraged to read the complete
text of the License Agreement, including variations, which are filed as exhibits to the Offering Statement of which this Offering
Circular is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Risks We Face</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An investment in our securities
involves a high degree of risk. You should carefully consider the risks summarized below. The risks are discussed more fully in
the &ldquo;Risk Factors&rdquo; section of this Offering Circular immediately following this Offering Circular summary. These risks
include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are controlled by our parent, LSBD, which owns the intellectual property rights to the biosensor platform that we license and is responsible for much of the development of the biosensor platform as well as the GBS System. The terms of the License Agreement present significant risks and payment and other obligations by us to LSBD.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Given our lack of revenue, we expect to need to raise additional capital, the availability to us of which on acceptable terms, if any, cannot be assured.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We may not generate revenue in the manner in which we anticipate. Further, we expect to incur losses for the foreseeable future.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The regulatory clearance processes in the China Region that we must navigate may be expensive, time-consuming, and uncertain and may prevent us from obtaining clearance for the commercialization of the GBS System or future product candidates, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our revenue is highly dependent on our principal product, which is yet to be approved, and, if approved, market acceptance of our product.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are subject to the risk of reliance on third parties to manufacture and supply our product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are subject to the risk of reliance on third parties to distribute our product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our relationships with LSBD are related party transactions and include commercial and capital arrangements and obligations. Our intellectual property primarily will consist of the license, rather than the outright ownership, of intellectual property rights from LSBD, so that we may commercialize the GBS System in the China Region.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If we or LSBD are unable to successfully protect our intellectual property and proprietary rights, our competitive position will be harmed.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If others claim we or LSBD infringes on their intellectual property rights, we may be subject to costly and time-consuming litigation.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We face competition from companies that have greater resources than we do and we may not be able to effectively compete against these companies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commercialization Hurdles</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a development
stage company formed in December 2016 as a new business and have not yet begun to commercialize our licensed technology or any
products. Our efforts to date have been organizational and formational, have depended on LSBD and its affiliates and have not
generated revenue, and it is still too early to predict if we will ever be able to generate revenues. Therefore, we are, and expect
for the foreseeable future to be, subject to all the risks and uncertainties inherent in a new business and the development and
sale of new medical devices and related software applications. We may be unable to fully develop, obtain regulatory approval for,
manufacture, market, sell and derive revenues from the GBS System and our inability to do so would materially and adversely impact
our viability. In addition, we still must establish many functions necessary to operate a business, including finalizing our managerial
and administrative structure, continuing product and technology development, assessing and commencing our marketing activities,
implementing financial systems and controls and personnel recruitment. This discussion of commercialization hurdles is subject
to and must be considered in the context of &ldquo;Risk Factors&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> The GBS System is in
the development stage with the core biosensor within the GBS System having developed a functioning laboratory prototype of the
core biosensor (sensor strip and readout device). The development for the full GBS System, comprised of the sensor strip, dedicated
&lsquo;smart&rsquo; reader device and smartphone application as a commercial grade medical device is in process. This Offering
is for preliminary financing toward pursuing further development and, if such development is successful, commercialization of
the GBS System. There are numerous hurdles required before commercialization will be possible, as to which there can be no assurances.
Those hurdles include, but are not limited to, and are not necessarily set forth in chronological order: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Additional Capital</U>. We expect that we will require more capital than is contemplated in
this Offering to reach commercialization of the GBS System. Such need for capital is an over-riding condition to the achievement
of many of the other hurdles to commercialization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Regulatory Approvals</U>. The research, design, testing, manufacturing, labeling, selling, marketing
and distribution of medical devices are subject to extensive regulation by country-specific regulatory authorities, which regulations
differ from country to country. We have not yet obtained any regulatory approvals in any jurisdiction. We must obtain all regulatory
approvals as will permit the commercialization of the GBS System as well as any eligible protection of any intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Clinical Studies</U>. To date, we have not conducted clinical studies and trials on the GBS
System. These studies and trials will be required prior to and in connection with obtaining all regulatory approvals. These studies
and trials will have to be successfully completed to obtain requisite regulatory approvals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Manufacture and Supply</U>. Neither we nor LSBD own or operate manufacturing facilities or maintain
the resources for the production of the GBS System and its components on a commercial scale. Therefore, we will have to rely on
outsourcing in this regard. We must identify and reach agreements with manufacturers and suppliers before we can commence commercialization
of the GBS System.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Marketing</U>. We are looking for and will depend in large part on qualified distributors for
the marketing and selling of our products. While we will depend on these distributors&rsquo; efforts, we will be unable to control
their efforts completely. We have not yet executed any distribution agreements in this regard.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Software Compatibility</U>. We must conduct software work to make the GBS System application
compatible with existing and potential future smart device platforms. This software work remains to be done.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Personnel</U>.
                                         In order to commercialize our GBS System, we will need to attract and retain highly skilled
                                         managerial, sales, scientific and technical personnel to advance the product beyond its
                                         current development stage. To date we have utilized certain employees of our parent LSBD,
                                         which arrangement will not be sufficient to move toward commercialization of the GBS
                                         System.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Intellectual property</U>. Before commencing any commercialization, we will need to assess the
eligibility of our intellectual property for suitable protections in the jurisdictions of the China Region and if possible implement
measures to achieve that protection. This will require significant work in each of those jurisdictions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; text-transform: uppercase">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Experts</U>. For purposes of most of the foregoing steps, including in particular regulatory
and intellectual property hurdles, we will need to engage third party experts, including in particular specialized local counsel
in certain jurisdictions.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; text-transform: uppercase">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Status
                                         of Product</U>. The GBS System is only in the development stage with the core biosensor
                                         within the GBS System having completed the proof of the concept stage. Significant work
                                         remains to move from the current stages of the product toward commercialization.</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_003"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; padding-left: 0.15in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.15in"><B>Issuer:</B></P></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-size: 10pt">Glucose Biosensor Systems (Greater China) Holdings, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Number of Shares of Common Stock
    Outstanding before the Offering:<SUP>1</SUP></B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">8,250,000 shares as the date hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Common Stock Offered by us:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">A minimum of 750,000 and a maximum of 2,083,334 shares of our
                                    common stock, par value $0.01 (&ldquo;Common Stock&rdquo;), at an offering price of $12.00
                                    per share (the &ldquo;Shares&rdquo;).</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Common Stock to be Outstanding
    after this Offering:<SUP>1</SUP></B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">10,739,864 shares, if the minimum amount of Shares is sold, and
12,079,198 shares, if the maximum amount of Shares are sold.</P> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Gross Proceeds to be Received in this Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$9,000,000, if the minimum amount of Shares is sold, and
    $25,000,000, if the maximum amount of Shares are sold.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Use of Proceeds:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We intend to use the net proceeds received from this offering to pursue the early stages of regulatory approvals processes and compliance with obligations under the License Agreement, and secondarily, to the extent available, for development of our software platform, sales and marketing efforts to penetrate the markets in the China Region, production arrangements, funding our working capital and for general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Controlled Company:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">LSBD currently beneficially owns 100% of our
                                    Common Stock. Upon the completion of this offering, LSBD will own 76.8% of our Common Stock
                                    if the minimum number of Shares is sold and 68.3% if the maximum number of Shares is sold.
                                    Since immediately following completion of this offering LSBD will control more than a majority
                                    of the total voting power of our outstanding Common Stock, LSBD will be able to control the
                                    outcome of all matters submitted to a vote of our stockholders, including, for example, the
                                    election of directors, amendments to our certificate of incorporation and mergers or other
                                    business combinations. See &ldquo;Description of Capital Stock&rdquo;. In addition, we currently
                                    intend to utilize the controlled company exemption under the Nasdaq corporate governance rules,
                                    and so you will not have the same protections afforded to stockholders of companies that are
                                    subject to such requirements.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>1</SUP>Excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-size: 10pt">1,222,506 shares issuable upon the exercise of outstanding
    warrants issued in connection with the placement of our Series A Convertible Preferred Stock, at an exercise price of $12.00
    per share, which warrants are exercisable only during the one-year period commencing on the second anniversary of the closing
    of this Offering;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">500,000 shares that will become available for future issuance
    under our 2017 Equity Incentive Plan; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">conversion of the warrants (the &ldquo;Placement Agent Warrants&rdquo;)
    to purchase shares of Common Stock equal to 5.0% of the aggregate Shares sold in this Offering, which Placement Agent Warrants
    will be for the purchase of 37,500 shares in the event the minimum number of Shares  is sold and 104,167 shares in the event
    the maximum number of Shares  is sold.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless expressly indicated or the context requires
otherwise, all information in this Offering Circular:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">assumes the automatic conversion of 1,222,506 outstanding shares of our Series A Convertible Preferred Stock as of the date hereof into 1,222,506 shares of Common Stock in connection with this Offering;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">assumes the automatic conversion of an aggregate amount of
    $5,277,056 (including principal and accrued but unpaid interest) of convertible notes issued by the Company&rsquo;s subsidiary,
    Glucose Biosensor Systems (Greater China) Pty Ltd (&ldquo;GBS Pty Ltd&rdquo;) as of the date hereof into 517,358 shares
    of Common Stock at a price per share equal to $10.20 in connection with this Offering; and</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">presents share and per share amounts (except in historical
    financial information) reflecting the reverse stock split effected on August 9, 2018, of approximately one to 0.9167 shares
    that     resulted in     8,250,000 shares     of common stock being issued and outstanding as of the date
    hereof.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Proposed Listing:</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-size: 10pt">We have applied to list our Common Stock on The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;GBSG&rdquo;. There is no assurance that this application will be approved and investors may not know at the time that their investment becomes irrevocable whether this application will be approved or whether the Shares will ever be listed. Nonetheless, our Common Stock will not commence trading on Nasdaq unless and until (i) the minimum amount of this Offering is closed; (ii) this Offering is terminated and (iii) we have filed a post-qualification amendment to the Offering Statement, and a registration statement on Form 8-A (&ldquo;Form 8-A&rdquo;) under the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and such post-qualification amendment is qualified by the SEC and the Form 8-A has become effective. Pursuant to applicable rules under Regulation A, the Form 8-A will not become effective until the SEC qualifies the post-qualification amendment. We intend to file the post-qualification amendment and request its qualification immediately prior to the termination of the Offering in order that the Form 8-A may become effective as soon as practicable. Even if we meet the minimum requirements for listing on Nasdaq, we may wait before terminating the Offering and commencing the trading of our Common Stock on Nasdaq in order to raise additional proceeds. As a result, you may experience a delay between the closing of your purchase of shares of our Common Stock and the commencement of exchange trading of our Common Stock on Nasdaq. See &ldquo;Risk Factors &ndash; Our shares of Common Stock are not and may not be listed for trading on a national securities exchange.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Risk Factors:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An investment in our company is highly speculative and involves a significant degree of risk.&nbsp;&nbsp;See &ldquo;Risk Factors&rdquo; and other information included in this Offering Circular for a discussion of factors you should carefully consider before deciding to invest in our securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The purchase of the Company&rsquo;s
Common Stock involves substantial risks. You should carefully consider the following risk factors in addition to any other risks
associated with this investment. The Shares offered by the Company constitute a highly speculative investment and you should be
in an economic position to lose your entire investment. The risks listed do not necessarily comprise all those associated with
an investment in the Shares and are not set out in any particular order of priority. Additional risks and uncertainties may also
have an adverse effect on the Company&rsquo;s business and your investment in the Shares. An investment in the Company may not
be suitable for all recipients of this Offering Circular. You are advised to consult an independent professional adviser or attorney
who specializes in investments of this kind before making any decision to invest. You should consider carefully whether an investment
in the Company is suitable in the light of your personal circumstances and the financial resources available to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The discussions and information
in this Offering Circular may contain both historical and forward-looking statements. To the extent that the Offering Circular
contains forward-looking statements regarding the financial condition, operating results, business prospects, or any other aspect
of the Company&rsquo;s business, please be advised that the Company&rsquo;s actual financial condition, operating results, and
business performance may differ materially from that projected or estimated by the Company in forward-looking statements. The Company
has attempted to identify, in context, certain of the factors it currently believes may cause actual future experience and results
may differ from the Company&rsquo;s current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before investing, you should
carefully read and carefully consider the following risk factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Financial Position
and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We were formed in December 2016 and are
thus subject to the risks associated with new businesses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were formed in December
2016 as a new business and have not yet begun to commercialize our licensed technology or any products. As such, this limited
operating history may not be adequate to enable you to fully assess our ability to develop and commercialize the GBS System, achieve
market acceptance of the GBS System and respond to competition. Our efforts to date have been organizational and formational,
have depended on LSBD and its affiliates and have not generated revenue, and it is still too early to predict if we will ever
be able to generate revenues. Therefore, we are, and expect for the foreseeable future to be, subject to all the risks and uncertainties,
inherent in a new business and the development and sale of new medical devices and related software applications. As a result,
we may be unable to fully develop, obtain regulatory approval for, commercialize, manufacture, market, sell and derive revenues
from the GBS System and our inability to do so would materially and adversely impact our viability. In addition, we still must
establish many functions necessary to operate a business, including finalizing our managerial and administrative structure, continuing
product and technology development, assessing and commencing our marketing activities, implementing financial systems and controls
and personnel recruitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, you should
consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in their
initial revenue generating stages, particularly those in the medical device and digital heath fields. In particular, potential
investors should consider that there is a significant risk that we will not be able to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">implement or execute our current business plan, or that our business plan is sound;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">maintain our management team and Board of Directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">raise sufficient funds in the capital markets or otherwise to effectuate our business plan;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">determine that the technologies that have been developed are commercially viable; and/or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">attract, enter into or maintain contracts with, and retain customers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the event that we do
not successfully address these risks, our business, prospects, financial condition, and results of operations could be materially
and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Given our lack of revenue and our negative
cash flow, we expect to need to raise additional capital, which may be unavailable to us or, even if consummated, may cause dilution
or place significant restrictions on our ability to operate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to our
management&rsquo;s estimates, based on our budget and proposed schedules of development, approvals and organization, we believe,
although there can be no assurances, that if we raise the minimum amount of this Offering then we will have sufficient capital
resources to enable us to continue to implement our business plan and remain in operation for at least the next 12 months, but
there can be no assurances how long, if at all, after such 12 months we might be able to continue as such without raising additional
capital. We do not anticipate generating any revenues within 24 months from the date of this Offering. We believe, although there
can be no assurances, that raising more than the minimum and less than the maximum amount of this Offering will enable us to continue
to implement our business plan and remain in operation for an indeterminate amount of time longer than just raising the minimum
amount, with the amount raised in excess over that minimum amount generally allowing for more additional time, but we will still
be required to promptly seek and obtain additional sources of capital. Even if we raise the maximum amount of this Offering, we
will need additional capital before we are able to fully implement our business plan and commercialize our products for public
sale, as to which there can be no assurances as to success. In any event, there can be assurances that we will ever be able to
raise additional capital.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since we might be unable
to generate revenue or cash flow to fund our operations for the foreseeable future, we expect to need to seek additional equity
or debt financing to provide the capital required to maintain or expand our operations. We may also need additional funding for
developing products and services, increasing our sales and marketing capabilities, and promoting brand identity, as well as for
working capital requirements and other operating and general corporate purposes. Moreover, the regulatory compliance arising out
of being a publicly registered company will increase our costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently have
any arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will be able to raise
sufficient additional capital on acceptable terms, or at all. If such financing is not available on satisfactory terms, or is not
available at all, we may be required to delay, scale back or eliminate the development of business opportunities and our operations
and financial condition may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we raise additional
capital by issuing equity securities, the percentage ownership of our existing stockholders may be reduced, and accordingly these
stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and
privileges senior to those of our Common Stock. Given our need for cash and that equity-based offerings are the most common type
of fundraising, the risk of dilution is particularly significant for our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Debt financing, if obtained,
may involve agreements that include liens on our assets, covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, could increase our expenses and require that our assets be provided as a security for such debt.
Debt financing would also be required to be repaid regardless of our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we raise additional
funds through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or candidate
products, or to grant licenses on terms that are not favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have incurred significant losses since
inception. As such, you cannot rely upon our historical operating performance to make an investment decision regarding our company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since our
inception, we have engaged primarily in formational activities and have not yet entered the commercialization stage. We have
financed our operations primarily through financing from pre-IPO capital raising and have incurred losses since inception,
including a net loss of $3,166,586 for the period from  July 1, 2017 through March 31, 2018. We do not know whether or when we
will become profitable. Our ability to generate revenue and achieve profitability depends upon our ability, alone or with
others, to launch the GBS System in the China Region and manufacture, market and sell the GBS System where approved. We may
be unable to achieve any or all of these goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The directors have
expressed in the notes to the financial statements that the Company will continue as a going concern dependent on its ability to
raise additional capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is an early
stage and emerging growth company and has not generated any revenues to date. As such, the Company is subject to all of the risks
associated with early stage and emerging growth companies. Since inception, the Company has incurred losses and negative cash flows
from operating activities. The Company does not expect to generate positive cash flows from operating activities in the near future
until such time, if at all, the Company completes the development process of its products, including regulatory approvals, and
thereafter, begins to commercialize and achieve substantial acceptance in the marketplace for the first of a series of products
in its medical device portfolio</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> The Company
incurred a net loss of $3,166,586 for the period from July 1, 2017 through March 31, 2018. At March 31, 2018, the Company had
an accumulated deficit of $3,478,258, negative working capital of $2,723,048, $5,510,638, in current liabilities of which
$5,205,435 are convertible notes issued by our subsidiary GBS Pty Ltd that will convert to Common Stock upon the proposed
IPO, and cash of $1,054,650. In the near future, the Company anticipates incurring operating losses and does not expect to
experience positive cash flows from operating activities and may continue to incur operating losses until it completes the
development of its products and seeks regulatory approvals to market such products. These factors may raise doubt about
the Company&rsquo;s ability to continue as a going concern without sufficient capital. See Note 1 to Consolidated Financial
Statements for the period from July 1, 2017 through March 31, 2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A failure to raise sufficient
capital, obtain regulatory approvals for the Company&rsquo;s products, generate sufficient product revenues, or control expenditures,
among other factors, may adversely impact the Company&rsquo;s ability to meet its financial obligations as they become due and
payable and to achieve its intended business objectives, and therefore, raises substantial doubt of the Company&rsquo;s ability
to continue as a going concern. The Company&rsquo;s consolidated financial statements have been prepared on a going concern basis
which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our License Agreement with our wholly-owning
parent, LSBD, which relates to the Company&rsquo;s principal asset consisting of licensed intellectual property, contains numerous
significant performance, payment, liability, compliance, termination and intellectual property risks that may threaten the Company&rsquo;s
viability or otherwise have a material adverse effect on the Company and its business, assets and its prospects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The License Agreement is
limited to the China Region and includes the terms and related risks set forth below The Company has no contractual rights to the
intellectual property covered in the License Agreement other than as expressly set forth therein. The Company&rsquo;s plans, business,
prospects and viability are substantially dependent on that intellectual property and subject to the limitations relating thereto
as set forth in the License Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Under the License Agreement an exclusive license is granted to the Company covering certain glucose sensor intellectual property scheduled in the License Agreement and other data owned by LSBD, but solely to (i) hold regulatory marketing authorizations in the China Region, (ii) promote, market and import specific licensed products in the China Region, (iii) provide customer support on the licensed products in the China Region, (iv) use the licensed products in the China Region, and (v) collect data for LSBD regarding the use of the licensed products in the China Region. As granted solely for the specified purposes, the Company will be unable to use the license beyond the specified products for the specified purposes, thus limiting the potential commercialization of the applicable intellectual property, even as such commercialization might be appropriate, related, synergistic or enhanced by the Company&rsquo;s operations for the benefit of a third party, including LSBD. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The licensed products under the License Agreement are only those products that are procured by the Company from suppliers authorized by LSBD in the China Region under rights owned by LSBD. Accordingly, the Company will not have unfettered right to select its suppliers, regardless of whether unauthorized suppliers would provide products on better pricing, delivery, quality or other terms, thus potentially materially and adversely impacting those aspects of the Company&rsquo;s business, economies, profitability and prospects and making the Company subject to the terms offered by the authorized suppliers. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The licensed rights under the License Agreement do not cover digital or online use to users not physically in the China Region. Accordingly, to the extent that such users are prohibited, the Company will be unable to realize any commercialization from such users and ensure that such users do not do business with the Company, even as such commercialization and business might be appropriate, related, synergistic or enhanced by the Company&rsquo;s operations. In addition, the Company may be responsible for costs and other liabilities that might arise to the extent that users outside the China Region obtain such access, and may incur costs to comply with these prohibitions. Further, the non-coverage of digital or online use for users not physically in the China Region may constitute a material limitation on the ability of the Company to freely conduct business digitally, online or through any other medium that may reach outside of the China Region. This limitation may have a material adverse effect on the Company&rsquo;s marketing, sales, operational and other business efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The distribution license contained in the License Agreement is expressly limited by certain terms, which include the Company providing customer support on licensed products and collecting data for LSBD regarding the use thereof. The customer service and data collection and retention may be expensive in cost, resources, legal and regulatory compliance and other ways, none of which costs can be quantified at this time. Further, changing regulations with respect to medical and similar such data may make such compliance beyond the scope of the Company&rsquo;s capabilities. There can be no assurances that the costs and limited capabilities regarding these matters will not have a material adverse effect on the ability of the Company to comply with these distribution requirements on an economical basis, if at all.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company is required to meet specified performance milestones,
    including conducting clinical studies; obtaining regulatory approvals in the China Region within two years after the commencement
    of trading of the Shares on Nasdaq and within two years thereof placing orders with LSBD for a minimum number of products
    based on market growth, with annual increases; annually agree with LSBD as to that market growth; achieve annually that market
    share growth plus a minimum fixed percentage and quarterly orders with LSBD for products in quantities at that quarterly market
    share growth plus a minimum fixed percentage; conduct minimum marketing on standards reasonably determined by LSBD; and convert
    all glucose monitoring sales by the Company into glucose monitoring sales of the biosensor strip within five years; provided
    that (i) LSBD must supply all licensed product in accordance with the License Agreement, (ii) such product must be of merchantable
    quality and in accordance with local law, and (iii) certain end user data must be accessible to the Company. These milestones
    represent significant performance and other hurdles that may not be achievable. In addition, the parties must agree as to
    market share growth and then the Company must exceed that growth by the specified minimum fixed percentage each quarter and
    annually. There can be no assurances that agreement can be reached each quarter or that if reached it can be exceeded by the
    specified minimum percentage each time required. Failure to meet any such performance milestone or satisfy any related requirement
    under the License Agreement would create significant liabilities that would have a material adverse effect on our business,
    financial condition, prospects and assets.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon failure of any of these requirements, LSBD may require the Company to make cash payment of the value of any shortfall. These failure provisions may have a material adverse effect on the Company and its operations and may not be sustainable by the Company. Each failure requires a full cash payment for the shortfall, effectively guaranteeing to LSBD a return regardless of the performance by the Company. There can be no assurances that the Company will have or be able to obtain sufficient cash to make the required shortfall payments. In particular, the failure to pay the amount of any shortfall within 14 business days of being due will subject the amount due to monthly compounding interest at the rate of LIBOR plus 4%, without any relief or defenses set forth in the License Agreement, which amounts may significantly increase and be or become unbearable or unsustainable to the Company. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the licensed rights in general are limited to those expressly set forth in the License Agreement and are non-transferable, non-assignable and non-sub-licensable, with the only exception that LSBD will in good faith consider any Company request for any sub-license, which consideration does not imply any commitment to agree to any such sub-license, the absence of all of which may have a material adverse effect on the Company and its business, assets and prospects. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The non-exclusive, non-transferable use of specified trademarks for marketing the licensed products is subject to certain limitations that may limit the ability of the Company to develop its own branding, trade name and other intangible value, which may have a material adverse effect on the Company and its business, assets and prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">LSBD may require or make any changes to licensed products at no cost to LSBD. This right of LSBD may create material expense, relationship, practical, reputational and other adverse harm to the Company, its business and its prospects without any control over these changes by the Company. Further, there are no material limitations, indemnities or cost-sharing provisions imposed on LSBD that would ameliorate the impact on the Company of these changes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must notify LSBD of infringements of any licensed intellectual property and cooperate with and as instructed by LSBD, at LSBD&rsquo;s expense, in preventing such infringement, but may take no other action regarding infringement. These provisions leave the Company little control over whether, to what extent and at what consequences any infringement protection may be undertaken, thus potentially resulting in protective conduct that may have a material adverse effect on the Company, its business and its prospects without any control or even input by the Company over these protective actions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must market, sell and distribute the licensed products in accordance with law and distribution requirements set forth in the License Agreement, including delivering licensed products without inclusion of any other product, only as supplied by LSBD, without changing LSBD&rsquo;s packaging or branding thereof and only in quantities as directed by LSBD; complying with all regulations; and keeping specified records and batch samples relating to its activities. These limitations expose the Company to a breach to the extent it fails to comply with marketing, sales and distribution requirements and further limits the ability of the Company to expand its business or strategy by linking or bundling licensed products with other Company products as may become strategically indicated or perceived as beneficial to the Company. Likewise, the Company may be limited in its ability to realize marketing or other synergies from any marketing, distribution or sales platforms or networks that it may develop or design, thereby having a material adverse effect on the Company, its operations or its prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must file for and obtain all legal permits for marketing and selling licensed products. There can be no assurances that the Company will be able to obtain or maintain any or all required permits.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must pay LSBD, subject to a monthly late charge, a one-time fixed license fee within 14 days of the obtaining of required regulatory approvals in China; fixed royalty percentages on the sale of specified licensed products on sales of commercial units and certain other devices; application license fees and fees for patient education services, all as determined from time to time by LSBD. These payment requirements may have a material adverse effect on the Company, its operations or its prospects, since the Company may not be able to make these substantial payments as and when incurred, which payments are required based on milestones unrelated to the Company&rsquo;s cash flow, liquidity, profitability or other set-offs.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must obtain, retain and provide to LSBD certain end user and other data and notify LSBD as to a variety of matters relating to the data, all of which data shall be solely owned by LSBD, provided that the Company will own certain of the data during the term of the License Agreement. There can be no assurances that the Company will have the resources or that it will be economical for the Company to comply with these data requirements or that it will be able to do so in complete compliance with all applicable regulations and law. Further, the ownership of the data as noted represents a limitation on the ability of the Company to fully exploit for its own legally permissible purposes customer and other data that it may obtain in the course of its operations, which data may have intrinsic, intangible or other value that will result from the Company&rsquo;s efforts. Further, the rights of the Company to use the data do not survive the License Agreement and thus do not necessarily represent a reliable future asset of the Company. These limitations on the ownership and use of data may have a material adverse effect on the Company, its operations and its prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">LSBD will own all of the right, title and interest in substantially all of the intellectual property covered by the License Agreement and LSBD shall have the right to control the protection of that licensed intellectual property as assisted by the Company, which shall have no rights to control or otherwise conduct protective activities. The full ownership by LSBD of the licensed intellectual property as noted represents a limitation on the ability and incentives of the Company to fully exploit for its own legally permissible purposes that property. The licensed rather than owned nature of the property also represent a significant limitation on the ability of the Company to realize returns on investments made in, or the increase in the value of, that property. These limitations may have a material adverse effect on the Company, its operations and its prospects.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The parties generally agree to keep confidential, subject to customary exceptions, all confidential information of the other party, subject to express exceptions. There can be no assurances that these confidentiality provisions will not have a limitation on the ability of the Company to exploit for its own benefit certain information that it learns in the course of its business or that it will not inadvertently violate the terms of that confidentiality, with material adverse consequences to the Company, its business or its prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Except with respect to LSBD&rsquo;s ownership of all intellectual property rights in respect of the licensed property and the non-infringement by the Company&rsquo;s exercise of those rights, LSBD provides no, and disclaims all, representations, warranties or covenants relating to the licensed intellectual property or any other matters under the License Agreement and in particular disclaims any fitness of the property for any purpose.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">LSBD is indemnified by the Company for any losses that may be incurred relating to any conduct, including any data collection or retention, by the Company under or relating to the License Agreement or the intellectual property under it, or any negligent or willful misconduct or violation of law by the Company, with no reciprocal indemnity; provided that LSBD indemnifies the Company for any losses arising that may be incurred related to (i) any third party claim that the exercise by the Company of its rights in respect of a licensed product violates its property or rights, and (ii) any regulatory or quality recall or any consumer or user claims or liability in relation to a licensed product (regardless of any contributory or comparative negligence of any Licensee Indemnitee, subject to contributory negligence.. These provisions effectively give the Company limited recourse the event that the licensed intellectual property is flawed, defective, inadequate, incomplete, uncommercial, wrongly described or otherwise not useful for purposes of the Company&rsquo;s expectations, plans or strategies. The Company has not independently verified any of the technical, scientific, commercial, legal, medical or other circumstances or nature of the licensed intellectual property and therefore there can be no assurances that any of the foregoing risks have been reduced or eliminated. These provisions represent a significant risk of a material adverse impact on the Company, its business or its prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"> The term of the License Agreement runs until the final date of protection afforded to the
                                                                                                              patent portfolio covered by the License Agreement, which is currently until 2033, provided that either party may terminate
                                                                                                              the License Agreement earlier following any uncured material breach by the other party of it, the discontinuation of the
                                                                                                              other party&rsquo;s operations or an actual or prospective change in control of the other party, where change in control
                                                                                                              means, among other things, (i) any change of 50% ownership of outstanding Common Stock or voting rights, (ii) a merger
                                                                                                              resulting in our pre-merger voting securities failing to represent at least 50% of all voting power immediately post-merger,
                                                                                                              (iii) a sale of substantially all assets, (iv) solely with respect to the Company, without LSBD&rsquo;s prior approval a
                                                                                                              majority                                                                                                               change
                                                                                                              in                                                                                                                 the
                                                                                                              composition                                                                                                               of
                                                                                                              our board of
                                                                                                              directors (unless such change was pre-approved by our board, a nominating or other independent
                                                                                                              committee thereof) or (v) the dissolution or liquidation of the other party. In the event of a change in control of LSBD, LSBD must pay the
Company an amount equal to the greater of the five-year projected net sales or five times the prior year&rsquo;s actual net sales
of the Company, as adjusted depending on how much of the term of the License Agreement remains. No similar payment is required
by the Company in the event of a change in control of the Company.
 These termination provisions represent a significant risk
    that the License Agreement may be terminated by LSBD or by way of certain transactions, which termination would have an immediate,
    material and existential adverse impact on the Company and its operations, assets and prospects. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding the change of control risks described above, the License Agreement imposes severe consequences upon the Company upon the expiration, termination or cancellation of the License Agreement in any way. These consequences would require (i) the cessation of substantially all of the Company&rsquo;s operations, (ii) the forfeiture to LSBD of substantially all of the Company&rsquo;s intellectual property, and (iii) the payment of due amounts, effectively threatening the Company&rsquo;s viability and otherwise having a material adverse effect on the Company and its business, assets and prospects.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preceding risks are
subject to, and you are encouraged to read, the complete text of the License Agreement, including variations, which are filed as
exhibits to the Offering Statement of which this Offering Circular is a part. These risks are not exclusive and any one or more
thereof have the risks described above or elsewhere herein and may otherwise materially and adversely affect, or represent existential
risks to, the Company, its business and it prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Neither we nor LSBD have yet begun commercializing
the GBS System and the ability to do so will depend on the acceptance of the GBS System in the Chinese healthcare market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither we nor LSBD have
yet begun commercializing the GBS System and it has not yet received regulatory approvals in China or elsewhere. We have limited
experience engaging in commercial activities and limited established relationships with physicians and hospitals as well as third-party
suppliers on whom we will depend for the manufacture of our product. We are faced with the risk that the China Region marketplace
will not be receptive to the GBS System over competing products and that we will be unable to enter the marketplace or compete
effectively. Factors that could affect our ability to establish the GBS System or any potential future product include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the development of products or devices which could result in a shift of customer preferences away from our device and services and significantly decrease revenue;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the increased use of improved diabetes drugs that could encourage certain diabetics to test less often, resulting in less usage of self-monitoring (saliva-based, blood-based or otherwise) test device for certain types of diabetics;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the challenges of developing (or acquiring externally-developed) technology solutions that are adequate and competitive in meeting the requirements of next-generation design challenges;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the significant number of current competitors in the glucose monitoring market who have significantly greater brand recognition and more recognizable trademarks and who have established relationships with diabetes healthcare providers and payors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">intense competition to attract acquisition targets, which may make it more difficult for us to acquire companies or technologies at an acceptable price or at all.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
the GBS System or any future product will gain market acceptance. If the market for the GBS System or any future product fails
to develop or develops more slowly than expected, or if any of the technology and standards supported by us do not achieve or sustain
market acceptance, our business and operating results would be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We cannot accurately predict the volume
or timing of any sales, making the timing of any revenues difficult to predict.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may be faced with lengthy
and unpredictable customer evaluation and approval processes associated with the GBS System. Consequently, we may incur substantial
expenses and devote significant management effort and expense in developing customer adoption of the GBS System, which may not
result in revenue generation. We must also obtain regulatory approvals of the GBS System in each respective jurisdiction, which
is subject to risk and potential delays, and may actually occur. As such, we cannot accurately predict the volume, if any, or timing
of any future sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If the GBS System fails to satisfy current
or future customer requirements, we may be required to make significant expenditures to redesign the product, and we may have insufficient
resources to do so.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System is being
designed to address an existing marketplace and must comply with current and evolving customer requirements in order to gain market
acceptance. There is a risk that the GBS System will not meet anticipated customer requirements or desires. If we are required
to redesign our products to address customer demands or otherwise modify our business model, we may incur significant unanticipated
expenses and losses, and we may be left with insufficient resources to engage in such activities. If we are unable to redesign
our products, develop new products or modify our business model to meet customer desires or any other customer requirements that
may emerge, our operating results would be materially adversely affected and our business might fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We expect to derive substantially all
of our revenues from a principal technology, which we license from LSBD and which leaves us subject to the risk of reliance on
LSBD and its technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to derive substantially
all of our revenues from sales of products derived from a principal technology, which we license exclusively from LSBD. Our initial
product utilizing this technology is the GBS System. As such, any factor adversely affecting sales of the GBS System, including
the product development and release cycles, regulatory issues, market acceptance, product competition, performance and reliability,
reputation, price competition and economic and market conditions, would likely harm our operating results. We may be unable to
fully develop the GBS System or other products utilizing our technology, which would likely lead to the failure of our business.
Moreover, in spite of our efforts related to the registration of our technology, if intellectual property protection is not available
for our principal technology, the viability of the GBS System and any other products that may be derived from such technology would
likely be adversely impacted to a significant degree, which would materially impair our prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will be dependent upon third-party
manufacturers and suppliers making us vulnerable to contractual relationships and market forces, supply shortages and problems
and price fluctuations, which could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither we nor LSBD own
or operate manufacturing facilities or maintain the resources for the production of the GBS System and its components on a commercial
scale. Therefore, we will have to rely on outsourcing in this regard. Third party manufacturers and suppliers may encounter problems
for a variety of reasons, including, for example, failure to follow specific protocols and procedures, failure to comply with applicable
legal and regulatory requirements, equipment malfunction and environmental factors, failure to properly conduct their own business
affairs, and infringement of third-party intellectual property rights, any of which could delay or impede their ability to meet
our requirements. Reliance on these third-party suppliers also subjects us to other risks where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may not be able to obtain an adequate manufacture or supply in a timely manner or on commercially reasonable terms;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">third party manufacturers or suppliers make errors that could adversely affect the efficacy or safety of the GBS System or cause delays in shipment;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may have difficulty locating and qualifying alternative suppliers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">switching components or suppliers may require product redesign and possibly submission to Chinese or other regulatory bodies, which could significantly impede or delay our commercial activities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">sole-source suppliers fail to supply components of the GBS System; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">third party manufacturers or suppliers encounter financial or other business hardships unrelated to us, interfering with their fulfillment of our orders and requirements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may not be able
to quickly establish additional or alternative suppliers if necessary, in part because we may need to undertake additional activities
to establish such suppliers as required by the regulatory approval process. Any interruption or delay in obtaining products from
our third-party suppliers, or our inability to obtain products from qualified alternate sources at acceptable prices in a timely
manner, could impair our ability to meet the demand of our customers and cause them to switch to competing products. Given our
potential reliance on certain single-source suppliers, we may well be susceptible to supply shortages because we would not have
alternate suppliers readily available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are looking for and expect to rely
in part on third-party distributors to effectively distribute our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are looking for and
will depend in part on qualified distributors for the marketing and selling of our products. We will depend on these distributors&rsquo;
efforts to market our products, yet we will be unable to control their efforts completely. We have not yet executed any distribution
agreements in this regard and there can be no assurances that suitable distributors will be engaged on terms acceptable to us.
These distributors typically would sell a variety of other, non-competing products that may limit the resources they dedicate to
selling the GBS System. In addition, we are unable to ensure that our distributors will comply with all applicable laws regarding
the sale of our products. If our distributors fail to effectively market and sell the GBS System in full compliance with applicable
laws, our operating results and business may suffer. Recruiting and retaining qualified third-party distributors and training them
in our technology and product offering will require significant time and resources. To develop and expand our distribution, we
will be required to scale and improve our processes and procedures that support our distributors. Further, if our relationship
with a successful distributor terminates, we may be unable to replace that distributor without disruption to our business. If we
fail to develop or maintain positive relationships with our distributors, including in new markets, fail to manage, train or incentivize
these distributors effectively, or fail to provide distributors with competitive products on attractive terms, or if these distributors
are not successful in their sales efforts, we may not achieve or may have a reduction in revenue and our operating results, reputation
and business would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Failure in our conventional, online and
digital marketing efforts could significantly impact our ability to generate sales.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to engage in
conventional marketing strategies and also may utilize online and digital marketing in order to create awareness to the GBS System.
Our management believes that using a wide variety of marketing strategies, including online advertisement and a variety of other
pay-for-performance methods may be effective for marketing and generating sales of the GBS System as opposed to relying exclusively
on traditional, expensive retail channels. In any event, there is a risk that any or all of our marketing strategies could fail.
We cannot predict whether the use of traditional or non-traditional retail sales tools and reliance on healthcare providers to
educate our customers about the GBS System will be successful or if we may achieve any successful marketing of the GBS System.
The failure of our marketing efforts could significantly and negatively impact our ability to generate sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The GBS System may utilize a smart device
platform and maybe in the future other platforms. If we are unable to achieve or maintain a good relationship with these platforms,
or if the platform store or any other applicable platform were unavailable for any prolonged period of time, our business will
suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A key component of the
GBS System is a smart device application that includes tools to help diabetic patients manage their disease. This application will
be compatible with various operating platforms. If we are unable to make the GBS System application compatible with these platforms,
or if there is any deterioration in our relationship with either platform providers or others after our application is available,
our business would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to each
of the standard terms and conditions for application developers, which govern the promotion, distribution and operation of games
and other applications on their respective storefronts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>As we intend to conduct business internationally,
we are susceptible to risks associated with international relationships.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to operate our
business in the China Region and initially in China. The international operation of our business requires significant management
attention, which could negatively affect our business if it diverts their attention from their other responsibilities. In the event
that we are unable to manage the complications associated with international operations, our business prospects could be materially
and adversely affected. In addition, doing business with foreign customers subjects us to additional risks that we do not generally
face in the United States. These risks and uncertainties include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">management, communication and integration problems resulting from cultural differences and geographic dispersion;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">localization of products and services, including translation of foreign languages;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delivery, logistics and storage costs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">longer accounts receivable payment cycles and difficulties in collecting accounts receivable;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">difficulties supporting international operations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">difficulties supporting customer services;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in economic and political conditions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">impact of trade protection measures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">complying with import or export licensing requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">exchange rate fluctuations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">competition from companies with international operations, including large international competitors and entrenched local companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">potentially adverse tax consequences, including foreign tax systems and restrictions on the repatriation of earnings;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">maintaining and servicing computer hardware in distant locations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">keeping current and complying with a wide variety of foreign laws and legal standards, including local labor laws;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">securing or maintaining protection for our intellectual property; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reduced or varied protection for intellectual property rights, including the ability to transfer such rights to third parties, in some countries.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The occurrence of any or
all of these risks could adversely affect our international business and, consequently, our results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Failure to make adequate contributions
to various employee benefit plans as required by Chinese regulations may subject us to penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Companies operating in
China are required to participate in various government-sponsored employee benefit plans, including certain social insurance, housing
funds and other welfare-oriented payment obligations, and contribute to the plans in amounts equal to certain percentages of salaries,
including bonuses and allowances, of their employees up to a maximum amount specified by the local government from time to time
at locations where they operate their businesses. While we intend to comply with all material aspects of relevant regulations,
the requirements governing employee benefit plans have not been implemented consistently by the local governments in China given
the different levels of economic development in different locations. If we are subject to late fees or fines in relation to the
underpaid employee benefits, our financial condition and results of operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Non-U.S. governments often impose strict
price controls, which may adversely affect our future profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If successfully developed,
we intend to seek approval to market the GBS System in the China Region. If we obtain approval in one or more of the jurisdictions
within our License Agreement, we will be subject to rules and regulations in those jurisdictions relating to our products. In some
countries, each of which may have developed its own rules and regulations, pricing may be subject to governmental control under
certain circumstances. In these countries, pricing negotiations with governmental authorities can take considerable time after
the receipt of requisite marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required
to conduct a clinical trial that compares the cost-effectiveness of our product to other available products. If reimbursement of
our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable
to achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The software application and associated
business processes of the GBS System may contain undetected errors, which could limit our ability to provide our services and diminish
the attractiveness of our service offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System may contain
undetected errors, defects or bugs. As a result, our customers or end users may discover errors or defects in our products, software
or the systems we design, or the products or systems incorporating our designs and intellectual property may not operate as expected.
We may discover significant errors or defects in the future that we may not be able to fix. Our inability to fix any of those errors
could limit our ability to provide our products, impair the reputation of our brand and diminish the attractiveness of our product
offerings to our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we may utilize
third party technology or components in our products and we rely on those third parties to provide support services to us. Failure
of those third parties to provide necessary support services could materially adversely impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our future performance will depend on
the continued engagement of key members of our management team.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future performance
depends to a large extent on the continued services of members of our current management including, in particular, our President.
In the event that we lose the continued services of such key personnel for any reason, this could have a material adverse effect
on our business, operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are not able to attract and retain
highly skilled managerial, scientific and technical personnel, we may not be able to implement our business model successfully.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that our management
team must be able to act decisively to apply and adapt our business model in the markets in which we will compete. In addition,
we will rely upon technical and scientific employees or third-party contractors to effectively establish, manage and grow our business.
Consequently, we believe that our future viability will depend largely on our ability to attract and retain highly skilled managerial,
sales, scientific and technical personnel. In order to do so, we may need to pay higher compensation or fees to our employees or
consultants than we currently expect and such higher compensation payments would have a negative effect on our operating results.
Competition for experienced, high-quality personnel is intense and we cannot assure that we will be able to recruit and retain
such personnel. We may not be able to hire or retain the necessary personnel to implement our business strategy. Our failure to
hire and retain such personnel could impair our ability to develop new products and manage our business effectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Product Development and
Regulatory Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The regulatory clearance process which
we may be required to navigate may be expensive, time-consuming, and uncertain and may prevent us from obtaining clearance for
the commercialization of the GBS System or our any future product.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will not be permitted
to market the GBS System until we receive regulatory clearance. To date, we have not received regulatory clearance in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The research, design, testing,
manufacturing, labeling, selling, marketing and distribution of medical devices are subject to extensive regulation by country-specific
regulatory authorities, which regulations differ from country to country. There can be no assurance that, even after such time
and expenditures, we will be able to obtain necessary regulatory approvals for clinical testing or for the manufacturing or marketing
of any products. In addition, during the regulatory process, other companies may develop other technologies with the same intended
use as our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also will be subject
to numerous post-marketing regulatory requirements, which may include labeling regulations and medical device reporting regulations,
which may require us to report to different regulatory agencies if our device causes or contributes to a death or serious injury,
or malfunctions in a way that would likely cause or contribute to a death or serious injury. In addition, these regulatory requirements
may change in the future in a way that adversely affects us. If we fail to comply with present or future regulatory requirements
that are applicable to us, we may be subject to enforcement action by regulatory agencies, which may include, among others, any
of the following sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">customer notification, or orders for repair, replacement or refunds;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">voluntary or mandatory recall or seizure of our current or future products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">imposing operating restrictions, suspension or shutdown of production;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusing our requests for clearance or pre-market approval of new products, new intended uses or modifications to the GBS System or future products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">rescinding clearance or suspending or withdrawing pre-market approvals that have already been granted; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">criminal prosecution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The occurrence of any of
these events may have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have not conducted clinical studies
of the GBS System. Clinical and pre-clinical data is susceptible to varying interpretations, which could delay, limit or prevent
additional regulatory clearances.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, we have not
conducted clinical studies on the GBS System. There can be no assurance that we will successfully complete any clinical studies
necessary to receive regulatory approvals in certain jurisdictions. While preliminary studies conducted by LSBD have produced
results we believe to be encouraging and indicative of the potential efficacy of the GBS System, data already obtained, or in
the future obtained, from pre-clinical studies and clinical studies do not necessarily predict the results that will be obtained
from later pre-clinical studies and clinical studies. Moreover, pre-clinical and clinical data are susceptible to varying interpretations,
which could delay, limit or prevent additional regulatory approvals. The failure to adequately demonstrate the safety and effectiveness
of an intended product under development could delay or prevent regulatory clearance of the device, resulting in delays to commercialization,
and could materially harm our business. There can be no assurance that we will be able to receive approval for any potential applications
of our principal technology, or that we will receive regulatory clearances from targeted regions or countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be unable to complete required
clinical trials, or we may experience significant delays in completing such clinical trials, which could significantly delay our
targeted product launch timeframe and impair our viability and business plan.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The completion of any future
clinical trials for the GBS System or other trials that we may be required to undertake in the future could be delayed, suspended
or terminated for several reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our failure or inability to conduct the clinical trial in accordance with regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">sites participating in the trial may drop out of the trial, which may require us to engage new sites for an expansion of the number of sites that are permitted to be involved in the trial;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">patients may not enroll in, remain in or complete, the clinical trial at the rates we expect; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">clinical investigators may not perform our clinical trial on our anticipated schedule or consistent with the clinical trial protocol and good clinical practices.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our clinical trials
are delayed it will take us longer to ultimately commercialize the GBS System and generate revenues. Moreover, our development
costs will increase if we have material delays in our clinical trial or if we need to perform more or larger clinical trials than
planned. We may be faced with similar risks in connection with future trials we conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we or our manufacturers fail to comply
with the regulatory quality system regulations or any applicable equivalent regulations, our proposed operations could be interrupted
and our operating results would suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We, our manufacturers and
suppliers will be required, to the extent of applicable regulation, to follow the quality system regulations of each jurisdiction
it will seek to penetrate and also will be subject to the regulations of these jurisdictions regarding the manufacturing processes.
If we, our manufacturers or our suppliers are found to be in significant non-compliance or fail to take satisfactory corrective
action in response to adverse regulatory findings in this regard, regulatory agencies could take enforcement actions against us
and our manufacturers, which could impair or prevent our ability to produce our products in a cost-effective and timely manner
in order to meet customers&rsquo; demands. Accordingly, our operating results would suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to the risk of reliance
on third parties to conduct our clinical trial work.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will depend on independent
clinical investigators to conduct our clinical trials. Contract research organizations may also assist us in the collection and
analysis of data. These investigators and contract research organizations will not be our employees and we will not be able to
control, other than by contract, the amount of resources, including time that they devote to products that we develop. If independent
investigators fail to devote sufficient resources to our clinical trials, or if their performance is substandard, it will delay
the approval or clearance and commercialization of any products that we develop. Further, regulatory bodies in the China Region
require that we comply with standards, commonly referred to as good clinical practice, for conducting, recording and reporting
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial subjects are protected. If our independent clinical investigators and contract research organizations fail to comply with
good clinical practice, the results of our clinical trials could be called into question and the clinical development of our product
candidates could be delayed. Failure of clinical investigators or contract research organizations to meet their obligations to
us or comply with federal regulations could adversely affect the clinical development of our product candidates and harm our business.
Moreover, we intend to have several clinical trials in order to support our marketing efforts and business development purposes.
Such clinical trials will be conducted by third parties as well. Failure of such clinical trials to meet their primary endpoints
could adversely affect our marketing efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to healthcare fraud
and abuse laws and regulations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Many international healthcare
laws and regulations apply to the glucose monitoring business and medical devices. We will be subject to certain regulations regarding
commercial practices false claims. The medical device industry worldwide has been under heightened scrutiny as the subject of government
investigations and enforcement actions involving manufacturers who allegedly offered unlawful inducements to potential or existing
customers in an attempt to procure their business, including arrangements with physician consultants. If our operations or arrangements
are found to be in violation of such governmental regulations, we may be subject to civil and criminal penalties, damages, fines
and the curtailment of our operations. All of these penalties could adversely affect our ability to operate our business and our
financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Product liability suits, whether or not
meritorious, could be brought against us due to an alleged defective product or for the misuse of the GBS System. These suits could
result in expensive and time-consuming litigation, payment of substantial damages, and an increase in our insurance rates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the GBS System are defectively
designed or manufactured, contain defective components or are misused, or if someone claims any of the foregoing, whether or not
meritorious, we may become subject to substantial and costly litigation. Misusing our device or failing to adhere to the operating
guidelines or the device producing inaccurate meter readings could cause significant harm to patients, including death. In addition,
if our operating guidelines are found to be inadequate, we may be subject to liability. Product liability claims could divert management&rsquo;s
attention from our core business, be expensive to defend and result in sizable damage awards against us. While we expect to maintain
product liability insurance, we may not have sufficient insurance coverage for all future claims. Any product liability claims
brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing
coverage, could harm our reputation in the industry and could reduce revenue. Product liability claims in excess of our insurance
coverage would be paid out of cash reserves harming our financial condition and adversely affecting our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are found to have violated laws
protecting the confidentiality of patient health information, we could be subject to civil or criminal penalties, which could increase
our liabilities and harm our reputation or our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Part of our business plan
includes the storage and potential monetization of data of users of the GBS System. There are a number of laws around the world
protecting the confidentiality of certain patient health information, including patient records, and restricting the use and disclosure
of that protected information. Privacy rules protect medical records and other personal health information by limiting their use
and disclosure, giving individuals the right to access, amend and seek accounting of their own health information and limiting
most use and disclosures of health information to the minimum amount reasonably necessary to accomplish the intended purpose. We
may face difficulties in holding such information in compliance with applicable law. If we are found to be in violation of the
privacy rules, we could be subject to civil or criminal penalties, which could increase our liabilities, harm our reputation and
have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We depend on intellectual property licensed
from our parent, Life Science Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;), and termination of this license could result
in the loss of significant rights, which would significantly harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are dependent on know-how
and proprietary technology, both our own and licensed from others, including, in particular, LSBD. Any termination or absence of
legal effect of a license could result in the loss of significant rights and could harm our ability to commercialize the GBS System.
Disputes may also arise between us and our licensors, including LSBD, regarding intellectual property subject to the License Agreement,
including those relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the scope of rights, if any, granted under the License Agreement and other interpretation-related issues;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the License Agreement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether our licensor or its licensor had the right to grant the License Agreement;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property without their authorization;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our right to sublicense intellectual property and other rights to third parties under collaborative development relationships;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether we are complying with our obligations with respect to the use of the licensed technology in relation to our development and commercialization of product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the amounts of royalties, milestones or other payments due under the License Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If disputes over intellectual
property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms,
or are insufficient to provide us the necessary rights to use the intellectual property, we may be unable to successfully develop
and commercialize the affected product candidates. If we or any such licensors fail to adequately protect this intellectual property,
our ability to commercialize our products could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will depend primarily on LSBD to file,
prosecute, maintain, defend and enforce intellectual property that we license from it and that is material to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The intellectual property
relating to the GBS System is controlled by LSBD and licensed to us. LSBD generally has the right to file, prosecute, maintain
and defend the intellectual property we have licensed from LSBD. If LSBD or any other licensees and in some cases, co-owners from
which we do not yet have licenses, having rights to file, prosecute, maintain, and defend our intellectual property rights fail
to conduct these activities for intellectual property protection covering any of our product candidates, our ability to develop
and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making,
using or selling competing products. We cannot be certain that such activities by LSBD and any other licensors have been or will
be conducted in compliance with applicable laws and regulations or will result in valid and enforceable intellectual property rights.
Pursuant to the terms of the License Agreement with LSBD, it may have the right to control enforcement of our licensed intellectual
property or defense of any claims asserting the invalidity of that intellectual property and, even if we are permitted to pursue
such enforcement or defense, we cannot ensure the cooperation of LSBD. We cannot be certain that LSBD will be able to and effectively
allocate sufficient resources or prioritize their or our enforcement of such intellectual property or defense of such claims to
protect our interests in the licensed intellectual property. Even if we are not a party to these legal actions, an adverse outcome
could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate
our business. In addition, even when we have the right to control prosecution of licensed intellectual property and related applications,
enforcement of licensed intellectual property, or defense of claims asserting the invalidity of that intellectual property, we
may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior
to or after our assuming control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The failure to obtain or maintain licensing
agreements and other intellectual property could materially impact our ability to compete effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In order for our business
to be viable and to compete effectively, we need to develop and maintain, and we will heavily rely on, our proprietary position
with respect to our technologies and intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are significant risks
associated with our actual or proposed intellectual property. The risks and uncertainties that we face with respect to our proprietary
rights principally include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 86%; text-align: justify"><FONT STYLE="font-size: 10pt">pending intellectual property applications, we have filed or will file may not result in acquired intellectual property or may take longer than we expect to result in acquired intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be subject to interference proceedings;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be subject to opposition proceedings in foreign countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any intellectual property that is acquired by us may not provide meaningful protection;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 86%; text-align: justify"><FONT STYLE="font-size: 10pt">we may not be able to develop additional proprietary technologies that is protectable;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other companies may challenge intellectual property licensed or acquired by us;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other companies may have independently developed and/or protected (or may in the future independently develop and protect) similar or alternative technologies, or duplicate our technologies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a freedom-to-operate analysis has not been done to determine the IP rights that third parties may have related to this technology;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other companies may design their technologies around technologies we have licensed or developed; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">enforcement of intellectual property is complex, uncertain and very expensive.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
intellectual property protection will be issued as a result of any of our pending or future applications, or that any of our intellectual
property, once issued, will provide us with adequate protection from competing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is also possible that
others may have or may obtain intellectual property protection that could prevent us from commercializing our products or require
us to obtain licenses requiring the payment of significant fees or royalties in order to enable us to conduct our business. As
to the intellectual property that we have licensed, our rights depend on maintaining our obligations to the licensor under the
applicable license agreement, and we may be unable to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Costly litigation may be necessary to
protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property rights
of others.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A freedom-to-operate analysis
will have to be done in China and other Licensed Territories to determine the rights that third parties may have related to this
technology in order to mitigate expensive litigation risks. We may face significant expense and liability as a result of litigation
or other proceedings relating to intellectual property rights of others. In the event that another party has intellectual property
protection relating to an invention or technology claimed by us or LSBD, we may be required to participate in an interference proceeding
declared by the regulatory authorities to determine priority of invention, which could result in substantial uncertainties and
costs for us, even if the eventual outcome was favorable to us. We, or our licensors, also could be required to participate in
interference proceedings involving intellectual property of another entity. An adverse outcome in an interference proceeding could
require us to cease using the technology, substantially modify it or to license rights from prevailing third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The cost to us of any intellectual
property litigation or other proceeding relating to our licensed intellectual property, even if resolved in our favor, could be
substantial, especially given our early stage of development. Our ability to enforce our intellectual property protection could
be limited by our financial resources, and may be subject to lengthy delays. A third party may claim that we are using inventions
claimed by their intellectual property and may go to court to stop us from engaging in our normal operations and activities, such
as research, development and the sale of any future products. Such lawsuits are expensive and would consume significant time and
other resources. There is a risk that a court will decide that we are infringing the third party&rsquo;s intellectual property
and will order us to stop the activities claimed by the intellectual property. In addition, there is a risk that a court will order
us to pay the other party damages for having infringed their intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, there is no guarantee
that any prevailing intellectual property owner would offer us a license so that we could continue to engage in activities claimed
by the intellectual property, or that such a license, if made available to us, could be acquired on commercially acceptable terms.
In addition, third parties may, in the future, assert other intellectual property infringement claims against us with respect to
our services, technologies or other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have limited foreign intellectual
property rights and may not be able to protect our intellectual property rights throughout the China Region.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.7pt; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.7pt; text-align: justify; text-indent: 0.45in">The only trademark
right identified in the Licensing Agreement is a common law trademark to &ldquo;Glucose Biosensor.&rdquo; Common law trademarks
are not recognized in China. Notwithstanding the terms of the Licensing Agreement, we may not be able to register the mark &ldquo;Glucose
Biosensor&rdquo; in China or other territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have limited intellectual
property rights, consisting primarily of intellectual property licensed from LSBD. Filing, prosecuting and defending intellectual
property on devices in all countries throughout the China Region would be prohibitively expensive, and our intellectual property
rights in some countries can be less extensive than those in the United States. In addition, the laws of some foreign countries
do not protect intellectual property to the same extent as laws in the United States. Consequently, we may not be able to prevent
third parties from practicing our inventions or from selling or importing products made using our inventions. Competitors may use
our technologies in jurisdictions where we have not obtained intellectual property rights to develop their own products and further,
may export otherwise infringing products to territories where we have intellectual property protection, but enforcement is not
as strong as that in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The legal systems of certain
countries, particularly China and certain other developing countries, do not favor the enforcement of trade secrets and other intellectual
property, particularly those relating to medical device products, which could make it difficult for us to stop the infringement
of our intellectual property or marketing of competing products in violation of our proprietary rights generally. Certain countries
in the China Region and developing countries, including China, have compulsory licensing laws under which an intellectual property
owner may be compelled to grant licenses to third parties. In those countries, we and LSBD may have limited remedies if our intellectual
property is infringed or if we or LSBD are compelled to grant a license to a third party, which could materially diminish the value
of that intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We and our principal licensor, LSBD,
rely on confidentiality agreements that could be breached and may be difficult to enforce, which could result in third parties
using our intellectual property to compete against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we believe that
we and our principal licensor, LSBD, take reasonable steps to protect our intellectual property, including the use of agreements
relating to the non-disclosure of confidential information to third parties, as well as agreements that purport to require the
disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants
while we employ them, the agreements can be difficult and costly to enforce. Although we and LSBD seek to enter into these types
of agreements with contractors, consultants, advisors and research collaborators, to the extent that employees and consultants
utilize or independently develop intellectual property in connection with any of our projects, disputes may arise as to the intellectual
property rights associated with our technology. If a dispute arises, a court may determine that the right belongs to a third party.
In addition, enforcement of our rights can be costly and unpredictable. We and LSBD also rely on trade secrets and proprietary
know-how that we and LSBD may seek to protect in part by confidentiality agreements with employees, contractors, consultants, advisors
or others. Despite the protective measures we employ, we and LSBD still face the risk that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">these agreements may be breached;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">these agreements may not provide adequate remedies for the applicable type of breach;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our proprietary know-how will otherwise become known; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our competitors will independently develop similar technology or proprietary information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to claims challenging
the invention of the intellectual property that we license from LSBD.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LSBD and we may be subject
to claims that former employees, collaborators or other third parties have an interest in intellectual property as an inventor
or co-inventor. For example, LSBD and we may have inventorship disputes arise from conflicting obligations of consultants or others
who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging
inventorship. If LSBD and we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a
material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management and other employees. As a result, it is unclear whether and, if so, to what
extent employees of LSBD or us may be able to claim compensation with respect to our future revenue. We may receive less revenue
from future products if any of employees of LSBD or us successfully claim compensation for their work in developing our intellectual
property, which in turn could impact our future profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have entered in to the
License Agreement with LSBD for intellectual property essential to us, the terms of which agreement present risks to us and our
business and prospects. In August 2017, the Company entered into the license relating to the saliva glucose biosensor system for
the China Region. The key highlights of the Licensing Agreement are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must
                                    obtain regulatory approval in the China Region</FONT> within 24 months after the engagement
                                    of trading of the Shares on Nasdaq <FONT STYLE="font-size: 10pt">and this approval will flow
                                    through to the platform owned by LSBD;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company has certain naming rights to the biosensor and the system;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company must execute a Quality of Life clinical study prior to regulatory approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">within 24 months following receipt of all required regulatory approvals in China initially, the Company must have placed orders with the Licensor (or Authorised Supplier) for a minimum of commercial units;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">after 24 months, the Company must have placed orders each year with the Licensor (or Authorized Supplier) for the greater of a minimum of commercial units or an amount that is equivalent to the average of all distributors of Licensed Products sales in the previous 12 months multiplied by the Expected Market Growth plus a fixed percentage;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company must engage in a marketing campaign and ensure &ldquo;Share of Voice&rdquo; in the Territory must be at a fixed percentage no later than 12 months following receipt of all required regulatory approvals in China. The Share of Voice will be determined by the Licensor acting reasonably and relying on a reputable third-party report as to the applicable Share of Voice; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company will have access to the data generated by glucose monitoring but the data will be owned by LSBD.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We face intense competition in the self-monitoring
of glucose market, particularly blood-based products, and as a result we may be unable to effectively compete in our industry.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With our first product,
the GBS System, we expect to compete directly and primarily with large medical device companies, as well as with second and third
tier companies having various levels of sophistication and resources. The large companies have most of the glucose monitoring business
and strong research and development capacity. Their dominant market position over the last few decades and significant control
over markets could significantly limit our ability to introduce the GBS System or effectively market and generate sales of the
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not yet entered
the commercial stage and most of our competitors have long histories and strong reputations within the industry. They have significantly
greater brand recognition, financial and human resources than we do. They also have more experience and capabilities in researching
and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing and marketing
those products than we do. There is a significant risk that we may be unable to overcome the advantages held by our competition,
and our inability to do so could lead to the failure of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Competition in the glucose
monitoring markets is intense, which can lead to, among other things, price reductions, longer selling cycles, lower product margins,
loss of market share and additional working capital requirements. To succeed, we must, among other critical matters, gain consumer
acceptance for the GBS System, technical solutions, prices and response time, or a combination of these factors, than those of
other competitors. If our competitors offer significant discounts on certain products, we may need to lower our prices or offer
other favorable terms in order to compete successfully. Moreover, any broad-based changes to our prices and pricing policies could
make it difficult to generate revenues or cause our revenues, if established, to decline. Moreover, if our competitors develop
and commercialize products that are more desirable than the GBS System or the other products that we may develop, we may not convince
customers to use our products. Any such changes would likely reduce our commercial opportunity and revenue potential and could
materially adversely impact our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we or LSBD fail to respond quickly
to technological developments our products may become uncompetitive and obsolete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The glucose monitoring
market may experience rapid technology developments, changes in industry standards, changes in customer requirements and frequent
new product introductions and improvements. If we or LSBD are unable to respond to these developments, we may lose competitive
position, and the GBS System or any other device or technology may become uncompetitive or obsolete, causing our business and prospects
to suffer. In order to compete, we and LSBD may have to develop, license or acquire new technology on a schedule that keeps pace
with technological developments and the requirements for products addressing a broad spectrum and designers and designer expertise
in our industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If third-party payors do not provide
coverage and reimbursement for the use of the GBS System, our business and prospects may be negatively impacted.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Third-party payors, whether
foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare
costs. In addition, in certain countries, no uniform policy of coverage and reimbursement for medical device products and services
exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services can differ significantly
from payor to payor. In addition, payors continually review new technologies for possible coverage and can, without notice, deny
coverage for these new products and procedures. As a result, the coverage determination process is often a time-consuming and costly
process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with
no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Reimbursement systems in
international markets vary significantly by country and by region within some countries, and reimbursement approvals must be obtained
on a country-by-country basis. In many international markets, a product must be approved for reimbursement before it can be approved
for sale in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, many international
markets have government-managed healthcare systems that control reimbursement for new devices and procedures. For example, no government
in the areas where we hold our license has approved reimbursement of the GBS System in particular. In most markets, there are private
insurance systems as well as government-managed systems. If sufficient coverage and reimbursement is not available for our current
or future products, in any country where our license operates, the demand for our products and our revenues will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Proposed Operations
in the China Region</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We intend to establish operations and
seek approval to commercialize the GBS System in the China Region, in particular in China, and a number of risks associated with
international operations could materially and adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to be subject
to a number of risks related with our international operations, many of which may be beyond our control. These risks include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">different regulatory requirements for medical product approvals in foreign countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">different standards of care in various countries that could complicate the evaluation of our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">different U.S. and foreign medical product import and export rules;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reduced protection for intellectual property rights in certain countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">different reimbursement systems and different competitive medical products indicated for glucose testing;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compliance with the Foreign Corrupt Practices Act (the &ldquo;FCPA&rdquo;), and other anti-corruption and anti-bribery laws;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">foreign taxes, including withholding of payroll taxes;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">potential liability resulting from development work conducted by third party foreign distributors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The medical device and other medical
product industries in China are highly regulated and such regulations are subject to change.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The medical devices and
other medical product industries in China are subject to comprehensive government regulation and supervision, encompassing the
approval, registration, manufacturing, packaging, licensing and marketing of new products. In recent years, the regulatory framework
in China regarding our industry has undergone significant changes, and we expect that it will continue to undergo significant changes.
Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful
development or commercialization of our product candidates in China. Chinese authorities have become increasingly vigilant in enforcing
laws in the medical devices and other medical product industries, in some cases launching industry-wide investigations, oftentimes
appearing to focus on foreign companies. The costs and time necessary to respond to an investigation can be material. Any failure
by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and
permits may result in the suspension or termination of our business activities in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Even if the GBS System is approved in
China, we may experience difficulties in successfully generating sales of the GBS System in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if the GBS System
is approved for sale in China, we may experience difficulties in our marketing, commercialization and sales efforts in China, and
our business and operations could be adversely affected. In particular, sales of the GBS System in China may be limited due to
the complex nature of the healthcare system, low average personal income, lack of patient cost reimbursement and pricing controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The retail prices of any product that
we develop may be subject to control, including periodic downward adjustment, by Chinese government authorities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The price for medical products
is highly regulated in China, both at the national and provincial level. Price controls may reduce prices to levels significantly
below those that would prevail in less regulated markets or limit the volume of products which may be sold, either of which may
have a material and adverse effect on potential revenues from sales of the GBS System in China. Moreover, the process and timing
for the implementation of price restrictions is unpredictable, which may cause potential revenues from the sales of the GBS System
to fluctuate from period to period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our operations in China would be subject
to restrictions on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A portion of our operations
may require a corporate presence, but not necessarily any manufacturing, marketing or distribution in China, through a subsidiary
to be located there. This presence is expected to be limited by our arrangements with independent distributors operating in China.
To the extent of any such corporate presence in China, we may rely on dividends and royalties paid by the subsidiary for a portion
of our cash needs, including the funds necessary to service any debt we may incur and to pay our operating expenses. The payment
of dividends by the subsidiary will be subject to limitations. Regulations in China currently permit payment of dividends only
out of accumulated profits as determined in accordance with accounting standards and regulations in China. Our subsidiary would
not be permitted to distribute any profits until losses from prior fiscal years have been recouped and in any event, must maintain
certain minimum capital requirements. Our subsidiary would also be required to set aside at least 10.0% of its after-tax profit
based on Chinese accounting standards each year to its statutory reserve fund until the cumulative amount of such reserves reaches
50.0% of its registered capital. Statutory reserves are not distributable as cash dividends. In addition, if our subsidiary incurs
debt on its own behalf in the future, the agreements governing such debt may restrict its ability to pay dividends or make other
distributions to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Any capital contributions from us to
our operating subsidiary in China must be approved by the Ministry of Commerce in China, and failure to obtain such approval may
materially and adversely affect the liquidity position of the subsidiary.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Ministry of Commerce
in China or its local counterpart must approve the amount and use of any capital contributions from us to any potential subsidiary
in China, and there can be no assurance that we will be able to complete the necessary government registrations and obtain the
necessary government approvals on a timely basis, or at all. If we fail to do so, we may not be able to contribute additional capital
to fund our Chinese operations, and the liquidity and financial position of the subsidiary may be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to currency exchange
rate fluctuations and currency exchange restrictions with respect to our operations in China, which could adversely affect our
financial performance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the GBS System is approved
for sale in China, a portion of our product sales may occur in local Renminbi (&ldquo;RMB&rdquo;) and our operating results may
be subject to volatility from currency exchange rate fluctuations. We have not hedged and do not expect to hedge against the risks
associated with fluctuations in exchange rates and, therefore, exchange rate fluctuations could have an adverse impact on our future
operating results. Currently, the Renminbi is permitted to fluctuate within a narrow and managed band against a basket of certain
foreign currencies. Any significant currency exchange rate fluctuations may have a material adverse effect on our business and
financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the Chinese
government imposes controls on the convertibility of the Renminbi into foreign currencies and the remittance of foreign currency
out of China for certain transactions. Shortages in the availability of foreign currency may restrict the ability of our operating
subsidiary in China to remit sufficient foreign currency to pay dividends or other payments to us, or otherwise satisfy their foreign
currency-denominated obligations. Under existing Chinese foreign exchange regulations, payments of current account items, including
profit distributions, interest payments and balance of trade, can be made in foreign currencies without prior approval from the
State Administration of Foreign Exchange (&ldquo;SAFE&rdquo;) by complying with certain procedural requirements. However, approval
from SAFE or its local branch is required where Renminbi is to be converted into foreign currency and remitted out of China to
pay capital expenses such as the repayment of loans denominated in foreign currencies. The Chinese government may also at its discretion
restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents
us from obtaining sufficient foreign currency to satisfy our operational requirements, our liquidity and financial position may
be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Because our China subsidiary&rsquo;s
funds will be held in banks that do not provide insurance, the failure of any bank in which it deposits its funds could adversely
affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Banks and other financial
institutions in China do not provide insurance for funds held on deposit. As a result, in the event of a bank failure, our China
subsidiary may not have access to funds on deposit. Depending upon the amount of money the subsidiary maintains in a bank that
fails, its inability to have access to cash could materially impair its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to tax inefficiencies
and have not ascertained the impact of the new U.S. tax laws on the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The tax regulations of
the U.S. and other jurisdictions in which we operate are extremely complex and subject to change. New laws, new interpretations
of existing laws, such as the Base Erosion Profit Shifting project initiated by the Organization for Economic Co-operation and
Development and any legislation proposed by the relevant taxing authorities, or limitations on our ability to structure our operations
and intercompany transactions may lead to inefficient tax treatment of our revenue, profits, royalties and distributions, if any
are achieved.&nbsp;&nbsp;In the U.S., in December 2017, comprehensive tax reform was enacted. We have not yet ascertained what
impact the new law will have on our future effective tax rate, corporate structure and the Company in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we and our
foreign subsidiaries, none of which has been formed (other than Glucose Biosensor Systems (Greater China) Pty Ltd), will have various
intercompany transactions. We may not be able to obtain certain benefits under relevant tax treaties to avoid double taxation on
certain transactions among our subsidiaries. If we are not able to avail ourselves of the tax treaties, we could be subject to
additional taxes, which could adversely affect our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our foreign operations, particularly
those in China, are subject to significant risks involving the protection of intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We and LSBD may be required
to seek to protect the products and technology that we consider important to our business by pursuing intellectual property protections
in China and other countries, relying on intellectual property, trade secrets or medical product regulatory protection or employing
a combination of these methods. We note that the application for intellectual property protection does not mean that protection
will be granted, or that any protection eventually granted will be as broad as requested or will be sufficient to protect our technology.
There are a number of factors that could cause our intellectual property, if acquired, to become invalid or unenforceable or that
could cause our intellectual property protections not to be granted. Furthermore, the terms of the intellectual property owned
by LSBD and licensed by us are limited by what has been and/or may be granted under law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Intellectual property rights
and confidentiality protections in China may not be as effective as those in the U.S. or other countries for many reasons, including
lack of procedural rules for discovery and evidence, low damage awards, and lack of judicial independence. Implementation and enforcement
of China intellectual property laws have historically been deficient and ineffective and may be hampered by corruption and local
protectionism. Policing unauthorized use of proprietary technology is difficult and expensive, and we may need to resort to litigation
to enforce or defend our intellectual property or to determine the enforceability and validity of our proprietary rights or those
of others. The experience and capabilities of China courts in handling intellectual property litigation varies and outcomes are
unpredictable. An adverse determination in any such litigation could materially impair our intellectual property rights and may
harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to laws and regulations
governing business conduct, which will require us to develop and implement costly compliance programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We must comply with a wide
range of laws and regulations to prevent corruption, bribery, and other unethical business practices, including the FCPA, anti-bribery
and anti-corruption laws in other countries, particularly China. The creation and implementation of international business practices
compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Anti-bribery laws prohibit
us, our employees, and some of our agents or representatives from offering or providing any personal benefit to covered government
officials to influence their performance of their duties or induce them to serve interests other than the missions of the public
organizations in which they serve. Certain commercial bribery rules also prohibit offering or providing any personal benefit to
employees and representatives of commercial companies to influence their performance of their duties or induce them to serve interests
other than their employers. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting
provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including
international subsidiaries, and devise and maintain an adequate system of internal accounting controls for international operations.
The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement
of the books and records provisions of the FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Compliance with these anti-bribery
laws is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the anti-bribery
laws present particular challenges in the medical products industries because in many countries including China, hospitals are
state-owned or operated by the government, and doctors and other hospital employees are considered foreign government officials.
Furthermore, in certain countries (China in particular), hospitals and clinics are permitted to sell medical devices to their patients
and are primary or significant distributors of medical devices. Certain payments to hospitals in connection with clinical studies,
procurement of medical devices and other work have been deemed to be improper payments to government officials that have led to
vigorous anti-bribery law enforcement actions and heavy fines in multiple jurisdictions, particularly in the U.S. and China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is not always possible
to identify and deter violations, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming
from a failure to be in compliance with such laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the medical products
industries, corrupt practices include, among others, acceptance of kickbacks, bribes or other illegal gains or benefits by the
hospitals and medical practitioners from medical device manufacturers, distributors or their third-party agents in connection with
the prescription of certain medical devices or disposables. If our employees, affiliates, distributors or third-party marketing
firms violate these laws or otherwise engage in illegal practices with respect to their sales or marketing of our products or other
activities involving our products, we could be required to pay damages or heavy fines by multiple jurisdictions where we operate,
which could materially and adversely affect our financial condition and results of operations. The Chinese government has also
sponsored anti-corruption campaigns from time to time, which could have a negative effect on any future marketing efforts by us
to new hospital customers or intermediaries. There have been recent occurrences in which certain hospitals have denied access to
sales representatives from medical device companies because the hospitals wanted to avoid the perception of corruption. If this
attitude becomes widespread among our potential customers, our ability to promote our products to hospitals may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As we expand our operations
in the China Region, we will need to increase the scope of our compliance programs to address the risks relating to the potential
for violations of the FCPA and other anti-bribery and anti-corruption laws. Our compliance programs will need to include policies
addressing not only the FCPA, but also the provisions of a variety of anti-bribery and anti-corruption laws in multiple jurisdictions,
including China, provisions relating to books and records that apply to us as a public company, and include effective training
for our personnel throughout our organization. The creation and implementation of anti-corruption compliance programs is costly
and such programs are difficult to enforce, particularly where reliance on third parties is required. Violation of the FCPA and
other anti-corruption laws can result in significant administrative and criminal penalties for us and our employees, including
substantial fines, suspension or debarment from government contracting, prison sentences, or even the death penalty in extremely
serious cases in certain countries. The SEC also may suspend or bar us from trading securities on U.S. exchanges for violation
of the FCPA&rsquo;s accounting provisions. Even if we are not ultimately punished by government authorities, the costs of investigation
and review, distraction of company personnel, legal defense costs, and harm to our reputation could be substantial and could limit
our profitability or our ability to develop or commercialize our product candidates. In addition, if any of our competitors are
not subject to the FCPA, they may engage in practices that will lead to their receipt of preferential treatment from foreign hospitals
and enable them to secure business from foreign hospitals in ways that are unavailable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Uncertainties with respect to the China
legal system could have a material adverse effect on us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The legal system of China
is a civil law system primarily based on written statutes. Unlike in a common law system, prior court decisions may be cited for
reference but are not binding. Because the China legal system continues to rapidly evolve, the interpretations of many laws, regulations
and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties, which may limit legal
protections available to us. Moreover, decision makers in the China judicial system have significant discretion in interpreting
and implementing statutory and contractual terms, which may render it difficult for our China subsidiary to enforce the contracts
it has entered into with our business partners, customers and suppliers. Different government departments may have different interpretations
of certain laws and regulations, and licenses and permits issued or granted by one government authority may be revoked by a higher
government authority at a later time. Navigating the uncertainty and change in the China legal system will require the devotion
of significant resources and time, and there can be no assurance that our contractual and other rights will ultimately be enforced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Changes in China&rsquo;s economic, political
or social conditions or government policies could have a material adverse effect on our business and operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Chinese economy and
Chinese society continue to undergo significant change. Adverse changes in the political and economic policies of the Chinese government
could have a material adverse effect on the overall economic growth of China, which could adversely affect our ability to conduct
business in China. The Chinese government continues to adjust economic policies to promote economic growth. Some of these measures
benefit the overall Chinese economy, but may also have a negative effect on us. For example, our financial condition and results
of operations in China may be adversely affected by government control over capital investments or changes in tax regulations.
As the Chinese medical products industries grow and evolve, the Chinese government may also implement measures to change the structure
of foreign investment in this industry. We are unable to predict any such policy changes, any of which could materially and adversely
affect our Chinese subsidiary&rsquo;s liquidity, access to capital and its ability to conduct business in China. Any failure on
our part to comply with changing government regulations and policies could result in the loss of our ability to develop and commercialize
our product candidates in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our operations in China subject us to
various Chinese labor and social insurance laws, and our failure to comply with such laws may materially and adversely affect our
business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to China
Labor Contract Law. The Labor Contract Law places certain restrictions on the circumstances under which employers may terminate
labor contracts and require economic compensation to employees upon termination of employment, among other things. In addition,
companies operating in China are generally required to contribute to labor union funds and the mandatory social insurance and housing
funds. Any failure by us to comply with Chinese labor and social insurance laws may subject us to late fees, fines and penalties,
or cause the suspension or termination of our ability to conduct business in China, any of which could have a material and adverse
effect on business, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fluctuation in the value of the RMB may
have a material adverse effect on your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The conversion of RMB into
foreign currencies, including U.S. dollars, is based on rates set by the People&rsquo;s Bank of China (&ldquo;PBOC&rdquo;). It
is difficult to predict how market forces or Chinese or U.S. government policy may impact the exchange rate between the RMB and
the U.S. dollar in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A substantial portion of
our revenues and costs may be denominated in RMB. Any significant revaluation of the RMB may materially affect our cash flows,
net revenues, earnings and financial position, and the value of, and any dividends payable on, our Common Stock in U.S. dollars.
For example, an appreciation of the RMB against the U.S. dollar would make any new RMB-denominated investments or expenditures
costlier to us, to the extent that we need to convert U.S. dollars into RMB for such purposes. Conversely, a significant depreciation
of the RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent of our earnings, which in turn could adversely
affect the price of our Common Stock. If we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends
on our Common Stock, strategic acquisitions or investments or other business purposes, appreciation of the U.S. dollar against
the RMB would have a negative effect on the U.S. dollar amount available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Very few hedging options
are available in China to reduce our exposure to exchange rate fluctuations. In addition, our currency exchange loss may be magnified
by Chinese exchange control regulations that restrict our ability to convert RMB into foreign currency. As a result, fluctuations
in exchange rates and restrictions on exchange may have a material adverse effect on your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to this Offering and the Ownership
of Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our parent company may exert significant
influence over our affairs, including the outcome of matters requiring stockholder approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this
Offering Circular, without giving effect to the recent private placement, our parent company, LSBD, has 100% beneficial ownership
of the Company. Even after the expected dilution on completion of this Offering, such parent will have the ability to control the
election of our directors and the outcome of corporate actions requiring stockholder approval, such as: (i) a merger or a sale
of our company, (ii) a sale of all or substantially all of our assets, and (iii) amendments to our certificate of incorporation
and by-laws. This concentration of voting power and control could have a significant effect in delaying, deferring or preventing
an action that might otherwise be beneficial to our other stockholders and be disadvantageous to our stockholders with interests
different from those individuals. Therefore, you should not invest in reliance on your ability to have any control over our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have broad discretion in the use of
the net proceeds from this offering and may use the net proceeds in ways with which you may not agree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;Our management will
have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not
advance our business plan, achieve proposed objectives, improve our financial condition, generate revenue or enhance the value
of our securities. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you
will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately.
The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse
effect on our business, cause the price of our securities to decline and delay the development of our product candidates. Pending
the application of these funds, we may invest the net proceeds from this offering in a manner that does not produce income or that
loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Certain important information may not
be known and events may not have occurred at the time that an investor&rsquo;s investment decision to invest in the Shares becomes
irrevocable, thus creating doubt and related risk as to whether that information will be known and those events will occur as anticipated
if at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain important information
may not be known and events may not have occurred at the time that an investor&rsquo;s investment decision to invest in the Shares
becomes irrevocable. As noted elsewhere herein, including &ldquo;Risk Factors &ndash; Our shares of Common Stock are not and may
not be listed for trading on a national securities exchange&rdquo; below, an investor may not know whether our Common Stock will
be listed for trading on Nasdaq until after the investor&rsquo;s investment decision has become irrevocable. We will also be, if
we achieve Nasdaq listing for our Common Stock, a &ldquo;controlled company&rdquo; under the corporate governance standards for
Nasdaq listed companies and will be exempt from certain corporate governance requirements of the rules. In the event of such achievement,
we intend to utilize those exemptions. Accordingly, stockholders would not have the same protections afforded to stockholders of
companies that are subject to all of the Nasdaq corporate governance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We qualify as a &ldquo;controlled
company&rdquo; within the meaning of the Nasdaq rules. As a result, we qualify for, and if Nasdaq listing is achieved intend to
rely on, exemptions from corporate governance requirements that provide protection to stockholders of other companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Immediately following completion
of this offering, LSBD will control more than a majority of the total voting power of our outstanding Common Stock. As a result,
LSBD will be able to control the outcome of all matters submitted to a vote of our stockholders, including, for example, the election
of directors, amendments to our certificate of incorporation and mergers or other business combinations. See &ldquo;Description
of Capital Stock&rdquo;. In addition, we currently intend to utilize the controlled company exemption under the Nasdaq corporate
governance rules, and so you will not have the same protections afforded to stockholders of companies that are subject to such
requirements, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the requirement that a majority of our Board of Directors consist of &ldquo;independent directors&rdquo;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the requirement that we have a compensation committee that is composed entirely of independent
directors with a written charter addressing the committee&rsquo;s purpose and responsibilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the requirement that we have a nominating and corporate governance committee that is composed entirely
of independent directors with a written charter addressing the committee&rsquo;s purpose and responsibilities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the requirement for an annual performance evaluation of the compensation and nominating and corporate
governance committees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, we will not
have a nominating and corporate governance committee and our compensation committee may not consist entirely of independent directors.
Accordingly, you will not have the same protections afforded to stockholders of companies that are subject to all of the corporate
governance requirements of the Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, Nasdaq has
developed listing standards regarding compensation committee independence requirements and the role and disclosure of compensation
consultants and other advisers to the compensation committee that, among other things, requires:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">compensation committees be composed of independent directors, as determined pursuant to new independence
requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">compensation committees be explicitly charged with hiring and overseeing compensation consultants,
legal counsel and other committee advisors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">compensation committees be required to consider, when engaging compensation consultants, legal
counsel or other advisors, independence factors, including factors that examine the relationship between the consultant or advisor&rsquo;s
employer and us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a controlled company, we will not be subject
to these compensation committee independence requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Investors in this offering will experience
immediate and substantial dilution in net tangible book value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You will incur immediate
and substantial dilution as a result of this offering. After giving effect to the sale by us of up to 2,083,334 shares of Common
Stock at an assumed public offering price of $12.00 per share, and before
deducting the commissions and estimated offering expenses, investors in this offering
can expect an immediate dilution to net tangible assets (which excludes a value for the License Agreement) of a decrease of $10.30
per share down from $12.00 to $1.70 immediately after the offering. See &ldquo;Dilution&rdquo; for a more complete description
of how the value of your investment in our Common Stock will be diluted upon the completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our shares of Common Stock are not and may not be listed for
trading on a national securities exchange.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have submitted an application
to list our Common Stock on The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;GBSG&rdquo;. There is no assurance
that this application will be approved and investors may not know at the time that their investment becomes irrevocable whether
this application will be approved or whether the Shares will ever be listed. Nonetheless, our Common Stock will not commence trading
on Nasdaq unless and until (i) the minimum amount of this Offering is closed; (ii) this Offering is terminated and (iii) we have
filed a post-qualification amendment to the Offering Statement, and a registration statement on Form 8-A (&ldquo;Form 8-A&rdquo;)
under the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and such post-qualification amendment is qualified
by the SEC and the Form 8-A has become effective. Pursuant to applicable rules under Regulation A, the Form 8-A will not become
effective until the SEC qualifies the post-qualification amendment. We intend to file the post-qualification amendment and request
its qualification immediately prior to the termination of the Offering in order that the Form 8-A may become effective as soon
as practicable. Even if we meet the minimum requirements for listing on Nasdaq, we may wait before terminating the Offering and
commencing the trading of our Common Stock on Nasdaq in order to raise additional proceeds. As a result, you may experience a delay
between the closing of your purchase of shares of our Common Stock and the commencement of exchange trading of our Common Stock
on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Whether we meet Nasdaq&rsquo;s
minimum listing criteria will be determined by Nasdaq in its discretion. If we do not meet the criteria, or Nasdaq does not make
necessary discretionary exceptions, as to which there can be no assurance, then we will not be able to list our Common Stock on
Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no assurance that
such listing will ever be obtained. You may not be able to sell your securities at the time desired or at the price desired. The
failure of our securities to be approved for trading on Nasdaq may have the effect of limiting the trading activity of our securities
and reducing the liquidity of an investment in our Common Stock. The effects of not being able to list our securities on a national
exchange include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited dissemination of the market price of our securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited news coverage;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited interest by investors in our securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">volatility of the prices of our stock and any warrants we may issue, due to low trading volume;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increased difficulty in selling our securities in certain states due to &ldquo;blue sky&rdquo; restrictions; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited ability to issue additional securities or to secure additional financing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we fail to meet the
minimum requirements for listing on Nasdaq, we may seek to have our Common Stock quoted over-the-counter, such as on the OTCQX.
The OTCQX is not a stock exchange, and if our Common Stock trades on the OTCQX rather than Nasdaq, there may be significantly less
trading volume and analyst coverage of, and significantly less investor interest in, our Common Stock, which may lead to lower
trading prices for our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If initially listed, we may not be able
to satisfy listing requirements of The Nasdaq Stock Market to maintain a listing of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our Common Stock is
listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate the Nasdaq listing
requirements, our Common Stock may be delisted. If we fail to meet any of the Nasdaq&rsquo;s listing standards, our Common Stock
may be delisted. In addition, our board may determine that the cost of maintaining our listing on a national securities exchange
outweighs the benefits of such listing. A delisting of our Common Stock from Nasdaq may materially impair our stockholders&rsquo;
ability to buy and sell our Common Stock and could have an adverse effect on the market price of, and the efficiency of the trading
market for, our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The market price of our Common Stock
may be significantly volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market price for our
Common Stock may be significantly volatile and subject to wide fluctuations in response to factors including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">actual or anticipated fluctuations in our quarterly or annual operating results;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in financial or operational estimates or projections;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">conditions in markets generally;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in the economic performance or market valuations of companies similar to ours; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">general economic or political conditions in the United States or elsewhere.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In particular, the market
prices for securities of medical device companies have historically been particularly volatile. Some of the factors that may cause
the market price of our Common Stock to fluctuate include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay in or the results of our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay in manufacturing of our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay with the approval for reimbursement for the patients from their insurance companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our failure to comply with regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the announcements of clinical trial data, and the investment community&rsquo;s perception of and reaction to those data;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results of clinical trials conducted by others on products that would compete with ours;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay or failure to receive clearance or approval from regulatory agencies or bodies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our inability to commercially launch products or market and generate sales of our products, including the GBS System;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failure of the GBS System or any other products, even if approved for marketing, to achieve any level of commercial success;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our failure to obtain intellectual property protection for any of our technologies and products (including those related to the GBS System) or the issuance of third party intellectual property that cover our proposed technologies or products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">developments or disputes concerning our product&rsquo;s intellectual property rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our or our competitors&rsquo; technological innovations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">general and industry-specific economic conditions that may affect our expenditures;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in market valuations of similar companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments, new technologies, or intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failure to adequately manufacture the GBS System or any other products through third parties;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">future sales of our Common Stock or other securities, including shares issuable upon the exercise of outstanding warrants or otherwise issued pursuant to certain contractual rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">period-to-period fluctuations in our financial results; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">low or high trading volume of our Common Stock due to many factors, including the terms of our financing arrangements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, if we fail
to reach an important research, development or commercialization milestone or result by a publicly expected deadline, even if by
only a small margin, there could be significant impact on the market price of our Common Stock. Additionally, as we approach the
announcement of anticipated significant information and as we announce such information, we expect the price of our Common Stock
to be volatile and negative results would have a substantial negative impact on the price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some cases, following
periods of volatility in the market price of a company&rsquo;s securities, stockholders have often instituted class action securities
litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management
attention and resources, which could significantly harm our business operations and reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Shares eligible for future sale may adversely
affect the market for our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We have a significant
number of shares of Common Stock underlying outstanding preferred stock and the convertible notes of our subsidiary GBS Ltd.,
the future sale of which shares could depress the price of our publicly-traded stock. As of the date of this Offering Circular:
(i) 1,222,506 shares of Common Stock are issuable upon the completion of this Offering by mandatory conversion of such outstanding
preferred stock convertible at a one-to-one ratio; (ii) 517,358 shares of Common Stock are issuable upon the completion of this
Offering by mandatory conversion of $5,277,056 of such debt at an effective exercise price at a 15% discount to the price per
Share in this Offering; and (iii) and 1,222,506 shares of Common Stock are issuable during the one year period commencing on the
second anniversary of the completion of this Offering by exercise of outstanding warrants that were issued in connection with
the issuance of the preferred stock. In addition, from time to time, certain of our stockholders may be eligible to sell all or
some of their shares of Common Stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144, promulgated
under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, after satisfying a six month holding
period: (i) affiliated stockholder (or stockholders whose shares are aggregated) may, under certain circumstances, sell within
any three month period a number of securities which does not exceed the greater of 1% of the then outstanding shares of Common
Stock or the average weekly trading volume of the class during the four calendar weeks prior to such sale and (ii) non-affiliated
stockholders may sell without such limitations, provided we are current in our public reporting obligations. Rule 144 also permits
the sale of securities by non-affiliates that have satisfied a one year holding period without any limitation or restriction.
Any substantial sale of our Common Stock pursuant to Rule 144 or pursuant to any resale report may have a material adverse effect
on the market price of our securities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>As an &ldquo;emerging growth company&rdquo;
under applicable law, we will be subject to lessened disclosure requirements, which could leave our stockholders without information
or rights available to stockholders of more mature companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For as long as we remain
an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act, we have elected to take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo;
including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">taking advantage of an extension of time to comply with new or revised financial accounting standards;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to take advantage
of these reporting exemptions until we are no longer an &ldquo;emerging growth company&rdquo;. Because of these lessened regulatory
requirements, our stockholders would be left without information or rights available to stockholders of more mature companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Because we have elected to use the extended
transition period for complying with new or revised accounting standards for an &ldquo;emerging growth company&rdquo; our financial
statements may not be comparable to companies that comply with public company effective dates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have elected to use
the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public
and private companies until those standards apply to private companies. While we are not currently delaying the implementation
of any relevant accounting standards, in the future we may avail ourselves of these rights, and as a result of this election, our
financial statements may not be comparable to companies that comply with public company effective dates. Because our financial
statements may not be comparable to companies that comply with public company effective dates, investors may have difficulty evaluating
or comparing our business, performance or prospects in comparison to other public companies, which may have a negative impact on
the value and liquidity of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Common Stock may be considered a
 &ldquo;penny stock&rdquo;, and thereby be subject to additional sale and trading regulations that may make it more difficult to
sell.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Stock may be
considered to be a &ldquo;penny stock&rdquo; if it does not qualify for one of the exemptions from the definition of &ldquo;penny
stock&rdquo; under Section 3a51-1 of the Exchange Act. Our Common Stock may be a &ldquo;penny stock&rdquo; if it meets one or more
of the following conditions: (i) the stock trades at a price less than $5 per share; (ii) it is not traded on a &ldquo;recognized&rdquo;
national exchange; or (iii) is issued by a company that has been in business less than three years with net tangible assets less
than $5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The principal result or
effect of being designated a &ldquo;penny stock&rdquo; is that securities broker-dealers participating in sales of our Common Stock
will be subject to the &ldquo;penny stock&rdquo; regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange
Act. Moreover, Rule 15g-9 requires broker-dealers in penny stocks to approve the account of any investor for transactions in such
stocks before selling any penny stock to that investor. This procedure requires the broker-dealer to: (i) obtain from the investor
information concerning his or her financial situation, investment experience and investment objectives; (ii) reasonably determine,
based on that information, that transactions in penny stocks are suitable for the investor and that the investor has sufficient
knowledge and experience as to be reasonably capable of evaluating the risks of penny stock transactions; (iii) provide the investor
with a written statement setting forth the basis on which the broker-dealer made the determination in (ii) above; and (iv) receive
a signed and dated copy of such statement from the investor, confirming that it accurately reflects the investor&rsquo;s financial
situation, investment experience and investment objectives. Compliance with these requirements may make it more difficult and time
consuming for holders of our Common Stock to resell their shares to third parties or to otherwise dispose of them in the market
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our compliance with complicated U.S.
regulations concerning corporate governance and public disclosure is expensive. Moreover, our ability to comply with all applicable
laws, rules and regulations is uncertain given our management&rsquo;s relative inexperience with operating U.S. public companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a publicly reporting
company, we are faced with expensive and complicated and evolving disclosure, governance and compliance laws, regulations and standards
relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and the Dodd-Frank Act. New or changing
laws, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and, as
a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which
could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure
and governance practices. As a result, our efforts to comply with evolving laws, regulations and standards of a U.S. public company
are likely to continue to result in increased general and administrative expenses and a diversion of management time and attention
from revenue-generating activities to compliance activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, our executive
officers have little experience in operating a U.S. public company, which makes our ability to comply with applicable laws, rules
and regulations uncertain. Our failure to company with all laws, rules and regulations applicable to U.S. public companies could
subject us or our management to regulatory scrutiny or sanction, which could harm our reputation and stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Anti-takeover provisions in our charter
documents and Delaware law could discourage, delay or prevent a change in control of our company and may affect the trading price
of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We are a Delaware corporation
and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control
by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the
person becomes an interested stockholder, even if a change in control would be beneficial to our existing stockholders. In addition,
our certificate of incorporation and by-laws may discourage, delay or prevent a change in our management or control over us that
stockholders may consider favorable. Our certificate of incorporation and by-laws currently provide for: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">the issuance of &ldquo;blank check&rdquo; preferred stock
    that could be issued by our Board of Directors to thwart a takeover attempt;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"> that vacancies on our Board of Directors, including newly created directorships, may be
    filled only by a majority vote of directors then in office; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">that special meetings of stockholders may only be called
    by our Chief Executive Officer, our Board of Directors or a majority of our stockholders;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not provide stockholders with the ability to cumulate their votes; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">provide that our Board of Directors or our stockholders may
    amend our by-laws.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not currently intend to pay dividends
on our Common Stock in the foreseeable future, and consequently, your ability to achieve a return on your investment will depend
on appreciation in the price of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not anticipate paying
any cash dividends to holders of our Common Stock in the foreseeable future. Consequently, investors must rely on sales of their
Common Stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.
There is no guarantee that shares of our Common Stock will appreciate in value or even maintain the price at which our stockholders
have purchased their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>As a result of becoming a public company,
we will be obligated to develop and maintain a system of effective internal control over financial reporting. We may not complete
our analysis of our internal control over financial reporting in a timely manner, or these internal controls may not be determined
to be effective, which may harm investor confidence in our company and, as a result, the value of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will be required, pursuant
to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal
control over financial reporting in the second annual report we file with the SEC. This assessment will need to include disclosure
of any material weaknesses identified by our management in our internal control over financial reporting. However, our auditors
will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section
404 until we are no longer an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act if we take advantage of the exemptions
available to us through the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are in the very early
stages of the costly and challenging process of compiling the system and process documentation necessary to perform the evaluation
needed to comply with Section 404. In this regard, we will need to continue to dedicate internal resources, engage outside consultants
and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps
to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement
a continuous reporting and improvement process for internal control over financial reporting. As we transition to the requirements
of reporting as a public company, we may need to add additional finance staff. We may not be able to remediate any future material
weaknesses, or to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and
testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable
to assert that our internal controls are effective. If we are unable to assert that our internal control over financial reporting
is effective, or if our auditors are unable to express an opinion on the effectiveness of our internal controls when they are required
to issue such opinion, investors could lose confidence in the accuracy and completeness of our financial reports, which could harm
our stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company has engaged in certain transactions
with related persons.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please see the section
of this Offering Circular entitled &ldquo;Interest of Management and Others in Certain Transactions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company may undertake additional
equity or debt financing that may dilute the shares in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company may undertake
further equity or debt financing which may be dilutive to existing shareholders, including you, or result in an issuance of securities
whose rights, preferences and privileges are senior to those of existing shareholders, including you, and also reducing the value
of shares subscribed for under this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If the maximum offering is not raised,
it may increase the amount of long-term debt or the amount of additional equity we need to raise.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no assurance that
the maximum number of Shares in this offering will be sold. If the maximum Offering amount is not sold, we may need to incur indebtedness
or raise additional equity in order to finance our operations. Incurring debt will create debt service obligations and make less
cash available for operations. Increasing the amount of additional equity that we will have to seek in the future will further
dilute those investors participating in this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Investor funds will not accrue interest
while in escrow prior to closing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until we achieve the minimum
offering amount, the proceeds for the Offering will be kept in an escrow account. Upon achievement of the minimum offering amount
and the closing on such amount, the proceeds from the minimum offering amount will be distributed to the Company and the associated
Shares will be issued to the investors in the Initial Closing. If the Offering does not close for any reason, the proceeds for
the Offering will be promptly returned to investors, without deduction and generally without interest. Prime Trust, LLC will serve
as the escrow agent. Proceeds from investors after the Initial Closing also will be kept in escrow subject to an Additional Closing,
each of which the Company may undertake from time to time on a rolling basis without any minimum amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company has made assumptions in its
projections and in forward-looking statements that may not be accurate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The discussions and information
in this Offering Circular may contain both historical and &ldquo;forward-looking statements&rdquo; which can be identified by the
use of forward-looking terminology including the terms &ldquo;believes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;continues,&rdquo;
 &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
or, in each case, their negative or other variations or comparable terminology. You should not place undue reliance on forward-looking
statements. These forward-looking statements include matters that are not historical facts. Forward-looking statements involve
risk and uncertainty because they relate to future events and circumstances. Forward-looking statements contained in this Offering
Circular, based on past trends or activities, should not be taken as a representation that such trends or activities will continue
in the future. To the extent that the Offering Circular contains forward-looking statements regarding the financial condition,
operating results, business prospects, or any other aspect of the Company&rsquo;s business, please be advised that the Company&rsquo;s
actual financial condition, operating results, and business performance may differ materially from that projected or estimated
by the Company. The Company has attempted to identify, in context, certain of the factors it currently believes may cause actual
future experience and results to differ from its current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company has significant discretion
over the net proceeds of this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has significant
discretion over the net proceeds of this Offering. As is the case with any business, particularly one without a proven business
model, it should be expected that certain expenses unforeseeable to management at this juncture will arise in the future. There
can be no assurance that management&rsquo;s use of proceeds generated through this offering will prove optimal or translate into
revenue or profitability for the Company. Investors are urged to consult with their attorneys, accountants and personal investment
advisors prior to making any decision to invest in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The offering price for the shares offered
has been determined by the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The price at which the
Shares are being offered has been arbitrarily determined by the Company. There is no relationship between the offering price and
our assets, book value, net worth, or any other economic or recognized criteria of value. Rather, the price of the Shares was derived
as a result of internal decisions based upon various factors including prevailing market conditions, our future prospects and our
capital structure. These prices do not necessarily accurately reflect the actual value of the Shares or the price that may be realized
upon disposition of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The preparation of our financial statements
involves the use of estimates, judgments and assumptions, and our financial statements may be materially affected if such estimates,
judgments or assumptions prove to be inaccurate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financial statements prepared
in accordance with accounting principles generally accepted in the United States of America typically require the use of estimates,
judgments and assumptions that affect the reported amounts. Often, different estimates, judgments and assumptions could reasonably
be used that would have a material effect on such financial statements, and changes in these estimates, judgments and assumptions
may occur from period to period over time. Significant areas of accounting requiring the application of management&rsquo;s judgment
include, but are not limited to, determining the fair value of assets and the timing and amount of cash flows from assets. These
estimates, judgments and assumptions are inherently uncertain and, if our estimates were to prove to be wrong, we would face the
risk that charges to income or other financial statement changes or adjustments would be required. Any such charges or changes
could harm our business, including our financial condition and results of operations and the price of our securities. See &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; for a discussion of the accounting estimates, judgments
and assumptions that we believe are the most critical to an understanding of our financial statements and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If securities industry analysts do not
publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our Common
Stock could be negatively affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any trading market for
our Common Stock will be influenced in part by any research reports that securities industry analysts publish about us. We do not
currently have and may never obtain research coverage by securities industry analysts. If no securities industry analysts commence
coverage of us, the market price and market trading volume of our Common Stock could be negatively affected. In the event we are
covered by analysts, and one or more of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues
coverage or us, the market price and market trading volume of our Common Stock could be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will incur increased costs as a result
of operating as a public company and our management will be required to devote substantial time to new compliance initiatives and
corporate governance practices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a public company, and
particularly after we are no longer an &ldquo;emerging growth company,&rdquo; we will incur significant legal, accounting and other
expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public
companies. Our management and other personnel will need to devote a substantial amount of time to compliance with these requirements.
Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more
time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive
for us to obtain directors&rsquo; and officers&rsquo; liability insurance, which could make it more difficult for us to attract
and retain qualified members of our board of directors. We cannot predict or estimate the amount of additional costs we will incur
as a public company or the timing of such costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Future issuances of our Common Stock
or securities convertible into our Common Stock, or the expiration of lock-up agreements that restrict the issuance of new Common
Stock or the trading of outstanding Common Stock, could cause the market price of our Common Stock to decline and would result
in the dilution of your holdings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Future issuances
of our Common Stock or securities convertible into our Common Stock, or the expiration of lock-up agreements that restrict
the issuance of new Common Stock or the trading of outstanding Common Stock, could cause the market price of our Common Stock
to decline. We cannot predict the effect, if any, of future issuances of our Common Stock or securities convertible into our
Common Stock, or the future expirations of lock-up agreements, on the price of our Common Stock. In all events, future
issuances of our Common Stock would result in the dilution of your holdings. In addition, the perception that new issuances
of our Common Stock, or other securities convertible into our Common Stock, could occur, or the perception that locked-up
parties will sell their securities when the lock-ups expire, could adversely affect the market price of our Common Stock.
Further, our directors, officers and more than 5% stockholders will enter into agreements pursuant to which, subject to
certain exceptions, such persons will not sell any shares of our Common Stock that they own for one year after the date of
this Offering Circular, as further described in &ldquo;Plan of Distribution&rdquo;.&nbsp;Other investors in our outstanding
Series A Convertible Preferred Stock and the notes issued by our subsidiary GBS Pty Ltd, all of which automatically convert into
shares of Common Stock immediately prior to the initial closing of this Offering, have agreed to the same lock-up, but for a
period of 180 days rather than one year. In addition to any adverse effects that may arise upon the expiration of these
lock-up agreements, the lock-up provisions in these agreements may be waived, at any time and without notice. If the
restrictions under the lock-up agreements are waived, our Common Stock may become available for resale, subject to applicable
law, including without notice, which could reduce the market price for our Common Stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Neither the Offering nor the Shares have
been registered under Federal or State Securities Laws, leading to an absence of certain regulation applicable to the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company also has relied
on exemptions from securities registration requirements under applicable federal securities laws. Investors in the Company, therefore,
will not receive any of the benefits that such registration would otherwise provide. Prospective investors must therefore assess
the adequacy of disclosure and the fairness of the terms of this Offering on their own or in conjunction with their personal advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN ADDITION TO THE RISKS
LISTED ABOVE, BUSINESSES ARE OFTEN SUBJECT TO RISKS NOT FORESEEN OR FULLY APPRECIATED BY MANAGEMENT. IT IS NOT POSSIBLE TO FORESEE
ALL RISKS THAT MAY AFFECT THE COMPANY. MOREOVER, THE COMPANY CANNOT PREDICT WHETHER THE COMPANY WILL SUCCESSFULLY EFFECTUATE THE
COMPANY&rsquo;S CURRENT BUSINESS PLAN. EACH PROSPECTIVE PURCHASER IS ENCOURAGED TO CAREFULLY ANALYZE THE RISKS AND MERITS OF AN
INVESTMENT IN THE SECURITIES AND SHOULD TAKE INTO CONSIDERATION WHEN MAKING SUCH ANALYSIS, AMONG OTHER FACTORS, THE RISK FACTORS
DISCUSSED ABOVE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <A NAME="partii_0022"></A><B>CAPITALIZATION</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The following table sets forth our capitalization as of March&nbsp;31,
2018: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">on
                                         an actual basis;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &bull; </TD><TD STYLE="text-align: justify"> on a pro forma basis, assuming
                                         the sale in this Offering of the minimum amount of shares being offered, at an assumed
                                         offering price to the public of $12.00 per share, resulting in net proceeds to us of
                                         $7,620,000 (after deducting underwriting discount and commissions of $630,000 and our
                                         estimated other offering expenses of $750,000); and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &bull; </TD><TD STYLE="text-align: justify"> on a pro forma, as adjusted
                                         basis, assuming the sale in this offering of the maximum amount of shares being offered,
                                         at an assumed offering price to the public of $12.00 per share, resulting in net proceeds
                                         to us of $22,500,000 (after deducting underwriting discount and commissions of $1,750,000
                                         and our estimated other offering expenses of $750,000). </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> You should read this table together with
our audited consolidated financial statements as of and for the year ended June&nbsp;30, 2017 and the interim period ended March
31, 2018 and the related notes thereto, included elsewhere in this Offering Circular. Our use of proceeds from this offering is
discussed under &ldquo;Use of Proceeds.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> As&nbsp;of&nbsp;March&nbsp;31,&nbsp;2018 </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0.125in; text-indent: -0.125in"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Actual </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Pro&nbsp;Forma<BR>
    Assuming<BR> Minimum<BR> Offering<BR> Amount<BR> (Unaudited) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Pro&nbsp;Forma<BR>
    Assuming<BR> Maximum<BR> Offering<BR> Amount<BR> (Unaudited) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in"> Stockholders&rsquo; equity (deficit): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; padding-left: 0.25in; text-indent: -0.125in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Shares, $0.01 par value, 2,000,000 shares authorized, 1,012,850 shares issued and outstanding as of March&nbsp;31, 2018<SUP>1</SUP></FONT> </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 12%; text-align: right"> 7,143,340 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in"> Common Shares, $0.01 par value, 20,000,000 shares authorized, 9,000,000
    shares issued and outstanding as of March&nbsp;31, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares, 2,036,000 shares issued and outstanding as of March&nbsp;31, 2018<SUP>2</SUP></FONT> </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,459,091 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,459,091 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,459,091 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (8,116,902 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;11,146,005</FONT> </TD><TD STYLE="text-align: left"> <SUP>3</SUP> </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;26,026,005</FONT> </TD><TD STYLE="text-align: left"> <SUP>3</SUP> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in"> Accumulated deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (3,478,258 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (3,478,258 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (3,478,258 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in"> Accumulated Other comprehensive income </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 269,650 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 269,650 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 269,650 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in"> Total stockholders&rsquo; equity (deficit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2,723,048 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;9,396,489</FONT> </TD><TD STYLE="text-align: left"> <SUP>4</SUP> </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 24,276,489 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in"> Total capitalization </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2,482,387 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 9,396,489 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 24,276,489 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"> &nbsp; </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <SUP>1</SUP> These shares automatically convert to shares of
our Common Stock in connection with the Offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <SUP>2</SUP> These ordinary shares are
issued by our subsidiary, GBS Pty Ltd, and remain outstanding following the completion
of this Offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <SUP>3 </SUP>These amounts equal the
net proceeds raised in the minimum and maximum offerings ($7,620,000 and $22,500,000, respectively), plus the aggregate
outstanding amount of the convertible notes issued by our subsidiary GBS Pty Ltd ($5,205,435) as of March 31, 2018, minus
deferred charges to be written off against share capital in connection with this Offering ($1,679,430). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <SUP>4</SUP> These amounts reflect the
automatic conversion of the foregoing convertible notes into 510,337 shares of Common Stock at a price per share equal to $10.20
(representing a 15% discount to the $12.00 price per share in this Offering). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The table above excludes the following
securities: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">1,222,506
                                         shares issuable upon the exercise of outstanding warrants issued in connection with the
                                         placement of our Series A Convertible Preferred Stock, at an exercise price of $12.00
                                         per share, which warrants are exercisable only during the one-year period commencing
                                         on the second anniversary of the closing of this Offering;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">500,000
                                         shares that will become available for future issuance under our 2017 Equity Incentive
                                         Plan; and </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">conversion
                                         of the warrants (the &ldquo;Placement Agent Warrants&rdquo;) to purchase shares of Common
                                         Stock equal to 5.0% of the aggregate Shares sold in this Offering, which Placement Agent
                                         Warrants will be for the purchase of&nbsp;37,500 shares in the event the minimum number
                                         of Shares is sold and 104,167 shares in the event the maximum number of Shares is sold.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_005"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;dilution&rdquo;
refers to the reduction (as a percentage of the aggregate Shares outstanding) that occurs for any given share of stock when additional
shares are issued. If all of the Shares in this offering are fully subscribed and sold, the Shares offered herein will constitute
approximately 16.2% of the total Shares of stock of the Company (excluding the impact of outstanding warrants). The Company anticipates
that subsequent to this offering the Company may require additional capital and such capital may take the form of Common Stock,
other stock or securities or debt convertible into stock. Such future fund-raising will further dilute the percentage ownership
of the Shares sold herein in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The share
and per share amounts set forth below reflects the reverse stock split of approximately one to 0.916 shares that resulted
in 8,250,000 shares of Common Stock being issued and outstanding on August 9, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If you invest
in our Common Stock, your interest will be diluted immediately to the extent of the difference between the offering price per
share of our Common Stock and the pro forma net tangible book value per share of our Common Stock after this offering. As of
31 March 2018, the net tangible book value of the Company was approximately negative $4,402,000 (including the impact of
outstanding convertible notes issued by our subsidiary GBS Pty Ltd) since the Company has not generated any revenue to date.
Based on 8,250,000 shares of Common Stock issued and outstanding as of the date of this Offering Circular, that equates to a
net tangible book value of approximately minus $0.53 per share on a pro forma basis. Net tangible book value per share
consists of shareholders&rsquo; equity adjusted for the intangible assets , divided by the total number of shares
outstanding. The pro forma net tangible book value, assuming full subscription in this Offering, would be $1.70 per
share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Thus, if the Offering
is fully subscribed, the net tangible book value per share owned by our current shareholders will have immediately increased by
approximately $2.23 without any additional investment on their part and the net tangible book value per Share for new investors
will be immediately diluted to $1.70 per Share, which represents a $10.30 dilution per share to new investors. These calculations
do not include the costs of the Offering and dilution from exercising of warrants, will cause further dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
illustrates this per Share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Offering price per Share*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net Tangible Book Value per Share before Offering (based on 8,250,000 shares)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.53</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in Net Tangible Book Value per Share Attributable to Shares Offered Hereby (based
    on 2,083,334 shares)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net Tangible Book Value per Share after Offering and Conversion of Preferred Stock and Convertible
    Notes (based on 12,073,198 shares)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dilution of Net Tangible Book Value per Share to Purchasers in this Offering**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">* Before deduction
of offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">** Excludes the value of the
License Agreement due to it being intangible in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a
material disparity between the price of the Shares in this Offering and the effective cash cost to existing shareholders for
Shares acquired by them in a transaction during the past year. The Company&rsquo;s operations to date have been funded by
LSBD as well as by $14,064,863 proceeds from the equivalent of 1,746,925 shares of Common Stock in preferred stock, warrants and convertible note issuances. As a result, the average effective cash contribution for shares acquired by them
in a transaction during the past year was approximately $8.05 per share, whereas the public contribution under this public
offering will be $12.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The following table
sets forth, assuming the sale of 2,083,334 shares of our Common Stock offered for sale if the maximum amount is sold in this Offering,
as of the date hereof, the total number of shares previously issued and sold to existing investors including holders of our Series
A Convertible Preferred Stock and holders of our subsidiary&rsquo;s notes convertible into our Common Stock, the total consideration
paid for the foregoing and the average price per share. As the table shows, new investors purchasing shares of Common Stock may
in certain circumstances pay an average price per share substantially higher than the average price per shares paid by our existing
stockholders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Purchased</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Consideration</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date Hereof</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-align: left">Existing Stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">68.3</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Convertible Note Holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,277,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Convertible Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,222,506</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,715,793</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22.4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">New Investors (maximum offering)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,083,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17.3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64.1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">12,073,198</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100.00</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">38,992,850</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100.00</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007" TITLE="Plan of Distribution"></A>PLAN OF DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
this offering, we will enter into a placement agency agreement with Cuttone &amp; Co., LLC on or immediately prior to the date
on which the SEC initially qualifies the Offering Statement (the &ldquo;Qualification Date&rdquo;), pursuant to which Cuttone
will offer the Shares on a &ldquo;best efforts, minimum-maximum basis.&rdquo; The minimum offering amount is $9,000,000; and the
maximum offering amount is $25,000,000.&nbsp;Subject to certain conditions, Cuttone &amp; Co., LLC (&ldquo;Cuttone&rdquo;
or the Placement Agent) has agreed to use its best efforts to procure potential purchasers for the Offered Shares. This offering
is being undertaken on a best efforts only basis. The Placement Agent is not required to take or pay for any specific number or
dollar amount of our Common Stock. The Placement Agent will have the right to engage such other FINRA member firms as it determines
to assist in this offering. The Shares will initially be offered at the initial public offering price set forth on the cover of
this Offering Circular by the Placement Agent and by the participating broker-dealers included in the Placement Agent&rsquo;s
selling group syndicate (each a &ldquo;Dealer&rdquo; and collectively the &ldquo;Dealers&rdquo;), who will then sell the Shares
to the public at the initial public offering price. Sales commissions will be paid to the Dealers by the Placement Agent after
closing of the offering. We will not offer any discounts or pay any fees directly to the Dealers. After the initial offering of
the Shares, the offering price and other selling terms may be subject to change. The offering of the Shares is subject to receipt
and acceptance and subject to the right of the Company to reject any subscription in whole or in part, for any reason or no reason.
Neither the Placement Agent, nor any of its affiliates have provided any services to us or our affiliates in the past.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
Shares will be issued in one or more closings. For the Initial Closing and each Additional Closing, all proceeds for such
closing will be kept in a non-interest bearing escrow account maintained by the Escrow Agent, Prime Trust, LLC, which is
a &quot;bank&quot; under Rule 15c2-4,for the benefit of the investors in accordance with Rule 15c2-4 under the Exchange
Act.. Upon each closing, the proceeds collected for such closing will be disbursed to the Company and the Shares for such
closing will be issued to investors. The Placement Agent and the participating broker-dealers must sell the minimum number of
shares set forth in this Offering Circular (the &ldquo;Minimum Offering&rdquo; Underwriter nor the Dealers have any
obligation to sell any Shares. Sales of Shares to affiliates and persons associated with the Placement Agent and the Company,
if any, will be included for purposes of satisfying the Minimum Offering Amount. The escrow account will be opened
immediately prior to the Qualification Date  and will remain open until the offering terminates without the Minimum Offering
having been reached, or if the Initial Closing occurs, until the last Additional Closing date. All funds received into the
escrow account will be held in a non-interest bearing account in accordance with Rule 15c2-4 under the Exchange Act. All
funds will be transmitted directly by wire or electronic funds transfer via ACH to the specified bank account maintained by
the Escrow Agent per the instructions in the subscription agreement. The Escrow Agent may accept checks from investors if
such investors meet certain eligibility requirements. The Placement Agent will not accept or handle any funds. The
subscription agreement will be available at <U>________</U>. The Escrow Agent will notify the Placement Agent when the full
amount necessary to purchase the Minimum Offering has been received. If, on the Termination Date, investor funds are not
received in respect of the Minimum Offering, then all investor funds that were deposited into the escrow account will be
returned promptly to investors, without interest and without deduction, and the offering will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Technology and Escrow Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FundAmerica Securities,
LLC has been engaged to provide certain technology services and Prime Trust, LLC has been engaged to provide certain escrow services,
including acting as escrow agent, for the Offering. FundAmerica Securities, LLC and Prime Trust, LLC are not participating as an
underwriter or placement agent or sales agent of the Offering and will not solicit any investment in the Company, recommend the
Company's securities or provide investment advice to any prospective investor, or distribute this Offering Circular or other offering
materials to investors. All inquiries regarding this offering or escrow should be made directly to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prime Trust, LLC, a
broker-dealer registered with the Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority,
will perform the following administrative functions in connection with this offering in addition to acting as the escrow agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">review the subscription agreements to determine whether all of the necessary information has been
obtained from the investors, to determine compliance with the investment limitation requirement, and to perform anti-money laundering
checks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">contact the investors if necessary to gather additional information or clarification;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provide us with prompt notice for subscriptions that cannot be accepted; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">transmit the subscription information data to our transfer agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As compensation for
the services listed above, we have agreed to pay Prime Trust, LLC a fixed amount per each domestic investor and per each international
investor to conduct an anti-money laundering check. In addition, we will pay Prime Trust, LLC a flat fee for account set up, a
monthly fee for so long as this Offering is being conducted, and up to a fixed amount per investor for processing incoming funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we will
pay an affiliate of FundAmerica Securities, LLC a flat license fee, a monthly fee for &lsquo;Invest Now&rsquo; button technology,
and a fixed fee for each subscription agreement executed via electronic signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Engagement Agreement with the Placement
Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently party to an engagement
agreement with Cuttone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Offering Expenses</I>.</B> We
are responsible for all offering fees and expenses, including the following: (i) fees and disbursements of our legal counsel,
accountants, and other professionals we engage; (ii) fees and expenses incurred in the production of offering documents, including
design, printing, photograph, and written material procurement costs; (iii) all filing fees, including FINRA and blue sky filing
fees; (iv) all of the legal fees related to the registration and qualification of the Shares under state securities laws and FINRA
clearance; and (v) our transportation, accommodation, and other roadshow expenses. We are obligated to reimburse the Placement
Agent for reasonable travel expenses and other out-of-pocket expenses including legal fees and diligence costs associated or incurred
in connection with the offering, in an aggregate amount of $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Reimbursable Expenses in the
Event of Termination</I>.</B> In the event the offering does not close or the engagement agreement is terminated for any reason
(other than termination due to the Placement Agent&rsquo;s material failure to provide its services), we have agreed to reimburse
the Placement Agent for reasonable travel expenses and other out-of-pocket expenses including legal fees and diligence costs associated
or incurred in connection with the offering, in an aggregate amount of up to $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Strategic Transaction Advisory
Services</I></B>. If, during the term of the engagement agreement without consummation of this offering, we enter into a merger,
consolidation, purchase or sale of assets or similar strategic transaction, we have agreed to pay the Placement Agent a fee of
1.5% of the total consideration in the strategic transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Commission</I>.</B> We have agreed
to pay a commission of 7% of the gross offering proceeds to the Placement Agent as compensation immediately upon consummation
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Non-Accountable Expense Reimbursement.
</I></B>We have agreed to pay a non-accountable expense allowance equal to 0.75% of the gross proceeds to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Placement Agent&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon each closing of this offering,
we have agreed to issue warrants to the Placement Agent (&ldquo;Placement Agent&rsquo;s Warrants&rdquo;) to purchase a number
of shares of the Common Stock equal to 5.0% of the total Shares sold in such closing. The Placement Agent&rsquo;s Warrants are
exercisable commencing on the Qualification Date, and will be exercisable for five years after the Qualification Date. The Placement
Agent&rsquo;s Warrants are not redeemable by us. The exercise price for the Placement Agent&rsquo;s Warrants will be the amount
that is 10% greater than the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Placement Agent&rsquo;s Warrants
and the Common Stock underlying the Placement Agent&rsquo;s Warrants are deemed compensation by FINRA and therefore are subject
to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The Placement Agent, or permitted assignees under such rule, may not exercise,
sell, transfer, assign, pledge, or hypothecate the Placement Agent&rsquo;s Warrants or the Common Stock underlying the Placement
Agent&rsquo;s Warrants, nor will the Placement Agent or permitted assignees engage in any hedging, short sale, derivative, put,
or call transaction that would result in the effective economic disposition of the Placement Agent&rsquo;s Warrants or the underlying
Common Stock for a period of 180 days from the Qualification Date, except that they may be transferred, in whole or in part, by
operation of law or by reason of our reorganization, or to any placement agent or selected dealer participating in the offering
and their officers or partners if the Placement Agent&rsquo;s Warrants or the underlying Common Stock so transferred remain subject
to the foregoing lock-up restrictions for the remainder of the time period. The Underwriter&rsquo;s Warrants will provide
for adjustment in the number and price of the Underwriter&rsquo;s Warrants and the Common Stock underlying such Placement
Agent&rsquo;s Warrants in the event of recapitalization, merger, stock split, or other structural transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Future Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to provide the Placement
Agent with the first option to act as our investment banker for a period of 18 months following the fiscal closing of this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our directors, officers and more than
5% have agreed, or will agree, with the Placement Agent, subject to certain exceptions, that, without the prior written consent
of the Placement Agent, we and they will not, directly or indirectly, during the period ending one year after the date of the
Offering Circular (180 days for investors in our Series A Convertible Preferred Stock and the outstanding notes convertible into
shares of our Common Stock): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-align: justify; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD STYLE="text-align: justify">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of the
Common Stock or any securities convertible into or exchangeable or exercisable for the Common Stock, whether now owned or hereafter
acquired by us or each such principal stockholder or with respect to which us or each such principal stockholder has or hereafter
acquires the power of disposition; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.4pt"></TD><TD STYLE="width: 14.2pt">&#9679;</TD><TD STYLE="text-align: justify">enter into any swap or any other agreement or any transaction that transfers, in whole or in part,
the economic consequence of ownership of the Common Stock, whether any such swap or transaction is to be settled by delivery of
the Common Stock or other securities, in cash or otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> These agreements do not apply, in our
case, to securities issued pursuant to existing employee benefit plans or securities issued upon exercise of options, and other
exceptions, and in the case of our officers, directors and other holders of our securities, exercise of stock options issued pursuant
to a stock option or similar plans, and other exceptions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing on a National Securities Exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have applied to
list our Common Stock on The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;GBSG&rdquo;. Our Common Stock will
not commence trading on Nasdaq, however, unless and until the (i) this Offering is closed in amounts sufficient to meet the minimum
listing criteria of Nasdaq; (ii) this Offering is terminated and (iii) we have filed a post-qualification amendment to the Offering
Statement, and a registration statement on Form 8-A (&ldquo;Form 8-A&rdquo;) under the Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and such post-qualification amendment is qualified by the SEC and the Form 8-A has become effective. Pursuant to applicable
rules under Regulation A, the Form 8-A will not become effective until the SEC qualifies the post-qualification amendment. We intend
to file the post-qualification amendment and request its qualification immediately prior to the termination of the Offering in
order that the Form 8-A may become effective as soon as practicable. Even if we meet the minimum requirements for listing on Nasdaq,
we may wait before terminating the Offering and commencing the trading of our Common Stock on Nasdaq in order to raise additional
proceeds. As a result, you may experience a delay between the closing of your purchase of shares of our Common Stock and the commencement
of exchange trading of our Common Stock on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether we meet Nasdaq&rsquo;s
minimum listing criteria will be determined by Nasdaq in its discretion. If we do not meet the criteria, or Nasdaq does not make
necessary discretionary exceptions, as to which there can be no assurance, then we will not be able to list our Common Stock on
Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance
that such listing will ever be obtained and investors may not know at the time that their investment becomes irrevocable whether
the listing application will be approved. If we fail to meet the minimum requirements for listing on Nasdaq, we will seek to have
our Common Stock quoted on an alternative exchange, trading platform or over-the-counter, such as on the OTCQX. The OTCQX is not
a stock exchange, and if our Common Stock trades on the OTCQX rather than Nasdaq, there may be significantly less trading volume
and analyst coverage of, and significantly less investor interest in, our Common Stock, which may lead to lower trading prices
for our Common Stock. See &ldquo;Risk Factors &ndash; Our shares of Common Stock are not and may not be listed for trading on
a national securities exchange.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pricing of the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the offering, there has been
no public market for the Offered Shares. The initial public offering price was determined by negotiation between us and the Placement
Agent. The principal factors considered in determining the initial public offering price include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>the information set forth in this Offering Circular
                                         and otherwise available to the Placement Agent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>our history and prospects and the history of and prospects for the industry in which we compete;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>our past and present financial performance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>our prospects for future earnings and the present state of our development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>the general condition of the securities markets at the time of this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD STYLE="text-align: justify">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>other factors deemed relevant by the Placement Agent
                                         and us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification and Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed
to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;), and to advance and reimburse its cost of defense of any claims asserted in connection with
the offering. If we are unable to provide this indemnification, we will contribute to the payments the Placement Agent and its
selling agents, affiliates and controlling persons may be required to make in respect of these liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Placement Agent
and its affiliates are engaged in various activities, which may include securities trading, commercial and investment banking,
financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
The Placement Agent and its affiliates may in the future perform various financial advisory and investment banking services for
us, for which they have received or will receive customary fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Relationship with the Underwriter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary
course of their various business activities, the Placement Agent and its affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans)
for their own account and for the accounts of their customers, and such investment and securities activities may involve our securities
and/or instruments. The Placement Agent and its affiliates may also make investment recommendations and/or publish or express
independent research views in respect of such securities or instruments, or recommend to clients that they acquire, long and/or
short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investment Limitations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As set forth in Title
IV of the JOBS Act, there are no limits on how many shares an investor may purchase if the Offering results in a listing of our
Common Stock on Nasdaq or other national securities exchange. The following would apply only if we are unable to obtain a listing
on a national securities exchange and we may seek for our Common Stock to trade on a platform of the OTC Markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, in the case
of trading on the over-the-counter markets, no sale may be made to you in this Offering if the aggregate purchase price you pay
is more than 10% of the greater of your annual income or net worth (please see under &ldquo;How to calculate your net worth&rdquo;).
Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does
not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing,
we encourage you to refer to <U>www.investor.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because this is a Tier
2, Regulation A offering, most investors in the case of trading on the over-the-counter markets must comply with the 10% limitation
on investment in the Offering. The only investor in this Offering exempt from this limitation is an &ldquo;accredited investor&rdquo;
as defined under Rule 501 of Regulation D under the Securities Act (an &ldquo;Accredited Investor&rdquo;). If you meet one of the
following tests you should qualify as an Accredited Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a natural person who has had individual income in excess of $200,000 in each of the two most recent years, or joint income
with your spouse in excess of $300,000 in each of these years, and have a reasonable expectation of reaching the same income level
in the current year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase
Shares (please see below under &ldquo;How to calculate your net worth&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are
an executive officer or general partner of the issuer or a manager or executive officer of the general partner of the issuer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the Code, a corporation,
a Massachusetts or similar business trust or a partnership, not formed for the specific purpose of acquiring the Shares, with total
assets in excess of $5,000,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered
pursuant to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered
under the Investment Company Act of 1940 (the &ldquo;Investment Company Act&rdquo;), or a business development company as defined
in that act, any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business
development company as defined in the Investment Advisers Act of 1940;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a trust with total assets in excess of $5,000,000, your purchase of Shares is directed by a person who either alone or with
his purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience
in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you
were not formed for the specific purpose of investing in the Shares; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its
political subdivisions, for the benefit of its employees, if such plan has assets in excess of $5,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Date</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This offering will start on or after the Qualification Date
and will terminate if the Minimum Offering is not reached or, if it is reached, on the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Offering Procedure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering
a minimum of 750,000 and a maximum of 2,083,334 shares (the &ldquo;Shares&rdquo;) of our common stock, par value $0.01 (&ldquo;Common
Stock&rdquo;), at an offering price of $12.00 per share for a minimum offering amount of $9,000,000 and a maximum offering amount
of $25,000,000 (the &ldquo;Offering&rdquo;). The Offering will terminate on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018, subject to extension by us for up to thirty (30) days; provided that, if we have received and accepted subscriptions for
the minimum number of Shares on or before &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, or the end of the thirty
(30) day extension, if exercised, then the Company will close on the minimum offering amount (the &ldquo;Initial Closing&rdquo;)
and this offering will continue until the earlier of (i) the date which is sixty (60) days after the Initial Closing, or (ii)
the date on which the maximum offering amount is sold (such earlier date, the &ldquo;Termination Date&rdquo;). If, on the Initial
Closing date, we have sold less than the maximum number of Shares, then we may hold one or more additional closings to sell additional
Shares (each, an &ldquo;Additional Closing&rdquo;), until the earlier of: (i) the sale of the maximum number of Shares or (ii)
the Termination Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the minimum
offering being raised, we will undertake one or more closings on a rolling basis as funds are received from investors. Funds tendered
by investors will be kept in an escrow account until the next closing after they are received by the escrow agent. At each closing,
funds held in escrow will be distributed to us, and the associated shares will be issued to the investors. All subscribers will
be instructed by us or our agents to transfer funds by wire, credit or debit cards or ACH transfer directly to the escrow account
established for this offering or deliver checks made payable to &ldquo;Prime Trust, LLC as Escrow Agent for Investors in Glucose
Biosensor Systems Offering&rdquo; which the escrow agent shall deposit into such escrow account and release to us at each closing.
Subject to the minimum offering being raised, we intend to close on all funds received from investors that are deposited in the
escrow account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will engage Prime
Trust, LLC, as escrow agent and the escrow agreement will be filed as an exhibit to the Offering Statement of which this Offering
Circular is a part. The escrow agent has not investigated the desirability or advisability of investment in our Common Stock nor
approved, endorsed or passed upon the merits of purchasing the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will use the website,
https://gbsgreaterchina.com, to provide information on the offering to potential investors. The website will be the exclusive means
by which prospective investors may subscribe in this offering. This Offering Circular will be furnished to prospective investors
via download 24 hours per day, 7 days per week on the foregoing website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be required
to complete a subscription agreement in order to invest. The subscription agreement includes a representation to the effect that,
if you are not an &ldquo;accredited investor&rdquo; as defined under securities law, you are investing an amount that does not
exceed the greater of 10% of your annual income or 10% of your net worth, as described in the subscription agreement. After we
receive your complete, executed subscription agreement (the form of which is attached to the Offering Statement as Exhibit 4.1)
and the funds required under the subscription agreement have been transferred to the escrow account, we have the right to review
and accept or reject your subscription in whole or in part, for any reason or for no reason. We will return all monies from rejected
subscriptions immediately to you, without interest or deduction. Upon our acceptance of a subscription agreement, we will countersign
the subscription agreement and issue the shares subscribed at closing. Once you submit the subscription agreement and it is accepted,
you may not revoke or change your subscription or request your subscription funds. All accepted subscription agreements are irrevocable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that
the net proceeds from the sale of the shares of our Common Stock will be approximately $22.50 million if the maximum offering
is completed and approximately $7.62 million if the minimum offering is completed, assuming a public offering price of $12.00
per share, after deducting the estimated placement agency discounts and commissions and estimated offering expenses payable by
us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we meet the
maximum offering it will enable the Company to better pursue the early stages of the regulatory approval process and comply with
obligations under the License Agreement. To the extent that we raise less than the maximum offering, we will have to raise that
much more capital in the future to pursue our business objectives. Since we have not yet developed detailed priorities for the
use of proceeds, pending our regulatory approvals analysis and other early stage activities, we are unable to describe what uses
of proceeds would be foregone to the extent we raise less than the maximum offering; provided that there can be no assurances
that even if we raise the maximum offering the net proceeds would be sufficient, without additional capital raised, to achieve
all necessary such regulatory approvals or compliance obligations. See &ldquo;Risk Factors &ndash; Given our lack of revenue and
our negative cash flow, we expect to need to raise additional capital, which may be unavailable to us or, even if consummated,
may cause dilution or place significant restrictions on our ability to operate.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We expect
that a substantial portion of the net proceeds used for the purposes described above will be paid to LSBD pursuant to the
License Agreement, pursuant to which LSBD will conduct a substantial portion of the activities that must be performed in the
near term to advance our business plan, including without limitation market data studies, delivery of a finalized
prototype, delivery of a manufacture-to-scale plan, delivery of a global regulatory strategy plan, commencing scale
manufacturing, commencement  of confidential testing, submitting and finalizing regulatory submissions through final
approvals, delivery of a finalized product for sale, and many other services. Not all of the services to be performed by LSBD
under the License Agreement are expected to be completed within the first year following this Offering. While the payments to
LSBD for all such services would exceed net proceeds in the event only the minimum amount of this Offering is received, the
Company expects that it will use such net proceeds for purposes as are most timely and appropriate in its judgment. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the
net proceeds received from this offering as described above and secondarily, if available, for development of our software platform,
sales and marketing efforts to penetrate the markets in the China Region, production arrangements, funding our working capital
and for general corporate purposes. We may find it necessary or advisable to reallocate portions of the net proceeds reserved for
one category to another, or to add additional categories, and we will have broad discretion in doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The broad expected
use of net proceeds of this offering represents our current intentions based upon our general plan and business conditions. The
amounts and timing of our use of net proceeds will vary depending on numerous factors. As a result, management will have broad
discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the
net proceeds of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending the use of
the net proceeds of this offering, we intend to invest the net proceeds in short-term investment-grade, interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A portion of the proceeds
from this Offering may be used to compensate or otherwise make payments to officers or directors of the issuer. The officers and
directors of the Company may be paid salaries and receive benefits that are commensurate with similar companies, and a portion
of the proceeds may be used to pay these ongoing business expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Company reserves the right to change
the use of proceeds set out herein based on the needs of the proposed business of the Company and the discretion of the Company&rsquo;s
management. The Company may reallocate the estimated use of proceeds among the various categories or for other uses if management
deems such a reallocation to be appropriate.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_007"></A>DESCRIPTION
OF BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Glucose Biosensor Systems
(Greater China) Holdings, Inc. (the &ldquo;Company&rdquo;) is a development stage medical device company that owns the license
to the novel and patent-protected biosensor saliva glucose monitoring system (the &ldquo;GBS System&rdquo;) in the region of Mainland
China, Hong Kong, Vietnam and Bangladesh (&ldquo;China Region&rdquo;). We were formed on December 5, 2016, as a Delaware corporation
with headquarters in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We are a wholly-owned
subsidiary of Life Science Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;), an Australian company that owns the worldwide intellectual
property rights to the biosensor platform invented at the University of Newcastle, Australia. LSBD is responsible for the development
of the biosensor platform and has licensed that technology to us to commercialize the GBS System in the China Region. We have
two subsidiaries: Glucose Biosensor Systems (Greater China), Inc., a Delaware corporation and Glucose Biosensor Systems (Greater
China) Pty Ltd (&ldquo;GBS Pty Ltd&rdquo;), an Australian corporation. We expect to form and utilize additional foreign subsidiaries
to facilitate our operations in certain jurisdictions and for other purposes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A major feature of
the GBS System will be its ability to detect glucose in saliva, obviating the need for patients or consumers to perform frequent
finger punctures as required by conventional blood glucose measurement techniques.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once developed, the
basic components of the GBS System will be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The biosensor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The single use
organic biosensor reacts with saliva and initiates an electrochemical reaction, producing a detectable electrical signal that
is proportional to the glucose present in the sample and converted by a smartphone or dedicated reading &lsquo;smart&rdquo; device into a real-time
saliva glucose reading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dedicated digital health care application</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our digital health
care application will be designed to enable user interaction, data interface, storage, analytics and patient support programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tv502124_img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">For <BR>
illustrative purposes only &ndash; not Company products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When the GBS System&rsquo;s
single-use organic biosensor interacts with saliva it initiates an electrochemical reaction, producing a measurable electrical
signal directly correlated to the amount of glucose present in the saliva. This measurement is then converted into a real-time
saliva glucose reading, by a smartphone or a dedicated reading &ldquo;smart&rdquo; device. This data set would then be securely
stored, in analyzed and/or raw form, in a non-relational database in the cloud, for further evaluation and processing. This digital
platform, combined with the clinically-relevant data, is designed to enable diabetics to achieve better glucose control, including
through an accumulation of lifestyle data, thereby helping prevent or delay long term medical complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the
core innovation of our business will be the ability to measure glucose in saliva non-invasively. The core technology is the biosensor
that enables the wider glucose management system. While complex in materials, technology and architecture, the biosensor is a
recognized technology that is being transformed into a medical device that we expect to conform with the highest global medical
device standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The non-invasive
attributes of the technology, the ability for real-time measurement and remote monitoring, could make it easier for a patient
to monitor their glucose levels. This means that we have the potential to collect a greater amount of information from a larger
proportion of patients. This increased data flow, for both the patient and their healthcare professionals, opens significant opportunities
to improve the way diabetes is managed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through the deployment
of our digital ecosystem, we propose to enable an entire patient/user community providing educational resources, enabling patient
support groups and taking patient care beyond the health care provider&rsquo;s office. This would create a tool extending beyond
a simple stand-alone device, in essence a system that enables the patient to take greater control of their levels of glucose. This
would all be possible due to the following attributes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">No more multiple daily routine finger prick testing.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Programmable notifications and reminders.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Insight and practical understanding of factors that affect patient/user glucose levels.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biosensor is
currently in development and within the next 24 months, the Company intends to advance the technology to conform to the regulatory
requirements of the China Food&nbsp;&amp;&nbsp;Drug Administration (CFDA) with the aim of generating revenue once approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This digital platform,
combined with the clinically-relevant data, is designed to enable diabetics to achieve better glucose control, including through
an accumulation of lifestyle data, thereby helping prevent or delay long term medical complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The convergence of
the biosensor with the digital networks and non-relational databases, placed within the Chinese diabetes patient community creates
a redefined value chain with projected revenue generated from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Biosensor sales to patients.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Alternative revenue streams that could potentially be generated from the well stratified patient database and network unified under the digital platform.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will market,
distribute and sell the product across the geographic region through contracted distributors that already possess significant market
share within the self-testing blood glucose strips market. The Company is aiming to appoint multiple exclusive distributors across
31 territories in Mainland China initially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The GBS System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The GBS System consists
of a biosensor component that utilizes saliva to measure glucose, a digital health care application for smart devices and access
to a cloud based non-relational patient database. A major feature of the GBS System is its ability to detect glucose in saliva,
obviating the need for patients or consumers to perform frequent finger punctures as required by conventional blood glucose measurement
techniques.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When the GBS System&rsquo;s
single-use organic biosensor interacts with saliva it initiates an electrochemical reaction, producing a measurable electrical
signal directly correlated to the amount of glucose present in the saliva. This measurement is then converted into a real-time
saliva glucose reading, by a smartphone or other &lsquo;smart&rsquo; reading device. This data set is then securely stored, in analyzed and/or
raw form, in a non-relational database in the cloud, for further evaluation and processing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We contemplate that
the use of saliva-based sampling will make glucose monitoring more accessible to patients as no painful intervention is necessary.
The intuitive interface with smart devices would enable analytical capabilities accessed through the data stored on the non-relational
database. These attributes would be designed to unlock a broader opportunity in the personalized medicine sector of the healthcare
industry in the China Region. Our goals regarding this broader opportunity include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">using revenue generated from biosensor sales for working capital purposes, and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">capitalizing on and leveraging the dedicated, demographically-defined and segmented user network to be created through the institution of the proposed digital platform.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A saliva based glucose
monitoring system appears to be more patient-friendly as it eliminates the need for invasive finger pricks. This leads us to believe
that patients would increase the frequency of sampling saliva, giving them more insight into their glucose levels, resulting in
higher compliance and thus better glycemic control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The digital platform
combined with the clinically relevant data, will enable diabetics to achieve better glucose control through a greater understanding
of lifestyle factors, thereby helping prevent or delay long term medical complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The convergence of
the biosensor with the digital networks and non-relational databases, placed within the Chinese diabetes patient community, is
designed to create a redefined value chain through:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">revenue generated from biosensor sales to patients;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">revenue generated from sales to consumers who proactively monitor glucose levels (e.g., lifestyle users as part of a wellness, fitness, weight reduction program); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">revenue generated from the network and the non-relational database.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The smart device application
or dedicated reading device would allow every measurement to be stored locally and online. This data could then be used to improve
the daily management of diabetes. As the database builds knowledge, including by machine learning, and continuously updates with
the patient&rsquo;s activities, such as nutrition, exercise and sleep, and also cross correlates with the data of other users,
the biosensor system would provide intelligent suggestions and automated actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, a patient
who has demonstrated regular high readings of glucose on a particular day of the week may be prompted to reduce intake of carbohydrates
(such as sugar) that day or to increase the frequency of measurements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Saliva-Based Biosensor - The Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Self-testing blood
glucose monitors were introduced to the market in the 1970s and, since then, the method of glucose self-testing has not meaningfully
changed. The methodology of the GBS System represents a breakthrough in glucose monitoring as it represents the potential for a
non-invasive, painless, scientifically valid and cost-effective saliva-based method of measuring glucose levels. The core innovation
that the Company is introducing is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The sampling medium for detection of glucose, saliva.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The detection mechanism of glucose built in the biosensor.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While complex in
materials technology and architecture, the biosensor is built on recognized sensing technology. Through the research conducted
at the University of Newcastle, Australia, this technology is evolving into a medical device in conformity to the required highest
global medical device standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biosensor is
based on a modified organic thin film transistor architecture incorporating glucose oxidase as the recognition element. Through
prototypes, the biosensor exhibits linear glucose sensing at concentrations with greater sensitivity than commercial blood glucose
sensors, offering potential for the prospect of a saliva-based test for diabetic monitoring and diagnosis. It has been demonstrated
that the biosensor exhibits excellent sensitivity in the saliva glucose region of 8-200 &micro;M. The mechanism by which the glucose
sensing occurs involves the diffusion of protons (generated by the enzymatic oxidation of glucose) to, and subsequent doping of,
the poly (3-hexythiophene) transistor channel. The fundamentals of the biosensor technology have been well-characterized and have
a deep scientific history. Since their invention in 1947, transistors have dominated the mainstream microelectronics industry.
Field Effect Transistors (FETs) are a class of transistor in which the current between a pair of source and drain electrodes separated
by a semiconductor is controlled by a voltage applied to a third electrode known as the gate. The gate electrode is separated
from the source-drain region by a thin (~100 nm) insulating dielectric region and thus is coupled to the semiconductor. By altering
the bias voltage applied to the gate region, the source-drain region can be altered from conducting to insulating and thus the
device can be turned on or off. Importantly, the presence of a relatively small number of charges on the gate electrode alters
the flow of a great many charges between the source and drain electrodes. Accordingly, the FET acts as a switch as well as an
amplifier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biosensor makes
use of another scientific discovery known as organic electronic polymers. This work, which was conducted in the 1970s, focused
on the development of doped polyacetylene. Historically conductive polymers can also be traced back to the early 1960s. Conductive
polymers have several advantages over other organic conductors with regard to their processability and hence their use is becoming
increasingly widespread. The polymers that show the most promise in this area are based on the polythiophene structure. The flexible
nature of these polymers allows them to be processed into almost any desired shape or form, making them attractive for the low-cost
production of flexible electronic circuits, such as FETs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first demonstrated
combination of FETs and organic electronic polymers was in the solid-state organic thin film transistor (OTFT) developed in 1986
using polythiophene (an organic electronic polymer) as the semi-conducting layer, with a similar device being reported in 1988.
The performance of OTFTs in comparison with conventional silicon-based transistors has been considered encouraging and they have
already been used in applications in logic circuits or as the driving elements in active matrix displays. Sensor fabrication based
on organic electronics is also well-established, primarily driven by the appealing features offered by these materials such as
flexible and adjustable chemical properties, and room temperature operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the most
attractive features of organic electronics is the potential for flexible low-cost fabrication. A common feature of early OTFTs
was the use of silicon as the substrate material, and thus since these hybrid devices are not truly all-polymer-based they do
not offer all the advantages with respect to fabrication. In the world of sensors, the vast majority of previous scientific research
and subsequent technological implementation of organic sensors has involved electrochemically grown films exhibiting performance
levels that are, in most cases, inadequate for real applications. Solution-processed polymers, on the other hand, offer the greatest
potential for the fabrication of low-cost electronics since they can be easily processed as liquids, unlike the organic crystals
and short chain oligomers which are typically vapor deposited. Combining these unique material properties with low-cost techniques,
such as ink-jet printing, offers the ability to rapidly produce disposable printed electronic circuits. The first all-polymer
printed OTFT was reported in 1994. OTFTs are an exciting class of devices within the organic electronics field. The prospect of
low cost organic electronic modules incorporating OTFTs fabricated at low temperatures using low energy techniques is very attractive.
Low temperature solution-based processes, such as ink-jet printing, allow for compatibility with&nbsp;exible substrates, upon
which it would be impossible to fabricate conventional electronics. In addition, conducting polymers can be synthesized in a laboratory
without using rare or expensive materials meaning that they have the potential to be low cost when produced on a large scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The GBS System leverages
this history of all-polymer printed OTFTs. The organic polymeric semiconductor poly-3-hexylthiophene, which the biosensor is based
upon, is a relatively well understood material. The defining characteristic of our biosensor device is that it is based upon organic
materials that exhibit excellent performance and can be solution processed at low temperatures on flexible substrates via low cost,
high volume but highly sophisticated printing techniques. We believe that this indicates that inexpensive, non-medical waste disposable
biosensors can be easily produced in large quantities. However, as we have yet to manufacture our biosensors on a commercial scale,
there is no assurance that we will be able to manufacture the biosensors cost-effectively in commercial quantities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tv502124_img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B>For illustrative
purposes only &ndash; not a Company product</B></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>License Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2017,
the Company entered into the Technology License Agreement with LSBD, as amended by the Variation Agreement to Technology License
Agreement, dated as December 8, 2017, the Second Variation Agreement to Technology License Agreement, dated as of 18 April 2018,
and the Third Variation Agreement to Technology License Agreement dated July 10, 2018 (as so amended to date, cumulatively, the
 &ldquo;License Agreement&rdquo;), setting forth our contractual rights in and responsibilities relating to the saliva glucose
biosensor system for the China Region. The License Agreement includes the following summary terms:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">an exclusive license is granted to the Company covering certain glucose sensor intellectual property scheduled in the License Agreement and other data owned by LSBD, but solely to (i) hold regulatory marketing authorizations in the China Region, (ii) promote, market and import specific licensed products in the China Region, (iii) provide customer support on the licensed products in the China Region, (iv) use the licensed products in the China Region, and&nbsp;&nbsp;(v) collect data for LSBD regarding the use of the licensed products in the China Region;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the licensed products covered by the License Agreement are only those products that are procured by the Company from authorized suppliers in the China Region under rights owned by LSBD;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the licensed rights do not cover digital or online use to users not physically in the China Region;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the licensed rights are limited to those expressly set forth in the License Agreement and are non-transferable, non-assignable and non-sub-licensable, except that LSBD will in good faith consider any Company request for any sub-license;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company is
                                    required to meet specified performance milestones, including conducting clinical studies;
                                    obtaining regulatory approvals in the China Region within two years after the commencement
                                    of trading of the Shares on Nasdaq and within two years thereof placing orders with LSBD for
                                    a minimum number of products based on market growth, with annual increases; annually agree
                                    with LSBD as to that market growth; achieve annually that market share growth plus a minimum
                                    fixed percentage and quarterly orders with LSBD for products in quantities at that quarterly
                                    market share growth plus a minimum fixed percentage; conduct minimum marketing on standards
                                    reasonably determined by LSBD; and convert all glucose monitoring sales by the Company into
                                    glucose monitoring sales of the biosensor strip within five years; provided that (i) LSBD
                                    must supply all licensed product in accordance with the License Agreement, (ii) such product
                                    must be of merchantable quality and in accordance with local law, and (iii) certain end user
                                    data must be accessible to the Company;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">upon failure of any of these requirements, LSBD may require the Company to make cash payment of the value of any shortfall and the failure to pay this amount within 14 business days will subject it to monthly compounding interest at a rate of LIBOR plus 4%;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must notify LSBD of infringements of any licensed intellectual property and cooperate with and as instructed by LSBD, at LSBD&rsquo;s expense, in preventing such infringement, but may take no other action regarding infringement;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company must market, sell and distribute the licensed products in accordance with law and distribution requirements set forth in the License Agreement, including delivering licensed products without inclusion of any other product, only as supplied by LSBD, without changing LSBD&rsquo;s packaging or branding thereof and only in quantities as directed by LSBD; complying with all regulations; and keeping specified records and batch samples relating to its activities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must file for and obtain all legal permits for marketing and selling the licensed products;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must pay LSBD, subject to a monthly late charge, a one-time fixed license fee within 14 days of the obtaining of required regulatory approvals in China; fixed royalty percentages on the sale of specified licensed products on sales of commercial units and certain other devices; application license fees and fees for patient education services, all as determined from time to time by LSBD;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must obtain, retain and provide to LSBD certain end user and other data and notify LSBD as to a variety of matters relating to the data, almost all of which data will be solely owned by LSBD, provided that the Company will have rights to certain of the data during the term of the License Agreement;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">LSBD will own all of the right, title and interest in substantially all of the intellectual property covered by the License Agreement and LSBD shall have the right to control the protection of that licensed intellectual property as assisted by the Company, which shall have no rights to control or otherwise conduct protective activities;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the parties generally agree to keep confidential, subject to customary exceptions, all confidential information of the other party, subject to express exceptions;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">except with respect to LSBD&rsquo;s ownership of all intellectual property rights in respect of the licensed property and the non-infringement by the Company&rsquo;s exercise of those rights, LSBD provides no, and disclaims all, representations, warranties or covenants relating to the licensed intellectual property or any other matters under the License Agreement and in particular disclaims any fitness of the property for any purpose;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-size: 10pt">LSBD is indemnified
                                    by the Company for any losses that may be incurred relating to any conduct, including any
                                    data collection or retention, by the Company under or relating to the License Agreement or
                                    the intellectual property under it, or any negligent or willful misconduct or violation of
                                    law by the Company, with no reciprocal indemnity; provided that LSBD indemnifies the Company
                                    for any losses arising that may be incurred related to (i) any third party claim that the
                                    exercise by the Company of its rights in respect of a licensed product violates its property
                                    or rights, and (ii) any regulatory or quality recall or any consumer or user claims or liability
                                    in relation to a licensed product (regardless of any contributory or comparative negligence
                                    of any Licensee Indemnitee, subject to contributory negligence;</FONT> </P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"> The term of the License Agreement runs until the final date of protection
                                    afforded to the
                                    patent portfolio covered by the License Agreement, which is currently until 2033, provided that either party may terminate
                                    the License Agreement earlier following any uncured material breach by the other party of it, the discontinuation of the
                                    other party&rsquo;s operations or an actual or prospective change in control of the other party, where change in control
                                    means, among other things, (i) any change of 50% ownership of outstanding Common Stock or voting rights, (ii) a merger
                                    resulting in our pre-merger voting securities failing to represent at least 50% of all voting power immediately post-merger,
                                    (iii) a sale of substantially all assets, (iv) solely with respect to the Company, without LSBD&rsquo;s prior approval a
                                    majority
                                    change                                                                                                               in
                                    the                                                                                                               composition
                                    of                                                                                                               our board of
                                    directors (unless such change was pre-approved by our board, a nominating or other independent
                                    committee thereof) or (v) the dissolution or liquidation of the other party. In the event of a change in control of LSBD,
                                    LSBD must pay the Company an amount equal to the greater of the five-year projected net sales  and five times the prior
                                    year&rsquo;s actual net sales of the Company, as adjusted depending on how much of the term of the License Agreement remains.
                                    No similar payment is required by the Company in the event of a change in control of the Company; and </P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the expiration, termination or cancellation of the License Agreement in any way, the Company the following consequences are required (i) the cessation of substantially all of the Company&rsquo;s operations, (ii) the forfeiture to LSBD of substantially all of the Company&rsquo;s intellectual property, and (iii) the payment of due amounts, effectively threatening the Company&rsquo;s viability and otherwise having a material adverse effect on the Company and its business, assets and prospects.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preceding summary
and all other references to the License Agreement in this Offering Circular is subject to, and you are encouraged to read, the
complete text of the License Agreement, including variations, which are filed as exhibits to the Offering Statement of which this
Offering Circular is a part. See &ldquo;Risk Factors &ndash; Our License Agreement with our wholly-owning parent, LSBD, which relates
to the Company&rsquo;s principle asset consisting of licensed intellectual property, contains numerous significant performance,
payment, liability, compliance, termination and intellectual property risks that may threaten the Company&rsquo;s viability or
otherwise have a material adverse effect on the Company, its business and its prospects.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Steps to Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development
stage company formed in December 2016 as a new business and have not yet begun to commercialize our licensed technology or any
products. Our efforts to date have been organizational and formational, have depended on LSBD and its affiliates and have not
generated revenue, and it is still too early to predict if we will ever be able to generate revenues. Therefore, we are, and expect
for the foreseeable future to be, subject to all the risks and uncertainties inherent in a new business and the development and
sale of new medical devices and related software applications. As a result, we may be unable to fully develop, obtain regulatory
approval for, commercialize, manufacture, market, sell and derive revenues from the GBS System and our inability to do so would
materially and adversely impact our viability. In addition, we still must establish many functions necessary to operate a business,
including finalizing our managerial and administrative structure, continuing product and technology development, assessing and
commencing our marketing activities, implementing financial systems and controls and personnel recruitment. This discussion of
commercialization hurdles is subject to and must be considered in the context of &ldquo;Risk Factors&rdquo; below, which you are
directed to read carefully in their entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Offering is for
preliminary financing toward pursuing commercialization of our proposed initial product, the GBS System. There are numerous hurdles
required before commercialization will be possible, as to which there can be no assurances. Those hurdles include, but are not
limited to, and are not necessarily set forth in chronological order:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Additional Capital</U>. We expect that we will require more capital than is contemplated in
this Offering to reach commercialization of the GBS System. Such need for capital is an over-riding condition to the achievement
of many of the other hurdles to commercialization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Regulatory Approvals</U>. The research, design, testing, manufacturing, labeling, selling, marketing
and distribution of medical devices are subject to extensive regulation by country-specific regulatory authorities, which regulations
differ from country to country. We have not yet obtained any regulatory approvals in any jurisdiction, including in particular
the China Region. We must obtain all regulatory approvals as will permit the commercialization of the GBS System as well as any
eligible protection of any intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Clinical Studies</U>. To date, we have not conducted clinical studies and trials on the GBS
System. These studies and trials will be required prior to and in connection with obtaining all regulatory approvals. These studies
and trials will have to be successfully completed to obtain approvals in order to commercialize the GBS System.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Manufacture and Supply</U>. Neither we nor LSBD own or operate manufacturing facilities or maintain
the resources for the production of the GBS System and its components on a commercial scale. Therefore, we will have to rely on
outsourcing in this regard. We must identify and reach agreements with manufacturers and suppliers before we can commence commercialization
of the GBS System.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Marketing</U>. We are looking for and will depend in part on qualified distributors for the
marketing and selling of our products. We will depend on these distributors&rsquo; efforts to market our products, yet we will
be unable to control their efforts completely. We have not yet executed any distribution agreements in this regard.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Software Compatibility</U>. We must conduct software work to make the GBS System application
compatible with existing and potential future smart device platforms. This software work remains to be done.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Personnel</U>.
                                         In order to commercialize our GBS System, we will need to attract and retain highly skilled
                                         managerial, sales, scientific and technical personnel to advance the product beyond its
                                         current development stage. To date we have utilized certain employees of our parent LSBD,
                                         which arrangement will not be sufficient to move toward commercialization of our product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Intellectual property</U>. Before commencing any commercialization, we will need to assess the
eligibility of our intellectual property for suitable protections in the jurisdictions of the China Region and if possible implement
measures to achieve that protection. This will require significant work in each of those jurisdictions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Experts</U>. For purposes of most of the foregoing steps, including in particular regulatory
and intellectual property hurdles, we will need to engage third party experts, including in particular specialized local counsel
in each jurisdiction, in order to assess our ability to commercialize our products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Status
                                         of Product</U>. A functioning laboratory prototype of the core biosensor (sensor strip
                                         and readout device) has been developed. The development for the full <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GBS
                                         System, comprised of the sensor strip, dedicated &lsquo;smart&rsquo; reader device and
                                         smartphone application (with cloud storage, database and analytical functionality) as
                                         a commercial grade medical device is in progress.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The feasibility work
for manufacturing has been completed and is now in development stage. LSBD currently is conducting trials to identify optimal printing
techniques. As new materials and designs are evaluated through the course of continuing development work, it is expected that improved
manufacturing and other processes will develop as well, including the expertise to print all components of the glucose sensor in
the requisite architecture on a small scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LSBD is working to
identify, negotiate and effectuate manufacturing know-how to mass-produce the biosensor with economies of scale. The manufacturing
methods, locations, and other pertinent terms and details applicable to our manufacturing sources are in the planning process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is anticipated that
the manufacturing process will include a standardization and calibration process that will be automatically initiated with every
new batch of biosensors purchased to ensure requisite, uniformity and performance characteristics. The validation process would
verify that the biosensor is authentic and not an unauthorized copy that might result in erroneous or dubious results. This process
would compare the batch sold against the batch produced, validating authenticity and quality control parameters. This is expected
to be a key component in the manufacturing process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Glucose Monitoring Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The blood glucose self-monitoring
market is currently estimated to reach in excess of $12 billion by 2020. Four companies &ndash; Roche, Abbott, Johnson &amp; Johnson
(LifeScan) and Bayer (recently acquired by Panasonic) &ndash; currently dominate the global market. Although the top four companies
appear to be losing some market share to smaller competitors, they are still believed to hold more than 70% global market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Self-Monitoring
of Blood Glucose (SMBG)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tv502124_img06.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Self-Monitoring of
blood glucose is the main approach for glucose monitoring and has been used for over 40 years. Currently, SMBG is conducted periodically
by the patient using a blood glucose measuring device. Blood glucometers require pricking a finger with a lancet and applying a
drop of blood on the test strip. The test strip is then inserted into the device which provides a reading of glucose level in blood.
Test strips are supplied by the glucometer manufacturer and are generally device-specific, although generic test strips are also
available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are more than
100 types of blood glucometers currently are commercially available and they differentiate based on size and weight, cost, data
storage capacity, test accuracy, blood sample size and screen visibility (users with poor eyesight may prefer larger screens).
Some glucometers also include high-tech features such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bluetooth: some meters
have Bluetooth capabilities, allowing data to be transmitted to a smartphone, tablet or computer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">USB Port: many meters
allow users to download data to a computer with a USB cable. Some meters plug directly into a computer&rsquo;s USB port; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bolus Calculator: meters
such as Roche&rsquo;s Accu-Chek Aviva Expert, use a bolus calculator that suggests a dose of meal-time insulin based on blood glucose
reading and specific meals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These systems, however,
still have shortcomings. In addition to the referenced strain on patients, a recent study of commercial blood glucose sensors has
shown that of the 34 systems completely assessed, seven systems did not fulfill the minimal accuracy requirements of the ISO standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Continuous Glucose
Monitoring (CGM)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Continuous Glucose
Monitoring is an alternative to periodic SMBG. The procedure involves the insertion of a glucose sensor into the subcutaneous tissue
layer or the hypodermis. The sensor, which measures glucose levels in interstitial fluid, is attached to a transmitter that sends
signals to either an insulin pump or a portable meter. These devices are generally worn for about one week and require regular
calibration through conventional blood glucose detection, about twice a day. While the accuracy of these devices has been an issue,
it has improved in recent years. CGM can track a patients&rsquo; glucose throughout the day and night, notifying the patient of
highs and lows so the person can act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subcutaneous glucose
levels change more slowly than plasma glucose, which can be a restriction to their effectiveness, particularly if glucose levels
are changing rapidly. Subcutaneous glucose levels have a time lag compared to blood glucose measurements, and measurements may
not always match blood glucose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CGM is commonly used
in conjunction with continuous subcutaneous insulin infusion (CSII), which involves a patient wearing an insulin pump and infusion
set that infuses insulin into the body. Although pumps are currently manually controlled by the patient, CGM with CSII could potentially
be used as part of a closed-loop. CSII is generally restricted to Type 1 diabetics, where the need for ongoing insulin infusion
is highest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CGM is mainly used
in a limited proportion of diabetics, particularly those concerned about severe, nocturnal hypoglycemia, pregnant women who require
meticulous glucose control or those who may not be able to easily administer an SMBG test (e.g., those living in remote or hostile
environments). However, CGM is more expensive than traditional SMBG and may be less eligible for reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Developments in
Saliva Glucose Monitoring</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that there
are a limited number of companies developing saliva-based glucose monitoring. In addition, we believe that a number of universities
across the world have a range of saliva based sensors at early stages of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Emerging approaches
to non-invasive glucose monitoring, none of which have reached widespread application, include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Optical Transducers &ndash; Optical transducers can potentially detect glucose in blood using light of variable frequencies. Different properties of light are used to interact with glucose molecules. The anterior chamber of the eye and the interstitial fluid are two regions where spectroscopic measurement of the reflected or transmitted light can be captured. Some emerging techniques in optical transducers include Kromoscopy, Photoacoustic spectroscopy, OCT, Occlusion spectroscopy, Polarimetry, Thermal infrared, Fluorescence, Raman spectroscopy, MIR spectroscopy, and NIR spectroscopy. Most of these systems are not suitable for point of care testing.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Transdermal Transducers &ndash; Transdermal transducers can be used to measure glucose. In this case, oxygen supply is not a limiting factor and hence the concentration of glucose can potentially be detected with less interference. Some techniques, such as reverse iontophoresis, demonstrate adequate precision for home-based blood glucose monitoring. The shortcoming of such transducer types is their inability to detect hypoglycemia with a sensitivity of 23% for glucose concentrations. Emerging techniques in transdermal transducers include impedance spectroscopy, skin suction blister, sonophoresis and reverse iontophoresis.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Use of Wearable Technologies for Diabetes Management &ndash; Several companies are developing wearable devices that are purported to be capable of monitoring glucose and tracking biometrics to monitor health. These devices commonly use the speckle pattern effect, i.e., using changing patterns of scattered light. Some wearable devices also use non-invasive spectrometric process combined with electrical sampling to determine glucose levels in blood using low-cost wavelength specific transmitters and receivers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further technologies in development include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="width: 35%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Technology</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 64%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Limitations and Impediments</B></FONT></TD></TR>
<TR>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Lasers</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety
        concerns with long-term use of lasers on the skin</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concerns
        with lag time between glucose levels in the skin and blood glucose levels</P></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Breath-based measurements</P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concerns
        that measuring breath does not accurately correlate with blood glucose levels</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potential
        for contamination</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
suitable for young children</FONT></P></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Tear sample</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concerns
        with lag time between glucose levels in tears and blood glucose levels</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May
        be affected by the patient&rsquo;s hydration</P></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Wearable technology to detect glucose through the skin</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reliability
        of results due to problems with sweat and body temperature</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Usability
        during sporting activities, particularly water sports</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Problems
        with skin irritation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
        suitable or practical for children</P></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Using ear lobe sensors or ear canals</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indiscreet
        and impractical</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Problems
        with ear wax and reliability of the measurements, especially in children</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Importance of Glucose Monitoring</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the main aims
of diabetes monitoring and management is to maintain blood glucose levels within a specified target range. Self-monitoring of blood
glucose should be part of a regular management plan for patients with diabetes to enable this. Self-monitoring provides information
regarding an individual&rsquo;s dynamic blood glucose profile. This information can help with the appropriate scheduling of food,
activity, and medication. It is also required for understanding of the timing of blood glucose variations. Lack of regular self-monitoring
predicts hospitalization for diabetes-related complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Self-monitoring of
blood glucose is an essential tool for people with diabetes who are taking insulin or for those who experience fluctuations in
their blood glucose levels, especially hypoglycemia. For patients taking insulin and adjusting their dose, self-monitoring is needed
for self-management. For others receiving oral medication, profiling glucose trends and the confirmation of high or low blood glucose
can be a useful addendum to successful management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Self-monitoring of
blood glucose aids the management of diabetes by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Facilitating the development of an individualized blood glucose profile, which can then guide health care professionals in treatment planning for an individualized diabetic regimen;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Giving people with diabetes and their families the ability to make appropriate day-to-day treatment choices in diet and physical activity as well as administration of insulin or other agents;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Improving patients&rsquo; recognition of hypoglycemia or severe hyperglycemia; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Enhancing patient education and patient empowerment regarding the effects of lifestyle and pharmaceutical intervention on glycemic control.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of blood glucose
control in preventing the development and progression of complications has been proven in both type 1 and type 2 diabetes, with
an especially strong relationship between intensive blood glucose control and complications such as neuropathy (affecting limbs)
and diabetic retinopathy (leading to blindness).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over time, glucose
measurements are expected to provide the patient and their health care professionals with the information and insights required
to determine the best management strategy for diabetes, potentially minimizing the fluctuations in their glucose levels and resulting
in better health outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of blood glucose
monitoring and control in preventing the development and progression of diabetes complications has been well established. Studies
show that those who properly monitored blood glucose levels had better health outcomes (such as reduced complications of diabetes)
compared to those who did not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a person with diabetes,
however, this daily process is not only painful but can be exhausting, disruptive, frustrating, frightening and consuming, which
often leads to poor compliance and poor health outcomes. People with diabetes have reported that stigma is a significant concern
to them. This causes tension and anxiety and, because the procedure is perceived as inconvenient and difficult, leads to suboptimal
monitoring and poor adherence. Many people with diabetes do not test as often as clinically recommended, increasing the risk of
complications. The reasons for under-compliant testing include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Inconvenience &ndash; patients with single-point finger stick devices must use them several times a day. The patient self-inflicts a painful prick and draws blood to measure blood glucose levels. This process is inconvenient and is often uncomfortable in social situations.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Pain &ndash; although the fingertip provides a good site to obtain a blood sample, it also is densely populated with highly sensitive nerve endings. As a result, lancing and subsequent manipulation of the finger to draw blood and multiple finger sticks can be painful.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Risk of infection
 &ndash; the Centers for Disease Control data suggests that Hepatitis B Virus morbidity and mortality may be higher in diabetics
than in non-diabetics.</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Difficulty of use &ndash; to obtain a blood sample with single-point finger stick devices, patients generally prick one of their fingertips and squeeze the area to produce the blood sample, with another prick required if insufficient blood volume is first obtained. The blood sample is then placed on a disposable test strip that is inserted into a blood glucose meter. This task can be difficult for patients who have decreased sense of touch and/or clarity of vision, which is not be uncommon for diabetics.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Medical Waste &ndash; used needles, lancets and blood strips are medical waste that must be disposed of accordingly.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Diabetes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Diabetes is the condition
in which the body does not properly process food for use as energy. Most of the food we eat is turned into glucose, or sugar, for
our bodies to use for energy. The pancreas, an organ that lies near the stomach, makes a hormone called insulin to help glucose
get into the cells of our bodies. When a person has diabetes, the body either does not make enough insulin or cannot use its own
insulin as well as it should. This causes sugars to build up in blood. Diabetes can cause serious health complications including
heart disease, blindness, kidney failure, and lower-extremity amputations. Self-monitoring of blood glucose is an important component
of modern therapy for diabetes and is recommended for people with diabetes by their health care professionals in order to achieve
normal levels of glycemia. The types of diabetes are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Type 1 Diabetes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Type 1 diabetes is
caused by an auto-immune reaction where the body&rsquo;s defense system attacks the insulin-producing cells located in a person&rsquo;s
pancreas. The reason why this occurs is not fully understood. People with Type 1 diabetes produce no insulin. The disease can affect
people of any age, but usually occurs in children or young adults. People with this form of diabetes need injections or infusions
of insulin every day to control the levels of glucose in their blood. Type 1 diabetes patients constitute approximately 10% of
the overall number of patients, but are much more extensive users of glucose monitoring systems, as these people with diabetes
need to measure their glucose levels over 6 times a day.</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When a person has lived
with diabetes for many years, a condition known as &ldquo;Hypoglycemia Unawareness&rdquo; can occur, affecting approximately 40%
of people with Type 1 diabetes. As a result, people with this condition monitor their glucose levels more frequently. It is a major
limitation to achieving tight diabetes control and significantly reduces quality of life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Type 2 Diabetes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Type 2 diabetes accounts
for at least 90% of all cases of diabetes. It is characterized by insulin resistance and relative insulin deficiency, either of
which may be present at the time that diabetes becomes clinically manifest. The diagnosis of Type 2 diabetes usually occurs after
the age of 40 but can occur earlier, especially in populations with high diabetes incidence. Type 2 diabetes can remain undetected
for many years and the diagnosis is often made from associated complications or incidentally through an abnormal blood or urine
glucose test. It is often, but not always, associated with obesity, which may contribute to insulin resistance and lead to elevated
glucose levels. As Type 2 diabetes is a progressive disease, a growing portion of Type 2 diabetes patients use insulin as part
of their treatment. Trends such as urbanization, unhealthy diets and reduced physical activity are all contributing lifestyle factors
that increase the risk of developing Type 2 diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Gestational Diabetes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gestational diabetes
is a form of diabetes consisting of high glucose levels during pregnancy. It develops in one in seven pregnancies worldwide and
is associated with complications in the period immediately before and after birth. Gestational diabetes usually disappears after
pregnancy, but afflicted women and their offspring are at an increased risk of developing Type 2 diabetes later in life. Approximately
half of women with a history of gestational diabetes go on to develop Type 2 diabetes within five to ten years after delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
GBS System also will be able to support patients with pre-diabetes, also called metabolic syndrome. Metabolic syndrome is a combination
of medical disorders that increase the risk of developing cardiovascular disease and diabetes. Approximately 493 million people
in China are understood to have pre-diabetes. This population is typically prescribed with periodic lab-based glucose level testing
which requires a doctor visit and typically does not involve the utilization of self-monitoring glucose devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Diabetes &ndash; The Global Epidemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Diabetes is a global
epidemic and it is growing rapidly. Some key statistics include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">In 2015, it was estimated that one in 11 people across the globe had diabetes. That&rsquo;s 415 million people. Changing lifestyles, diets, and urbanization has aided this rapid rise in diabetes.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">By 2040, it is estimated that one in 10 people will have diabetes, an increase of over 200 million people in 25 years.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Diabetes can lead to complications such as heart disease, blindness, kidney failure, and lower-extremity amputations and results in a huge burden on healthcare infrastructure.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Every six seconds, a person dies from diabetes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Diabetes in China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The International Diabetes
Federation (the &ldquo;IDF&rdquo;) recently noted that China has the world&rsquo;s largest diabetes epidemic, and it continues
to grow at a fearsome pace. Rapidly rising rates of diabetes have been seen in previous studies, and according to the latest data,
10.6% of Chinese adults have diabetes. The Chinese diabetic population stands at some 109 million people &mdash; about a third
of all people globally with diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The economic growth
of China has had a major impact on the incidence of the disease, such that China accounts for the fastest growing global market
segment. China has, by a significant number, the largest number of people with diabetes. In 2015, China alone had a similar number
of people with diabetes as the next three largest diabetes markets combined (India, USA and Brazil). China had 1.3 million deaths
due to diabetes in 2015 (26% of total global deaths due to diabetes), with 40.8% of those deaths occurring in people under 60.
Diabetes related health expenditure in China was US$51bn in 2015 alone and is expected to reach US$72bn by 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Journal of the
American Medical Association identified that out of 99,000 people surveyed in a study, half had pre-diabetes blood glucose levels
 &ndash; abnormally high but not high enough for a diagnosis of diabetes. Approximately 493 million people in China are understood
to have pre-diabetes. These findings indicate the enormity of diabetes as a public health problem in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Diabetes is set to
become the heaviest burden on the Chinese healthcare system, as the IDF estimates diabetes accounts for 13% of all medical expenditures
in China.&nbsp;The number of people affected by diabetes has spiked in recent years and is expected to reach 150 million Chinese
by 2040. The biggest challenge for the Chinese government in this context is to&nbsp;raise public awareness&nbsp;of the symptoms
of diabetes and the benefits of early diagnosis. Adding to this burden is the indirect cost associated with informal care by relatives
or caregivers &ndash; while it is difficult to calculate, some studies suggest this could constitute up to half the cost of diabetes.
Further, lost productivity from diabetes is a drain on the economy, amounting to 0.6% of China&rsquo;s GDP. People with diabetes
in China spend nine times more money on health care than healthy people of the same age and sex without diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A significant portion
of the direct costs of diabetes, and its broader economic impact, arises due to associated complications such as heart disease,
kidney disease, amputations, cerebral conditions and blindness &ndash; over 70% of patients have at least one complication. A recent
study using actual electronic insurance claims data (from 2009-2011) in China found that the average direct cost of treatment (US$1,857
per patient) increased significantly with the number of diabetes-related complications up to over US$3,000. The average annual
cost per patient with at least one hospitalization (about 20% of patients) in a year (US$6,301 in 2009) was more than four-fold
the costs per patient with only outpatient visits. These complications and hospitalizations are far more likely if diabetes is
undiagnosed or poorly monitored and managed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Patent Protection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 74%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Official Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">US 9,766,199</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Granted</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">CN 201380022888</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>Notice of Allowance</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">AU2016/050555</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Filed</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The original patent
application, which claims a priority date of March 2012, has been granted in the United States and the Chinese Patent Office has
issued a Notice of Allowance in China (CN 201380022888). A second international patent application (PCT/AU2016/050555) claiming
iterations to the device design has been filed with a priority date of June 2016 and will soon enter national phase in certain
jurisdictions, and further patent applications are in preparation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Healthcare Industry and the Digital
Effect &ndash; China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare industry
in China is undergoing significant change, driven by ongoing healthcare reforms, the review of government policies and the introduction
and adoption of new technologies such as wearable devices and mobile apps. Combined with an aging population and a healthcare infrastructure
that has struggled to keep up with the pace of socioeconomic change, this creates significant opportunity in China to enhance efficiency
through innovation. In 2012, the Ministry of Health invested approximately US$1.4billion (RMB 9.5 billion) to develop electronic
medical records, improve hospital information systems and intensify digital healthcare. These costs may be only the beginning as
the combination of an aging population with long-term inefficiencies and unmet needs within the healthcare system trigger subsequent
reforms to address issues within the Chinese healthcare system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The broad scope of
digital health includes categories such as mobile health (mHealth), health information technology, wearable devices, telehealth
and telemedicine, and personalized medicine. Providers and other stakeholders are using digital health in their efforts to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">reduce inefficiencies;&nbsp;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">improve access;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">reduce cost;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">increase quality; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">make medicine more personalized for patients.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is widely believed
that patients and consumers can use digital health to better manage and track their health and wellness related activities. In
2016, to address challenges presented by demographic change, China&rsquo;s State Council announced a plan for deepening reform
of the country&rsquo;s health-care system. The plan, which aims to guide medical reforms in specific regions, was widely seen as
encouraging the further development of digital health programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This growth in digital
healthcare is expected to be driven in large part by solutions to address current inefficiencies and unmet needs in the Chinese
healthcare system for diabetes sufferers. The promise of digital health &ndash; also termed &lsquo;connected health&rsquo; &ndash;
in this context is to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">allow for remote diagnosis and monitoring;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">facilitate self-managed care;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">deliver care outside traditional settings, with better access at lower cost; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">assist chronic disease management to improve population health outcomes.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, there
are several diabetes websites in China offering education, information and the potential to connect with health care professionals.
Many of these websites collect patient information using blood glucose monitors that are often provided by major pharmaceutical
companies and not part of one complete ecosystem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
opportunity to unlock substantial savings in the Chinese healthcare value chain is significant. Recently, there appears to have
been a significant increase in Chinese digital healthcare resources, such as online patient-doctor communication and consulting
services, disease management applications, social networks for medical professionals, and even &ldquo;internet hospitals&rdquo;
that provide remote diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China&rsquo;s digital
healthcare market is expected to grow considerably in the next few years, with US$110 billion expected to be invested in 2020,
of which US$35 billion is expected to be invested in disease management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Digital Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that
the non-invasive attributes of our technology will make it easier for a patient to monitor their glucose levels. Accordingly,
we anticipate having the potential to collect a greater amount of information from a larger proportion of patients. This increased
data flow, for both the patient and their health care professionals, would open significant opportunities to improve the way diabetes
is monitored, as highlighted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tv502124_img03.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&#9;For illustrative
purposes only &ndash; device is not a Company product</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, with
the cloud-based application across web and mobile, we anticipate our holistic system would be used as a disease management tool
and address many of the systemic issues inherent in diabetes management in China through:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the storage and analysis of patient data generated by the biosensor and or the dietary and fitness inputs generated by the app and the output to the user;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the connectivity of patients and patient results with health care team or relatives (as per patient requirements);</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">reminder and flagging service for patients;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">a medium for pharmaceutical companies to implement patient support programs (as per regulatory restrictions); and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">education services for lifestyle, diet and glucose management.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Regulatory/Clinical Development Framework</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be permitted
to market the GBS System until we receive regulatory clearance. To date, we have not received regulatory clearance in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The research, design,
testing, manufacturing, labeling, selling, marketing and distribution of medical devices are subject to extensive regulation by
country-specific regulatory authorities, which regulations differ from country to country. We also will be subject to numerous
post-marketing regulatory requirements, which may include labeling regulations and medical device reporting regulations, which
may require us to report to different regulatory agencies if our device causes or contributes to a death or serious injury, or
malfunctions in a way that would likely cause or contribute to a death or serious injury. In addition, these regulatory requirements
may change in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have conducted
limited testing on the GBS System. While preliminary feasibility studies conducted by the University of Newcastle, Australia have
produced results we believe to be encouraging and indicative of the potential performance of the GBS System, data already obtained,
or in the future obtained, from clinical and performance testing may not necessarily predict the results that will be obtained
from later pre-clinical studies and clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The completion of any
future clinical testing for the GBS System or other testing that we may be required to undertake in the future will be subject
to, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the conduct of performance testing in accordance with regulatory requirements;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the availability of patients participating in the testing; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the work of clinical investigators performing clinical trials on our anticipated schedule and consistent with regulatory standards and protocols.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be responsible
for obtaining requisite regulatory approvals in the jurisdictions of the China Region, initially engaging the China Food and Drug
Administration. We do not yet have the necessary regulatory approvals to put to service our biosensor systems or any other product
in the China Region. We plan initially to launch our products, once approved, in China first. We have not yet considered the subsequent
regulatory requirements and strategies in other jurisdictions in the China Region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Distribution, Sales and Marketing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We propose to enter
into arrangements with distributors to market and sell our products. We have entered into an agreement in principle with a medical
affairs specialty company to drive prelaunch activity for 18 months with the scope to create awareness and build share of voice
with local referring physicians, diabetes educators, patient associations, government organizations and general practitioners.
This agreement is our Medical Affairs Services Agreement with Clinical Research Corporation, which an affiliate controlled by LSBD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek local provincial
distributors in China that will stock, market and sell the product across the region. While a single licensee may seek exclusive
distribution rights to the device, it is anticipated there will be multiple distributors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial strategy
for distributor selection and appointment includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">appointment of a global consulting firm to screen the top three distributors per province;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">determining selection criteria that include capability, capacity, volume of test strips currently sold and experience in sector;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">defining the time frame to implement a &ldquo;switch&rdquo; strategy for distributors to replace the conventional blood glucose testing devices; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment of local provincial / regional distributors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are looking for
and will depend in part on qualified distributors for the marketing and selling of our products. We will depend on these distributors&rsquo;
efforts to market our products, yet we will be unable to control their efforts completely. These distributors typically would sell
a variety of other, non-competing products and will be expected to devote certain resources to selling the GBS System. We expect
to devote suitable time and effort to recruiting and retaining qualified third-party distributors and training them in our technology
and product offering. To develop and expand our distribution, we intend to scale and improve our processes and procedures that
support our distributors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend, assuming
the completion of development and regulatory approval, to commercialize, market and distribute our GBS System in Mainland China,
Hong Kong, Vietnam and Bangladesh in that order of priority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Market Penetration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to commence
our market penetration strategy initially in China. Our commercialization strategy will be to switch users from the current finger-lancing
capillary blood test product to our GBS System. The strategy for this market penetration will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">developing an early stage website to generate market awareness and engage with future users;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">creating &ldquo;Share of Voice&rdquo; for the GBS System in the China Region;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">creating market awareness among patients through various promotions; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">partnering with patient diabetes associations and sponsor patient support groups in China.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This early strategy
is designed to be driven by patients and validated by the physicians and health care professionals through the generation of evidentiary
data. We expect that this data will demonstrate that patients will achieve better glycemic control when using the GBS System as
compared to conventional blood glucose testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company has
utilized for its benefit certain employees of its parent GBS Pty Ltd. The Company is not incurring or accruing any financial or
other obligations other than certain shared corporate overhead in connection with this utilization. The Company intends to continue
this utilization through completion of this Offering while employing its own employees as it deems necessary. Through its use
of parent employees, the Company is currently utilizing the following staff, in addition to the directors of the Company: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Commercialization Director</FONT></P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Commercialization Manager</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Medical Affairs Director</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Science Officer</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Finance Director and support team</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Head &ndash; Legal and Commercial Affairs</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently not
a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that we believe is not
ordinary routine litigation incidental to our business or otherwise material to the financial condition of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_008"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>
AND RESULTS OF OPERATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Prospective
investors should read the following discussion and analysis of our financial condition and results of operations together with
our consolidated financial statements and the related notes and other financial information included elsewhere in this Offering
Circular. Some of the information contained in this discussion and analysis or set forth elsewhere in this Offering Circular,
including information with respect to our plans and strategy for our business, includes forward-looking statements that involve
risks and uncertainties. See &ldquo;Cautionary Note Regarding Forward-Looking Statements.&rdquo; You should review the &ldquo;Risk
Factors&rdquo; section of this Offering Circular for a discussion of important factors that could cause actual results to differ
materially from the results described in or implied by the forward-looking statements contained in the following discussion and
analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>On
November 5, 2017, the Company effected a stock split of one to 90,000 shares resulting in 9,000,000 issued and outstanding
shares of common stock as of that date and the date hereof. On August 9, 2018, the Company effected a reverse stock split of
approximately one to 0.9167 shares that resulted in the Company having 8,250,000 issued and outstanding shares of common
stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development
stage medical device company with licensed rights to commercialize a novel &ldquo;smart&rdquo; biosensor salivary glucose monitoring
system (the &ldquo;GBS System&rdquo;) in the China Region, comprised of Mainland China, Hong Kong, Vietnam and Bangladesh. We were
formed on December 5, 2016, as a Delaware corporation with headquarters in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently are a
wholly-owned subsidiary of Life Science Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;), an Australian company that owns the
worldwide intellectual property rights to the biosensor platform from University of Newcastle, Australia. LSBD is responsible for
the development of the biosensor platform and has licensed to us that technology for us to commercialize the GBS System in the
China Region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The
consolidated financial statements show a loss of $3,166,586 from 1 July, 2017 through March 31, 2018. The Company has funded
its operations to date with the net proceeds from private placements outside of the United States in the amount of $8,715,793
of Series A Preferred Stock and $5,277,056 of convertible notes issued by our subsidiary GBS Pty Ltd. Net shareholder&rsquo;s
equity was ($2,723,048) as of March 31, 2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles in the
United States (&ldquo;US GAAP&rdquo;). Our fiscal year ends June 30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations discuss our consolidated financial statements, which have
been prepared in accordance with US GAAP. The preparation of these consolidated financial statements requires making estimates
and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
at the date of the consolidated financial statements, as well as the reported revenues and expenses for the reporting periods.
On an ongoing basis, we evaluate such estimates and judgments. We base our estimates on historical experience and on various other
factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ (perhaps
significantly) from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While all the accounting
policies impact the consolidated financial statements, certain policies may be viewed to be critical. Our management believes that
the accounting policies which involve more significant judgments and estimates used in the preparation of our consolidated financial
statements, include revenue recognition, inventories, liability related to certain warrants, and accounting for production lines
and its related useful life and impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Revenue Recognition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not generated
any revenues to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues from product
sales would be recognized in accordance with ASC 605-10, &ldquo;Revenue Recognition&rdquo;, when delivery has occurred, persuasive
evidence of an agreement exists, the vendor&rsquo;s fee is fixed or determinable, no further obligation exists and collectability
is probable. We do not intend to grant a right of return. We will assess whether the fee is fixed or determinable based on the
nature of the fee charged for the products delivered, the existing contractual arrangements and the distributor&rsquo;s consistency
of payments. When evaluating collectability, we consider whether we have sufficient history to reliably estimate the distributor&rsquo;s
payment patterns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a sales arrangement
were to contain multiple elements, such as software and non-software components, we would allocate revenue to each element based
on a selling price hierarchy as required according to ASC 605-25, &ldquo;Multiple-Element Arrangements&rdquo;, or ASC 605-25. The
selling price for a deliverable will be based on its Vendor Specific Objective Evidence, or VSOE, or, if available, third party
evidence, or TPE, if VSOE is not available, or estimated selling price, or ESP, if neither VSOE nor TPE is available. The best
estimate of selling price is established considering several internal factors including, but not limited to, historical sales,
pricing practices and geographies in which we offer our products. The determination of ESP is judgmental.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues from software
components in sales arrangements containing multiple elements will be recognized when all criteria outlined in ASC 985-605, &ldquo;Software
Revenue Recognition&rdquo;, or ASC 985-605, are met (when persuasive evidence of an arrangement exists, delivery of the product
has occurred or the services have been rendered, the fee is fixed or determinable and collectability is probable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For multiple element
arrangements within ASC 985-605, revenues will be allocated to the different elements in the arrangement under the &ldquo;residual
method&rdquo; when VSOE of fair value exists for all undelivered elements and no VSOE exists for the delivered elements. Under
the residual method, at the outset of the arrangement with the customer, we will defer revenue for the fair value of its undelivered
elements and recognize revenue for the remainder of the arrangement fee attributable to the elements initially delivered in the
arrangement when the basic criteria in ASC 985-605 have been met. Any discount in the arrangement will be allocated to the delivered
element.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since VSOE does not
exist for undelivered elements, revenues will be recognized as one unit of accounting, on a straight-line basis over the term of
the last deliverable based on ASC 605-15 and ASC 985-605.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Liability Related to Certain Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value
of the liability for certain warrants issued to investors will be calculated after the closing of the proposed IPO when the events
have occurred to allow a fair value to be determined for these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Fair
                                         value for each reporting period will be calculated based on the following assumptions:</FONT></P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Risk-free interest
                                    rate&nbsp;&mdash;&nbsp;based on yield rates of non-index linked U.S. Federal Reserve treasury
                                    bonds.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Expected volatility&nbsp;&mdash;&nbsp;was
                                    calculated based on actual historical stock price movements of the Company together with companies
                                    in the same industry over a term that is equivalent to the expected term of the option.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Expected life&nbsp;&mdash;&nbsp;the
                                    expected life was based on the expiration date of the warrants.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expected dividend yield&nbsp;&mdash;&nbsp;the Company does
    not expect to pay dividends to its shareholders in the foreseeable future.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Capitalization of Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Extended Transition Period for &ldquo;Emerging
Growth Companies&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to
use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public
and private companies until those standards apply to private companies. As a result of this election, our financial statements
may not be comparable to companies that comply with public company effective dates. Because our financial statements may not be
comparable to companies that comply with public company effective dates, investors may have difficulty evaluating or comparing
our business, performance or prospects in comparison to other public companies, which may have a negative impact on the value and
liquidity of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2018,
we had $1,054,650 in cash and cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced
cumulative losses of $3,478,258 from inception through March 31, 2018, and have a stockholders&rsquo; equity position of ($2,723,048)
at March 31, 2018. In addition, we have not completed our efforts to establish a source of revenues sufficient to cover our operating
costs and expect to continue to generate losses for the foreseeable future. There is no assurance that we will be able to obtain
an adequate level of financing needed for our near-term requirements or the long-term development and commercialization of our
product. Due to these conditions, our ability to continue as a &ldquo;going concern&rdquo; depends in part on our ability to raise
sufficient capital. See Note 1 to Consolidated Financial Statements for the period from July 1, 2017&nbsp;through March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Since
inception, we have financed our operations primarily through funding from affiliates, and a private placement of convertible
notes of our subsidiary GBS Pty Ltd and our Series A Convertible Preferred Stock accompanied by warrants. The convertible
notes bear interest at 7% per annum and are convertible to Common Stock at a 15% discount to the price per Share in this
Offering. The Series A Convertible Preferred Stock are convertible into Common Stock at a one-to-one ratio upon completion of
this Offering. One warrant was issued along with each share of Series A Convertible Preferred Stock. Each warrant is
exercisable at the price per Share in this Offering during the one year period commencing on the second anniversary of the
completion of this Offering, and the underlying Common Stock must be held at the time of exercise.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to our
management&rsquo;s estimates, based on our budget and proposed schedules of development, approvals and organization, we believe,
although there can be no assurances, that if we raise the minimum amount of this Offering then we will have sufficient capital
resources to enable us to continue to implement our business plan and remain in operation for at least the next 12 months, but
there also can be no assurances how long after, if at all, such 12 months we might be able to continue as such without raising
additional capital. We do not anticipate generating any revenues for at least 24 months, if at all, from the date of this Offering.
We believe, although there can be no assurances, that raising more than the minimum and less than the maximum amount of this Offering
will enable us to continue to implement our business plan and remain in operation for an indeterminate amount of time longer than
just raising the minimum amount, with the amount raised in excess over that minimum amount generally allowing for more additional
time, but we will still be required to promptly seek and obtain additional sources of capital. Even if we raise the maximum amount
of this Offering, we will need additional capital before we are able to fully implement our business plan and commercialize our
products for public sale, as to which implementation and commercialization there can be no assurances as to success. In any event,
there can be assurances that we will ever be able to raise additional capital.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As such, we have a
significant present need for capital. If we are unable to scale up our development, approvals and organization efforts of the
GBS System or meet our commercialization targets (or if we are unable to generate any revenue at all), and if we are unable to
obtain additional capital resources in the near term, we may be unable to continue activities absent material alterations in our
business plans and our business might fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, readers
are advised that available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional
funding sooner than expected. Should this occur, we will need to seek additional capital earlier than anticipated in order to fund
(i) further development and, if needed, testing of our the GBS System and its related application and data storage components,
(ii) our efforts to obtain regulatory clearances or approvals necessary to be able to commercially launch the GBS System, (iii)
sales and marketing efforts and (iv) general working capital. Such funding may be unavailable to us on acceptable terms, or at
all. Our failure to obtain such funding when needed could create a negative impact on our stock price or could potentially lead
to the failure of our company. This would particularly be the case if we are unable to commercially launch the GBS System in the
jurisdictions and in the timeframes we seek.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not have during
the period presented, and we do not currently have, any off-balance sheet arrangements as defined under Securities and Exchange
Commission rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for our
contingent liabilities in accordance with ASC 450 &ldquo;Contingencies&rdquo;. A provision is recorded when it is both probable
that a liability has been incurred and the amount of the loss can be reasonably estimated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to legal
matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice
of legal counsel and other information and events pertaining to a particular matter. Currently, we are not a party to any ligation
that we believe could have a material adverse effect on our business, financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_009"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All directors hold
office for one-year terms until the election and qualification of their successors. Officers are appointed by our Board of Directors
and serve at the discretion of our Board of Directors, subject to applicable employment agreements. The following table sets forth
information regarding our executive officers and the members of Board of Directors as of the date of this Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt"><B>Name</B></FONT> </TD>
    <TD STYLE="width: 1%; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 6%; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Age</B></FONT> </TD>
    <TD STYLE="width: 1%; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 61%; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Position(s)</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Jonathan S. Hurd</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">47</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Chairman of the Board</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Harry Simeonidis</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">49</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">President and Director</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Dr. Jean-Claude Becker</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">59</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Chief Operating Officer, Executive Vice President and Director</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Victoria Gavrilenko</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">37</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Operations Manager, Secretary, Treasurer and Director</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Dr. Yong-Jiang Hei</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">57</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Dr. John Caminis</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">59</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Harry Simeonidis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Harry Simeonidis
has been our President since 2017. Mr. Simeonidis has more than 25 years of experience in senior management roles in healthcare,
pharmaceutical and life sciences businesses in Australia, New Zealand and Asia. Since March 2017, he has been the General Manager
of Farmaforce Limited, an Australian company listed on the Australian Stock Exchange. FarmaForce is a contract sales organization
catering to the Australian Pharmaceutical Industry. FarmaForce is majority-owned by iQnovate Limited, which also owns a majority
of LSBD. iQnovate Limited is an Australian life sciences organization that provides intellectual property asset management services
and scientific advice to the biopharmaceutical industry. Mr. Simeonidis was General Manager Surgery Asia Pacific of GE Healthcare.
From 2003 to 2012, Mr. Simeonidis was the CEO of GE Healthcare ANZ, a healthcare company operating in Australia and New Zealand
and affiliated with General Electric Company.&nbsp;Mr. Simeonidis&rsquo; duties nominally will consist of the duties of President
contemplated by the Company&rsquo;s by-laws and will consist of formulating market entry strategy and public relations but will
not include general management of the Company&rsquo;s operations, which will be managed by Dr. Becker. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Dr. Jean-Claude
Becker</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">J.C. Becker, M.D.
is a Rheumatologist and global researcher with expertise in developing and positioning innovative products in autoimmune diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more
than the last five years Dr. Becker has been an independent consultant in the pharmaceutical and biomedical industries. Prior
thereto, for 12 years Dr. Becker was Group Director Global Clinical Research in Immunology at
Bristol-Myers Squibb, where he has led the clinical development of Abatacept, leading to advancements in treating Rheumatoid
Arthritis and Lupus. Dr. Becker has significant experience conceiving and designing clinical development strategies for
biologics and drugs that treat autoimmune diseases such as Rheumatoid Arthritis and Lupus. He also has successfully
conducted clinical trials toward obtaining regulatory approvals as well as projects to position and profile biologics/drugs
with post-approval studies to achieve marketing and commercial objectives. He has collaborated and led on projects in global
markets including North America, Europe and Asia, specifically Japan, Korea, Taiwan and China as well as Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to his work
at Bristol-Myers Squibb, Dr. Becker held senior research positions at other large pharmaceutical companies, including Sandoz and
Pfizer as well as smaller biotechnology firms, such as Genetics Institute, Inc. and Texas Biotech. His experience encompasses
biologics to small molecules and ranges from early clinical development to medical affairs with marketing and international setup.
Prior to joining the pharmaceutical industry, he worked as a consultant in Rheumatology and was a senior lecturer in Immunology
at Hospital Universities in Paris.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Becker received
his M.D. from, and specialized in Rheumatology at, the Paris VI University in France. He has been widely published in major scientific
publications and medical journals and has reported at major international congresses for more than 25 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The Becker Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In conjunction with Dr. Becker&rsquo;s
service in his executive officer positions as a director of the Company, we have entered into a Service Provider Agreement dated
as August 13, 2018, with Becker Clinical Research Consulting, LLC (an entity wholly-owned by Dr. Becker (the &ldquo;Becker Agreement&rdquo;))
pursuant to which he will perform certain of his duties to the Company. The Becker Agreement has a one-year term and automatically
renews for successive one-year periods unless terminated by either party prior to the end of the then-current term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Becker Agreement requires that Dr. Becker perform for
the Company the functions typically served by a chief operating officer/executive vice president, with such customary responsibilities,
duties and authority normally associated with such positions and as may from time to time be assigned to him by the Company&rsquo;s
Board of Directors or an authorized committee thereof. Under the Becker Agreement, Dr. Becker and his selected staff will report
directly to the Company&rsquo;s Board or a committee thereof. The Becker Agreement authorizes Dr. Becker to select that staffing
to support him in his duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other terms of the Becker Agreement
governing Dr. Becker&rsquo;s duties to the Company, Dr. Becker will supervise all personnel working for the Company and as such
will be responsible for the proper operation of the business of the Company. Those duties include, but are not limited to, to
primary responsibility for directing clinical, medical affairs strategy, regulatory, pharmacovigilance and other supervisory activities
listed in his responsibilities, primary responsibility for all activities that are listed in his responsibilities and are those
that are pertinent to the regulatory and clinical process, responsibility for coordinating staff and contractors for educating
key opinion leaders and other stakeholders in the field of glucose monitoring and diabetes, coordinating all staff and contractors,
clinical, medical and regulatory matters, and the Company&rsquo;s publication strategy, primary responsibility for directing,
controlling and coordinating, the preparation and implementation of pre-launch activities, market access, reimbursement, advocacy
and awareness, medical affairs operations (such as medical information service, post market surveillance, promotional material,
training and education programs to healthcare professionals and patients), branding, distribution, and scientific due diligence
as needed. In particular, the Becker Agreement requires that Dr. Becker supervise the operations of the Company and personnel
from the Company&rsquo;s New York City headquarters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Service Provider
will receive as compensation for Dr. Becker&rsquo;s services under the Becker Agreement $50,000 per year payable monthly plus
fees at the rate of $300 per hour. The Becker Agreement also contains non-competition, non-disclosure, invention assignment and
customary representations and warranties from Dr. Becker. Under the Becker Agreement, the Service Provider shall receive a Form
1099 at the end of each tax year for the fees paid thereunder.</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Victoria Gavrilenko</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Victoria
Gavrilenko has been our Operations Managers&rsquo; Secretary and Treasurer and a director since July 2018. Ms. Gavrilenko is
based full-time at the Company&rsquo;s New York City headquarters and will report directly to Dr. Becker. From 2007 to 2009,
Ms. Gavrilenko was an executive assistant and contractor liaison at Southern California Steel Inc, a steel fabricator. From
2010 to 2013 she was an executive assistant to the CEO at John Carris Investments, LLC, a boutique investment banking firm
providing financial advisory services. From 2013-2015, Ms. Gavrilenko was a real estate agent at Centric New York, a boutique
agency. From 2016 until August 2018, Ms. Gavrilenko was the Office Manager at the New York City Offices of IQ Capital. Ms.
Gavrilenko graduated from California State University San Marcos.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-indent: 28.9pt">Ms. Gavrilenko&rsquo;s duties
will include, under Dr. Becker&rsquo;s ultimate authority:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-indent: 28.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Primarily
                                         directing all prelaunch and regulatory tactical steps, ensuring recruitment process and
                                         business plan are executed in accordance with the business plan</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Controlling
                                         employees, contractors and others to ensure effective and efficient tactical outcomes</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Primary
                                         responsible for upkeep of governance and compliance, coordination of board activities
                                         and input to the board agenda</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Informing
                                         stakeholders of relevant information</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Coordinating
                                         board meetings</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Responsibility for coordination of activities within the US as
    well as overseas business partners and contractors, all subject to her reporting to Dr. Becker and other senior executives</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>





<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in">&nbsp;</TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Coordination
                                         of the Company&rsquo;s treasury functions</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is
managed under the direction of our Board of Directors. Our Board of Directors currently consists of Messrs. Hurd and Simeonidis,
Ms. Gavrilenko and Drs. Becker, Caminis and Yong-Jiang Hei.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Jonathan S. Hurd</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Hurd joined
our Board in April 2018 and was appointed Chairman in August 2018. Mr. Hurd founded Asgard Regulatory Group in 2008, providing
broker-dealer and investment adviser compliance consulting services clients both domestic and abroad. Mr. Hurd has expertise in
broker-dealer and investment advisory regulations and is well versed in FINRA and SEC rules and regulations. Prior to starting
Asgard Regulatory Group, Mr. Hurd was the Chief Compliance Officer for several financial institutions. His experience involves
full-service broker-dealer, investment advisory services, bank-broker-dealers, and securitizations of mortgage-backed securities.
Jon also served on the Board of Directors for many of these companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this,
Jon was a Supervisor of Examiners at FINRA, previously NASD, in the New York District Office. While with FINRA, he supervised
routine examinations of FINRA member firms, conducted large- scale enforcement cases jointly with the Justice Department and Federal
Bureau of Investigations. Mr. Hurd also assisted the District Office with its ongoing training of new examiners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Mr.
Hurd was a Senior Adjunct Professor in the Townsend School of Business at Dowling College whereby he provided in-depth knowledge
and related work experience to MBA students as it related to the U.S. securities markets and financial institutions. He was responsible
for introducing students to the subjects of financial derivatives, foreign stock exchange, hedge transactions and risk management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Hurd earned
his BBA in Accounting and his MBA in Banking and Finance from Dowling College. Mr. Hurd is also a Certified Anti-Money Laundering
Specialist (CAMS) and holds the Series 7, 24, 27, 53, 55, 63, 66, 79 and 99 licenses as well as his NYS Life and Health Insurance
licenses.&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dr. John Caminis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Dr. Caminis
was our original sole director and served until August 2017. He rejoined our Board in April 2018. Dr. Caminis is a
pharmaceutical physician with a successful track record in clinical development, medical affairs and pharmacovigilance. He has wide-ranging
experience in the design and execution of clinical trials in diverse therapeutic areas including metabolic/metastatic bone
disease, oncology, gastroenterology, pain, immunology, infectious disease and dermatology. Dr. Caminis has made many
contributions in providing medical direction for new products and business development efforts. Dr. Caminis is currently the
Therapeutic Area Head (Gastroenterology &amp; Metabolism for Global Drug Safety) at Shire. His experience includes: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.15pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Former CR&amp;MA head &ndash; Biosimilars, Baxalta (Shire)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Former Senior Medical Director, UCB</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Former Director Clinical Development &amp; Medical Affairs, Novartis</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Former Medical Science Leader, Roche</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dr. Yong-Jiang Hei</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Yong-Jiang
Hei joined our Board in April 2018. Dr. Yong-Jiang Hei is a physician executive with leadership responsibility for product development
strategy and portfolio management in oncology. Expertise and hands-on experience in clinical strategy, clinical trial design and
conduct, and regulatory filings. Track record of success building and leading cross-functional project teams. US and global working
experience in large pharma as well as small biotech settings including setting up a clinical /medical group as the medical head
for Amgen China. Dr. Yong-Jiang Hei is currently Corporate VP and Chief Medical Officer, Qilu Pharmaceuticals, Shanghai, China.
His experience includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pharmaceutical product development, portfolio management, and corporate strategy</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Clinical trial design &amp; conduct including global phase III trials &amp; companion diagnostics</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Experience interacting with US &amp; global health authorities</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Regulatory filings (IND/NDA with FDA, EMA, PMDA (Japan), and cFDA (China)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">US and global opinion leader network</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">US, global, and country affiliate level working experience</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family
relationships between any of our directors or executive officers to be reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Leadership Structure </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
recognizes that one of its key responsibilities is to evaluate and determine its optimal leadership structure so as to provide
effective oversight of management. Our bylaws and corporate governance guidelines, which will become effective immediately prior
to the consummation of this offering, will provide our board of directors with flexibility to combine or separate the positions
of chairperson of the board of directors and chief executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Oversight of Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although management
is responsible for the day to day management of the risks we face, our Board of Directors and its committees will take an active
role in overseeing management of our risks and have the ultimate responsibility for the oversight of risk management. The Board
will regularly review information regarding our operational, financial, legal and strategic risks. Specifically, senior management
will attend periodic meetings of the Board, provides presentations on operations including significant risks, and is available
to address any questions or concerns raised by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scientific Advisory Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">We
have assembled a scientific advisory board with expertise in biology for medical applications. The members of our
scientific advisory board have made significant scientific contributions in their individual fields, have published in
leading journals and have been recognized with numerous awards and distinctions. Members of our scientific advisory board
provide strategic advice to us in fields pertinent to the GBS System and applicable technology and perform such other
services as may be mutually determined by us and the scientific advisory board member. Our scientific advisory board will
meet on an as-needed basis, based on our need for advice in their fields of expertise from time to
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dr. George Syrmalis MD, PhD, FACNP, MAAPP</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Executive Chairman and CEO of The iQ Group Global</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Syrmalis is
trained in Nuclear Medicine-radiation immunology and established iQnovate, part of The iQ Group Global, in 2011. Previously, Dr.
Syrmalis founded and led as CEO and Chairman The Bionuclear Group SA, (1995-2005) incorporating Antisoma SA, Bionuclear Institute
of Diagnosis and Therapy SA, Bionuclear Research and Development SA and Vitalcheck SA. He developed a business model by addressing
unmet clinical needs and leveraging on synergies between Bionuclear Group companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Antisoma
                                         SA: focused on development of novel biologic compounds both radio diagnostic and radio
                                         therapeutic in the area of oncology.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Bionuclear
                                         Institute for Diagnosis and Therapy SA: expanded into medical centers-renal dialysis
                                         clinics and the development of Europe&rsquo;s most prominent reference pathology service.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Bionuclear
                                         Research and Development SA: novel and generic radiopharmaceutical production.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Vitalcheck
                                         SA: Research, development and commercialization of point of care tests for professional
                                         and layman use. From 2005 onwards George continued his career as advisor to the Biopharmaceutical
                                         industry, advising on translational clinical trials, biomarkers and strategy to commercialize
                                         novel biologic entities in the areas of oncology, epilepsy and autoimmune diseases.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Professor Paul Dastoor - Inventor</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>PhD, University of Cambridge, Bachelor of Arts (Honours),
University of Cambridge</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Paul Dastoor is
a Professor in Physics in the School of Mathematical and Physical Sciences and the director of the Centre for Organic Electronics
at the University of Newcastle in Australia. He received his B.A. degree in Natural Sciences from the University of Cambridge
in 1990 and his PhD in Surface Physics, also from the University of Cambridge, in 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After completing
his doctorate, he joined the Surface Chemistry Department at British Steel in 1994 before taking up his present appointment at
the University of Newcastle in 1995. He was an EPSRC Visiting Research Fellow at Fitzwilliam College, Cambridge, UK in 2002 and
a Centre for the Central Laboratory Research Councils Visiting Research Fellow at the Daresbury Laboratory, Cheshire, UK in 2004-05.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">His expertise covers
surface analysis, electron spectroscopy, thin film growth, organic electronics, organosilane chemistry, polymer films, atom beam
optics and microscopy and medical devices. His research can be grouped in 3 main areas: (1) Helium Atom Microscopy, (2) Polymer
Adsorption on Metal Surfaces and (3) Organic Electronic Devices. Helium Atom Microscopy Atomic scattering from surfaces has matured
into a unique analytical technique for the study of formation of thin film structures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Principal Place of Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although certain
formational and capital-raising activities of the Company to date have occurred outside of the United States, the Company&rsquo;s
principal place of business is its offices in New York City and elsewhere in the United States. As noted above, Dr. Becker is
the executive officer primarily directing, controlling and coordinating the operations of the Company in the United States. Further,
Ms. Gavrilenko works at the Company&rsquo;s dedicated offices in New York City and the Company intends to hire additional personnel
there as contemplated by the Becker Agreement. As noted under &ldquo;Executive Compensation&rdquo; below, until the recent hiring
of Dr. Becker and Ms. Gavrilenko, the persons providing organizational and capital-raising services to the Company have been employees
of the Company&rsquo;s parent entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we expect
that Board committees will assist the Board in fulfilling its oversight responsibilities regarding risk. The Audit Committee will
coordinate the Board&rsquo;s oversight of the Company&rsquo;s internal control over financial reporting, disclosure controls and
procedures, related party transactions and code of conduct and corporate governance guidelines and management will regularly report
to the Audit Committee on these areas. The Compensation Committee will assist the Board in fulfilling its oversight responsibilities
with respect to the management of risks arising from our compensation policies and programs. When any of the committees receives
a report related to material risk oversight, the chairperson of the relevant committee will report on the discussion to the full
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Controlled Company Exception </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect
to this offering, LSBD will continue to control a majority of the voting power of our outstanding common stock. As a result, under
our certificate of incorporation, LSBD will be able to nominate a majority of the total number of directors comprising our Board
and we will remain a &ldquo;controlled company&rdquo; within the meaning of the Nasdaq corporate governance standards. Under the
Nasdaq corporate governance standards, a company of which more than 50% of the voting power is held by an individual, group or
another company is a &ldquo;controlled company&rdquo; and may elect not to comply with certain corporate governance standards,
including (1) the requirement that a majority of the Board consist of independent directors, (2) the requirement that we have a
compensation committee that is composed entirely of independent directors with a written charter addressing the committee&rsquo;s
purpose and responsibilities, (3) the requirement that we have a nominating and corporate governance committee that is composed
entirely of independent directors with a written charter addressing the committee&rsquo;s purpose and responsibilities, and (4)
the requirement for an annual performance evaluation of the nominating and corporate governance and compensation committees. We
intend to utilize these exemptions if we achieve listing of our Common Stock on Nasdaq. As a result, we will not have a nominating
and corporate governance committee and our compensation committee may not be composed entirely of independent directors. Accordingly,
you would not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance
requirements. In the event that we cease to be a &ldquo;controlled company,&rdquo; we would be required to comply with these provisions
within the transition periods specified in the Nasdaq corporate governance rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the initial
closing of this Offering, our Board of Directors will have two standing committees: an Audit Committee and a Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Audit
Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the initial
closing of this Offering, our Audit Committee will be formed and comprised of independent directors, at least one of whom will
be an &ldquo;audit committee financial expert&rdquo; as defined in Item 407(d)(5)(ii) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee
will oversee our corporate accounting, financial reporting practices and the audits of financial statements. For this purpose,
the Audit Committee will have a charter (which will be reviewed annually) and performs several functions. The Audit Committee charter
will be available on our website. The Audit Committee also will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">evaluate the independence and performance of, and assesses the qualifications of, our independent auditor and engage such independent auditor;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">approve the plan and fees for the annual audit, quarterly reviews, tax and other audit-related services and approve in advance any non-audit service to be provided by our independent auditor;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">monitor the independence of our independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review the financial statements to be included in our filings with the SEC and reviews with management and our independent auditor the results of the annual audit and reviews of our quarterly financial statements; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">oversee all aspects our systems of internal accounting control and corporate governance functions on behalf of the board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the closing
of this Offering, our Compensation Committee will be formed and will have a written charter addressing the committee&rsquo;s purpose
and responsibilities, but it will not be composed entirely of independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
will review or recommend the compensation arrangements for our management and employees and also assists our Board of Directors
in reviewing and approving matters such as company benefit and insurance plans, including monitoring the performance thereof. The
Compensation Committee will have a charter (which will be reviewed annually) and perform several functions. The Compensation Committee
charter will be available on our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
will have the authority to directly engage, at our expense, any compensation consultants or other advisers as it deems necessary
to carry out its responsibilities in determining the amount and form of employee, executive and director compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the closing
of this Offering, we will adopt a written code of business conduct and ethics that will apply to our directors, officers and employees,
including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons
performing similar functions. Upon the listing of our Common Stock on Nasdaq, we will post on our website a current copy of the
code and all disclosures that are required by law or Nasdaq rules in regard to any amendments to, or waivers from, any provision
of the code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation of Directors Liability and
Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Delaware General
Corporation Law authorizes corporations to limit or eliminate, subject to certain conditions, the personal liability of directors
to corporations and their stockholders for monetary damages for breach of their fiduciary duties. Our certificate of incorporation
limits the liability of our directors to the fullest extent permitted by Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We propose to purchase
director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services
to us, including matters arising under the Securities Act. Our certificate of incorporation and by-laws also provide that we will
indemnify our directors and officers who, by reason of the fact that he or she is one of our officers or directors, is involved
in a legal proceeding of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no pending
litigation or proceeding involving any of our directors, officers, employees or agents in which indemnification will be required
or permitted. We are not aware of any threatened litigation or proceedings that may result in a claim for such indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this Offering
our Common Stock was not registered under Section 12 of the Exchange Act and our directors and executive officers and persons who
beneficially own more than 10% of our Common Stock were not required to file with the SEC various reports as to their ownership
of and activities relating to our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Dr. Becker
and Ms. Gavrilenko, both of whom reside in the New York City metropolitan area, will perform their work for the Company based
at the Company&rsquo;s office in New York. Dr. Becker receives annual director fees of $50,000 plus fees at the rate of $300
per hour for his other services to be performed for the Company under the Becker Agreement. Each other director receives
annual director fees of $30,000, and no other fees, except that Ms. Gavrilenko receives $30,000 annually for her other
services to be performed for the Company. In addition, the Company intends to grant each current director 3,000 shares of
Common Stock for serving on the Company&rsquo;s board of directors after completion of agreed milestones. The Company intends
to employ additional employees as it deems necessary, including those employees to be selected by Dr. Becker for employment
in the Company&rsquo;s New York City offices. The Company also plans to utilize where suitable the services of employees of
our parent Life Science Glucose Biosensors Diagnostics Pty Ltd. Besides the previous amounts, to date we have not experienced
material executive compensation expense directly to our executives. See &ldquo;Description of Business &ndash;
Employees&rdquo; and &ldquo;Interests of Management and Others in Certain Transactions &ndash; Relationships with
Affiliates.&rdquo; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment and Related Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the
foregoing, other than the Becker Agreement, we currently have no written employment agreements directly with any of our officers,
each of whom serves on an &ldquo;at-will&rdquo; basis, and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 29, 2017,
the Board of Directors approved the 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;) and recommended that our stockholders
consider the 2017 Plan and approve its adoption, effective as of the date that the Company completes this Offering. We have reserved
500,000 shares of our Common Stock for issuance under the 2017 Plan. Participation in the 2017 Plan will continue until all of
the benefits to which the participants are entitled have been paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of our
2017 Plan is to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable,
to encourage a sense of proprietorship and to stimulate an active interest of such persons in our development and financial achievements.
The 2017 Plan will be administered by the Compensation Committee of our Board of Directors or by the full board, which may determine,
among other things, the (a) terms and conditions of any option or stock purchase right granted, including the exercise price and
the vesting schedule, (b) persons who are to receive options and stock purchase rights and (c) the number of shares to be subject
to each option and stock purchase right. The 2017 Plan will provide for the grant of (i) &ldquo;incentive&rdquo; options (qualified
under section 422 of the Internal Revenue Code of 1986, as amended) to employees of our company and (ii) non-qualified options
to directors and consultants of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the administration of our 2017 Plan, our Compensation Committee will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">determine which employees and other persons will be granted awards under our 2017 Plan;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">grant the awards to those selected to participate;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">determine the exercise price for options; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">prescribe any limitations, restrictions and conditions upon any awards, including the vesting conditions of awards.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee
will: (i) interpret our 2017 Plan; and (ii) make all other determinations and take all other action that may be necessary or advisable
to implement and administer our 2017 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Plan provides
that in the event of a change of control event, the Compensation Committee or our Board of Directors shall have the discretion
to determine whether and to what extent to accelerate the vesting, exercise or payment of an award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our Board
of Directors may amend our 2017 Plan at any time. However, without stockholder approval, our 2017 Plan may not be amended in a
manner that would:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">increase the number of shares that may be issued under our 2017 Plan;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">materially modify the requirements for eligibility for participation in our 2017 Plan;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">materially increase the benefits to participants provided by our 2017 Plan; or</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">otherwise disqualify our 2017 Plan for coverage under Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Awards previously granted
under our 2017 Plan may not be impaired or affected by any amendment of our 2017 Plan, without the consent of the affected grantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Description of Awards under the 2017 Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Awards to Company
Employees</U><I>.</I> Under the 2017 Plan, the compensation committee, which will administer the plan (the &ldquo;Committee&rdquo;),
may award to eligible employees incentive and nonqualified stock options, stock appreciation rights, restricted stock, restricted
stock units, performance units and performance shares.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Awards to Non-Employees</U><I>.</I>
The Committee may award to non-employees, including non-employee directors, non-qualified stock options, SARs, restricted stock
and restricted stock units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee has discretion
to award incentive stock options (&ldquo;ISOs&rdquo;), which are intended to comply with Section 422 of the Code, or nonqualified
stock options (&ldquo;NQSOs&rdquo;), which are not intended to comply with Section 422 of the Code. The exercise price of an option
may not be less than the fair market value of the underlying shares of Common Stock on the date of grant. The 2017 Plan defines
 &ldquo;fair market value&rdquo; as the closing sale price at which shares of our Common Stock have been sold regular way on the
principal securities exchange on which the shares are traded or, if there is no such sale on the relevant date, then on the last
previous day on which there was such a sale. If an award of stock options is intended to qualify as performance-based compensation
under Section 162(m) of the Code, the maximum number of shares which may be subject to stock options granted in any calendar year
to any one participant who is a &ldquo;covered employee&rdquo; is 200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Options granted to
employees under the 2017 Plan will expire at such times as the Committee determines at the time of the grant; provided, however,
that no option will be exercisable later than ten years after the date of grant. Each option award agreement will set forth the
extent to which the participant will have the right to exercise the option following termination of the participant&rsquo;s employment
with the Company. The termination provisions will be determined within the discretion of the Committee, might not be uniform among
all participants and might reflect distinctions based on the reasons for termination of employment. Notwithstanding the preceding
sentences, unless the terms of the award agreement otherwise provide for a shorter exercise period, ISOs must be exercised within
three months after an employee&rsquo;s termination of employment. However, if the termination is due to disability (as defined
under Code Section 22(e)(3)), the ISOs must be exercised within one year after an employee&rsquo;s termination of employment. If
the termination is due to death, the ISOs may be exercised at any time during the option term. Subject to the specific terms of
the 2017 Plan, the Committee will have discretion to set such additional limitations on such grants as it deems appropriate. The
award agreement will reflect these limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the exercise of
an option granted under the 2017 Plan, the option price is payable in full to the Company, either: (a) in cash or its equivalent,
(b) if permitted in the award agreement, by tendering shares having a fair market value at the time of exercise equal to the total
option price (provided that such shares have been held by the optionee for at least six months prior to their tender) or (c) by
any combination of the foregoing methods of payment. The Committee may also allow options granted under the 2017 Plan to be exercised
by a cashless exercise through a broker, as permitted under Federal Reserve Board Regulation T, or any other means the Committee
determines to be consistent with the 2017 Plan&rsquo;s purpose and applicable law, including by cashless exercise directly with
the Company whereby the Company, following its receipt of the participant&rsquo;s notice of exercise, would withhold the proper
number of Company shares which would have a fair market value on the date of exercise equal to the option exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Stock Appreciation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may award
stock appreciation rights (&ldquo;SARs&rdquo;) under the 2017 Plan upon such terms and conditions as it may establish. At the discretion
of the Committee, the payment upon SAR exercise may be in cash, in shares of Company Common Stock of equivalent value, or in some
combination thereof. The Committee&rsquo;s determination regarding the form of payment for the exercised SAR will be set forth
in the award agreement. The Committee may award either (i) freestanding SARs, which are SARs granted as an independent instrument
and are not granted in conjunction with any stock options, or (ii) SARs in tandem with stock options (a &ldquo;tandem SAR&rdquo;).
A tandem SAR entitles the participant to exercise it as an option or as an SAR. The election of one type of exercise prevents it
from being exercised as the other type. A tandem SAR may not be granted to a non-employee Director unless the related option is
a NQSO. The exercise price of a freestanding SAR will equal the fair market value of a share of Common Stock on the date of grant,
whereas the exercise price of a tandem SAR issued in connection with a stock option will equal the option price of the related
option. If an award of SARs is intended to qualify as performance-based compensation under Section 162(m) of the Code, the maximum
number of shares which may be subject to SARs awarded in any calendar year to any one participant who is a &ldquo;covered employee&rdquo;
is 200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee will
determine in its discretion the term of an SAR granted under the 2017 Plan. Each award agreement will set forth the extent to which
the participant will have the right to exercise the SAR following termination of the participant&rsquo;s employment with the Company.
The termination provisions will be determined by the Committee in its sole discretion, need not be uniform among all participants
and may reflect distinctions based on the reasons for termination of employment. The term of an SAR may not exceed ten years from
the date of grant. Therefore, no SAR may be exercisable later than ten years after the date of award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise
limited by the 2017 Plan, freestanding SARs may be exercised upon whatever terms and conditions the Committee, in its sole discretion,
imposes upon them. The Committee will determine the number of shares of Common Stock covered by and the exercise period of the
SAR. Upon exercise of a freestanding SAR, the participant will receive an amount equal to the excess of the fair market value of
one share of Common Stock on the date of exercise over the grant price, multiplied by the number of shares of stock exercised under
the SAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of a tandem
SAR, the Committee may determine the exercise period of the SAR, except that the exercise period may not exceed that of the related
option. The participant may exercise the tandem SAR when the option is exercisable and receive on exercise an amount equal to the
excess of the fair market value of one share of Common Stock on the date of exercise over the option purchase price, multiplied
by the number of shares of stock covered by the surrendered option. Upon exercise of an SAR awarded in tandem with a stock option,
the number of shares of our Common Stock for which the related option was exercisable will be reduced by the number of shares for
which the SAR was exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any
other provision of this 2017 Plan to the contrary, with respect to a tandem SAR granted in connection with an ISO (i) the tandem
SAR will expire no later than the expiration of the underlying ISO; (ii) the value of the payout with respect to the tandem SAR
may be for no more than 100% of the difference between the option price of the underlying ISO and the fair market value of the
shares subject to the underlying ISO at the time the tandem SAR is exercised; and (iii) the tandem SAR may be exercised only when
the fair market value of the shares subject to the ISO exceeds the option price of the ISO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Restricted Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may impose
restrictions and conditions as to awards of shares of restricted stock as it deems advisable. As specified in the relevant award
agreement, restrictions may include a requirement that participants pay a stipulated purchase price for each share of restricted
stock, restrictions based upon the achievement of specific performance goals (Company-wide, divisional and/or individual), time-based
restrictions on vesting following the attainment of the performance goals and/or restrictions under applicable federal or state
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may retain in our
possession the certificates representing shares of restricted stock until the time when all conditions and/or restrictions applicable
to those shares awarded under the 2017 Plan have been satisfied. Generally, shares of restricted stock covered by each restricted
stock grant made under the 2017 Plan will become freely transferable by the participant following the last day of the applicable
period of restriction. However, even after the satisfaction of the restrictions and conditions imposed by the 2017 Plan and the
particular award agreement, shares owned by an affiliate of the Company will be subject to restrictions on transfer under the Securities
Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Awards to
Employees</U>.</I> The Committee may choose to award shares of restricted stock under the 2017 Plan upon such terms and conditions
as it may establish. If an award of restricted stock is intended to qualify as performance-based compensation under Section 162(m)
of the Code, the maximum number of shares which may be granted in the form of restricted stock in any one calendar year to any
one participant who is a &ldquo;covered employee&rdquo; is 200,000. The award agreement will specify the period(s) of restriction,
the number of shares of restricted stock granted, requirements that a participant pay a stipulated purchase price for each share,
restrictions based upon the achievement of specific performance objectives, other restrictions governing the subject award and/or
restrictions under applicable federal or state securities laws. Recipients may have the right to vote these shares from the date
of grant, as determined by the Committee on the date of award. As determined by the Committee on the date of award, participants
may receive dividends on their shares of restricted stock. Dividends accrued on restricted stock will be paid only if the restricted
stock vests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each award agreement
for restricted stock will specify the extent to which the participant will have the right, if any, to retain unvested restricted
stock following termination of the participant&rsquo;s employment with the Company. In its sole discretion, the Committee will
make these determinations; these provisions need not be uniform among all awards of restricted stock issued under the 2017 Plan
and may reflect distinctions based on reasons for termination of employment. Except in the case of terminations by reason of
death or disability, restricted stock, which is intended to qualify for performance-based compensation under Section 162(m) and
which is held by &ldquo;covered employees&rdquo; under Section 162(m), will be forfeited by the participant to the Company upon
termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Awards to Non-Employee
Directors</U>.</I> Restricted stock awards to non-employee Directors will be subject to the restrictions for a period (the &ldquo;Restricted
Period&rdquo;), which will commence upon the date when the restricted stock is awarded and will end on the earliest of the first
to occur of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the retirement of the non-employee Director from the Board in compliance with the Board&rsquo;s retirement policy as then in effect;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board as a result of the non-employee Director&rsquo;s not being nominated for reelection by the Board;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board because of the non-employee Director&rsquo;s resignation or failure to stand for reelection with the consent of the Board (which means approval by at least 80% of the Directors voting, with the affected non-employee Director abstaining);</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board because the non-employee Director, although nominated for reelection by the Board, is not reelected by the stockholders;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board because of (i) the non-employee Director&rsquo;s resignation at the request of the Nominating and Governance Committee of the Board, (ii) the non-employee Director&rsquo;s removal by action of the stockholders or by the Board, or (iii) a change in control of the Company, as defined in the 2017 Plan;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board because of disability or death; or</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the vesting of the award.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date specified
by the Committee, each non-employee Director will be awarded that number of shares of restricted stock as determined by the Board,
after consideration of the recommendations of the Committee. A non-employee Director who is first elected to the Board on a date
subsequent to the date so specified will be awarded that number of shares of restricted stock as determined by the Board, after
consideration of the recommendations of the Committee. The amount of the award for the upcoming 2017 Plan year will be disclosed
in the Company&rsquo;s proxy statement for the Company&rsquo;s annual meeting of stockholders. The 2017 Plan provides that non-employee
Directors receiving restricted stock may have, subject to the provisions of the 2017 Plan, all of the rights of a stockholder with
respect to the shares of restricted stock, including the right to vote the shares and receive cash dividends and other cash distributions
thereon. If a non-employee Director ceases to be a member of the Board for any other reason, including removal or resignation for
 &ldquo;Cause,&rdquo; as defined in the 2017 Plan, the non-employee Director will forfeit to the Company all restricted stock awarded
to him or her for which the Restricted Period has not ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Restricted Stock Units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may award
restricted stock units (&ldquo;RSUs&rdquo;). Each RSU will have a value equal to the fair market value of a share of the Company&rsquo;s
Common Stock on the date of grant. The maximum aggregate award of RSUs to any one participant who is a &ldquo;covered employee&rdquo;
during any one fiscal year will be equal to the fair market value of 200,000 shares; provided, further, that the maximum aggregate
award of restricted stock and RSUs for any one fiscal year will be coordinated so that in no event will any one participant be
awarded more than the fair market value of 200,000 shares taking into account all such awards. In its discretion, the Committee
may impose conditions and restrictions on RSUs, as specified in the RSU award agreement, including restrictions based upon the
achievement of specific performance goals and time-based restrictions on vesting. As determined by the Committee at the time of
the award, settlement of vested RSUs may be made in the form of cash, shares of Company stock, or a combination of cash and Company
stock. Settlement of vested RSUs will be in a lump sum as soon as practicable after the vesting date. The amount of the settlement
will equal the fair market value of the RSUs on the vesting date. Each RSU will be credited with an amount equal to the dividends
paid on a share of Company stock between the date of award and the date the RSU is paid to the participant, if at all. Dividend
equivalents will vest, if at all, upon the same terms and conditions governing the vesting of the RSUs under the 2017 Plan. Payment
of the dividend equivalent will be paid at the same time as payment of the RSU. The holders of RSUs will have no voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each award agreement
for RSUs will specify the extent to which the participant will have the right, if any, to retain unvested RSUs following termination
of the participant&rsquo;s employment with the Company or, in the case of a non-employee Director, service with the Board. In
its sole discretion, the Committee will make these determinations; these provisions need not be uniform among all awards of RSUs
issued under the 2017 Plan and may reflect distinctions based on reasons for termination of employment or, in the case of a non-employee
Director, service with the Board. Except in the case of terminations by reason of death or disability, RSUs awarded to participants
who are &ldquo;covered employees&rdquo; and which are intended to qualify as performance-based compensation under Section 162(m),
will be forfeited by the participant to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Performance Units/Performance Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee has
the discretion to award performance units and performance shares under the 2017 Plan upon such terms and conditions as it may
establish, as evidenced in the relevant award agreement. If an award of performance units or performance shares is intended to
qualify as performance-based compensation under Section 162(m) of the Code, the maximum aggregate payout for awards of performance
shares which may be granted in any one calendar year to any one participant who is a &ldquo;covered employee&rdquo; will be the
fair market value of 200,000 shares, whereas the maximum aggregate payout for awards of performance units which may be granted
in any one calendar year to any one participant will be $1,500,000. Performance units will have an initial value as determined
by the Committee, whereas performance shares will have an initial value equal to one share of Common Stock on the date of award.
At the time of the award of the performance units or shares, the Committee in its discretion will establish performance goals
which, depending on the extent to which they are met, will determine the number and/or value of performance units or shares that
will be paid out to the participant. Under the terms of the 2017 Plan, after the applicable performance period has ended, the
holder of performance units or shares will be entitled to receive payout on the number and value of performance units or shares
earned by the participant over the performance period. The payout on the number and value of the performance units and performance
shares will be a function of the extent to which corresponding performance goals are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of performance
shares and performance units will be made in a single lump sum following the close of the applicable performance period. Upon satisfaction
of the specified performance goals, the Committee will pay the earned performance shares in shares of Company Common Stock. In
its discretion, the Committee may pay earned performance units in cash, in shares of Company stock or in a combination of cash
and stock, which will have an aggregate fair market value equal to the value of the earned performance share or performance unit
at the close of the applicable performance period. Participants will not be entitled to dividend or voting rights with respect
to any performance shares or performance units earned but not yet distributed to a participant. Unless otherwise determined by
the Committee, in the case of death or disability during the performance period, the participant, or his or her estate, will not
be entitled to receive any payout of the performance shares or performance units. In the case of any other termination of the participant&rsquo;s
employment during the performance period, all performance shares and performance units intended to qualify as performance-based
compensation will be forfeited by the participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Adjustment and Amendments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Plan provides
for appropriate adjustments in the number of shares of Company stock subject to awards and available for future awards in the event
of changes in outstanding Common Stock by reason of a merger, stock split, stock dividend, or certain other events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Plan may be
modified or amended by the board at any time and for any purpose which the Board deems appropriate. However, no such amendment
may adversely affect any outstanding awards without the affected holder&rsquo;s consent. No amendment may, without stockholder
approval, (i) materially increase the benefits earned by participants under the 2017 Plan, (ii) materially increase the number
of shares which may be issued under the 2017 Plan or (iii) materially modify the requirements for participation in the 2017 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Change in Control</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a change
in control, as defined in the 2017 Plan, generally all options and SARs granted under the 2017 Plan will become immediately exercisable;
and restriction periods and other restrictions imposed on restricted stock and RSUs which are not intended to qualify as performance-based
compensation under Section 162(m) under the Code will lapse. Any award intended to qualify as performance-based under Section 162(m)
must be earned in accordance with the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Non-transferability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No award under the
2017 Plan may be sold, transferred, pledged, assigned or otherwise transferred in any manner by a participant except by will or
by the laws of descent and distribution; and any award will be exercisable during a participant&rsquo;s lifetime only by the participant
or by the participant&rsquo;s guardian or legal representative. These limitations may be waived by the Committee, subject to restrictions
imposed under the SEC&rsquo;s short-swing trading rules and federal tax requirements relating to incentive stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Duration of the 2017 Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Plan will
remain in effect until all shares subject to the 2017 Plan have been purchased or acquired under the terms of the 2017 Plan, and
all performance periods for performance-based awards granted under the 2017 Plan have been completed. However, no award is permitted
to be granted under the 2017 Plan on or after the day prior to the tenth anniversary of the date the board approved the 2017 Plan.
The board, upon recommendation of the Committee, may at any time amend, suspend or terminate the 2017 Plan in whole or in part
for any purpose the Committee deems appropriate, subject, however, to the limitations referenced in &ldquo;Adjustment and Amendments,&rdquo;
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
there are no options, warrants or other rights outstanding under any equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Remuneration Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors of the
Company are entitled to compensation of $30,000 (plus $10,000 for the Chairman of the Board and except that Dr. Becker will receive
$50,000 for his Board service and certain related duties) in cash per year of service on our Board of Directors, commencing on
the completion of this Offering and payable in full thereon for the ensuing year. We currently do not have any equity compensation
arrangements with our non-employee directors. Service as a member or chair of any of the committees of the Board do not entitle
our non-employee directors to any additional compensation. To date, none of our non-employee directors has been paid any amounts
as compensation for serving on our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_010"></A>SECURITY
OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth information regarding the beneficial ownership of our Common Stock as of the date hereof by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">each person known by us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">each of our named executive officers and directors; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all our executive officers and directors as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership
is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Except
as otherwise indicated, each person or entity named in the table has sole voting and investment power with respect to all shares
of our capital shown as beneficially owned, subject to applicable community property laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In computing the number
and percentage of shares beneficially owned by a person, shares that may be acquired by such person within 60 days of the date
hereof are counted as outstanding, while these shares are not counted as outstanding for computing the percentage ownership of
any other person. Unless otherwise indicated, the address of each person listed below is c/o the Company at 733 Third Ave, Floor
15, New York, NY 10017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Name of Beneficial Owner</B> </P></TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Shares of</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Common</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Stock</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Owned</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percent of</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Common</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Stock</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Owned</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"> <FONT STYLE="font-size: 10pt">Life Science Biosensor Diagnostics Pty Ltd*</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 10%; text-align: right"> <FONT STYLE="font-size: 10pt">8,250,000</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 10%; text-align: right"> <FONT STYLE="font-size: 10pt">100.0</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt">Jonathan S. Hurd</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt">Harry Simeonidis</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt">Dr. Jean-Claude Becker</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt">Victoria Gavrilenko</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt">Dr. John Caminis</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt">Dr. Yong-Jiang Hei</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt"><I>All Executive Officers and Directors as a group (6 persons)</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> * Life Science
Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;) is an Australian company that is 81% owned by iQnovate Limited, which is
an Australian company that is 24% beneficially owned and controlled by Dr. George Syrmalis and whose shares are
otherwise publicly-owned and traded on the National Stock Exchange of Australia. Dr. Syrmalis is an Australian citizen and resident,
whose address is Level 9, 85 Castlereagh Street, Sydney NSW 2000. Accordingly, Mr. Syrmalis may be deemed to have sole voting
and dispositive power over the Common Stock held by LSBD. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_011"></A>INTEREST
OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Relationships with Affiliates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company has
entered into the License Agreement with LSBD pursuant to which it licenses the saliva glucose biosensor system for the China Region.
For a detailed description of the License Agreement and considerations relating thereto, see &ldquo;Description of Business &ndash;
License Agreement&rdquo; and &ldquo;Risk Factors &ndash; Risk Related to Our Intellectual Property &ndash; Our License Agreement
with our wholly-owning parent, LSBD, which relates to the Company&rsquo;s principle asset consisting of licensed intellectual
property, contains numerous significant performance, payment, liability, compliance, termination and intellectual property risks
that may threaten the Company&rsquo;s viability or otherwise have a material adverse effect on the Company, its business and its
prospects.&rdquo; The License Agreement requires, among many material provisions, that the Company pay to LSBD (i) a fixed fee
after all regulatory approvals in Mainland China are obtained, (ii) royalties equal to percentages of net sales of commercial
units and net sales of an optional dedicated reading device, and (iii) certain application fees. From August 5, 2016 to March
31, 2018, the Company paid LSBD a total of $7,561,321 under the License Agreement and $1,159,260 in relation to general administration
expenses. As of March 31, 2018, it had incurred $1,543,300 (including a trade creditors liability to LSBD of $37,983) in relation
to research and development and regulatory approval costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We expect that
a substantial portion of the net proceeds used for the purposes described above will be paid to LSBD pursuant to the License
Agreement, pursuant to which LSBD will conduct a substantial portion of the activities that must be performed in the near
term to advance our business plan, including without limitation market data studies, delivery of a finalized prototype, delivery of a manufacture-to-scale plan, delivery of a global regulatory strategy plan, commencing
scale manufacturing, commencement and confidential testing, submitting and finalizing regulatory submissions through
final approvals, delivery of a finalized product for sale, and many other services. Not all of the services to be performed
by LSBD under the License Agreement are expected to be completed within the first year following this Offering. While the
payments to LSBD for all such services would exceed net proceeds in the event only the minimum amount of this Offering is
received, the Company expects that it will use such net proceeds for purposes as are most timely and appropriate in its
judgment. See &ldquo;Use of Proceeds.&rdquo; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered
into a master services agreement (the &ldquo;MSA Agreement&rdquo;) with IQ3CORP LIMITED ACN 160 238 282 (&ldquo;IQ3&rdquo;), which
is an affiliate of the Company by virtue of being under common control. The MSA Agreement sets forth certain basic terms and provisions
applicable to services provided and to be provided by IQ3 to the Company pursuant to specific service acquisition orders entered
into by the parties from time to time. One outstanding such order from January 2016 covers the following services provided directly
or indirectly to the Company for the following costs: business plan preparation and review &ndash; $120,000; due diligence &ndash;
$40,000; private placement capital-raising assistance &ndash; $250,000 plus 8% of proceeds raised outside the United States (payable
in accordance with IQ3&rsquo;s Australian Financial Services License); investor relations services &ndash; $20,000 per month commencing
in July 2017; and certain other services. All of the foregoing amounts accrued to date have been paid in full. In addition, the
MSA Agreement provides that hourly rates are payable for corporate advisory services to the Company, which amounts will be payable
as accrued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2017, the
Company entered into a three-year Medical Affairs Services Agreement (the &ldquo;MAS Agreement&rdquo;) with Clinical Research Corporation
(&ldquo;CRC&rdquo;), a wholly-owned Australian subsidiary of iQnovate Limited, an Australian entity that is an affiliate of the
Company by virtue of being under common control. iQnovate Limited also majority-owns LSBD. The MAS Agreement provides certain master
terms pursuant to which CRC would be engaged in the future by the Company from time to time to perform certain medical affairs
services on behalf of the Company. The master terms include minimum professional indemnity insurance, liability insurance and products
liability insurance that will be required and indemnification by the Company of CRC, except where liability has resulted solely
from the negligence or willful misconduct of CRC. The MAS Agreement does not set forth specified projects, services or costs in
connection therewith, but provides general parameters pursuant to which such specific projects, services and costs would be detailed
in the future as procured. All of the specific projects, services, costs and related performance details will be set forth from
time to time in one or more &ldquo;statements of works&rdquo;. &nbsp;The Company and CRC have not entered into any material statements
of works as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Statement of Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception we
have been wholly-owned by LSBD. Since inception we have entered into transactions with LSBD that have not been negotiated, arranged
or otherwise implemented on an arms-length basis and that may favor LSBD. These transactions include in particular the License
Agreement and the employee sharing arrangements whereby the Company has not engaged its own exclusive employees. Nonetheless, since
inception all transactions (if any) between us and our officers or directors have been on terms no less favorable than could be
obtained from unaffiliated third parties and were unanimously approved by our directors. In the future, all transactions (if any)
between us and our officers or directors or five percent stockholders, and their respective affiliates, will be on terms no less
favorable than could be obtained from unaffiliated third parties and will be unanimously approved by our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the best of our
knowledge, other than as set forth above, there were no material transactions, or series of similar transactions, or any currently
proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds
the lesser of $120,000 or 1% of the average of our total assets at year end for the last two completed fiscal years, and in which
any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5% of any
class of our Common Stock, or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation
to our officers and directors in the ordinary course of business).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_012"></A>DESCRIPTION
OF OUR SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of
Incorporation authorizes us to issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">20,000,000 shares
                                    of common stock, par value $0.01 per share; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2,000,000 shares of preferred stock, par value $0.01 per
    share, of which 1,222,506 shares of our Series A Convertible Preferred Stock are issued and are outstanding as of the date
    hereof pursuant to a private placement prior to the date hereof.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 5,
2017, we gave effect by the filing of an amendment to our Certificate of Incorporation to effect a one-to-90,000 stock
split pursuant to which each outstanding share of common stock was converted into 90,000 shares of Common Stock. The
outstanding preferred stock, convertible notes and warrants exercisable or convertible into Common Stock have been
proportionately adjusted in accordance therewith. In addition, on August 9, 2018 we filed an amendment to our
Certificate of&nbsp;Incorporation to effect a reverse stock split of approximately one to 0.9167 shares that resulted in the
Company having 8,250,000 issued and outstanding shares of common stock. Share and per share amounts set forth herein (except
in any historical financial information) give effect to the reverse split, unless indicated otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
summarizes the most important terms of our capital stock, as they are expected to be in effect upon the closing of this Offering.
We expect to adopt an amended and restated certificate of incorporation and amended and restated by-laws in connection with this
Offering, and this description summarizes the provisions that are expected to be included in such documents. Because it is only
a summary, it does not contain all the information that may be important to you. For a complete description of the matters set
forth in &ldquo;Description of Securities,&rdquo; you should refer to our amended and restated certificate of incorporation and
amended and restated by-laws, which are or will be included as exhibits to the Offering Statement relating to this Offering Circular,
and to the applicable provisions of Delaware law. Immediately following the closing of this Offering, our authorized capital stock
will consist of 22,000,000 shares of Common Stock, $0.01 par value per share, and 2,000,000 shares of Preferred Stock, $0.01 par
value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date
hereof we have 8,250,000 shares of Common Stock issued and outstanding and owned by one stockholder. As of the date hereof, up
to 1,500,000 shares are reserved for issuance in connection with the conversion of our Series A Convertible Preferred Stock on
a one-to-one share basis, up to 600,000 shares are reserved for issuance in connection with the conversion of outstanding convertible
notes and 500,000 shares are reserved for issuance under the 2017 Plan. Upon the closing of this Offering, all shares of Series
A Convertible Preferred Stock will automatically convert into 1,222,506 shares of our Common Stock and all of the convertible
notes will automatically convert into 517,358 shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our
Common Stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including
the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding
shares of Common Stock entitled to vote in any election of directors can elect all of the directors standing for election, if they
so choose, other than any directors that holders of any Preferred Stock we may issue may be entitled to elect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to limitations
under Delaware law and preferences that may be applicable to any then outstanding Preferred Stock, holders of Common Stock are
entitled to receive ratably those dividends, if any, as may be declared by our Board of Directors out of legally available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any
voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our Common Stock will be entitled
to share ratably in the net assets legally available for distribution to stockholders after the payment of or provision for all
of our debts and other liabilities, subject to the prior rights of any Preferred Stock then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Rights and Preferences</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of Common Stock
have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable
to the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fully Paid and Non-assessable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All outstanding shares
of Common Stock are, and the Common Stock to be outstanding upon completion of this Offering will be, duly authorized, validly
issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transfer Agent and Registrar</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have not
engaged an independent third party to act as the transfer agent for our Common Stock. We will engage prior to the qualification
of this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately prior
to the consummation of this Offering, all of the 1,222,506 outstanding shares of our Series A Convertible Preferred Stock will
be converted into shares of our Common Stock. Immediately after the consummation of this Offering, our amended and restated certificate
of incorporation will be amended and restated to delete all references to such shares of Series A Convertible Preferred Stock.
Our Board of Directors currently has the authority, without further action by our stockholders, to issue shares of preferred stock
in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges
could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms
and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights
of Common Stock. The issuance of preferred stock could adversely affect the voting power of holders of Common Stock and the likelihood
that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock
could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately
after consummation of this Offering, no shares of preferred stock will be outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
there are outstanding warrants issued in connection with the Series A Convertible Preferred Stock having an exercise price of $12.00
per share, which warrants are exercisable only during the one-year period commencing on the second anniversary of the closing of
this Offering. The warrants are not entitled to any adjustment in the number of shares or the exercise price in the event of any
adjustments in the number of outstanding shares of our capital stock for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition,
upon each closing of this Offering, we have agreed to issue warrants to the Placement Agent (&ldquo;Placement Agent&rsquo;s
Warrants&rdquo;) to purchase a number of shares of the Common Stock equal to 5.0% of the total Shares sold in such closing.
Accordingly, if the minimum number of shares are sold in this Offering then the Placement Agent&rsquo;s Warrants will be
exercisable for a total of 20,833 and if the maximum number of shares are sold in this Offering then the Placement Agent&rsquo;s
Warrants will be exercisable for a total of 104,166 shares. The Placement Agent&rsquo;s Warrants are exercisable commencing on
the date that the SEC initially qualifies the Offering Statement and will be exercisable for five years thereafter. The
Placement Agent&rsquo;s Warrants are not redeemable by us. The exercise price for the Placement Agent&rsquo;s Warrants will be 10% greater than the initial public offering price. The Placement Agent&rsquo;s Warrants
contain anti-dilution provisions that may be triggered by future events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Convertible Notes</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our
subsidiary,&nbsp;GBS Pty Ltd, has issued convertible notes in the outstanding aggregate principal amount of $5,277,056
(including principal and accrued interest) as of the date hereof, which notes will automatically amount into 517,358 shares
of Common Stock at a price per share equal to $10.20 in connection with this Offering. In the absence of the completion of
this Offering and such automatic conversion of the notes, the notes mature on December 31, 2019. These notes were issued along with ordinary shares of GBS Pty Ltd in a private placement conducted in the first quarter of
2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no registration
rights held by any party with respect to any of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Provisions
of Our Certificate of Incorporation, Our By-laws and Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some provisions of
Delaware law, our Certificate of Incorporation and our By-laws contain provisions that could make the following transactions more
difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the
removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish
or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including
transactions which provide for payment of a premium over the market price for our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These provisions, summarized
below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed
to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the benefits
of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to
acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could
result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Undesignated Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of our
Board of Directors, without action by the stockholders, to issue undesignated shares of Preferred Stock with voting or other rights
or preferences as designated by our Board of Directors could impede the success of any attempt to change control of us. These and
other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delaware Anti-Takeover Statute</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We are subject
to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed to be &ldquo;interested stockholders&rdquo;
from engaging in a &ldquo;business combination&rdquo; with a publicly held Delaware corporation for three years following the
date these persons become interested stockholders unless the business combination is, or the transaction in which the person became
an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &ldquo;interested
stockholder&rdquo; is a person who, together with affiliates and associates, owns, or within three years prior to the determination
of interested stockholder status did own, 15% or more of a corporation&rsquo;s voting stock. Generally, a &ldquo;business combination&rdquo;
includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The
existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the Board
of Directors. A Delaware corporation may &ldquo;opt out&rdquo; of these provisions with an express provision in its original certificate
of incorporation or an express provision in its certificate of incorporation or by-laws resulting from a stockholders' amendment
approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers
or other takeover or change in control attempts of us may be discouraged or prevented. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendment of Charter Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The DGCL generally
provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation's
certificate of incorporation or by-laws, unless either a corporation's certificate of incorporation or by-laws requires a greater
percentage. Our certificate of incorporation and bylaws that will be in effect upon the closing of this Offering will provide
the following terms. A majority vote of our Board of Directors or the affirmative vote of holders of a majority of the total votes
of our outstanding shares of capital stock entitled to vote with respect thereto will be required to amend, alter, change or repeal
the by-laws. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Authorized but Unissued Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized but
unissued shares of Common Stock and Preferred Stock will be available for future issuance without stockholder approval. These additional
shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate
acquisitions. The existence of authorized but unissued shares of Common Stock and Preferred Stock could render more difficult or
discourage an attempt to obtain control of a majority of our Common Stock by means of a proxy contest, tender offer, merger or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of Delaware
law, our Certificate of Incorporation and our By-laws could have the effect of discouraging others from attempting hostile takeovers
and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from
actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition
of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that
stockholders may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_013"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception,
we have not paid any dividends on our Common Stock, and we currently expect that, for the foreseeable future, all earnings (if
any) will be retained for the development of our business and no dividends will be declared or paid. In the future, our Board of
Directors may decide, at their discretion, whether dividends may be declared and paid, taking into consideration, among other things,
our earnings (if any), operating results, financial condition and capital requirements, general business conditions and other pertinent
facts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_014"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future sales of substantial
amounts of our Common Stock in the public market, including shares issued upon exercise of outstanding warrants, or the anticipation
of these sales, could adversely affect prevailing market prices from time to time and could impair our ability to raise equity
capital in the future. Before this Offering, there has not been a public market for shares of our Common Stock. Future sales of
substantial amounts of shares of our Common Stock, including shares issued upon the exercise of outstanding warrants that were
issued in connection with the issuance of the preferred stock, in the public market after this Offering, or the possibility of
these sales occurring, could cause the prevailing market price for our Common Stock to fall or impair our ability to raise equity
capital in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of the
date of this Offering Circular, we have outstanding 8,250,000 shares of Common Stock currently held by our sole stockholder.
In addition, as of the date of this Offering Circular: (i) 1,222,506 shares of Common Stock are issuable upon the completion
of this Offering by mandatory conversion of outstanding shares of our Series A Convertible Preferred Stock on a one-to-one
basis; (ii) 517,358 shares of Common Stock are issuable upon the completion of this Offering by mandatory conversion of
$5,277,056 of notes issued by our subsidiary GBS Pty Ltd at an effective conversion price at a 15% discount to the price per
Share in this Offering; (iii) 1,222,506 shares of Common Stock are issuable during the one year period commencing on the
second anniversary of the completion of this Offering by exercise of outstanding warrants; and (iv) up to 104,167 shares of
Common Stock will be issuable pursuant to warrants issuable to the Placement Agent in this Offering, the actual amount of
such shares to be equal to 5.0% of the Shares sold in this Offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the foregoing
shares that will be outstanding after this Offering, other than the Shares sold in this Offering, are or will be upon issuance
 &ldquo;restricted securities&rdquo; as that term is defined in Rule 144 under the Securities Act. These restricted securities are
eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration
under Rule 144 under the Securities Act, which are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a person
who has beneficially owned restricted shares of our Common Stock for at least twelve months, in the event we are a reporting company
under Regulation A, or at least six months, in the event we have been a reporting company under the Exchange Act for at least 90
days before the sale, would be entitled to sell such securities, provided that such person is not deemed to be an affiliate of
ours at the time of sale or to have been an affiliate of ours at any time during the 90 days preceding the sale. A person who is
an affiliate of ours at such time would be subject to additional restrictions, by which such person would be entitled to sell within
any three-month period only a number of shares that does not exceed the greater of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">1% of the number of shares of our Common Stock then outstanding; or</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the average weekly trading volume of our Common Stock during the four calendar weeks preceding the filing by such person of a notice on Form 144 with respect to the sale;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that, in each case, we are subject
to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule 144 trades must also comply
with the manner of sale, notice and other provisions of Rule 144, to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, although
not applicable to any of the shares that will be outstanding upon the closing of this Offering Rule 701 allows a stockholder who
purchased shares of our capital stock pursuant to a written compensatory plan or contract and who is not deemed to have been an
affiliate of ours during the immediately preceding 90 days to sell those shares in reliance upon Rule 144, but without being required
to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. All holders of Rule
701 shares, however, are required to wait until 90 days after the date of this Offering Circular before selling shares pursuant
to Rule 701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our directors,
officers and more than 5% have agreed, or will agree, with the Placement Agent, subject to certain exceptions, that, without the
prior written consent of the Placement Agent, we and they will not, directly or indirectly, during the period ending one year
after the date of the Offering Circular (180 days for investors in our Series A Convertible Preferred Stock and the outstanding
notes convertible into shares of our Common Stock): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of the Common Stock or any securities convertible into or exchangeable or exercisable for the Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition; or</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">enter into any swap or any other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of the Common Stock, whether any such swap or transaction is to be settled by delivery of the Common Stock or other securities, in cash or otherwise.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> These agreements
do not apply, in our case, to securities issued pursuant to existing employee benefit plans or securities issued upon exercise
of options, and other exceptions, and in the case of our officers, directors and other holders of our securities, exercise of
stock options issued pursuant to a stock option or similar plans, and other exceptions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Statement on Form S-8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
no awards of any kind have been made under the 2017 Plan. We intend to file a registration statement on Form S-8 under the Securities
Act to register shares that may be issued pursuant to the 2017 Plan. The registration statement on Form S-8 is expected to become
effective immediately upon filing, and shares covered by the registration statement will then become eligible for sale in the public
market, subject to the Rule 144 limitations applicable to affiliates, vesting restrictions and any applicable lock-up agreements
and market standoff agreements. For a description of our equity incentive plans, see &quot;Management&mdash;2017 Equity Incentive
Plan.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_015"></A>DISQUALIFYING
EVENTS DISCLOSURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent changes to Regulation
A promulgated under the Securities Act prohibit an issuer from claiming an exemption from registration of its securities under
such rule if the issuer, any of its predecessors, any affiliated issuer, any director, executive officer, other officer participating
in the offering of the interests, general partner or managing member of the issuer, any beneficial owner of 20% or more of the
voting power of the issuer&rsquo;s outstanding voting equity securities, any promoter connected with the issuer in any capacity
as of the date hereof, any investment manager of the issuer, any person that has been or will be paid (directly or indirectly)
remuneration for solicitation of purchasers in connection with such sale of the issuer&rsquo;s interests, any general partner or
managing member of any such investment manager or solicitor, or any director, executive officer or other officer participating
in the offering of any such investment manager or solicitor or general partner or managing member of such investment manager or
solicitor has been subject to certain &ldquo;Disqualifying Events&rdquo; described in Rule 506(d)(1) of Regulation D subsequent
to September 23, 2013, subject to certain limited exceptions. The Company is required to exercise reasonable care in conducting
an inquiry to determine whether any such persons have been subject to such Disqualifying Events and is required to disclose any
Disqualifying Events that occurred prior to September 23, 2013 to investors in the Company. The Company believes that it has exercised
reasonable care in conducting an inquiry into Disqualifying Events by the foregoing persons and is aware of the no such Disqualifying
Events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that
(a) Disqualifying Events may exist of which the Company is not aware and (b) the SEC, a court or other finder of fact may determine
that the steps that the Company has taken to conduct its inquiry were inadequate and did not constitute reasonable care. If such
a finding were made, the Company may lose its ability to rely upon exemptions under Regulation A, and, depending on the circumstances,
may be required to register the Offering of the Company&rsquo;s Common Stock with the SEC and under applicable state securities
laws or to conduct a rescission offer with respect to the securities sold in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_016"></A>ERISA
CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trustees and other
fiduciaries of qualified retirement plans or IRAs that are set up as part of a plan sponsored and maintained by an employer, as
well as trustees and fiduciaries of Keogh Plans under which employees, in addition to self-employed individuals, are participants
(together, &ldquo;ERISA Plans&rdquo;), are governed by the fiduciary responsibility provisions of Title 1 of the Employee Retirement
Income Security Act of 1974 (&ldquo;ERISA&rdquo;). An investment in the Shares by an ERISA Plan must be made in accordance with
the general obligation of fiduciaries under ERISA to discharge their duties (i) for the exclusive purpose of providing benefits
to participants and their beneficiaries; (ii) with the same standard of care that would be exercised by a prudent man familiar
with such matters acting under similar circumstances; (iii) in such a manner as to diversify the investments of the plan, unless
it is clearly prudent not do so; and (iv) in accordance with the documents establishing the plan. Fiduciaries considering an investment
in the Shares should accordingly consult their own legal advisors if they have any concern as to whether the investment would be
inconsistent with any of these criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fiduciaries of certain
ERISA Plans which provide for individual accounts (for example, those which qualify under Section 401(k) of the Code, Keogh Plans
and IRAs) and which permit a beneficiary to exercise independent control over the assets in his individual account, will not be
liable for any investment loss or for any breach of the prudence or diversification obligations which results from the exercise
of such control by the beneficiary, nor will the beneficiary be deemed to be a fiduciary subject to the general fiduciary obligations
merely by virtue of his exercise of such control. On October 13, 1992, the Department of Labor issued regulations establishing
criteria for determining whether the extent of a beneficiary&rsquo;s independent control over the assets in his account is adequate
to relieve the ERISA Plan&rsquo;s fiduciaries of their obligations with respect to an investment directed by the beneficiary. Under
the regulations, the beneficiary must not only exercise actual, independent control in directing the particular investment transaction,
but also the ERISA Plan must give the participant or beneficiary a reasonable opportunity to exercise such control, and must permit
him to choose among a broad range of investment alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trustees and other
fiduciaries making the investment decision for any qualified retirement plan, IRA or Keogh Plan (or beneficiaries exercising control
over their individual accounts) should also consider the application of the prohibited transactions provisions of ERISA and the
Code in making their investment decision. Sales and certain other transactions between a qualified retirement plan, IRA or Keogh
Plan and certain persons related to it (e.g., a plan sponsor, fiduciary, or service provider) are prohibited transactions. The
particular facts concerning the sponsorship, operations and other investments of a qualified retirement plan, IRA or Keogh Plan
may cause a wide range of persons to be treated as parties in interest or disqualified persons with respect to it. Any fiduciary,
participant or beneficiary considering an investment in Shares by a qualified retirement plan IRA or Keogh Plan should examine
the individual circumstances of that plan to determine that the investment will not be a prohibited transaction. Fiduciaries, participants
or beneficiaries considering an investment in the Shares should consult their own legal advisors if they have any concern as to
whether the investment would be a prohibited transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulations issued
on November 13, 1986, by the Department of Labor (the &ldquo;Final Plan Assets Regulations&rdquo;) provide that when an ERISA Plan
or any other plan covered by Code Section 4975 (e.g., an IRA or a Keogh Plan which covers only self-employed persons) makes an
investment in an equity interest of an entity that is neither a &ldquo;publicly offered security&rdquo; nor a security issued by
an investment company registered under the Investment Company Act of 1940, the underlying assets of the entity in which the investment
is made could be treated as assets of the investing plan (referred to in ERISA as &ldquo;plan assets&rdquo;). Programs which are
deemed to be operating companies or which do not issue more than 25% of their equity interests to ERISA Plans are exempt from being
designated as holding &ldquo;plan assets.&rdquo; Management anticipates that we would clearly be characterized as an &ldquo;operating
company&rdquo; for the purposes of the regulations, and that it would therefore not be deemed to be holding &ldquo;plan assets.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Classification of our
assets of as &ldquo;plan assets&rdquo; could adversely affect both the plan fiduciary and management. The term &ldquo;fiduciary&rdquo;
is defined generally to include any person who exercises any authority or control over the management or disposition of plan assets.
Thus, classification of our assets as plan assets could make the management a &ldquo;fiduciary&rdquo; of an investing plan. If
our assets are deemed to be plan assets of investor plans, transactions which may occur in the course of its operations may constitute
violations by the management of fiduciary duties under ERISA. Violation of fiduciary duties by management could result in liability
not only for management but also for the trustee or other fiduciary of an investing ERISA Plan. In addition, if our assets are
classified as &ldquo;plan assets,&rdquo; certain transactions that we might enter into in the ordinary course of our business might
constitute &ldquo;prohibited transactions&rdquo; under ERISA and the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Code Section
408(i), as amended by the Tax Reform Act of 1986, IRA trustees must report the fair market value of investments to IRA holders
by January 31 of each year. The Service has not yet promulgated regulations defining appropriate methods for the determination
of fair market value for this purpose. In addition, the assets of an ERISA Plan or Keogh Plan must be valued at their &ldquo;current
value&rdquo; as of the close of the plan&rsquo;s fiscal year in order to comply with certain reporting obligations under ERISA
and the Code. For purposes of such requirements, &ldquo;current value&rdquo; means fair market value where available. Otherwise,
current value means the fair value as determined in good faith under the terms of the plan by a trustee or other named fiduciary,
assuming an orderly liquidation at the time of the determination. We do not have an obligation under ERISA or the Code with respect
to such reports or valuation although management will use good faith efforts to assist fiduciaries with their valuation reports.
There can be no assurance, however, that any value so established (i) could or will actually be realized by the IRA, ERISA Plan
or Keogh Plan upon sale of the Shares or upon liquidation of us, or (ii) will comply with the ERISA or Code requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The income earned by
a qualified pension, profit sharing or stock bonus plan (collectively, &ldquo;Qualified Plan&rdquo;) and by an individual retirement
account (&ldquo;IRA&rdquo;) is generally exempt from taxation. However, if a Qualified Plan or IRA earns &ldquo;unrelated business
taxable income&rdquo; (&ldquo;UBTI&rdquo;), this income will be subject to tax to the extent it exceeds $1,000 during any fiscal
year. The amount of unrelated business taxable income in excess of $1,000 in any fiscal year will be taxed at rates up to 36%.
In addition, such unrelated business taxable income may result in a tax preference, which may be subject to the alternative minimum
tax. It is anticipated that income and gain from an investment in the Shares will not be taxed as UBTI to tax exempt shareholders,
because they are participating only as passive financing sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_017"></A>INVESTOR
ELIGIBILITY STANDARDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Shares will be
sold only to a person who is not an accredited investor if the aggregate purchase price paid by such person is no more than 10%
of the greater of such person&rsquo;s annual income or net worth, not including the value of his primary residence, as calculated
under Rule 501 of Regulation D promulgated under Section 4(a)(2) of the Securities Act of 1933, as amended. In the case of sales
to fiduciary accounts (Keogh Plans, Individual Retirement Accounts (IRAs) and Qualified Pension/Profit Sharing Plans or Trusts),
the above suitability standards must be met by the fiduciary account, the beneficiary of the fiduciary account, or by the donor
who directly or indirectly supplies the funds for the purchase of Shares. Investor suitability standards in certain states may
be higher than those described in this Offering Circular. These standards represent minimum suitability requirements for prospective
investors, and the satisfaction of such standards does not necessarily mean that an investment in the Company is suitable for such
persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each investor must
represent in writing that he/she meets the applicable requirements set forth above and in the Subscription Agreement, including,
among other things, that (i) he/she is purchasing the Shares for his/her own account and (ii) he/she has such knowledge and experience
in financial and business matters that he/she is capable of evaluating without outside assistance the merits and risks of investing
in the Shares, or he/she and his/her purchaser representative together have such knowledge and experience that they are capable
of evaluating the merits and risks of investing in the Shares. Transferees of Shares will be required to meet the above suitability
standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_018"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters
with respect to the shares of Common Stock offered hereby will be passed upon by Hughes Hubbard &amp; Reed LLP, New York, New
York. Schiff Hardin LLP, Washington, DC, is acting as counsel to the Placement Agent in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_019"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements
of the Company appearing elsewhere in this Offering Circular have been included herein in reliance upon the report of BDO East
Coast Partnership, an independent registered public accounting firm, appearing elsewhere herein, and upon the authority of BDO
East Coast Partnership as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_020"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with
the SEC a Regulation A Offering Statement on Form 1-A under the Securities Act with respect to the shares of Common Stock offered
hereby. This Offering Circular, which constitutes a part of the Offering Statement, does not contain all of the information set
forth in the Offering Statement or the exhibits and schedules filed therewith. For further information about us and the Common
Stock offered hereby, we refer you to the Offering Statement and the exhibits and schedules filed therewith. Statements contained
in this Offering Circular regarding the contents of any contract or other document that is filed as an exhibit to the Offering
Statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of
such contract or other document filed as an exhibit to the Offering Statement. Upon the completion of this Offering, we will be
required to file periodic reports, proxy statements, and other information with the SEC pursuant to the Exchange Act. You may
read and copy this information at the SEC&rsquo;s Public Reference Room, 100 F Street, N.E., Room 1580, Washington, D.C. 20549.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains
an Internet website that contains reports, proxy statements and other information about issuers, including us, that file electronically
with the SEC. The address of this site is <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><A NAME="partii_021"></A>&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>GLUCOSE BIOSENSOR
SYSTEMS</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(GREATER CHINA)
HOLDINGS, INC. AND</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SUBSIDIARIES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE PERIOD
FROM JULY 1, 2017 THROUGH</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MARCH 31, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="color: #2F5496; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contents</P>

<P STYLE="color: #2F5496; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><A HREF="#balancesheet"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
    BALANCE SHEETS</B></FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#balancesheet"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-3</B></FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#operations"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED STATEMENTS
    OF OPERATIONS</B></FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#operations"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-4</B></FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#stockequity"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED STATEMENTS
    OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</B></FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#stockequity"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-5</B></FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#cashflow"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED STATEMENTS
    OF CASH FLOWS</B></FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#cashflow"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-7</B></FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#finnotes"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES TO CONSOLIDATED
    FINANCIAL STATEMENTS</B></FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#finnotes"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-8
    - F-17</B></FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="balancesheet"></A>CONSOLIDATED
BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Note</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">As of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">March 31,<BR> 2018</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">June 30,<BR> 2017</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">(audited)</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold">Assets</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 10pt">Current Assets:</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 65%; font-size: 10pt; color: Black; text-align: left; padding-left: 20pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: center; padding-left: 5.4pt">7</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">1,054,650</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">56,033</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 20pt">Deferred charges</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center; padding-left: 5.4pt">3</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1,679,430</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">611,194</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Other current assets</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">4</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">53,510</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total current assets</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">2,787,590</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">667,227</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 10pt">Intangibles</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Licensing rights,
    net of accumulated amortization</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">5</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; font-weight: bold; text-align: right">2,787,590</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; font-weight: bold; text-align: right">667,227</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left">Liabilities and shareholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 10pt">Current liabilities:</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 20pt">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center; padding-left: 5.4pt">6</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">305,203</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">339,174</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 20pt">Convertible Notes Payable</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center; padding-left: 5.4pt">8</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">5,205,435</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">3,534,322</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Due to Life Science
    Biosensor Diagnostics Pty Ltd</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">10</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">2,706,241</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total current liabilities</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">5,510,638</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">6,579,737</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">5,510,638</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">6,579,737</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left">Commitments &amp; Contingencies</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left">Shareholders' Equity</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 10pt">Common shares (20,000,000 shares authorised
    and 9,000,000 issued)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 10pt">Preferred shares (2,000,000 shares authorised
    and 1,012,850 issued)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">7,143,370</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 10pt">Ordinary shares (2,036,000 issued)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1,459,091</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(8,116,902</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(5,603,556</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(3,478,258</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(311,672</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 10pt">Accumulated Other comprehensive income</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">269,650</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">2,717</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Shareholders&rsquo;
    (deficit) equity</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(2,723,048</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(5,912,510</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities
    and shareholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; font-weight: bold; text-align: right">2,787,590</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; font-weight: bold; text-align: right">667,227</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements shall be read in conjunction
with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B></B></FONT></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="operations"></A>CONSOLIDATED STATEMENTS
OF OPERATIONS</P>

<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold">(unaudited)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">9 Months to</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">March 31, 2018</P></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">August 4, 2016 (inception) to</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">March 31, 2017</P></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black">Revenue:</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Interest
    income</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">278</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">62</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.375in">Audit &amp; Accountancy Fees</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">68,000</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">0</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.375in">General &amp; Administrative Expenses</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1,184,928</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">47,828</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.375in">Interest Expense</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">357,149</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">74,783</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.375in">Rent Expense</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">13,487</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">15,390</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Research &amp;
    Development Expense</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">1,543,300</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total operating
    expenses</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">3,166,864</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">138,001</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Profit / (Loss)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: right">(3,166,586</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: right">(137,939</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left">Other Comprehensive Income</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt">Foreign Currency Translation&nbsp;&nbsp;Gain</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">266,933</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Other Comprehensive
    income for the period</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">266,933</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Comprehensive
    income for the period</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: right">(2,899,653</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: right">(135,222</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">March 31 2018</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">March 31 2017</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; color: Black; text-align: left">Loss per share based on Net Profit /(Loss)&nbsp;&nbsp;(note
    14):</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Basic and diluted
    net loss per share attributed to common&nbsp;&nbsp;shareholders</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(0.3838</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(0.0167</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 0.375in">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt; padding-left: 0.375in">Weighted-average number of shares</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">8,250,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">8,250,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: left; color: Black; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Note:
The weighted average number of shares used in calculating the basic net loss per share in the comparatives was based upon the
retroactive effect of the share consolidation to 8,250,000 as per note 12 . This is shown retrospectively in the comparatives.
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements shall be read in conjunction
with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="stockequity"></A>CONSOLIDATED STATEMENTS
OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR THE PERIOD FROM AUGUST 4, 2016 (INCEPTION) THROUGH JUNE
30, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Common Shares</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Total Subscribed Value</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Additional paid-in capital</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">(Accumulated deficit)</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Other comprehensive income</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold">At inception August 4, 2016</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; font-size: 10pt; color: Black; text-align: left">Issuance of common stock</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; color: Black; text-align: right">100</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; color: Black; text-align: right">1</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; color: Black; text-align: right">768</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; color: Black; text-align: right">769</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left">&nbsp;Subscriptions to purchase ordinary
    shares of Glucose Biosensor Systems (Greater China) Holdings Inc.</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">2,126,476</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">2,126,476</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left">&nbsp;Cost of issuance of convertible
    subordinated notes that have elected to convert to shares</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(169,479</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(169,479</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left">&nbsp;Deemed dividend in accordance
    with FASB ASC 805 for amounts incurred to parent to procure license</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(7,561,321</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(7,561,321</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left">&nbsp;Foreign currency translation</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">2,717</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">2,717</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1pt">&nbsp;Net Profit
    /(loss)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt">Balance at June 30,2017</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right">(5,603,556</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right">(5,912,510</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Refer to Note 3 for par values</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements shall be read in conjunction
with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="stockequity2018"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">FOR THE PERIOD FROM July 1, 2017 to
March 31, 2018</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black; white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common
    Shares</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total
    Subscribed Value</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">No
    of Preferred Shares (1)</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total
    Value</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">No
    of Ordinary Shares in GBSGC Pty Ltd</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total
    Value</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Additional
    paid-in capital</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(Accumulated
    deficit)</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Other
    comprehensive income</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Stockholders&rsquo;
    equity</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; font-size: 10pt; color: Black; font-weight: bold; white-space: nowrap"><FONT STYLE="font-size: 8pt">Balance
    at July 1, 2017</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">100</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">(5,603,556</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">(311,672</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">2,717</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">(5,912,510</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in; white-space: nowrap"><FONT STYLE="font-size: 8pt">Subscriptions
    to purchase </FONT><BR>
    <FONT STYLE="font-size: 8pt">convertible preference shares of </FONT><BR>
    <FONT STYLE="font-size: 8pt">Glucose Biosensor Systems </FONT><BR>
    <FONT STYLE="font-size: 8pt">(Greater China) Holdings Inc group</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">6,752,390</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">6,752,390</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in; white-space: nowrap"><FONT STYLE="font-size: 8pt">Issuance
    of convertible preferred </FONT><BR>
    <FONT STYLE="font-size: 8pt">shares and ordinary shares</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">1,012,850</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">7,143,370</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">2,036,000</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">1,459,091</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">(8,602,461</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">0</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in; white-space: nowrap"><FONT STYLE="font-size: 8pt">Cost
    of issuance of convertible</FONT><BR>
    <FONT STYLE="font-size: 8pt">preferred shares that may convert</FONT><BR>
    <FONT STYLE="font-size: 8pt">to ordinary shares</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">(663,275</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">(663,275</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in; white-space: nowrap"><FONT STYLE="font-size: 8pt">Additional
    Shares allotted due to </FONT><BR>
    <FONT STYLE="font-size: 8pt">Stock Split</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">8,999,900</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">0</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in; white-space: nowrap"><FONT STYLE="font-size: 8pt">Foreign
    currency translation gain</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">266,933</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">266,933</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; white-space: nowrap"><FONT STYLE="font-size: 8pt">Net
    profit /(loss)</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">(3,166,586</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 8pt">(3,166,586</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"><FONT STYLE="font-size: 8pt">Balance
    at March 31, 2018</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">9,000,000</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,012,850</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">7,143,370</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">2,036,000</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,459,091</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(8,116,902</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(3,478,258</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">269,650</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(2,723,048</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Convertible
                                         Preference Shares are convertible at a potential IPO to 1 ordinary share and one option
                                         exercisable at the IPO price between 2 &ndash; 3 years after the IPO providing the option
                                         holder holds the underlying share.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Refer
                                         to Note 3 for par values</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements shall be read in conjunction
with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="cashflow"></A>CONSOLIDATED
STATEMENTS OF CASH FLOWS</P>

<P STYLE="color: #2F5496; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">9 Months to</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">March 31, 2018</P></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">From August 4 2016 (inception) to</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">March 31, 2017</P></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left">Operating Activities:</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Net Profit / (Loss)</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">(3,166,586</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">(137,939</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.25in"><P STYLE="margin-top: 0; margin-bottom: 0">Adjustments
                                         to reconcile net loss to net cash</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-indent: -0.25in; margin-left: 0.125in">provided
                                         by operating activities:</P></TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Change in assets and liabilities:</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.25in">Accounts payable and accrued expenses
    &amp; deferred charges</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">126,269</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">97,868</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other debtors</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(53,342</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(18,422</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash used in
    operating activities</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(3,093,659</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(58,493</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left">Investing Activities:</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Net cash provided by investing activities</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left">Financing Activities:</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Cash proceeds from the issuance of convertible
    notes payable</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1,560,280</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">3,006,408</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Cash received from subscribers for convertible
    shares convertible to ordinary shares</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">7,086,622</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1,466,800</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Cash paid for debt issuance costs</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(122,864</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(176,235</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Cash paid to raise funds by the issuance
    of shares</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(663,275</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(85,985</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Cash paid for expenditures relating
    to the issuance of new shares and debt and preparation for listing costs</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(1,077,130</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">(140,027</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid in to
    procure license</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(2,706,322</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(3,962,465</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash provided
    by financing activities</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">4,077,311</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">108,496</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Net Cash Provided
    by Operational, Investing &amp; Finance Activities</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">983,652</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">50,003</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left">Cash at the beginning of the period</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">56,033</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Effect of exchange
rate on cash and cash equivalents</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">14,965</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash at the end of
    the period</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: right">1,054,650</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: Black; text-align: right">50,003</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">Supplemental disclosure of cash flow information</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Interest paid</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">357,149</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">74,783</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Interest income</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">278</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">62</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements shall be read in conjunction
with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="finnotes"></A>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 1.</B></TD><TD STYLE="text-align: justify"><B><U>GOING
                                         CONCERN</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 205-40, <I>Presentation of Financial Statements
- Going Concern</I> (ASC 205-40) requires management to assess an entity&rsquo;s ability to continue as a going concern within
one year of the date of the financial statements are issued. In each reporting period, including interim periods, an entity is
required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether it
is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial
doubt about an entity&rsquo;s ability to continue as a going concern exists when conditions and events, considered in the aggregate,
indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the
date the financial statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an early stage and emerging
growth company and has not generated any revenues to date. As such, the Company is subject to all of the risks associated with
early stage and emerging growth companies. Since inception, the Company has incurred losses and negative cash flows from operating
activities. The Company does not expect to generate positive cash flows from operating activities in the near future until such
time, if at all, the Company completes the development process of its products, including regulatory approvals, and thereafter,
begins to commercialize and achieve substantial acceptance in the marketplace for the first of a series of products in its medical
device portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred a net loss of
$3,166,586 for the nine months to March 31, 2018 (Net loss $137,939 for the period from August 4, 2016 (inception) through to
March 31 2017). At March 31, 2018, the Company had an accumulated deficit of $3,478,258, negative working capital of $2,723,048,
$5,510,638, in current liabilities of which $5,205,435 are convertible notes that will convert to equity upon the proposed IPO,
and cash of $1,054,650 (at June 30, 2017, the Company had an accumulated deficit of $311,672, negative working capital of $5,912,510,
$6,579,737, in current liabilities of which $3,534,322 are convertible notes that will convert to equity upon the proposed IPO,
and cash of $56,033). In the near future, the Company anticipates incurring operating losses and does not expect to experience
positive cash flows from operating activities and may continue to incur operating losses until it completes the development of
its products and seeks regulatory approvals to market such products. These factors raise may raise doubt about the Company&rsquo;s
ability to continue as a going concern without sufficient capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s ability to fund
its operations is dependent upon management&rsquo;s plans, which include raising additional capital, including the Proposed Public
Offering, obtaining regulatory approvals for its products currently under development, commercializing and generating revenues
from products currently under development, and continuing to control expenses. However, there is no assurance the Company will
be successful in these efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 1.</B></TD><TD STYLE="text-align: justify"><B><U>GOING
                                         CONCERN (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A failure to raise sufficient capital,
obtain regulatory approvals for the Company&rsquo;s products, generate sufficient product revenues, or control expenditures, among
other factors, may adversely impact the Company&rsquo;s ability to meet its financial obligations as they become due</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and payable and to achieve its intended
business objectives, and therefore, raises substantial doubt of the Company&rsquo;s ability to continue as a going concern.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s consolidated financial
statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities
and commitments in the normal course of business. The consolidated financial statements do not include any adjustments relating
to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the
Company be unable to continue as a going concern.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>STOCK SPLIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective November 5, 2017, each share
of our issued and outstanding common stock became 90,000 shares of common stock and no fractional shares were issued. The accompanying
financial statements and related disclosures give retroactive effect to the stock split &amp; the reverse share split noted in
note 12 for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 2.</B></TD><TD STYLE="text-align: justify"><B><U>ORGANIZATION
                                         AND DESCRIPTION OF THE BUSINESS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Glucose Biosensor Systems (Greater
China) Holdings, Inc. (&quot;Holdings&quot;) and its wholly owned subsidiary, Glucose Biosensor Systems (Greater China), Inc.
are formed under the laws of the state of Delaware, and were formed on December 5, 2016 (collectively, the &ldquo;Group&rdquo;)
and Glucose Biosensor Systems (Greater China) Pty Ltd (&quot;GBSPL&quot;), which was formed on August 4, 2016.&nbsp; These three
companies (collectively, the &quot;Company&quot;) were formed to provide a noninvasive, pain free innovation to make it easier
for people to manage diabetes.&nbsp; As more fully described in Note 5,&nbsp;the Company purchased the license rights relating
to saliva glucose biosensor technology for the Greater China Region from Life Science Biosensor Diagnostics Pty Ltd. (&quot;Life
Science&quot;), the shareholder of the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Basis of presentation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group prepares its consolidated
financial statements using the accrual basis of accounting in conformity with accounting principles generally accepted in the
United States of America (&quot;GAAP&quot;) and the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Principles of consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 29, 2017, Life Science transferred
to Holdings, in a non-reciprocal transfer, its shares in GBSPL. These shares comprised its 100% ownership of GBSPL. As a result,
the accompanying consolidated financial statements include the accounts of the following entities, all of which are under common
control. All significant intercompany transactions and balances have been eliminated upon consolidation. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the shares authorized
and issued of each company at March 31, 2018 and June 30, 2017 are listed below. (Refer to Note 12 for changes in capital structure
since 31 March 2018).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>At June 30, 2017:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold">Name of entity</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Country of incorporation</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Shares authorized</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Shares issued</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">Par value per share</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-size: 10pt; color: Black; text-align: left">Glucose Biosensor Systems (Greater China) Holdings,
    Inc.</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 20%; font-size: 10pt; color: Black; text-align: center">United States</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">1,000</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">100</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; color: Black; text-align: right">USD$0.01</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">Glucose Biosensor Systems (Greater China) Pty Ltd</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center">Australia</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1,000</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1,000</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: right">N/A (1)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">Glucose Biosensor Systems (Greater China), Inc.</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center">United States</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">1,000</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">100</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: right">USD$0.01</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>At March 31, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">Name of entity</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Country
    of incorporation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares
                                         </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>authorized</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Shares
    issued (Ordinary)</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Par value
    per share</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Shares
    Issued (Convertible Preference)</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Par
    Value Per Share</FONT></TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 16%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">Glucose Biosensor
    Systems (Greater China) Holdings, Inc.</FONT></TD><TD STYLE="width: 2%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; font-size: 10pt; color: Black; text-align: center"><FONT STYLE="font-size: 10pt">United States</FONT></TD><TD STYLE="width: 2%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">22,000,000</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">9,000,000</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">USD$0.01</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">1,012,850</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">US$.01</FONT></P></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">Glucose Biosensor Systems (Greater
    China) Pty Ltd</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center"><FONT STYLE="font-size: 10pt">Australia</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">99,800,000</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">99,800,000</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">N/A (1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">Glucose Biosensor Systems (Greater
    China), Inc.</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: center"><FONT STYLE="font-size: 10pt">United States</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD><TD STYLE="font-size: 10pt; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">USD$0.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Australia does
                                         not have the concept of par value per share</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 29, 2017, in a nonreciprocal
transfer, Life Sciences transferred ownership of its 1,000 shares of Glucose Biosensor Systems (Greater China) Pty Ltd to Glucose
Biosensor Systems (Greater China) Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2017 the authorized
capital was increased to 22,000,000 with a par value of $0.01 each consisting of 20,000,000 shares of common stock and 2,000,000
shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 5, 2017 the Company conducted
a stock split of one to 90,000 resulting in issued common stock of 9,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended
31<SUP>st</SUP> March 2018, the group received cash subscriptions for $1,560,280 regarding
the issuance of notes that are convertible to equity at the completion of an initial public offering (&quot;IPO&quot;) and
$7,086,622 (inclusive of foreign exchange gains) regarding the issuance of Convertible Preference Shares convertible to
ordinary shares at the completion of an initial public offering (&quot;IPO&quot;) and ordinary shares. The Convertible
Preference Shares carry the same rights as ordinary shares except the right to vote at general meetings of shareholders.
Further particulars are at Note 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Equity offering costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group complies with the requirements
of Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification ASC 340 with regards to offering
costs. Prior to the completion of an offering, offering costs will be capitalized as deferred offering costs on the balance sheet.
The deferred offering costs will be charged to stockholders&rsquo; equity (deficit) upon the completion of an offering or to expense
if the offering is not completed.&nbsp; Offering costs amounting to $1,679,430 were capitalized as of March 31, 2018 (June 30,
2017: $611,194). The Company anticipates significant offering costs in connection with the proposed&nbsp;offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall recognize revenues
when there is persuasive evidence of an arrangement, delivery has occurred or services are rendered, the sales price is determinable,
and collectability is reasonably assured. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Debt issuance cost</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Debt issuance costs are being amortized
using the effective interest rate method over the term of the loan and the amortization expense is recorded as part of interest
expense of the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Income taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions of
Financial Accounting Standards Board Accounting Standards Codification (&quot;FASB ASC&quot;) 740, Income Taxes, tax positions
initially need to be recognized in the consolidated financial statements when it is more likely than not that the positions will
be sustained upon examination by taxing authorities. It also provides guidance for de-recognition, classification, interest and
penalties, accounting in interim periods, disclosure, and transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2018, the Group had
no uncertain tax positions that qualified for either recognition or disclosure in the consolidated financial statements. Additionally,
the Group had no interest and penalties related to income taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2017, the Group had
no uncertain tax positions that qualified for either recognition or disclosure in the consolidated financial statements. Additionally,
the Group had no interest and penalties related to income taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for current and
deferred income taxes and, when appropriate, deferred tax assets and liabilities are recorded with respect to temporary differences
in the accounting treatment of items for financial reporting purposes and for income tax purposes. Where, based on the weight
of all available evidence, it is more likely than not that some amount of the recorded deferred tax assets will not be realized,
a valuation allowance is established for that amount that, in management's judgment, is sufficient to reduce the deferred tax
asset to an amount that is more likely than not to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Foreign currency translation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities of foreign subsidiaries
are translated from local (functional) currency to presentation currency (U.S. dollar) at the rate of exchange in effect on the
consolidated balance sheets date; income and expenses are translated at the average rate of exchange prevailing during the year.
Foreign currency movements resulted in a gain of $266,933 (June 30, 2017 foreign currency translation gain of $2,717).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Net Loss Per Share Attributable
to Common Stockholders (&ldquo;EPS&rdquo;)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates earnings per
share attributable to common stockholders in accordance with ASC Topic 260, &ldquo;Earning Per Share.&rdquo; Basic net income
(loss) per share attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders
by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated
by dividing net income (loss) attributable to common stockholders by weighted-average common shares outstanding during the period
plus potentially dilutive common shares, such as stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Potentially dilutive common shares
shall be calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options
are used to repurchase common stock at market value. The amount of shares remaining after the proceeds are exhausted represents
the potentially dilutive effect of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has incurred net losses
during the period ended 31 March 2018 and the conversion of the convertible notes payable or the effect of the completion of the
issuance of convertible preference shares in a private placement would be anti-dilutive, and thus is not included in loss per
share calculation (see Note 8&mdash;Convertible Notes Payable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Use of estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Subsequent events</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with FASB ASC 855, <I>Subsequent
Events</I>, management has evaluated subsequent events through August 14, 2018 the date on which these unaudited consolidated
financial statements were available to be issued. There were no material subsequent events that required recognition or additional
disclosure in these consolidated financial statements, except for a reverse stock split which occurred where the total number
of common issued stock has been consolidated to 8,250,000 from 9,000,000 as disclosed in Note 12 herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently adopted accounting pronouncement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2014, the FASB issued ASU
2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern, which amends FASB ASC 205,
Presentation of Financial Statements. This update requires management to assess an entity&rsquo;s ability to continue as a going
concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. ASU 2014-15 is effective
for the Company&rsquo;s annual reporting period ending June 30, 2017. The adoption of FASB ASU 2014-15 did not have a material
effect on the Group&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently issued but not yet effective</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB issued Accounting
Standards Update (&ldquo;ASU&rdquo;) No. 2014-09, Revenue from Contracts with Customers (&ldquo;ASU 2014-09&rdquo;), which requires
an entity to recognize revenue to depict the transfer of promised good or services to customers in an amount that reflects the
consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU will replace most existing
revenue recognition guidance in GAAP, including industry specific guidance, when it becomes effective. This new guidance is effective
for years beginning after December 15, 2017.&nbsp; The standard permits the use of either the retrospective or cumulative effect
transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and
related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued ASU
No. 2016-02, <I>Leases </I>(&quot;ASU 2016-02&quot;). This update requires all leases with a term greater than 12 months to be
recognized on the balance sheet through a right-of-use asset and a lease liability and the disclosure of key information pertaining
to leasing arrangements. This new guidance is effective for years beginning after December 15, 2019, with early adoption permitted.
The Company is evaluating the effect that ASU 2016-02 will have on its financial statements and related disclosures, but has not
yet determined the timing of adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 4.</B></TD><TD STYLE="text-align: justify"><B><U>OTHER
                                         ASSETS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">As of</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">March 31, <BR>2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">June 30, <BR>2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; color: Black; text-align: left">Goods &amp; Services Tax Receivable</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">53,342</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">168</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">Total</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">53,510</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 5.</B></TD><TD STYLE="text-align: justify"><B><U>LICENSING
                                         RIGHTS:</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensing rights consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">As of</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">March 31, <BR>2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">June 30, <BR>2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; width: 72%">Licensing rights:</TD><TD STYLE="font-size: 10pt; color: Black; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-left: 0.125in">Amount incurred to procure license</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">7,561,321</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Less charged to
    equity as per FASB ASC 805</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(7,561,321</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Licensing rights
    net of amortization and charged to equity</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From 1<SUP>st </SUP>July 2017 to 31
March 2018, the Company paid its liability in relation to outstanding license rights procurement costs to Life Science Biosensor
Diagnostics Pty Ltd a total of $2,706,241 ($4,855,080 August 5, 2016 to June 30, 2017) in relation to the development and approval
process technology that is described in Notes 2 and 11.&nbsp; The Company shall pay royalties of sales &amp; milestone payments,
as defined.&nbsp; The agreement shall be for the term of the applicable patents.&nbsp; The licensing agreement has a twenty-five
year term. No royalties have been incurred through March 31, 2018 (June 30, 2017: nil).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The licensing rights are carried at
Life Science&rsquo;s historical cost of $0, with the excess of the amount paid over historical cost reflected as a deemed dividend,
given this was a transaction between entities under common control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 6.</B></TD><TD STYLE="text-align: justify"><B><U>ACCOUNTS
                                         PAYABLE &amp; ACCRUED EXPENSES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">As of</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">March 31, <BR>2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">June 30, <BR>2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; color: Black; text-align: left">Trade Creditors</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">235,511</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">339,174</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; padding-left: 5.4pt">Accruals</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">8,609</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Amounts payable to
    Life Science Biosensor Diagnostics Pty Ltd</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">61,083</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt; padding-left: 8.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">305,203</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">339,174</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 7.</B></TD><TD STYLE="text-align: justify"><B><U>CASH
                                         &amp; CASH EQUIVALENTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">As of</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">March 31, <BR>2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">June 30, <BR>2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; color: Black; text-align: left">Cash at Bank</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">1,054,650</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">56,033</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash
equivalents, which may at times be in excess of the Australia Financial Claims Scheme or the United States' Federal Deposit Insurance
Corporation insurance limits, with high credit quality financial institutions and attempts to limit the amount of credit exposure
with any one institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 8.</B></TD><TD STYLE="text-align: justify"><B><U>CONVERTIBLE
                                         NOTES PAYABLE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Convertible notes payable consists
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center">As of</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">March 31, <BR>2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">June 30, <BR>2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; color: Black; text-align: left">Convertible Notes Payable</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">5,642,570</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; color: Black; text-align: right">3,848,593</TD><TD STYLE="width: 1%; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt">Less unamortized debt issuance costs</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(437,135</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(314,271</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt">Debt less unamortized debt issuance costs</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">5,205,435</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">3,534,322</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors have subscribed to a Glucose
Biosensor Systems (Greater China) 7% Convertible Note Issue during the periods in the above table.&nbsp; The Notes bear interest
at the rate of 7% per annum payable quarterly in arrears. &nbsp; The Notes are unsecured and mature on December 31, 2019.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notes also provide that there shall
be a 15% discount on the potential IPO Price on the offer document intended to be filed with an approved stock exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 9.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSCRIPTIONS
                                         TO PURCHASE CONVERTIBLE PREFERENCE SHARES OF ORDINARY SHARES OF GLUCOSE BIOSENSOR SYSTEMS
                                         (GREATER CHINA) HOLDINGS INC AND ORDINARY SHARES IN GLUCOSE BIOSENSOR SYSTEMS (GREATER
                                         CHINA) PTY LTD</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has received subscriptions
to purchase convertible preference shares and with the subsequent conversion of notes payable to shares, the Company estimates
that a maximum of 12,073,198 shares shall be on issue upon the successful completion of the IPO.&nbsp; The company has issued
1,012,850 convertible preference shares and 2,036,000 ordinary shares and the amounts representing these subscriptions to purchase
shares are credited to additional paid-in-capital in the amount of $6,752,390. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each convertible preference share will
convert to one ordinary share upon the successful completion of the IPO, plus with each share one Loyalty Warrant Entitlement.&nbsp;
The terms of the Entitlement provide that the holder can exercise one warrant to purchase one common share at the IPO price during
years two through to year three following the IPO. At exercise date, the shareholder must hold for each warrant to be exercised,
one underlying common share to exercise the option The warrants are not transferable and apply to the number of shares that were
subscribed for.&nbsp; In addition, the warrants do not apply to the convertible note holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 10.</B></TD><TD STYLE="text-align: justify"><B><U>LOANS
                                         PAYABLE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at June 30, 2017 the company had
a liability to its parent Life Science of $2,706,241 as a result of procuring the license. This has been repaid during the period
to March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 11.</B></TD><TD STYLE="text-align: justify"><B><U>RELATED-PARTY
                                         TRANSACTIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following transactions occurred
with Life Science Glucose Biosensor Diagnostics Pty Ltd during the period July 1, 2017 to March 31, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As more fully described in Note 5,
the Company has paid its liability in relation to license procurement of $2,706,241 (June 30, 2017 $4,855,080). Further payments
in relation to research &amp; development will be due upon the achievements of milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred a total of $1,543,300
towards the services in connection with development and regulatory approval pathway for the technology. There is a trade creditors
liability of $37,983 remaining on these transactions as at March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred a total of $1,159,260
towards overhead cost reimbursement which includes salaries, rents and other related overheads directly attributable to the company
which are included in General &amp; Administration Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid rent last year to
31 March 2017 of $15,390. This financial year to date the rent has been paid to a third party as a result of moving premises.
The third party lease is a monthly tenancy at $2,009 per month with a 3 months&rsquo; notice period to terminate. There is no
fixed term lease agreement, rather it rolls month to month. The above transactions have been determined by directors to be on
an arm&rsquo;s length basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.
 &amp; Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited Consolidated Financial Statements</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 12.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSEQUENT
                                         EVENTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since March 31, 2018, as at the date
of this report the following have occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an
                                         additional $1,572,427 received for the equivalent of 209,656, convertible preference
                                         shares resulting in the total share offering reaching $8,715,797.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">convertible
                                         notes gross amount payable has been reduced from $5,642,570 to $5,277,056 due to a refund
                                         of $7500 and foreign exchange fluctuations</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                         reverse share split whereas the total number of common issued stock has been consolidated
                                         from 9,000,000 to 8,250,000</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 13.</B></TD><TD STYLE="text-align: justify"><B><U>NET
                                         OPERATING LOSSES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall file its income tax
returns with the Internal Revenue Service and Australian Taxation Office.&nbsp; The Company has net operating loss carry forwards
of $3,478,258 which are derived from its operations in Australia and the US and are available to reduce future taxable income.
Such loss carryforwards may be carried forward indefinitely, subject to compliance with tests of continuity and additional rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net operating loss carried forward
give rise to a deferred tax asset of approximately $1,040,000. However, the Company has determined that a valuation allowance
of $1,040,000 against such deferred tax asset is necessary, as it cannot be determined that the carryforwards will be utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 14.</B></TD><TD STYLE="text-align: justify"><B><U>LOSS
                                         PER SHARE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9
                                         Months to</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March
                                         31, 2018</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">From&nbsp;&nbsp;August 4, 2016 (inception)&nbsp;to</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">March 31, 2017</P></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt">Total Loss</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(3,166,586</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(137,939</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt">On November 5, 2017 a stock split occurred
    where the total number of common issued stock had been split to 9,000,000 from 90,000. Subsequent to the split, the revised
    loss per share was:</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share attributed
    to common&nbsp;&nbsp;shareholders</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(0.3518</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(0.0153</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">Weighted-average number of shares used in calculating
    basic     and diluted net loss per share attributable to common shareholders </TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">9,000,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">9,000,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 9, 2018, a reverse stock split occurred
                                                                                                              where                                                                                                               the
                                                                                                              total                                                                                                               number
                                                                                                              of                                                                                                               common
                                                                                                              issued stock had been consolidated to 8,250,000 from 9,000,000.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent
                                         to the reverse split, the revised loss per share was:</P></TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share attributed
    to common&nbsp;&nbsp;shareholders</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(0.3838</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">(0.0167</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: Black; text-align: left; padding-bottom: 1pt">Weighted-average number of shares used
    in calculating basic &amp; diluted net loss per share attributable to common shareholders</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">8,250,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black; text-align: right">8,250,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>GLUCOSE BIOSENSOR
SYSTEMS (GREATER</B><BR>
<B>CHINA) HOLDINGS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE PERIOD
FROM AUGUST 4, 2016 (INCEPTION)</B><BR>
<B>THROUGH JUNE 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 89%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.5pt; text-indent: -8.5pt"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Report
    of Independent Registered Public Accounting Firm</B></FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_001">F-<FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.5pt; text-indent: -8.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidated
    Financial Statements&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Balance
    Sheet</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_002">F-21</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement
    of Operations</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-22</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement
    of Changes in Stockholders' Equity</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-23</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement
    of Cash Flows</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-24</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
    to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-25
    - F-32</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="width: 32%">&nbsp;<IMG SRC="tv502124_img07.jpg" ALT=""></TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Tel:
    +61 2 9251 4100</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Level
    11, 1 Margaret St</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Fax:
    +61 2 9240 9821</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Sydney
    NSW 2000</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">www.bdo.com.au</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Australia</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the members of Glucose Biosensor Systems (Greater China)
Holdings Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_001"></A><B>Report on the Audit of the Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheet
of Glucose Biosensor Systems (Greater China) Holdings Inc. as of June 30, 2017 and the related consolidated statement of operations,
changes in stockholders&rsquo; equity, and cash flows for the period from August 4, 2016 through June 30, 2017. These financial
statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on these financial
statements based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit in accordance with the standards
of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration
of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our
opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial position of Glucose Biosensor Systems (Greater China) Holdings
Inc. at June 30, 2017, and the results of its operations and its cash flows for the period from August 4, 2016 through June 30,
2017, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BDO East Coast Partnership </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ BDO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sydney, Australia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 28, 2017, except for the effect of the stock split
described in Note 1 of the financial statements, as to which the date is June 7, 2018.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 119; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>CONSOLIDATED
BALANCE SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JUNE 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center"><U>ASSETS</U></TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">56,033</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred charges (Note 3)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">611,194</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">667,227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Licensing rights, net of accumulated amortization
    (Note 4)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-bottom: 1pt">Total other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">667,227</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">LIABILITIES AND SHAREHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339,174</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes payable (note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,534,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Due to Life Science Biosensor Diagnostics Pty Ltd
    (Note 8)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,706,241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,579,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,579,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shareholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common Shares ( 20,000,000 shares authorised and 9,000,000 issued)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,603,556</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(311,672</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total Shareholders&rsquo; (deficit) equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,912,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">667,227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">These financial statements shall be
read in conjunction with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 120; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>CONSOLIDATED
STATEMENT OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE PERIOD FROM AUGUST 4, 2016
(INCEPTION) THROUGH JUNE 30, 2017&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest income:</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">74</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,749</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Rent expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,493</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">127,504</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">311,746</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">NET LOSS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Loss per share (Note 12):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Basic and diluted net loss per share attributable
    to common shareholders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.0346</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Weighted-average number of shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">These financial statements shall be
read in conjunction with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 121; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE PERIOD FROM AUGUST 4, 2016
(INCEPTION) THROUGH JUNE 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common<BR> Shares<BR>
    (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Par Value<BR> (2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Additional<BR> Paid-In<BR>
    Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Accumulated<BR> Deficit)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Other<BR> Comprehensive<BR>
    Income</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stockholders&rsquo;<BR>
    Equity</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">9,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.00001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">768</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">769</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Subscriptions to purchase ordinary shares of
    Glucose Biosensor Systems (Greater China) Holdings Inc..</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,126,476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,126,476</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cost of issuance of convertible subordinated
    notes that have elected to conversion to shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169,479</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169,479</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Deemed dividend in accordance with FASB ASC
    805 for amounts incurred to parent to procure license</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,561,321</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,561,321</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Foreign currency translation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,717</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Net Profit /(loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">BALANCE - JUNE 30, 2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,000.000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.00001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,603,556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,912,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>This gives a retroactive effect to the stock split
                                         as per Note 10 in relation to changes in share structure since year end</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>This reflects the retroactive effect on par value originally
                                         at $1 as a result of the share split as per Note 10</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">These financial statements shall be
read in conjunction with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 122; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>CONSOLIDATED
STATEMENT OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE PERIOD FROM AUGUST 4, 2016
(INCEPTION) THROUGH JUNE 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Operating Activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net loss</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">(311,672</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Adjustments to reconcile
    net loss to net cash provided by operating activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other comprehensive income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Changes in assets and liabilities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65,067</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(243,888</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Investing Activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash provided by investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Financing Activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash proceeds from the issuance of convertible
    notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">3,848,593</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash proceeds from the issuance of shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">769</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash received from subscribers to ordinary shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2,126,476</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid for debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(314,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid to raise funds by the issuance of shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(169,479</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid for expenditures relating to the issuance
    of new shares and debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(337,087</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid in to procure license</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,855,080</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">299,921</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; padding-bottom: 1pt; padding-left: 0.25in">CASH &ndash; ENDING</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56,033</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Supplemental disclosure of cash flow information:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Interest paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">138,749</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">These financial statements shall be
read in conjunction with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 123; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_006"></A><B>NOTES TO AND FORMING PART OF THE
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 1.</B></TD><TD STYLE="text-align: justify"><B><U>GOING
                                         CONCERN</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 205-40, <I>Presentation of Financial
Statements - Going Concern</I> (ASC 205-40) requires management to assess an entity&rsquo;s ability to continue as a going concern
within one year of the date of the financial statements are issued. In each reporting period, including interim periods, an entity
is required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether
it is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial
doubt about an entity&rsquo;s ability to continue as a going concern exists when conditions and events, considered in the aggregate,
indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the
date the financial statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is an early
stage and emerging growth company and has not generated any revenues to date. As such, the Company is subject to all of the risks
associated with early stage and emerging growth companies. Since inception, the Company has incurred losses and negative cash
flows from operating activities. The Company does not expect to generate positive cash flows from operating activities in the
near future until such time, if at all, the Company completes the development process of its products, including regulatory approvals,
and thereafter, begins to commercialize and achieve substantial acceptance in the marketplace for the first of a series of products
in its medical device portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company incurred a net
loss of $311,672 for the period from August 4, 2016 (inception) through June 30, 2017. At June 30, 2017, the Company had an accumulated
deficit of $311,672, negative working capital of $5,912,510, $6,579,737, in current liabilities of which $3,534,322 are convertible
notes that will convert to equity upon the proposed IPO, and cash of $56,033. In the near future, the Company anticipates incurring
operating losses and does not expect to experience positive cash flows from operating activities and may continue to incur operating
losses until it completes the development of its products and seeks regulatory approvals to market such products. These factors
raise may raise doubt about the Company&rsquo;s ability to continue as a going concern without sufficient capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&rsquo;s ability
to fund its operations is dependent upon management&rsquo;s plans, which include raising additional capital, including the Proposed
Public Offering described in Note 3, obtaining regulatory approvals for its products currently under development, commercializing
and generating revenues from products currently under development, and continuing to control expenses. However, there is no assurance
the Company will be successful in these efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">A failure to raise sufficient
capital, obtain regulatory approvals for the Company&rsquo;s products, generate sufficient product revenues, or control expenditures,
among other factors, may adversely impact the Company&rsquo;s ability to meet its financial obligations as they become due and
payable and to achieve its intended business objectives, and therefore, raises substantial doubt of the Company&rsquo;s ability
to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 124; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 1.</B></TD><TD STYLE="text-align: justify"><B><U>GOING
                                         CONCERN (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&rsquo;s consolidated
financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction
of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should
the Company be unable to continue as a going concern.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><B>STOCK
SPLIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Effective November 5, 2017,
each share of our issued and outstanding common stock became 90,000 shares of common stock and no fractional shares were issued.
The accompanying financial statements and related disclosures give retroactive effect to the stock split for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 2.</B></TD><TD STYLE="text-align: justify"><B><U>ORGANIZATION
                                         AND DESCRIPTION OF THE BUSINESS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Glucose Biosensor Systems
(Greater China) Holdings, Inc. (the &quot;Holdings&quot;) and its wholly owned subsidiary, Glucose Biosensor Systems (Greater
China), Inc. are formed under the laws of the state of Delaware, and were formed on December 5, 2016 (collectively, the &ldquo;Group&rdquo;)
and Glucose Biosensor Systems (Greater China) Pty Ltd (&quot;GBSPL&quot;), which was formed on August 4, 2016.&nbsp; These three
companies (collectively, the &quot;Company&quot;) were formed to provide a noninvasive, pain free innovation to make it easier
for people to manage diabetes.&nbsp; As more fully described in Note 4,&nbsp;the Company purchased the license rights relating
to saliva glucose biosensor technology for the Greater China Region from Life Science Biosensor Diagnostics Pty Ltd. (&quot;Life
Science&quot;), the shareholder of the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><U>Basis of presentation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group prepares its consolidated
financial statements using the accrual basis of accounting in conformity with accounting principles generally accepted in the
United States of America (&quot;GAAP&quot;) and the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><U>Principles of consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On July 29, 2017, Life Science
transferred to Holdings, in a non-reciprocal transfer, its shares in GBSPL. These shares comprised its 100% ownership of GBSPL.
As a result, the accompanying consolidated financial statements include the accounts of the following entities, all of which are
under common control. All significant intercompany transactions and balances have been eliminated in consolidation. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">A summary of the shares
authorized and issued of each company at June 30, 2017 is listed below. (Refer to Note 10 for changes in capital structure since
year end)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Name&nbsp;of&nbsp;entity</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Country&nbsp;of</FONT><BR>
    <FONT STYLE="font-size: 10pt">incorporation</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Shares</FONT><BR>
    <FONT STYLE="font-size: 10pt">authorized</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Shares</FONT><BR>
    <FONT STYLE="font-size: 10pt">issued</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Par&nbsp;value&nbsp;per</FONT><BR>
    <FONT STYLE="font-size: 10pt">share</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Glucose
    Biosensor Systems (Greater China) Holdings, Inc.</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: left"><FONT STYLE="font-size: 10pt">United States</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USD$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">0.01</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Glucose Biosensor
    Systems (Greater China) Pty Ltd</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Australia</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Glucose Biosensor
    Systems (Greater China), Inc.</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">United States</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USD$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.01</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 125; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the period ended
June 30, 2017, Glucose Biosensors Systems (Greater China) Pty Ltd. raised $3,848,593 ($5,013,800 Australian currency) through
the issuance of notes that are convertible to equity at the completion of an initial public offering (&quot;IPO&quot;).&nbsp;
Through June 30, 2017, the subscribers to a private placement of ordinary shares amounting to $2,126,476 ($2,770,000 Australian
currency) were received. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Equity offering costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group complies with
the requirements of Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification ASC 340 with regards
to offering costs. Prior to the completion of an offering, offering costs will be capitalized as deferred offering costs on the
balance sheet. The deferred offering costs will be charged to stockholders&rsquo; equity (deficit) upon the completion of an offering
or to expense if the offering is not completed.&nbsp; Offering costs amounting to $611,194 were capitalized as of June 30, 2017
The Company anticipates significant offering costs in connection with the proposed&nbsp;offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Revenue recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company shall recognize
revenues when there is persuasive evidence of an arrangement, delivery has occurred or services are rendered, the sales price
is determinable, and collectability is reasonably assured. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Debt issuance cost</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Debt issuance costs are
being amortized using the effective interest rate method over the term of the loan and the amortization expense is recorded as
part of interest expense of the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Income taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with the provisions
of Financial Accounting Standards Board Accounting Standards Codification (&quot;FASB ASC&quot;) 740, Income Taxes, tax positions
initially need to be recognized in the consolidated financial statements when it is more likely than not that the positions will
be sustained upon examination by taxing authorities. It also provides guidance for de-recognition, classification, interest and
penalties, accounting in interim periods, disclosure, and transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of June 30, 2017, the
Group had no uncertain tax positions that qualified for either recognition or disclosure in the consolidated financial statements.
Additionally, the Group had no interest and penalties related to income taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group accounts for current
and deferred income taxes and, when appropriate, deferred tax assets and liabilities are recorded with respect to temporary differences
in the accounting treatment of items for financial reporting purposes and for income tax purposes. Where, based on the weight
of all available evidence, it is more likely than not that some amount of the recorded deferred tax assets will not be realized,
a valuation allowance is established for that amount that, in management's judgment, is sufficient to reduce the deferred tax
asset to an amount that is more likely than not to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 126; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"><U>Foreign currency translation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Assets and liabilities of
foreign subsidiaries are translated from local (functional) currency to presentation currency (U.S. dollar) at the rate of exchange
in effect on the consolidated balance sheets date; income and expenses are translated at the average rate of exchange prevailing
during the year. Foreign currency translation adjustments resulted in a gain of $2,717, which is included in the &quot;other comprehensive
income&quot; line item on the consolidated statement of cashflows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Net Loss Per Share Attributable
to Common Stockholders (&ldquo;EPS&rdquo;)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company calculates earnings
per share attributable to common stockholders in accordance with ASC Topic 260, &ldquo;Earning Per Share.&rdquo; Basic net income
(loss) per share attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders
by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated
by dividing net income (loss) attributable to common stockholders by weighted-average common shares outstanding during the period
plus potentially dilutive common shares, such as stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Potentially dilutive common
shares shall be calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all
options are used to repurchase common stock at market value. The amount of shares remaining after the proceeds are exhausted represents
the potentially dilutive effect of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has incurred
net losses during the period ended June 30, 2017 and the conversion of the convertible notes payable or the effect of the completion
of the issuance of the shares in a private placement would be anti-dilutive, and thus is not included in loss per share calculation
(see Note 6&mdash;Convertible Notes Payable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Use of estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of consolidated
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements,
and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Subsequent events</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with FASB
ASC 855, <I>Subsequent Events</I>, management has evaluated subsequent events through December 28, , 2017, the date on which these
consolidated financial statements were available to be issued. There were no material subsequent events that required recognition
or additional disclosure in these consolidated financial statements, except as disclosed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 127; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Recently adopted accounting
pronouncement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In August 2014, the FASB
issued ASU 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern, which amends FASB
ASC 205, Presentation of Financial Statements. This update requires management to assess an entity&rsquo;s ability to continue
as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. ASU 2014-15
is effective for the Company&rsquo;s annual reporting period ending June 30, 2017. The adoption of FASB ASU 2014-15 did not have
a material effect on the Group&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Recently issued but not
yet effective accounting pronouncemen</U>t (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In May 2014, the FASB issued
Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2014-09, Revenue from Contracts with Customers (&ldquo;ASU 2014-09&rdquo;),
which requires an entity to recognize revenue to depict the transfer of promised good or services to customers in an amount that
reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU will replace
most existing revenue recognition guidance in GAAP, including industry specific guidance, when it becomes effective. This new
guidance is effective for years beginning after December 15, 2017.&nbsp; The standard permits the use of either the retrospective
or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial
statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In February 2016, the FASB
issued ASU No. 2016-02, <I>Leases </I>(&quot;ASU 2016-02&quot;). This update requires all leases with a term greater than 12 months
to be recognized on the balance sheet through a right-of-use asset and a lease liability and the disclosure of key information
pertaining to leasing arrangements. This new guidance is effective for years beginning after December 15, 2019, with early adoption
permitted. The Company is evaluating the effect that ASU 2016-02 will have on its financial statements and related disclosures,
but has not yet determined the timing of adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 128; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 4.</B></TD><TD STYLE="text-align: justify"><B><U>LICENSING
                                         RIGHTS:</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At June 30, 2017, licensing
rights consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Licensing rights</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%; text-align: left; padding-left: 0.125in">Amount Incurred to procure license</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">7,561,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-bottom: 1pt">Less charged to equity as per&nbsp;&nbsp;FASB ASC
    805</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(7,561,321</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Licensing rights, net of amortization &amp; charged
    to equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">From August 5, 2016 to 30<SUP>th
</SUP>June 2017, the Company paid Life Science a total of $4,855,080 and has a liability of $2,706,241 to procure the right to
license and develop the technology that is described in Notes 2 and 9.&nbsp; The Company shall pay royalties of sales, as defined.&nbsp;
The agreement shall be for the term of the applicable patents.&nbsp; The licensing agreement has a twenty five year term. No royalties
have been incurred through June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The licensing rights are
carried at Life Science&rsquo;s historical cost of $0, with the excess of the amount paid over historical cost reflected as a
deemed dividend, given this was a transaction between entities under common control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 5.</B></TD><TD STYLE="text-align: justify"><B><U>CONCENTRATION
                                         OF CREDIT RISK</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company places its cash
and cash equivalents, which may at times be in excess of the Australia Financial Claims Scheme or the United States' Federal Deposit
Insurance Corporation insurance limits, with high credit quality financial institutions and attempts to limit the amount of credit
exposure with any one institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 6.</B></TD><TD STYLE="text-align: justify"><B><U>CONVERTIBLE
                                         NOTES PAYABLE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At June 30, 2017, convertible
notes payable consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left">Convertible Notes Payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,848,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less unamortized debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(314,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Debt less unamortized debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,534,322</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Investors have subscribed
to a Glucose Biosensor Systems (Greater China) 7% Convertible Note Issue during the period ended June 30, 2017.&nbsp; The Notes
bear interest at the rate of 7% per annum payable quarterly in arrears. The Notes are unsecured and mature on December 31, 2019.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Notes also provide that
there shall be a 15% discount on the IPO Price on the offer document intended to be filed with an approved stock exchange. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 129; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 7.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSCRIPTIONS
                                         TO PURCHASE ORDINARY SHARES OF GLUCOSE BIOSENSOR SYSTEMS (GREATER CHINA) PTY LTD</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has received
subscriptions to purchase ordinary shares of Glucose Biosensor Systems (Greater China) Pty Ltd&nbsp; and with the subsequent conversion
of notes payable to shares, the Company estimates that a maximum of 12,083,333 shares shall be on issue upon the successful completion
of the IPO.&nbsp; The amounts representing these subscriptions to purchase ordinary shares are credited to additional paid-in-capital
in the amount of $2,126,476. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">With each share is a Loyalty
Option Entitlement.&nbsp; The terms of the Entitlement provide that the holder can exercise one option to purchase one common
share at the IPO price during years two through to year three following the IPO. At exercise date, the shareholder must hold for
each option to be exercised, one underlying common share to exercise the option The options are not transferable and apply to
the number of shares that were subscribed for.&nbsp; In addition, the options do not apply to the convertible note holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 8.</B></TD><TD STYLE="text-align: justify"><B><U>LOANS
                                         PAYABLE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As at 30<SUP>th</SUP> June
2017 the company had a liability to its parent Life Science of $2,706,241 as a result of procuring the license. This is payable
as and when the Company raises capital for the purpose of paying this amount otherwise the amount will be converted to capital.
This liability is not interest bearing.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 9.</B></TD><TD STYLE="text-align: justify"><B><U>RELATED-PARTY
                                         TRANSACTIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As more fully described
in Note 8, the Company has a liability of $2,706,241 to an affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As more fully described
in Note 4, the Company paid Life Science a total of $4,855,080 and has a liability of $2,706,241 to procure the right to license
and develop the technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company rents office
space from Life Science on a month-to-month basis. Rent expense incurred during the period ended June 30, 2017 amounted to $45,493.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The above transactions have
been determined by directors to be on an arm&rsquo;s length basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 10.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSEQUENT
                                         EVENTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On July 29, 2017, in a nonreciprocal
transfer, Life Sciences transferred ownership of its 1,000 shares of Glucose Biosensor Systems (Greater China) Pty Ltd to Glucose
Biosensor Systems (Greater China) Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On October 30, 2017 the
authorized capital was increased to 22,000,000 with a par value of $0.01 each consisting of 20,000,000 shares of common stock
and 2,000,000 shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 5, 2017 the
Company conducted a stock split of one to 90,000 resulting in issued common stock of 9,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Since the end of the financial
year, as at the date of this report there has been an additional $1,371,407 received for the equivalent of 1,371,407 convertible
notes resulting in the total proceeds received for the convertible note offering reaching $5,220,000 and an additional $4,430,330
received for the equivalent of 590,710 ordinary shares resulting in the total share offering reaching $6,556,806.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 130; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 11.</B></TD><TD STYLE="text-align: justify"><B><U>NET
                                         OPERATING LOSSES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company shall file its
income tax returns with the Internal Revenue Service and Australian Taxation Office.&nbsp; The Company has net operating loss
carry forwards of $311,672 which are derived from its operations in Australia and the US and are available to reduce future taxable
income. Such loss carryforwards may be carried forward indefinitely, subject to compliance with tests of continuity and additional
rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The net operating loss carried
forward give rise to a deferred tax asset of approximately $94,000. However, the Company has determined that a valuation allowance
of $ 94,000 against such deferred tax asset is necessary, as it cannot be determined that the carryforwards will be utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 12.</B></TD><TD STYLE="text-align: justify"><B><U>LOSS
                                         PER SHARE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 5, 2017 the
Company conducted a stock split of one to 90,000 resulting in issued common stock of 9,000,000. The loss per share as of 30<SUP>th
</SUP>June 2017 prior to the stock split was:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted net loss per share attributable to common stockholders based upon actual shares issued as at 30<SUP>th</SUP> June
    2017</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">(3,117</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Weighted-average
    number of shares used in calculating loss per share attributable to common stockholders, basic and diluted common shares based
    upon actual shares issued as at 30<SUP>th</SUP> June 2017</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Subsequent to the split,
the revised loss per share was :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Loss per share:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Basic and diluted net loss per share
    attributable to common stockholders based upon retroactive effect of 90,000 to 1 stock split post year end</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">(0.0346</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Weighted-average number of shares used in calculating
    loss per share attributable to common stockholders, basic and diluted common shares based upon retroactive effect of 90,000
    to 1 stock split post year end</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 131; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART III&mdash;EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Index to Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.9in; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit
Description</B></FONT></P></TD>
    <TD STYLE="width: 1in; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 1.1 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Form of Placement Agency Agreement between
                    the Company and Cuttone &amp; Co., LLC </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>2.1<SUP>1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Certificate of Incorporation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">2.2<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">2.3<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Certificate of Designations of Series A Convertible Preferred Stock</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> 2.4<SUP>1</SUP> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> Certificate of Amendment to Certificate of Incorporation (reverse stock split) </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">2.4<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Amended and Restated By-laws</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.1<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Form of Certificate of Series A Convertible Preferred Stock</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.2<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Form of Warrant issued in connection with the&nbsp;&nbsp;Series A Convertible Preferred
    Stock</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.3<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Form of Convertible Promissory Note</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> 3.4<SUP>1</SUP> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> Form of Placement Agent Warrant </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">4.1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">Form of Subscription Agreement</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">6.1<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">2017 Equity Incentive Plan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">6.2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">Technology License Agreement between the Company and Life Science Biosensor
    Diagnostics Pty Ltd, dated August 25, 2017</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">6.3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Variation Agreement to Technology License Agreement
    between the Company and Life Science Biosensor Diagnostics Pty Ltd, dated December 8, 2017</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">6.4<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Variation Agreement to Technology License Agreement
    between the Company and Life Science Biosensor Diagnostics Pty Ltd., dated April 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> 6.5<SUP>1</SUP> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> Third Variation Agreement to Technology License Agreement dated July 10, 2018 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">6.6<SUP>1</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Form of Lock-Up Agreement</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">6.7<SUP></SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Master Services Agreement between the Company
    and iQ3 Corp Limited, an affiliated party.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">6.8</FONT><SUP>1</SUP> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Medical Affairs Services Agreement between the
    Company and Clinical Research Corporation, an affiliated party.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> 6.9<SUP>1</SUP> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> Services Agreement between the Company and Dr. Jean-Claude Becker dated August
    13, 2018 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> 6.10 </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><P STYLE="margin: 0pt 0"> Form of Technology Services Agreement with FundAmerica,
                                         LLC. </P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">8.1<SUP>1</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Escrow Agreement with Prime Trust, LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">11.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Consent of BDO East Coast Partnership</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">11.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Consent of Hughes Hubbard &amp; Reed LLP (included in Exhibit 12.1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">12.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Opinion of Hughes Hubbard &amp; Reed LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> 24.1<SUP>1</SUP> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> Power of Attorney </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) Previously filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 132; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Pursuant to the requirements of Regulation
A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A
and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Sydney,
Australia, on September 10, 2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Glucose Biosensor Systems (Greater China) Holdings, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Harry Simeonidis</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Harry Simeonidis</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This offering statement has been signed by the following persons
in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ Jonathan S. Hurd</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dated:  September 10, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Jonathan S. Hurd</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Title:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Chairman of the Board</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ Harry Simeonidis</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dated:&nbsp;September 10, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"> <FONT STYLE="font-size: 10pt">Name:</FONT> </TD>
    <TD STYLE="width: 45%"> <FONT STYLE="font-size: 10pt">Harry Simeonidis</FONT> </TD>
    <TD STYLE="width: 10%"> &nbsp; </TD>
    <TD STYLE="width: 40%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Title:&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">President and Director (Principal Executive Officer, Principal Financial Officer and
    Principal Accounting Officer)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ Dr. Jean-Claude Becker</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dated:  September 10, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dr. Jean-Claude Becker</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Title:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Chief Operating Officer, Executive Vice President and Director&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ Victoria Gavrilenko</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dated:  September 10, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Victoria Gavrilenko</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Secretary, Treasurer and Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ Dr. Yong-Jiang Hei</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dated:  September 10, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dr. Yong-Jiang Hei</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Title:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ Dr. John Caminis</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dated:  September 10, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Dr. John Caminis</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Title:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 133; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-1 UNDR AGMT
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PLACEMENT AGENCY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Cuttone &amp; Co. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">11 Wall Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">New York, NY 10005</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">[&#9679;], 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This agreement (&ldquo;<U>Agreement</U>&rdquo;)
constitutes the agreement between Glucose Biosensor Systems (Greater China) Holdings, Inc. a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;)
and Cuttone &amp; Co., LLC (&ldquo;<U>Cuttone</U>&rdquo; or the &ldquo;<U>Placement Agent</U>&rdquo;) pursuant to which Cuttone
shall serve as the exclusive placement agent for the Company, on a &ldquo;best efforts&rdquo; basis, in connection with the proposed
offer and placement (the &ldquo;<U>Offering</U>&rdquo;) by the Company of its Securities (as defined Section 3 of this Agreement).
The Company expressly acknowledges and agrees that Cuttone&rsquo;s obligations to offer and sell the Securities hereunder are on
a &ldquo;best efforts&rdquo; basis only and that the execution of this Agreement does not constitute a &ldquo;firm commitment&rdquo;
by Cuttone to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or
the success of Cuttone placing the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>Appointment of Cuttone &amp; Co., LLC as Exclusive Placement Agent. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the basis of the
representations, warranties, covenants and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement, the Company hereby appoints the Placement Agent as its exclusive placement agent in connection with a distribution
of its Securities to be offered and sold by the Company pursuant to the Offering Statement (defined herein), and Cuttone agrees
to act as the Company&rsquo;s exclusive Placement Agent. Pursuant to this appointment, the Placement Agent will solicit offers
for the purchase of or attempt to place all or part of the Securities of the Company in the proposed Offering. Until the final
closing or earlier upon termination of this Agreement pursuant to Section 5 hereof, the Company shall not, without the prior written
consent of the Placement Agent, solicit or accept offers to purchase the Securities other than through the Placement Agent. The
Company acknowledges that the Placement Agent will act as an agent of the Company and use its &ldquo;best efforts&rdquo; to solicit
offers to purchase the Securities from the Company on the terms, and subject to the conditions, set forth in the Pricing Disclosure
Materials. The Placement Agent shall use its best efforts to assist the Company in obtaining performance by each Purchaser whose
offer to purchase Securities has been solicited by the Placement Agent, but the Placement Agent shall not, except as otherwise
provided in this Agreement, be obligated to disclose the identity of any potential purchaser or have any liability to the Company
in the event any such purchase is not consummated for any reason. Under no circumstances will the Placement Agent be obligated
to underwrite or purchase any Securities for its own account and, in soliciting purchases of the Securities, the Placement Agent
shall act solely as an agent of the Company. The services provided pursuant to this Agreement shall be on an &ldquo;agency&rdquo;
basis and not on a &ldquo;principal&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Placement Agent
will solicit offers for the purchase of the Securities in the Offering at such times and in such amounts as the Placement Agent
deems advisable. The Company shall have the sole right to accept offers to purchase Securities and may reject any such offer, in
whole or in part, in its sole discretion. The Placement Agent may retain other brokers or dealers acceptable to the Company in
its sole discretion to act as sub-agents on its behalf in connection with the Offering and may pay any sub-agent a solicitation
fee with respect to any Securities placed by it. The Company will not be liable or responsible to any such brokers or dealers for
direct payment of any fees to any such brokers or dealers, it being the sole and exclusive responsibility of the Placement Agent
for payment of compensation to such brokers or dealers. The Company and Placement Agent shall negotiate the timing and terms of
the Offering and acknowledge that the Offering and the provision of Placement Agent services related to the Offering are subject
to market conditions and the receipt of all required related clearances and approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>Fees; Expenses; Other Arrangements.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Placement Agent&rsquo;s Fee; Non-Accountable Expense Allowance</U>. As compensation for services rendered, the Company
shall pay to the Placement Agent in cash by wire transfer in immediately available funds to an account or accounts designated by
the Placement Agent an amount (the &ldquo;<U>Placement Fee</U>&rdquo;) equal to 7.0% of the aggregate gross proceeds received by
the Company from the sale of the Securities, at each Closing Date (as defined below); and the Company shall issue to the Placement
Agent or its designees at the Closing one five-year warrant to purchase such number of Shares (as defined in Section 3) equal to
5.0% of the Shares sold in this Offering at an exercise price of $ [&#9679;] (110% of the price per Share) (the &ldquo;<U>Placement
Agent Warrant</U>&rdquo; and together with the shares of Common Stock underlying the Placement Agent Warrant, the &ldquo;<U>Placement
Agent Securities</U>&rdquo;). The Company will also pay to the Placement Agent in cash by wire transfer in immediately available
funds to an account or accounts designated by the Placement Agent a non-accountable expense allowance equal to 0.75% of the aggregate
gross proceeds received by the Company from the sale of the Securities, at each Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Offering Expenses</U>. The Company will be responsible for and will pay all expenses relating to the Offering, including,
without limitation, (a) all filing fees and expenses relating to the registration of the Securities with the Commission; (b) all
FINRA Public Offering filing fees; (c) all fees and expenses relating to the listing of the Company&rsquo;s common stock on the
Nasdaq Stock Market; (d) all fees, expenses and disbursements, if any, relating to the registration or qualification of the Securities
under the &ldquo;blue sky&rdquo; securities laws of such states and other jurisdictions as Cuttone may reasonably designate; (e)
the costs of all mailing and printing of the Offering documents; (f) transfer and/or stamp taxes, if any, payable upon the transfer
of Securities from the Company to Investors; (g) the fees and expenses of the Company&rsquo;s accountants; and (h) diligence expenses
and legal fees of Cuttone&rsquo;s counsel not to exceed in the aggregate $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tail Financing; Right of First Refusal</U><I>.</I> If a Closing pursuant to the Offering is completed, the Placement
Agent shall be entitled to fees equal to 7.0% of the aggregate gross proceeds received by the Company from any public or private
offering cash financing or capital-raising transaction of any kind (&ldquo;<U>Tail Financing</U>&rdquo;) to the extent that such
Tail Financing is provided to the Company by any investors that either participate in the Offering or that the Placement Agent
has in good faith introduced to the Company during the term of the Placement Agent&rsquo;s engagement for this Offering, if such
Tail Financing is consummated at any time within the 12-month period following the initial Closing Date. If a Closing pursuant
to the Offering is completed, for a period of 18 months from the initial Closing Date, the Company grants Cuttone the right of
first refusal to act as lead managing underwriter or book runner, or as lead placement agent, for any and all equity or equity-linked
offerings during such period, of the Company, or any successor to or any subsidiary of the Company. For the avoidance of doubt,
the foregoing entitlement of the Placement Agent shall not apply to the offer or sale of any (i) securities or other rights issued
to employees, officers, directors, contractors, advisors or consultants of the Company or other similar arrangements; (ii) securities
issued upon the exercise or conversion of any options, warrants (including without limitation the Placement Agent Warrant) or other
rights to purchase any securities of the Company outstanding as of the final Closing Date or issued thereafter under an exception
contained in this sentence; (iii) securities issued as consideration for a merger, acquisition, joint venture or similar business
combination approved by the Board of Directors of the Company; (iv) securities issued as consideration for strategic transactions
or issued in connection with any loan, equipment leasing or similar commercial debt transaction in each case approved by the Board
of Directors of the Company; and (v) securities issued in connection with any recapitalization of the Company (that is, securities
issued in exchange for other securities of the Company)(subsections (i)-(ii) of the foregoing, &ldquo;<U>Excepted Issuances</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>Description of the Offering. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Securities to be
offered directly to various investors (each, an &ldquo;<U>Investor</U>&rdquo; or &ldquo;<U>Purchaser</U>&rdquo; and, collectively,
the &ldquo;<U>Investors</U>&rdquo; or the &ldquo;<U>Purchasers</U>&rdquo;) in the Offering shall consist of a minimum of 416,667
shares of the Company&rsquo;s common stock (&ldquo;<U>Common Stock</U>&rdquo;) and a maximum of 2,083,334 shares of Common Stock
(collectively, the &ldquo;<U>Shares</U>&rdquo; or &ldquo;<U>Securities</U>&rdquo;). The purchase price for one Share shall be $[&#9679;]
per Share (the &ldquo;<U>Share Purchase Price</U>&rdquo;). If the Company shall default in its obligations hereunder to deliver
applicable Securities to a Purchaser whose offer it has accepted and who has tendered payment, the Company shall indemnify and
hold the Placement Agent harmless against any loss, claim, damage or expense arising from or as a result of such default by the
Company under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>Delivery and Payment; Closing.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that the Placement Agent receives any payment from an Investor in connection with the purchase of any Shares
by such investor, such payment shall be promptly transmitted to and deposited into the escrow account (the &ldquo;<U>Escrow Account</U>&rdquo;)
established by the Company in connection with the Offering with Prime Trust, LLC, as escrow agent (the &ldquo;<U>Escrow Agent</U>&rdquo;).
Among other things, the Placement Agent shall forward any checks so received by the Placement Agent to the Escrow Agent by noon
the next business day. The Placement Agent and the Company shall instruct Investors to make wire transfer payments to [&#9679;],
Account No. [&#9679;], with the name and address of the Investor making payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Prior to the Initial Closing (as defined below) date of the Offering and any Subsequent Closing date, (i) each Investor
will execute and deliver a Subscription Agreement (each, an &ldquo;<U>Investor Subscription Agreement</U>&rdquo;) to the Company
and the Company will make available to each Placement Agent and the Escrow Agent copies of each such Investor Subscription Agreement;
(ii) each Investor will transfer to the Escrow Account funds in an amount equal to the price per Share as shown on the cover page
of the Final Offering Circular multiplied by the number of Shares subscribed by such Investor; (iii) subscription funds received
from any Investor will be promptly transmitted to the Escrow Account in compliance with Rule 15c2-4 of the Securities Exchange
Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and (iv) the Escrow Agent will notify the Company and the Placement
Agent in writing whether the balance of the Escrow Account contains collected funds in the amount equal to the proceeds for the
sale of at least 416,667 Shares offered hereby (the &ldquo;<U>Requisite Funds</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Escrow Agent shall have received at least the Requisite Funds on or before 9:00 a.m., New York City time, on [&#9679;],
2018, or at such other time(s) on such other date(s), not more than thirty (30) days thereafter, as may be agreed upon by the Company
and the Placement Agent (each such date, a &ldquo;<U>Closing Date</U>&rdquo;), the Escrow Agent will release the balance of the
Escrow Account for collection by the Company and the Placement Agent as provided in the Escrow Agreement and the Company shall
deliver the Shares purchased on such Closing Date to the Investors, which delivery may be made through the facilities of the Depository
Trust Company (&ldquo;<U>DTC</U>&rdquo;) or via book entry with the Company&rsquo;s securities registrar and transfer agent, [&#9679;]
(the &ldquo;<U>Transfer Agent</U>&rdquo;). The initial closing (the &ldquo;<U>Initial Closing</U>&rdquo;) and any subsequent closing
(each, a &ldquo;<U>Subsequent Closing</U>&rdquo;) shall take place at the office of the Placement Agent in New York City or such
other location as the Placement Agent and the Company shall mutually agree. The Initial Closing and all Subsequent Closings shall
each be referred to as a &ldquo;<U>Closing</U>.&rdquo; All actions taken at a Closing shall be deemed to have occurred simultaneously
on the date of such Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Requisite Funds have not been received immediately prior to the initial Closing Date, the Offering will not proceed
and the Escrow Agent will promptly return the funds to the investors without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>Term and Termination of Agreement. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the initial
Closing Date, this Agreement may be terminated by the Placement Agent by notice given to the Company if at any time (i) trading
or quotation in any of the Company&rsquo;s securities shall have been suspended by the Commission or by the NASDAQ or by any quotation
service; (ii) a general banking moratorium shall have been declared by any of federal, New York or Delaware authorities; or (iii)
there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any
change in the United States or international financial markets, or any substantial change or development involving a prospective
substantial change in United States&rsquo; or international political, financial or economic conditions that, in the reasonable
judgment of the Placement Agent, is material and adverse and makes it impracticable to market the Shares in the manner and on the
terms described in the Final Offering Circular or to enforce contracts for the sale of securities. Any termination pursuant to
this section shall be without liability on the part of (a) the Company to the Placement Agent, except that the Company shall be
obligated to reimburse the expenses of Placement Agent as provided for herein, (b) the Placement Agent to the Company, or (c) of
any party hereto to any other party except that the provisions of Section 2 (with respect to the reimbursement of out-of-pocket
accountable, bona fide expenses actually incurred by the Placement Agent or persons associated with the Placement Agent) and Section
9 shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>Representations, Warranties and Covenants of the Placement Agent. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date and
time of the execution of this Agreement and each Closing Date, the Placement Agent represents, warrants and covenants to the Company
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The
Placement Agent agrees that it shall not include any &ldquo;issuer information&rdquo; (as defined in Rule 433 under the Act) in
any Written Testing-the-Waters Communication used or referred to by such Placement Agent without the prior consent of the Company
(any such issuer information with respect to whose use the Company has given its consent, &ldquo;Permitted Issuer Information&rdquo;),
provided that &ldquo;issuer information&rdquo; (as defined in Rule 433 under the Act) within the meaning of this Section 6 shall
not be deemed to include information prepared by the Placement Agent on the basis of, or derived from, &ldquo;issuer information&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Neither the Placement Agent nor any broker or dealer, nor any managing member of the Placement Agent or any broker or dealer, nor
any director or executive officer of the Placement Agent or any broker or dealer or other officer of the Placement Agent or any
broker or dealer participating in the Offering is subject to the disqualification provisions of Rule 262 of the Rules and Regulations.&nbsp;&nbsp;No
registered representative of the Placement Agent or any broker or dealer, or any other person being compensated by or through the
Placement Agent or any broker or dealer for the solicitation of investors, is subject to the disqualification provisions of Rule
262 of the Securities Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The
Placement Agent and each broker and dealer is a member of FINRA and each of them and their respective employees and representatives
have all required licenses and registrations to act under this Agreement, and each shall remain a member or duly licensed, as the
case may be, during the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No
agreement will be made by the Placement Agent with any person permitting the resale, repurchase or distribution of any Shares purchased
by such person.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Except as otherwise consented to by the Company, the Placement Agent has not and will not use or distribute any written offering
materials other than the Preliminary Offering Circular, Pricing Disclosure Materials and the Final Offering Circular.&nbsp;The
Placement Agent has not and will not use any &ldquo;broker-dealer use only&rdquo; materials with members of the public, or has
not and will not make any unauthorized verbal representations or verbal representations which contradict or are inconsistent with
the statements made in the Offering Statement in connection with offers or sales of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as expressly
provided otherwise herein or as may create any conflict of interest or otherwise violate customary standards of conduct by placement
agents under similar circumstances under FINRA rules or otherwise, this Agreement shall not be construed to limit the ability of
the Placement Agent, its officers, directors, employees, agents, associated persons and any individual or entity &ldquo;controlling,&rdquo;
controlled by,&rdquo; or &ldquo;under common control&rdquo; with the Placement Agent (as those terms are defined in Rule 405 under
the Securities Act) to conduct its business including without limitation the ability to pursue, investigate, analyze, invest in,
or engage in investment banking, financial advisory or any other business relationship with any individual or corporation, partnership,
trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or
an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>Representations, Warranties and Covenants of the Company.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As of the date and time of the execution
of this Agreement and each Closing Date, the Company represents, warrants and covenants to the Placement Agent as follows; provided
that as used in this Section 7 or other provisions of this Agreement, the term &quot;the Company&rsquo;s knowledge&quot; or any
other reference to the knowledge of the Company shall mean and apply to the actual knowledge of the Company&rsquo;s officers and
directors named as such in the Offering Statement and not to any other persons or entities:<U>Registration Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">The Company has filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
an offering statement on Form 1-A (File No. 024- [&#9679;]) (collectively, with the various parts of such offering statement, each
as amended as of the Qualification Date for such part, including any Offering Circular and all exhibits to such offering statement,
the &ldquo;<U>Offering Statement</U>&rdquo;) relating to the Shares pursuant to Regulation A as promulgated under the Securities
Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), and the other applicable rules, orders and regulations (collectively
referred to as the &ldquo;<U>Securities Act Regulations</U>&rdquo;) of the Commission promulgated under the Securities Act. As
used in this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Applicable Time</U>&rdquo; means 12:00 p.m., Eastern time, on the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Final Offering Circular</U>&rdquo; means the final offering circular relating to the public offering of the Shares
as filed with the Commission pursuant to Regulation A of the Rules and Regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Preliminary Offering Circular</U>&rdquo; means any preliminary offering circular relating to the Shares included
in the Offering Statement pursuant to Regulation A of the Rules and Regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Pricing Disclosure Materials</U>&rdquo; means the most recent Preliminary Offering Circular and the materials
identified in <U>Schedule A</U> hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Qualification Date</U>&rdquo; means the date as of which the Offering Statement was or will be qualified with
the Commission pursuant to Regulation A, the Securities Act and the Securities Act Regulations; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Testing-the-Waters Communication</U>&rdquo; means any video or written communication with potential investors
undertaken in reliance on Rule 255 of the Securities Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">The Offering Statement has been filed with the Commission in accordance with the Securities Act
and Regulation A of the Securities Act Regulations; no order of the Commission preventing or suspending the qualification or use
of the Offering Statement, or any amendment thereto, has been issued, and no proceedings for such purpose have been instituted,
or, to the Company&rsquo;s knowledge, are contemplated by the Commission.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">The Offering Statement, at the time it became qualified, as of the date hereof, and as of each
Closing Date, conformed and will conform in all material respects to the requirements of Regulation A, the Securities Act and the
Securities Act Regulations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">iv.</TD><TD STYLE="text-align: justify">The Offering Statement, at the time it became qualified, as of the date hereof, and as of each
Closing Date, did not and will not, contain an untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">v.</TD><TD STYLE="text-align: justify">The Preliminary Offering Circular did not, as of its date, contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of
the circumstances under which they were made, not misleading; <U>provided</U>, <U>however</U>, that the Company makes no representation
or warranty with respect to such information provided by or on behalf of any Placement Agent consists solely of the following disclosure
contained in the following paragraphs in the &quot;Plan of Distribution&quot; section of the Preliminary Offering Circular: (i)
the name of the Placement Agent, (ii) the information under the subsection &ldquo;Engagement Agreement with the Placement Agent&rdquo;;
and (iii) the information under the subsection &ldquo;Future Services&rdquo; (the &ldquo;<U>Placement Agent's Information</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">vi.</TD><TD STYLE="text-align: justify">The Final Offering Circular will not, as of its date and on each Closing Date, contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>, <U>however</U>, that the
Company makes no representation or warranty with respect to the Placement Agent&rsquo;s Information contained in the Final Offering
Circular.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">vii.</TD><TD STYLE="text-align: justify">The Pricing Disclosure Materials and each Testing-the-Waters Communication, when considered together,
did not, as of the Applicable Time, contain an untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">viii.</TD><TD STYLE="text-align: justify">The disclosures in the Offering Statement, the Pricing Disclosure Materials and the Final Offering
Circular concerning the effects of federal, state, local and all foreign regulation on the Offering and the Company's business
as currently contemplated are correct in all material respects and no other such regulations are required to be disclosed in such
filings that are not so disclosed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">ix.</TD><TD STYLE="text-align: justify">Since the respective dates as of which information is given in the Offering Statement, the Pricing
Disclosure Materials and the Final Offering Circular, except as otherwise specifically stated therein there has been no material
adverse change in the financial position or results of operations of the Company, nor any change or development that, singularly
or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the condition
(financial or otherwise), results of operations, business or assets of the Company (a &ldquo;<U>Material Adverse Change</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">x.</TD><TD STYLE="text-align: justify">Subsequent to the respective dates as of which information is given in the Offering Statement,
the Pricing Disclosure Materials and the Final Offering Circular, and except as may otherwise be indicated or contemplated herein
or disclosed therein, the Company has not: (i) issued any securities (other than (i) grants under any stock compensation plan and
(ii) shares of common stock issued upon exercise or conversion of option, warrants or convertible securities described in the Offering
Statement, the Pricing Disclosure Materials and the Final Offering Circular) or incurred any liability or obligation, direct or
contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its capital
stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">xi.</TD><TD STYLE="text-align: justify">The Company is organized in, and its principal place of business is in, the United States.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">xii.</TD><TD STYLE="text-align: justify">The Company is not subject to the ongoing reporting requirements of Section 13 or 15(d) of the
Exchange Act and has not been subject to an order by the Commission denying, suspending, or revoking the registration of any class
of securities pursuant to Section 12(j) of the Exchange Act that was entered within five (5) years preceding the date the Offering
Statement was originally filed with the Commission. The Company is not, and has not been at any time during the two-year period
preceding the date the Offering Statement was originally filed with the Commission, required to file with the Commission the ongoing
reports required by the Securities Act Regulations under Regulation A.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">xiii.</TD><TD STYLE="text-align: justify">The Company is not, nor upon completion of the transactions contemplated herein will it be, an
&ldquo;investment company&rdquo; or an &ldquo;affiliated person&rdquo; of, or &ldquo;promoter&rdquo; or &ldquo;principal underwriter&rdquo;
for, an &ldquo;investment company,&rdquo; as such terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<U>Investment
Company Act</U>&rdquo;). The Company is not a development stage company or a &ldquo;business development company&rdquo; as defined
in Section 2(a)(48) of the Investment Company Act. The Company is not a blank check company and is not an issuer of fractional
undivided interests in oil or gas rights or similar interests in other mineral rights. The Company is not an issuer of asset-backed
securities as defined in Item 1101(c) of Regulation AB.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">xiv.</TD><TD STYLE="text-align: justify">Neither the Company, nor any predecessor of the Company; nor any other issuer affiliated with the
Company; nor any director or executive officer of the Company or other officer of the Company participating in the Offering, nor
any beneficial owner of twenty percent (20%) or more of the Company&rsquo;s outstanding voting equity securities, nor any promoter
connected with the Company, is subject to the disqualification provisions of Rule 262 of the Securities Act Regulations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">xv.</TD><TD STYLE="text-align: justify">Neither the Company nor any of the Subsidiaries (as defined herein), nor any of their respective
affiliates, officers, directors or, to the Company&rsquo;s knowledge, any beneficial owner of 5% or more of the Company's equity
securities, (i) is required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo; in accordance with the provisions of
the Exchange Act or the Exchange Act Regulations, or (ii) has any direct or indirect affiliation or association with any member
firm of Financial Industry Regulatory Authority, Inc. (&ldquo;<U>FINRA</U>&rdquo;) (as determined in accordance with the rules
and regulations of FINRA).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Exchange Listing</U>. The Shares are approved for listing on The NASDAQ Capital Market (the &ldquo;<U>Exchange</U>&rdquo;)
and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the
Exchange, nor has the Company received any notification that the Exchange is contemplating terminating such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Stop Orders, etc</U>. To the Company's knowledge, neither the Commission nor any state regulatory authority has issued
any order preventing or suspending the use of the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular
or has instituted or, to the Company's knowledge, threatened to institute, any proceedings with respect to such an order. The Company
has complied with each request (if any) from the Commission for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsidiaries</U>. The Company's subsidiaries have been duly incorporated and are validly existing as entities in good
standing under the laws of jurisdictions of their respective organization, with power and authority to own, lease and operate their
respective properties and conduct their respective businesses as described in the Preliminary Offering Circular, and have been
duly qualified as foreign corporations for the transaction of business and are in good standing under the laws of each other jurisdictions
in which they own or lease properties or conduct any business so as to require such qualification, except where the failure so
to qualify or be in good standing would not have a Material Adverse Change (as defined below); all of the issued and outstanding
capital stock (or other ownership interests) of such subsidiaries has been duly and validly authorized and issued, is fully paid
and non-assessable and is owned, directly and indirectly, by the Company free and clear of any security interest, mortgage, pledge,
lien, encumbrance, claim or equity. Unless otherwise set forth, all references in this Section 7 to the &ldquo;Company&rdquo; shall
include references to all such subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Independent Accountants</U>. To the knowledge of the Company, BDO East Coast Partnership, an independent registered public
accounting firm, during such time as it was engaged by the Company (collectively, the &ldquo;<U>Auditors</U>&rdquo;), is an independent
registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting
Oversight Board. During such time period in which the Auditors served as the Company's independent registered public accounting
firm the Auditors did not or have not, during the periods covered by the financial statements included in the Offering Statement,
the Pricing Disclosure Materials and the Final Offering Circular, provided to the Company any non-audit services, as such term
is used in Section 10A(g) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">F.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Financial Statements, etc</U>. The financial statements of the Company included in the Offering Statement comply in all
material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted
accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise
specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all
footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated
subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject,
in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. The financial statements, including the
notes thereto and supporting schedules included in the Offering Statement, the Pricing Disclosure Materials and the Final Offering
Circular, fairly present in all material respects the financial position and the results of operations of the Company at the dates
and for the periods to which they apply; and such financial statements have been prepared in conformity with GAAP, consistently
applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments
that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules
included in the Offering Statement present fairly in all material respects the information required to be stated therein. Except
as included therein, no historical or pro forma financial statements are required to be included in the Offering Statement, the
Pricing Disclosure Materials and the Final Offering Circular under the Securities Act or the Securities Act Regulations. The pro
forma and pro forma as adjusted financial information and the related notes, if any, included in the Offering Statement, the Pricing
Disclosure Materials and the Final Offering Circular have been properly compiled and prepared in accordance with the applicable
requirements of the Securities Act and the Securities Act Regulations and present fairly in all material respects the information
shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate
to give effect to the transactions and circumstances referred to therein. Each of the Offering Statement, the Pricing Disclosure
Materials and the Final Offering Circular discloses all material off-balance sheet transactions, arrangements, obligations (including
contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material
current or future effect on the Company's financial condition, changes in financial condition, results of operations, liquidity,
capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Offering
Statement, the Pricing Disclosure Materials and the Final Offering Circular, since December 31, 2017, (a) the Company has not incurred
any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary
course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to
its capital stock, (c) there has not been any change in the capital stock of the Company (other than (i) grants under any stock
compensation plan and (ii) shares of common stock issued upon exercise or conversion of option, warrants or convertible securities
described in the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular), and (d) there has not been
any Material Adverse Change in the Company's long-term or short-term debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">G.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Authorized Capital; Options, etc</U>. The Company had, at the date or dates indicated in the Offering Statement, the
Pricing Disclosure Materials and the Final Offering Circular, the duly authorized, issued and outstanding capitalization as set
forth therein. Based on the assumptions stated in the Offering Statement, the Pricing Disclosure Materials and the Final Offering
Circular, the Company will have on the Initial Closing date the adjusted stock capitalization set forth therein. Except as set
forth in, or contemplated by, the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular, on the
Qualification Date, as of the Applicable Time, on each Closing Date, there will be no stock options, warrants, or other rights
to purchase or otherwise acquire any authorized, but unissued shares of Common Stock of the Company or any security convertible
or exercisable into shares of Common Stock of the Company, or any contracts or commitments to issue or sell shares of Common Stock
or any such options, warrants, rights or convertible securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">H.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Valid Issuance of Securities, etc</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Outstanding Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated
by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have
no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none
of such securities were issued in violation of the preemptive rights of any holders of any security of the Company or similar
contractual rights granted by the Company. The authorized shares of Common Stock, Company preferred stock and other outstanding
securities conform in all material respects to all statements relating thereto contained in the Offering Statement, the Pricing
Disclosure Materials and the Final Offering Circular. The offers and sales of the outstanding shares of Common Stock were at all
relevant times either registered under the Securities Act and the applicable state securities or &ldquo;blue sky&rdquo; laws or,
based in part on the representations and warranties of the purchasers of such shares, exempt from such registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Securities Sold Pursuant to this Agreement</U>. The Securities and the Placement Agent Securities will, upon issuance,
have been duly authorized for issuance and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable;
the holders thereof are not and will not be subject to personal liability by reason of being such holders; the Securities are not
and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Securities has been
duly and validly taken. The Securities and Placement Agent Securities conform in all material respects to all statements with respect
thereto contained in the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights of Third Parties</U>. Except as set forth in the Offering Statement, the Pricing Disclosure Materials
and the Final Offering Circular, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable
into securities of the Company have the right to require the Company to register any such securities of the Company under the Securities
Act or to include any such securities in a registration statement to be filed by the Company (except for any such rights that have
been waived).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">J.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Validity and Binding Effect of Agreements</U>. This Agreement has been duly and validly authorized by the Company, and,
when executed and delivered, will constitute, the valid and binding agreement of the Company, enforceable against the Company in
accordance with its respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization
or similar laws affecting creditors' rights generally; (ii) as enforceability of any indemnification or contribution provision
may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and
other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">K.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement and all ancillary documents,
the consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the
terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in
a material breach of, or conflict with any of the terms and provisions of, or constitute a material default under, or result in
the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company
pursuant to the terms of any agreement or instrument to which the Company is a party; (ii) result in any violation of the provisions
of the Company's Certificate of Incorporation (as the same may be amended or restated from time to time, the &ldquo;<U>Charter</U>&rdquo;)
or the by-laws of the Company (as the same may be amended or restated from time to time, the &ldquo;<U>Bylaws</U>&rdquo;); or (iii)
violate in any material respect any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity
as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">L.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory</U>. Except as described in the Offering Statement, the Pricing Disclosure Materials and the Final Offering
Circular or as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change: (i)
the Company is and has been in material compliance with statutes, laws, ordinances, rules and regulations applicable to the Company
(collectively, &ldquo;<U>Applicable Laws</U>&rdquo;); (ii) the Company possesses all licenses, certificates, approvals, clearances,
consents, authorizations, qualifications, registrations, permits, and supplements or amendments thereto required by any such Applicable
Laws and/or to carry on its businesses as now conducted (&ldquo;<U>Authorizations</U>&rdquo;) and such Authorizations are valid
and in full force and effect and the Company is not in violation of any term of any such Authorizations; (iii) the Company has
not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any Governmental Entity or third party alleging that any product, operation or activity is in violation of any Applicable Laws
or Authorizations or has any knowledge that any such Governmental Entity or third party is considering any such claim, litigation,
arbitration, action, suit, investigation or proceeding, nor, to the best of the Company's knowledge, has there been any material
noncompliance with or violation of any Applicable Laws by the Company that could reasonably be expected to require the issuance
of any such communication or result in an investigation, corrective action, or enforcement action by a Governmental Entity; and
(iv) the Company has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit,
suspend, modify or revoke any Authorizations or has any knowledge that any such Governmental Entity has threatened or is considering
such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">M.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Defaults; Violations</U>. No material default exists in the due performance and observance of any term, covenant or
condition of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement
or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is
a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company
is not (i) in violation of any term or provision of its Charter or Bylaws, or (ii) in violation of any franchise, license, permit,
applicable law, rule, regulation, judgment or decree of any Governmental Entity applicable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">N.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Corporate Power; Licenses; Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as described in the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular, the Company
has all requisite corporate power and authority, and, except as would not reasonably be excepted to result in a Material Adverse
Change, has all necessary authorizations, approvals, orders, licenses, certificates and permits of and from all governmental regulatory
officials and bodies that it needs as of the date hereof to conduct its business purpose as described in the Offering Statement,
the Pricing Disclosure Materials and the Final Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions and conditions
hereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained. No consent,
authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance, sale
and delivery of the Securities and the consummation of the transactions and agreements contemplated by this Agreement and as contemplated
by the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular, except with respect to applicable
federal and state securities laws and the rules and regulations of the Financial Industry Regulatory Authority, Inc. (&ldquo;<U>FINRA</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">O.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation; Governmental Proceedings</U>. There is no material action, suit, proceeding, inquiry, arbitration, investigation,
litigation or governmental proceeding pending or, to the Company's knowledge, threatened against, or involving the Company or,
to the Company's knowledge, any executive officer or director which has not been disclosed in the Offering Statement, the Pricing
Disclosure Materials and the Final Offering Circular or in connection with the Company's listing application for the additional
listing of the Shares on the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">P.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Good Standing</U>. The Company has been duly organized and is validly existing as a corporation and is in good standing
under the laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in
each other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except
where the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material
Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Q.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. The Company carries or is entitled to the benefits of insurance, with, to the Company's knowledge, reputable
insurers, and in such amounts and covering such risks which the Company believes are reasonably adequate, and all such insurance
is in full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing insurance
coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or
appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">R.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transactions Affecting Disclosure to FINRA</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Finder's Fees</U>. Except as described in the Offering Statement, the Pricing Disclosure Materials and the Final Offering
Circular, there are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder's, consulting
or origination fee by the Company or any executive officer or director of the Company (each, an &ldquo;<U>Insider</U>&rdquo;) with
respect to the sale of the Securities hereunder or any other arrangements, agreements or understandings of the Company or, to the
Company's knowledge, any of its stockholders that may affect the Placement Agent&rsquo;s compensation, as determined by FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payments Within Twelve (12) Months</U>. Except as described in the Offering Statement, the Pricing Disclosure Materials
and the Final Offering Circular, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to:
(i) any person, as a finder's fee, consulting fee or otherwise, in consideration of such person raising capital for the Company
or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person
or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior
to the date hereof, other than the payment to the Placement Agent as provided hereunder in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Use of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA
member or its affiliates, except as specifically authorized herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FINRA Affiliation</U>. There is no (i) officer or director of the Company, (ii) beneficial owner of 5% or more of any
class of the Company's securities or (iii) beneficial owner of the Company's unregistered equity securities which were acquired
during the 180-day period immediately preceding the filing of the Offering Statement that is an affiliate or associated person
of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Information</U>. To the Company's knowledge, all information provided by the Company's officers and directors in their
FINRA Questionnaires to counsel to the Placement Agent specifically for use by counsel to the Placement Agent in connection with
its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">S.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Foreign Corrupt Practices Act</U>. Neither the Company nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any other person acting on behalf of the Company, has, directly or indirectly, given or
agreed to give any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business)
to any customer, supplier, employee or agent of a customer or supplier, or official or employee of any Governmental Entity or any
political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder
the business of the Company (or assist it in connection with any actual or proposed transaction) that (i) might subject the Company
to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might
have had a Material Adverse Change or (iii) if not continued in the future, might adversely affect the assets, business, operations
or prospects of the Company. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient
to cause the Company to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">T.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with OFAC</U>. Neither of the Company nor, to the Company's knowledge, any director, officer, agent, employee
or affiliate of the Company or any other person acting on behalf of the Company, is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<U>OFAC</U>&rdquo;), and the Company will
not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds
to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently
subject to any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Money Laundering Laws</U>. The operations of the Company are and have been conducted at all times in compliance with
applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or
similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;); and no action, suit or proceeding by or before any Governmental Entity involving the Company with
respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">V.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Officers' Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to you
pursuant to Section 8C hereof shall be deemed a representation and warranty by the Company to the Placement Agent as to the matters
covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">W.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Related Party Transactions</U>. There are no business relationships or related party transactions involving the Company
or any other person required to be described in the Offering Statement, the Pricing Disclosure Materials and the Final Offering
Circular that have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">X.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Board of Directors</U>. The qualifications of the persons serving as board members and the overall composition of the
board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder
(the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;) applicable to the Company and the current listing rules of the Exchange. At least
one member of the Audit Committee of the Board of Directors of the Company qualifies as an &ldquo;audit committee financial expert,&rdquo;
as such term is defined under Regulation S-K and the listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Y.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sarbanes-Oxley Compliance</U>. Subject in all respects to the fact that the Company is a &ldquo;controlled company&rdquo;
for purposes of NASDAQ rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or
15d-15 under the Exchange Act Regulations applicable to it, and such controls and procedures are effective to ensure that all material
information concerning the Company will be made known on a timely basis to the individuals responsible for the preparation of the
Company's Exchange Act filings and other public disclosure documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is, or at the Applicable Time and on each Closing Date will be, in material compliance with the provisions of
the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure
the Company's future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material
provisions of the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Z.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accounting Controls</U>. The Company maintains systems of &ldquo;internal control over financial reporting&rdquo; (as
defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act
and have been designed by, or under the supervision of, its principal executive and principal financial officers, or persons performing
similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient
to provide reasonable assurance that (i) transactions are executed in accordance with management's general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability; (iii) access to assets is permitted only in accordance with management's general or specific authorization;
and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. Except as disclosed in the Offering Statement, the Pricing Disclosure Materials and the
Final Offering Circular, the Company is not aware of any material weaknesses in its internal controls. The Auditors and the Audit
Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses,
if any, in the design or operation of internal controls over financial reporting which are known to the Company's management and
that have adversely affected or are reasonably likely to adversely affect the Company' ability to record, process, summarize and
report financial information; and (ii) any fraud, if any, known to the Company's management, whether or not material, that involves
management or other employees who have a significant role in the Company's internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AA.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of
the proceeds thereof as described in the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular,
will not be, required to register as an &ldquo;investment company,&rdquo; as defined in the Investment Company Act of 1940, as
amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">BB.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Labor Disputes</U>. No material labor dispute with the employees of the Company exists or, to the knowledge of the
Company, is imminent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CC.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property Rights</U>. To the Company's knowledge, the Company has, or can acquire on reasonable terms, license
to, or otherwise has the right to use, all inventions, know-how (including trade secrets and other proprietary or confidential
information, systems or procedures), patents, trademarks, service marks, trade names, copyrights, and applications thereto (collectively
&ldquo;<U>Intellectual Property</U>&rdquo;) material to carrying on its business as described in the Offering Statement, the Pricing
Disclosure Materials and the Final Offering Circular. The Company has not received any correspondence alleging (A) infringement
or misappropriation of, or conflict with, any Intellectual Property of a third party; (B) asserted rights of others with respect
to any Intellectual Property of the Company; or (C) that any Intellectual Property of the Company is invalid or otherwise inadequate
to protect the interest of the Company, that in each case (if the subject of any unfavorable decision, ruling or finding), individually
or in the aggregate, would have or would reasonably be expected to have a Material Adverse Change. To the Company&rsquo;s knowledge,
there are no third parties who have been able to establish any material rights to any Intellectual Property, except for the retained
rights of the owners or licensors of any Intellectual Property that is licensed to the Company. There is no pending or, to the
Company's knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the validity, enforceability or scope
of any Intellectual Property of the Company or (B) challenging the Company's rights in or to any Intellectual Property or (C) that
the Company materially infringes, misappropriates or otherwise violates or conflicts with any Intellectual Property or other proprietary
rights of others. The Company has complied in all material respects with the terms of each agreement described in the Offering
Statement, the Pricing Disclosure Materials and the Final Offering Circular pursuant to which any Intellectual Property is licensed
to the Company, and all such agreements related to products currently made or sold by the Company, or to product candidates currently
under development, are in full force and effect. Intellectual Property to which the Company has rights, has been or will be duly
and properly filed in the appropriate jurisdiction. The Company is not aware of any material information preventing the acquisition
of Intellectual Property rights material to carrying out its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DD.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Taxes</U>. The Company has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior
to the date hereof or has duly obtained extensions of time for the filing thereof. The Company has paid all taxes (as hereinafter
defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the Company, except
for such exceptions as could not be expected, individually or in the aggregate, to have a Material Adverse Change. The provisions
for taxes payable, if any, shown on the financial statements filed with or as part of the Offering Statement are sufficient for
all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial
statements. Except as disclosed in writing to the Placement Agent, (i) no issues have been raised (and are currently pending) by
any taxing authority in connection with any of the returns or taxes asserted as due from the Company, and (ii) no waivers of statutes
of limitation with respect to the returns or collection of taxes have been given by or requested from the Company. The term &ldquo;taxes&rdquo;
mean all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise,
profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium,
property, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any
interest and any penalties, additions to tax or additional amounts with respect thereto. The term &ldquo;returns&rdquo; means all
returns, declarations, reports, statements and other documents required to be filed in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">EE.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefit Laws</U>. To the extent applicable, the operations of the Company and its subsidiaries are and have
been conducted at all times in material compliance with the Employee Retirement Income Security Act of 1974, as amended, the rules
and regulations thereunder and any applicable related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the &ldquo;<U>Employee Benefit Laws</U>&rdquo;) and no action, suit or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or its subsidiaries with
respect to the Employee Benefit Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FF.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Laws</U>. The Company: (A) is and at all times has been in compliance with all Applicable Laws, except
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change; (B) has not received
any correspondence from any Governmental Entity alleging or asserting noncompliance with any Applicable Laws or any Authorizations;
(C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not
in material violation of any term of any such Authorizations, in each case except as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Change; (D) has not received written notice of any claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any
product operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental
Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has
not received written notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify
or revoke any Authorizations; and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and
that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were
complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT>GG.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Industry Data</U>. The statistical and market-related data included in each of the Offering Statement, the Pricing
Disclosure Materials and the Final Offering Circular are based on or derived from sources that the Company reasonably and in good
faith believes are reliable and accurate or represent the Company's good faith estimates that are made on the basis of data derived
from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT>HH.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Forward-Looking Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities
Act and Section 21E of the Exchange Act) contained in the Offering Statement, the Pricing Disclosure Materials and the Final Offering
Circular has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">II.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Margin Securities</U>. The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of
the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal Reserve Board</U>&rdquo;), and none of the proceeds
of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose
of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other
purpose which might cause any of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings
of Regulation T, U or X of the Federal Reserve Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT>JJ.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Confidentiality and Non-Competition</U>. To the Company's knowledge, no director, officer, key employee or consultant
of the Company is subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with
any employer or prior employer that could reasonably be expected to materially affect his ability to be and act in his respective
capacity of the Company or be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT>KK.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Restriction on Sales of Capital Stock</U>. The Company, on behalf of itself and any successor entity, agrees that
it will not, for a period of 180 days after the date of this Agreement (the &ldquo;<U>Lock-Up Period</U>&rdquo;), without the prior
written consent of the Placement Agent, except in the case of Excepted Issuances: (i) offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend,
or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or cause to be filed any registration
statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company other than the filing of a Registration Statement
on Form S-8; (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii) or (iii)
above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise; or
(iv) publicly announce an intention to effect any transaction specified in clause (i), (ii) or (iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>Conditions of the Obligations of the Placement Agent. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of
the Placement Agent hereunder shall be subject to the accuracy of the representations and warranties on the part of the Company
set forth in Section 7 hereof, in each case as of the date hereof and as of each Closing Date as though then made, to the timely
performance by each of the Company of its covenants and other obligations hereunder on and as of such dates, and to each of the
following additional conditions:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Qualification of Offering Statement</U>. The Offering Statement has become qualified, and the Company will file
the Final Offering Circular, subject to the prior approval of the Underwriters, pursuant to Rule 253 and Regulation A, within the
prescribed time period. The Company will not, during such period as the Final Offering Circular would be required by law to be
delivered in connection with sales of the Shares by a placement agent or dealer in connection with the offering contemplated by
this Agreement (whether physically or through compliance with Rules 251 and 254 under the Securities Act or any similar rule(s)),
file any amendment or supplement to the Offering Statement or the Final Offering Circular unless a copy thereof shall first have
been submitted to the Underwriters within a reasonable period of time prior to the filing thereof and the Underwriters shall not
have reasonably objected thereto in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stop Order</U>. (i) No stop order suspending the qualification of the Offering Statement shall have been issued, and
no proceedings for that purpose shall be pending or threatened by any securities or other governmental authority (including, without
limitation, the Commission), (ii) no order suspending the qualification of the Offering Statement or the qualification or exemption
of the Shares under the securities or Blue Sky laws of any jurisdiction shall be in effect and no proceeding for such purpose shall
be pending before, or threatened or contemplated by, any securities or other governmental authority (including, without limitation,
the Commission), (iii) any request for additional information on the part of the staff of any securities or other governmental
authority (including, without limitation, the Commission) shall have been complied with to the satisfaction of the staff of the
Commission or such authorities and (iv) after the date hereof no amendment or supplement to the Offering Statement or the Final
Offering Circular shall have been filed unless a copy thereof was first submitted to the Placement Agent and the Placement Agent
did not object thereto in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FINRA Clearance</U>. On or before the Initial Closing date of this Agreement, the Placement Agent shall have received
clearance from FINRA as to the amount of compensation allowable or payable to the Placement Agent as described in the Offering
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Counsel Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On each Closing Date, the Placement Agent shall have received the opinion of Hughes Hubbard LLP, outside United States corporate
counsel for the Company, dated the Closing Date and addressed to the Placement Agent, in such form as is reasonably acceptable
to the Placment Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Officers&rsquo; Certificates</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Officers&rsquo; Certificate</U>. The Company shall have furnished to the Placement Agent a certificate, dated the Closing
Date, of its Chief Executive Officer and its Chief Financial Officer stating that (i) such officers have carefully examined the
Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular and, in their opinion, the Offering Statement
and each amendment thereto, as of the Applicable Time and through such Closing Date did not include any untrue statement of a material
fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
and the Pricing Disclosure Materials, as of the Applicable Time through the such Closing Date, the Final Offering Circular and
each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue
statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances in which they were made, not misleading, (ii) no event has occurred which is required to have been set
forth in a supplement or amendment to the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular
that was not included in the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular, as the case
may be, (iii) to their knowledge, as of each Closing Date, the representations and warranties of the Company in this Agreement
are true and correct in all material respects, and the Company has complied with all agreements and satisfied all conditions in
all material respects on its part to be performed or satisfied hereunder at or prior to such Closing Date, and (iv) there has not
been, subsequent to the date of the most recent audited financial statements included in the Pricing Disclosure Materials, any
Material Adverse Change in the financial position or results of operations of the Company, or any change or development that, singularly
or in the aggregate, would constitute a Material Adverse Change, except as set forth in the Final Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Secretary&rsquo;s Certificate</U>. As of each Closing Date the Placement Agent shall have received a certificate of the
Company signed by the Secretary of the Company, dated the Closing Date, certifying: (i) that each of the Company&rsquo;s Charter
and Bylaws is true and complete, has not been modified and is in full force and effect; (ii) that the resolutions of the Company&rsquo;s
Board of Directors relating to the Offering are in full force and effect and have not been modified; and (iii) the good standing
of the Company and its subsidiaries, to the extent good standing certification is available in the jurisdictions involved. The
documents referred to in such certificate shall be attached to such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>Indemnification and Contribution; Procedures.&nbsp;</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of the Placement Agent</U>. The Company agrees to indemnify and hold harmless the Placement Agent, its
affiliates and each person controlling such Placement Agent (within the meaning of Section 15 of the Securities Act), and the directors,
officers, agents and employees of the Placement Agent, its affiliates and each such controlling person (the Placement Agent, and
each such entity or person hereafter is referred to as an &ldquo;<U>Indemnified Person</U>&rdquo;) from and against any losses,
claims, damages, judgments, assessments, costs and other liabilities (collectively, the &ldquo;<U>Liabilities</U>&rdquo;), and
shall reimburse each Indemnified Person for all fees and expenses (including the reasonable fees and expenses of a single counsel
for the Indemnified Persons, except as otherwise expressly provided in this Agreement) (collectively, the &ldquo;<U>Expenses</U>&rdquo;)
and agrees to advance payment of such Expenses as they are incurred by an Indemnified Person in investigating, preparing, pursuing
or defending any actions, whether or not any Indemnified Person is a party thereto, arising out of or based upon any untrue statement
or alleged untrue statement of a material fact contained in (i) the Offering Statement, the Pricing Disclosure Materials and the
Final Offering Circular or in any Testing-the-Waters Communication (as from time to time each may be amended and supplemented);
(ii) any materials or information provided to investors by, or with the prior written approval of, the Company in connection with
the marketing of the Offering, including any &ldquo;road show&rdquo; or investor presentations made to investors by the Company
(whether in person or electronically); or (iii) any application or other document or written communication (in this Section 9,
collectively called &ldquo;application&rdquo;) executed by the Company or based upon written information furnished by the Company
in any jurisdiction in order to qualify the Securities under the securities laws thereof or filed with the Commission, any state
securities commission or agency, any national securities exchange; or the omission or alleged omission therefrom of a material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, unless such statement or omission was made in reliance upon, and in conformity with, the Placement Agent&rsquo;s
information or is found by a court to have resulted from gross negligence, bad faith or willful misconduct of the Indemnified Person;
provided, however, that the Company will not be liable to the extent that such loss, claim, liability, expense or damage arises
from or is based solely on any Placement Agent&rsquo;s Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Procedure</U>. Upon receipt by an Indemnified Person of actual notice of an action against such Indemnified Person with
respect to which indemnity may reasonably be expected to be sought under this Agreement, such Indemnified Person shall promptly
notify the Company in writing; provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company
from any obligation or liability which the Company may have on account of this Section 9 or otherwise to such Indemnified Person,
except to the extent (and only to the extent) that its ability to assume the defense is actually impaired by such failure or delay.
The Company shall, be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying
person similarly notified, assume the defense of any such action (including the employment of counsel and reasonably satisfactory
to the Placement Agent) and, after notice from the Company to such Indemnified Person of its election so to assume the defense
thereof, the Company shall not be liable to such Indemnified Person for any legal expenses of other counsel or any other expenses,
in each case subsequently incurred by such Indemnified Person, in connection with the defense thereof other than reasonable costs
of investigation. Any Indemnified Person shall have the right to employ separate counsel in any such action and participate in
the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless and only
to the extent that: (i) the Company has failed promptly to assume the defense and employ counsel for the benefit of the Placement
Agent and the other Indemnified Persons or (ii) such Indemnified Person shall have been advised that in the opinion of counsel
that there is an actual or potential conflict of interest that prevents (or makes it imprudent for) the counsel engaged by the
Company for the purpose of representing the Indemnified Person, to represent both such Indemnified Person and any other person
represented or proposed to be represented by such counsel, it being understood, however, that the Company shall not be liable for
the expenses of more than one <FONT STYLE="background-color: white">separate counsel (together with local counsel), representing
</FONT>the Placement Agent and all Indemnified persons who are parties to such action. The Company shall not be liable for any
settlement of any action effected without its written consent (which shall not be unreasonably withheld). In addition, the Company
shall not, without the prior written consent of the Placement Agent, settle, compromise or consent to the entry of any judgment
in or otherwise seek to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification
or contribution may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise,
consent or termination (i) includes an unconditional release of each Indemnified Person, acceptable to such Indemnified Party,
from all Liabilities arising out of such action for which indemnification or contribution may be sought hereunder and (ii) does
not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any Indemnified Person.
The advancement, reimbursement, indemnification and contribution obligations of the Company required hereby shall be made by periodic
payments of the amount thereof during the course of the investigation or defense, as every Liability and Expense is incurred and
is due and payable, and in such amounts as fully satisfy each and every Liability and Expense as it is incurred (and in no event
later than 30 days following the date of any invoice therefor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of the Company</U>. The Placement Agent agrees to indemnify and hold harmless the Company, its directors,
its officers who signed the Offering Statement and persons who control the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act against any and all Liabilities, but only with respect to untrue statements or omissions,
or alleged untrue statements or omissions made in the Offering Statement, the Pricing Disclosure Materials and the Final Offering
Circular any amendment or supplement thereto, in reliance upon, and in conformity with, the Placement Agent&rsquo;s Information.
In case any action shall be brought against the Company or any other person so indemnified based on any Offering Statement, the
Pricing Disclosure Materials and the Final Offering Circular or any amendment or supplement thereto, and in respect of which indemnity
may be sought against the Placement Agent, the Placement Agent shall have the rights and duties given to the Company, and the Company
and each other person so indemnified shall have the rights and duties given to the Placement Agent by the provisions of Section
9.B. The Company agrees promptly to notify the Placement Agent of the commencement of any litigation or proceedings against the
Company or any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Securities or in connection with
the Offering Statement, the Pricing Disclosure Materials and the Final Offering Circular or any Testing-the-Waters Communication,
provided, that <FONT STYLE="background-color: white">failure by the Company so to notify the Placement Agent shall not relieve
the Placement Agent from any obligation or liability which the Placement Agent may have on account of this Section 9.C. or otherwise
to the Company, except to the extent the Placement Agent is materially prejudiced as a proximate result of such failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contribution</U>. In the event that a court of competent jurisdiction makes a finding that indemnity is unavailable to
any indemnified person, then each indemnifying person shall contribute to the Liabilities and Expenses paid or payable by such
indemnified person in such proportion as is appropriate to reflect (i) the relative benefits to the Company, on the one hand, and
to the Placement Agent and any other Indemnified Person, on the other hand, of the matters contemplated by this Agreement or (ii)
if the allocation provided by the immediately preceding clause is not permitted by applicable law, not only such relative benefits
but also the relative fault of the Company, on the one hand, and the Placement Agent and any other Indemnified Person, on the other
hand, in connection with the matters as to which such Liabilities or Expenses relate, as well as any other relevant equitable considerations;
provided that in no event shall the Company contribute less than the amount necessary to ensure that all Indemnified Persons, in
the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of commissions actually received by the
Placement Agent pursuant to this Agreement. The relative fault shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates
to information supplied by the Company on the one hand or the Placement Agent on the other and the parties&rsquo; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Placement
Agent agree that it would not be just and equitable if contributions pursuant to this subsection (D) were determined by pro rata
allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in
this subsection (D). For purposes of this paragraph, the relative benefits to the Company, on the one hand, and to the Placement
Agent on the other hand, of the matters contemplated by this Agreement shall be deemed to be in the same proportion as: (a) the
total value received by the Company in the Offering, whether or not such Offering is consummated, bears to (b) the commissions
paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within
the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from a party who was not guilty of fraudulent
misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. The advancement, reimbursement, indemnity and contribution obligations set forth in this Section 9 shall
remain in full force and effect regardless of any termination of, or the completion of any Indemnified Person&rsquo;s services
under or in connection with, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify"><U>Limitation of Cuttone&rsquo;s Liability to the Company. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cuttone and the Company
further agree that neither Cuttone nor any of its affiliates or any of their respective officers, directors, controlling persons
(within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any
liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the
Company (whether direct or indirect, in contract or tort, for an act of negligence or otherwise) for any losses, fees, damages,
liabilities, costs, expenses or equitable relief arising out of or relating to this Agreement or the services rendered hereunder,
except for losses, fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to
act by Cuttone or any of its affiliates or other such persons and that are finally judicially determined to have resulted from
the gross negligence, bad faith or willful misconduct of Cuttone or any of its affiliates or other such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><U>Limitation of Engagement to the Company. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges
that Cuttone has been retained only by the Company, that Cuttone is providing services hereunder as an independent contractor (and
not in any fiduciary or agency capacity) and that the Company&rsquo;s engagement of Cuttone is not deemed to be on behalf of, and
is not intended to confer rights upon, any shareholder, owner or partner of the Company or any other person not a party hereto
as against Cuttone or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents. Unless otherwise expressly
agreed in writing by Cuttone, no one other than the Company is authorized to rely upon any statement or conduct of Cuttone in connection
with this Agreement. The Company acknowledges that any recommendation or advice, written or oral, given by Cuttone to the Company
in connection with Cuttone&rsquo;s engagement is intended solely for the benefit and use of the Company&rsquo;s management, directors
and controlling stockholder in considering a possible Offering, and any such recommendation or advice is not on behalf of, and
shall not confer any rights or remedies upon, any other person or be used or relied upon for any other purpose. Cuttone shall not
have the authority to make any commitment binding on the Company. The Company, in its sole discretion, shall have the right to
reject any investor introduced to it by Cuttone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify"><U>Amendments and Waivers. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No supplement, modification
or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby. The failure of a party
to exercise any right or remedy shall not be deemed or constitute a waiver of such right or remedy in the future. No waiver of
any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless
of whether similar), nor shall any such waiver be deemed or constitute a continuing waiver unless otherwise expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><U>Confidentiality.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of the
consummation or public announcement of any Offering, Cuttone shall have the right to disclose its participation in such Offering,
including, without limitation, the placement at its cost of &ldquo;tombstone&rdquo; advertisements in financial and other newspapers
and journals, subject to the prior consent of the Company, which shall not be unreasonably withheld or delayed. Cuttone agrees
not to use any confidential information concerning the Company provided to Cuttone by the Company for any purposes other than those
contemplated under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify"><U>Headings. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The headings of the
various sections of this Agreement have been inserted for convenience of reference only and will not be deemed to be part of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify"><U>Counterparts. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may
be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be
deemed to be an original and all such counterparts shall together constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify"><U>Severability. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In case any provision
contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability
of the remaining provisions contained herein will not in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify"><U>Use of Information. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will furnish
Cuttone such written information as Cuttone reasonably requests in connection with the performance of its services hereunder. The
Company understands, acknowledges and agrees that, in performing its services hereunder, Cuttone will use and rely entirely upon
such information as well as publicly available information regarding the Company and other potential parties to an Offering and
that Cuttone does not assume responsibility for independent verification of the accuracy or completeness of any information, whether
publicly available or otherwise furnished to it, concerning the Company or otherwise relevant to an Offering, including, without
limitation, any financial information, forecasts or projections considered by Cuttone in connection with the provision of its services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify"><U>Absence of Fiduciary Relationship. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that: (a) the Placement Agent has been retained solely to act as Placement Agent in connection with the sale of the
Securities and that no fiduciary, advisory or agency relationship between the Company and the Placement Agent has been created
in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Placement Agent has advised or
is advising the Company on other matters; (b) the Share Purchase Price and other terms of the Securities set forth in this Agreement
were established by the Company following discussions and arms-length negotiations with the Placement Agent and the Company is
capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated
by this Agreement; (c) it has been advised that the Placement Agent and its affiliates are engaged in a broad range of transactions
that may involve interests that differ from those of the Company and that the Placement Agent has no obligation to disclose such
interest and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and (d) it has been advised
that the Placement Agent is acting, in respect of the transactions contemplated by this Agreement, solely for the benefit of the
Placement Agent, and not on behalf of the Company and that the Placement Agents may have interests that differ from those of the
Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Placement Agent arising
from an alleged breach of fiduciary duty in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify"><U>Survival of Indemnities, Representations, Warranties, Etc. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The respective indemnities,
covenants, agreements, representations, warranties and other statements of the Company and Placement Agent, as set forth in this
Agreement or made by them respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation
made by or on behalf of the Placement Agent, the Company, the Purchasers or any person controlling any of them and shall survive
delivery of and payment for the Securities. Notwithstanding any termination of this Agreement, including without limitation any
termination pursuant to Section 5, the payment, reimbursement, indemnity, contribution and advancement agreements contained in
Sections 2, 9, 10, and 11, respectively, and the Company&rsquo;s covenants, representations, and warranties set forth in this Agreement
shall not terminate and shall remain in full force and effect at all times. The indemnity and contribution provisions contained
in Section 9 and the covenants, warranties and representations of the Company contained in this Agreement shall remain operative
and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of
any Placement Agent, any person who controls any Placement Agent within the meaning of either Section 15 of the Securities Act
or Section 20 of the Exchange Act or any affiliate of any Placement Agent, or by or on behalf of the Company, its directors or
officers or any person who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of
the Exchange Act, and (iii) the issuance and delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify"><U>Governing Law. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement shall
be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be fully
performed therein. Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard only
in the state or federal courts located in the City of New York, State of New York. The parties hereto expressly agree to submit
themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York. The parties hereto expressly
waive any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City and State of New
York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify"><U>Notices. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All communications
hereunder shall be in writing and shall be mailed or hand delivered and confirmed to the parties hereto as follows:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Glucose Biosensor Systems
(Greater China) Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">733 Third Avenue, Floor
15,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New York, New York
10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attention: Chief Executive
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hughes Hubbard &amp;
Reed LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One Battery Park Plaza</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New York, New York
10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attention: Gary J.
Simon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to the Placement
Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cuttone &amp; Co. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">97 Main St., 2<SUP>nd</SUP>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Chatham, NJ 07928</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attention: Mr. Roger
Barra, Chief Compliance Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any party hereto may
change the address for receipt of communications by giving written notice to the others.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">22.</TD><TD STYLE="text-align: justify"><U>Miscellaneous. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement shall
not be modified or amended except in writing signed by Cuttone and the Company. This Agreement constitutes the entire agreement
of Cuttone and the Company, and supersedes any prior agreements, with respect to the subject matter hereof. If any provision of
this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in
any other respect, and the remainder of this Agreement shall remain in full force and effect. This Agreement may be executed in
counterparts (including facsimile or .pdf counterparts), each of which shall be deemed an original but all of which together shall
constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.</TD><TD STYLE="text-align: justify"><U>Successors. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement will
inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and
controlling persons referred to in Section 9 hereof, and to their respective successors, and personal representative, and, except
as set forth in Section 9 of this Agreement, no other person will have any right or obligation hereunder.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">24.</TD><TD STYLE="text-align: justify"><U>Partial Unenforceability. </U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The invalidity or unenforceability
of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section,
paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid
or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it
valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[SIGNATURE PAGE TO FOLLOW]<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In acknowledgment that
the foregoing correctly sets forth the understanding reached by Cuttone and the Company, and intending to be legally bound, please
sign in the space provided below, whereupon this letter shall constitute a binding Agreement as of the date executed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">GLUCOSE BIOSENSOR SYSTEMS
(GREATER CHINA) HOLDINGS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By:__________________________&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Agreed and accepted
as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CUTTONE &amp; CO.,
LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By:___________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-4 SUBS AGMT
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SUBSCRIPTION AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS INVESTMENT INVOLVES A HIGH DEGREE
OF RISK.</B> THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO
CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT THE MARKET FOR SUCH INVESTMENT MAY BE LIMITED
AND SPORADIC AND IS EXPECTED TO CONTINUE TO BE LIMITED AND SPORADIC FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET CURRENTLY
EXISTS FOR THE SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE SECURITIES OFFERED HEREBY HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR ANY STATE SECURITIES OR BLUE SKY LAWS
AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR
BLUE SKY LAWS.</B> ALTHOUGH AN OFFERING STATEMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE &ldquo;SEC&rdquo;),
THAT OFFERING STATEMENT DOES NOT INCLUDE THE SAME INFORMATION THAT WOULD BE INCLUDED IN A REGISTRATION STATEMENT UNDER THE ACT.
THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY,
NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION
AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO SUBSCRIBER IN CONNECTION WITH THIS OFFERING. ANY REPRESENTATION
TO THE CONTRARY IS UNLAWFUL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INVESTORS WHO ARE NOT &ldquo;ACCREDITED
INVESTORS&rdquo; (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE ACT) ARE SUBJECT TO LIMITATIONS
ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4.</B> THE COMPANY IS RELYING ON THE REPRESENTATIONS AND WARRANTIES SET FORTH
BY EACH SUBSCRIBER IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY SUBSCRIBER IN CONNECTION WITH THIS OFFERING
TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMPANY MAY NOT BE OFFERING THE
SECURITIES IN EVERY STATE.</B> THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION IN
WHICH THE SECURITIES ARE NOT BEING OFFERED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMPANY RESERVES THE RIGHT IN ITS
SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF THE OFFERING AND/OR ACCEPT OR
REJECT IN WHOLE OR IN PART ANY PROSPECTIVE INVESTMENT IN THE SECURITIES OR TO ALLOT TO ANY PROSPECTIVE INVESTOR LESS THAN THE AMOUNT
OF SECURITIES SUCH INVESTOR DESIRES TO PURCHASE. </B> EXCEPT AS OTHERWISE INDICATED, THE OFFERING MATERIALS SPEAK AS OF THEIR DATE.
NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN
NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">TO:</TD><TD STYLE="text-align: justify">Glucose Biosensor Systems (Greater China) Holdings, Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">733 Third Avenue, Floor
15,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New York, New York
10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>1. Subscription</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The undersigned
(&ldquo;Subscriber&rdquo;) hereby irrevocably subscribes for and agrees to purchase the common stock (the
&ldquo;Securities&rdquo; or &ldquo;Common Stock&rdquo;), of Glucose Biosensor Systems (Greater China) Holdings, Inc., a
Delaware corporation (the &ldquo;Company&rdquo;), at a purchase price of
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
per share of Common Stock (the &ldquo;Per Security Price&rdquo;), upon the terms and conditions set forth herein. The
minimum subscription is
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
The rights of Common Stock are as set forth in the Certificate of Incorporation and Bylaws included in the Exhibits to the
Offering Statement of the Company filed with the SEC (the &ldquo;Offering Statement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Subscriber understands that the Securities
are being offered pursuant to an offering circular dated _____________, 2018 (the &ldquo;Offering Circular&rdquo;) filed with the
SEC as part of the Offering Statement. By executing this Subscription Agreement, Subscriber acknowledges that Subscriber has received
this Subscription Agreement, copies of the Offering Circular and Offering Statement including exhibits thereto and any other information
required by the Subscriber to make an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) The Subscriber&rsquo;s subscription
may be accepted or rejected in whole or in part, at any time prior to a Closing Date (as hereinafter defined), by the Company at
its sole discretion. In addition, the Company, at its sole discretion, may allocate to Subscriber only a portion of the number
of Securities Subscriber has subscribed for. The Company will notify Subscriber whether this subscription is accepted (whether
in whole or in part) or rejected. If Subscriber&rsquo;s subscription is rejected, Subscriber&rsquo;s payment (or portion thereof
if partially rejected) will be returned to Subscriber without interest and all of Subscriber&rsquo;s obligations hereunder shall
terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) The aggregate number of Securities
sold shall not exceed _____________ (the &ldquo;Maximum Offering&rdquo;). The Company may accept subscriptions until _____________,
2018, unless otherwise extended by the Company in its sole discretion in accordance with applicable SEC regulations for such other
period required to sell the Maximum Offering (the &ldquo;Termination Date&rdquo;). Providing that subscriptions for _____________
Securities are received (the &ldquo;Minimum Offering&rdquo;), the Company may elect at any time to close all or any portion of
this offering, on various dates at or prior to the Termination Date (each a &ldquo;Closing Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) In the event of rejection of this subscription
in its entirety, or in the event the sale of the Securities (or any portion thereof) is not consummated for any reason, this Subscription
Agreement shall have no force or effect, except for Section 5 hereof, which shall remain in force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) The terms of this Subscription Agreement
shall be binding upon Subscriber and its transferees, heirs, successors and assigns (collectively, &ldquo;Transferees&rdquo;);
provided that for any such transfer to be deemed effective, the Transferee shall have executed and delivered to the Company in
advance an instrument in a form acceptable to the Company in its sole discretion, pursuant to which the proposed Transferee shall
be acknowledge, agree, and be bound by the representations and warranties of Subscriber, terms of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>2. Purchase Procedure</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) <U>Payment.</U> The purchase price
for the Securities shall be paid simultaneously with the execution and delivery to the Company of the signature page of this Subscription
Agreement. Subscriber shall deliver a signed copy of this Subscription Agreement, along with payment for the aggregate purchase
price of the Securities by a check for available funds made payable to &ldquo;_____________&rdquo;, by ACH electronic transfer
or wire transfer to an account designated by the Company, or by any combination of such methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) <U>Offering Deposit Account arrangements.</U>
Payment for the Securities shall be received by _____________ (the &ldquo;<B>Offering Deposit Account Agent</B>&rdquo;) from the
undersigned by transfer of immediately available funds, check or other means approved by the Company at least two days prior to
the applicable Closing Date, in the amount as set forth on the signature page hereto. Upon such Closing Date, the Offering Deposit
Account Agent shall release such funds to the Company. The undersigned shall receive notice and evidence of the digital entry of
the number of the Securities owned by undersigned reflected on the books and records of the Company and verified by _____________,
(the &ldquo;Transfer Agent&rdquo;), which books and records shall bear a notation that the Securities were sold in reliance upon
Regulation A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering Deposit Account Agent Name</B></FONT></TD>
    <TD STYLE="width: 52%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Routing Number</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Account Number </B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To Be Provided to Investor</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Account Name</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reference</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>3. Representations and Warranties of
the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company represents and warrants to
Subscriber that the following representations and warranties are true and complete in all material respects as of the date of each
Closing Date, except as otherwise indicated. For purposes of this Agreement, an individual shall be deemed to have &ldquo;knowledge&rdquo;
of a particular fact or other matter if such individual is actually aware of such fact. The Company will be deemed to have &ldquo;knowledge&rdquo;
of a particular fact or other matter if one of the Company&rsquo;s current officers has, or at any time had, actual knowledge of
such fact or other matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) <U>Organization and Standing.</U> The
Company is a corporation duly formed, validly existing and in good standing under the laws of the State of Delaware. The Company
has all requisite power and authority to own and operate its properties and assets, to execute and deliver this Subscription Agreement
and any other agreements or instruments required hereunder. The Company is duly qualified and is authorized to do business and
is in good standing as a foreign corporation in all jurisdictions in which the nature of its activities and of its properties (both
owned and leased) makes such qualification necessary, except for those jurisdictions in which failure to do so would not have a
material adverse effect on the Company or its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) <U>Issuance of the Securities</U>.
The issuance, sale and delivery of the Securities in accordance with this Subscription Agreement has been duly authorized by all
necessary corporate action on the part of the Company. The Securities, when so issued, sold and delivered against payment therefor
in accordance with the provisions of this Subscription Agreement, will be duly and validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) <U>Authority for Agreement</U>. The
execution and delivery by the Company of this Subscription Agreement and the consummation of the transactions contemplated hereby
(including the issuance, sale and delivery of the Securities) are within the Company&rsquo;s powers and have been duly authorized
by all necessary corporate action on the part of the Company. Upon full execution hereof, this Subscription Agreement shall constitute
a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except (i) as limited
by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of
creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief,
or other equitable remedies and (iii) with respect to provisions relating to indemnification and contribution, as limited by considerations
of public policy and by federal or state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) <U>Capitalization</U>. The authorized
and outstanding securities of the Company immediately prior to the initial investment in the Securities is as set forth &ldquo;Description
of Our Securities&rdquo; in the Offering Circular. Except as set forth in the Offering Circular, there are no outstanding options,
warrants, rights (including conversion or preemptive rights and rights of first refusal), or agreements of any kind (oral or written)
for the purchase or acquisition from the Company of any of its securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) <U>Litigation</U>. There is no pending
action, suit, proceeding, arbitration, mediation, complaint, claim, charge or investigation before any court, arbitrator, mediator
or governmental body, or to the Company&rsquo;s knowledge, currently threatened in writing (a) against the Company or (b) against
any consultant, officer, manager, director or key employee of the Company arising out of his or her consulting, employment or board
relationship with the Company or that could otherwise materially impact the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>4. Representations and Warranties of
Subscriber</U>. By executing this Subscription Agreement, Subscriber (and, if Subscriber is purchasing the Securities subscribed
for hereby in a fiduciary capacity, the person or persons for whom Subscriber is so purchasing) represents and warrants, which
representations and warranties are true and complete in all material respects as of such Subscriber&rsquo;s respective Closing
Date(s):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) <U>Requisite Power and Authority</U>.
Such Subscriber has all necessary power and authority under all applicable provisions of law to execute and deliver this Subscription
Agreement and any other agreements required hereunder and to carry out their provisions. All action on Subscriber&rsquo;s part
required for the lawful execution and delivery of this Subscription Agreement and other agreements required hereunder have been
or will be effectively taken prior to the Closing Date. Upon their execution and delivery, this Subscription Agreement and other
agreements required hereunder will be valid and binding obligations of Subscriber, enforceable in accordance with their terms,
except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting
enforcement of creditors&rsquo; rights and (b) as limited by general principles of equity that restrict the availability of equitable
remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) <U>Investment Representations</U>.
Subscriber understands that the Securities have not been registered under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;). Subscriber also understands that the Securities are being offered and sold pursuant to an exemption from registration
contained in the Securities Act based in part upon Subscriber&rsquo;s representations contained in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) <U>Limited Market and Continued Economic
Risk</U>. Subscriber acknowledges and agrees that the public market for the Securities may be limited and sporadic and that there
is no guarantee that a liquid market for their resale will ever exist. Subscriber must bear the economic risk of this investment
indefinitely and the Company has no obligation to take any steps with respect to facilitating active trading of the Securities.
Subscriber acknowledges that Subscriber is able to bear the economic risk of losing Subscriber&rsquo;s entire investment in the
Securities. Subscriber also understands that an investment in the Company involves significant risks and has taken full cognizance
of and understands all of the risk factors relating to the purchase of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) <U>Accredited Investor Status or Investment
Limits</U>. Subscriber represents that either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) Subscriber is an &ldquo;accredited
investor&rdquo; within the meaning of Rule 501 of Regulation D under the Securities Act, as defined on Appendix A of this Subscription
Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) The purchase price set out
in paragraph (b) of the signature page to this Subscription Agreement, together with any other amounts previously used to purchase
Securities in this offering, does not exceed 10% of the greater of the Subscriber&rsquo;s annual income or net worth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subscriber represents that to the extent
it has any questions with respect to its status as an accredited investor, or the application of the investment limits, it has
sought professional advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) <U>Shareholder information.</U> Within
five days after receipt of a request from the Company, the Subscriber hereby agrees to provide such information with respect to
its status as a shareholder (or potential shareholder) and to execute and deliver such documents as may reasonably be necessary
to comply with any and all laws and regulations to which the Company is or may become subject. <B>Subscriber further agrees that
in the event it transfers any Securities, it will require the transferee of such Securities to agree to provide such information
to the Company as a condition of such transfer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) <U>Company Information</U>. Subscriber
understands that the Company is subject to all the risks that apply to early-stage companies, whether or not those risks are explicitly
set out in the Offering Circular. Subscriber has had such opportunity as it deems necessary (which opportunity may have presented
through online chat or commentary functions) to discuss the Company&rsquo;s business, management and financial affairs with officers
and management of the Company and has had the opportunity to review the Company&rsquo;s operations and facilities. Subscriber has
also had the opportunity to ask questions of and receive answers from the Company and its management regarding the terms and conditions
of this investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g) <U>Valuation.</U> The Subscriber acknowledges
that the price of the Securities was set by the Company on the basis of the Company&rsquo;s internal valuation and no warranties
are made as to value. The Subscriber further acknowledges that future offerings of Securities may be made at lower valuations,
with the result that the Subscriber&rsquo;s investment will bear a lower valuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(h) <U>Domicile</U>. Subscriber maintains
Subscriber&rsquo;s domicile (and is not a transient or temporary resident) at the address shown on the signature page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) <U>No Brokerage Fees</U>. There are
no claims for brokerage commission, finders&rsquo; fees or similar compensation in connection with the transactions contemplated
by this Subscription Agreement or related documents based on any arrangement or agreement binding upon Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(j) <U>Foreign Investors</U>. If Subscriber
is not a United States person (as defined by Section&nbsp;7701(a)(30) of the Internal Revenue Code of 1986, as amended), Subscriber
hereby represents that it has satisfied itself as to the full observance of the laws of its home jurisdiction in connection with
any invitation to subscribe for the Securities or any use of this Subscription Agreement, including (i)&nbsp;the legal requirements
within its home jurisdiction for the purchase of the Securities, (ii)&nbsp;any foreign exchange restrictions applicable to such
purchase, (iii)&nbsp;any non-US governmental or other consents that may need to be obtained, and (iv)&nbsp;the income tax and other
tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Securities. Subscriber&rsquo;s
subscription and payment for and continued beneficial ownership of the Securities will not violate any applicable securities or
other laws of the Subscriber&rsquo;s home jurisdiction. For the avoidance of doubt, the term &ldquo;home jurisdiction&rdquo; shall
not refer to the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <U>Survival of Representations</U>.
The representations, warranties and covenants made by the Subscriber herein shall survive the Termination Date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <U>Governing Law; Jurisdiction</U>.
This Subscription Agreement shall be governed and construed in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EACH OF THE SUBSCRIBER AND THE COMPANY
CONSENTS TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION LOCATED WITHIN NEW YORK AND NO OTHER PLACE
AND IRREVOCABLY AGREES THAT ALL ACTIONS OR PROCEEDINGS RELATING TO THIS SUBSCRIPTION AGREEMENT MAY BE LITIGATED IN SUCH COURTS.
EACH OF SUBSCRIBER AND THE COMPANY ACCEPTS FOR ITSELF AND HIMSELF AND IN CONNECTION WITH ITS AND HIS RESPECTIVE PROPERTIES, GENERALLY
AND UNCONDITIONALLY, THE EXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY
AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS SUBSCRIPTION AGREEMENT. EACH OF SUBSCRIBER AND THE
COMPANY FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OUT OF ANY OF THE AFOREMENTIONED COURTS IN THE MANNER AND IN THE
ADDRESS SPECIFIED IN SECTION 7 AND THE SIGNATURE PAGE OF THIS SUBSCRIPTION AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The provisions in this Section 6 shall
not apply or limit any claims made by Subscriber (or any transferee of Securities purchased by Subscriber) under the federal securities
laws and the rules and regulations thereunder.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <U>Notices</U>. Notice, requests, demands
and other communications relating to this Subscription Agreement and the transactions contemplated herein shall be in writing and
shall be deemed to have been duly given if and when (a) delivered personally, on the date of such delivery; or (b) mailed by registered
or certified mail, postage prepaid, return receipt requested, in the third day after the posting thereof; or (c) emailed, telecopied
or cabled, on the date of such delivery to the address of the respective parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 56%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Company, to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Glucose Biosensor Systems (Greater China)
        Holdings, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">733 Third Avenue, Floor 15,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10017</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attention: Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to a Subscriber, to Subscriber&rsquo;s address as shown on the signature page hereto</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or to such other address as may be specified
by written notice from time to time by the party entitled to receive such notice. Any notices, requests, demands or other communications
by telecopy or cable shall be confirmed by letter given in accordance with (a) or (b) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>8. Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All pronouns and any variations thereof
shall be deemed to refer to the masculine, feminine, neuter, singular or plural, as the identity of the person or persons or entity
or entities may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) This Subscription Agreement is not
transferable or assignable by Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) The representations, warranties and
agreements contained herein shall be deemed to be made by and be binding upon Subscriber and its heirs, executors, administrators
and successors and shall inure to the benefit of the Company and its successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) None of the provisions of this Subscription
Agreement may be waived, changed or terminated orally or otherwise, except as specifically set forth herein or except by a writing
signed by the Company and Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) In the event any part of this Subscription
Agreement is found to be void or unenforceable, the remaining provisions are intended to be separable and binding with the same
effect as if the void or unenforceable part were never the subject of agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) The invalidity, illegality or unenforceability
of one or more of the provisions of this Subscription Agreement in any jurisdiction shall not affect the validity, legality or
enforceability of the remainder of this Subscription Agreement in such jurisdiction or the validity, legality or enforceability
of this Subscription Agreement, including any such provision, in any other jurisdiction, it being intended that all rights and
obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g) This Subscription Agreement supersedes
all prior discussions and agreements between the parties with respect to the subject matter hereof and contains the sole and entire
agreement between the parties hereto with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(h) The terms and provisions of this Subscription
Agreement are intended solely for the benefit of each party hereto and their respective successors and assigns, and it is not the
intention of the parties to confer, and no provision hereof shall confer, third-party beneficiary rights upon any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) The headings used in this Subscription
Agreement have been inserted for convenience of reference only and do not define or limit the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(j) This Subscription Agreement may be
executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one
and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(k) No failure or delay by any party in
exercising any right, power or privilege under this Subscription Agreement shall operate as a waiver thereof nor shall any single
or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.
The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>SIGNATURE PAGE FOLLOWS</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GLUCOSE BIOSENSOR SYSTEMS (GREATER CHINA)
HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION AGREEMENT SIGNATURE PAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned, desiring to purchase shares of Common Stock
of Glucose Biosensor Systems (Greater China) Holdings, Inc., by executing this signature page, hereby executes, adopts and agrees
to all terms, conditions and representations of the Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of Common Stock the undersigned hereby irrevocably subscribes for is:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(print number of Securities)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate purchase price (based on a purchase price of $_____________ per Security) for the shares of Common Stock the undersigned hereby irrevocably subscribes for is:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$_____________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(print aggregate purchase price)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Securities being subscribed for will be owned by, and should be recorded on the Company&rsquo;s books as held in the name of:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(print name of owner or joint owners)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Securities are to be purchased in joint names, both Subscribers must sign:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name (Please Print)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email address</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address 1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address 2</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">City/Municipality&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State/Province</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zip/Postal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Country</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Telephone Number</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID No.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date</P></TD>
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name (Please Print)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email address</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address 1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address 2</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">City/Municipality&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State/Province</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zip/Postal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Country</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Telephone Number</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID No.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Subscription is accepted</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">on ____________________.</P></TD>
    <TD STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Title:</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>APPENDIX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>An accredited investor includes the following categories
of investor:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) Any bank as defined in section 3(a)(2) of the Act, or any
savings and loan association or other institution as defined in section 3(a)(5)(A) of the Act whether acting in its individual
or fiduciary capacity; any broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934; any insurance
company as defined in section 2(a)(13) of the Act; any investment company registered under the Investment Company Act of 1940 or
a business development company as defined in section 2(a)(48) of that Act; any Small Business Investment Company licensed by the
U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established
and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions,
for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning
of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in section
3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or
if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made
solely by persons that are accredited investors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) Any private business development company as defined in section
202(a)(22) of the Investment Advisers Act of 1940;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) Any organization described in section 501(c)(3) of the Internal
Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring
the securities offered, with total assets in excess of $5,000,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) Any director, executive officer, or general partner of the
issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of
that issuer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5) Any natural person whose individual net worth, or joint
net worth with that person's spouse, exceeds $1,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(i) Except as provided in paragraph (a)(5)(ii) of
this section, for purposes of calculating net worth under this paragraph (a)(5):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(A) The person's primary residence shall not be included
as an asset;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(B) Indebtedness that is secured by the person's primary
residence, up to the estimated fair market value of the primary residence at the time of the sale of securities, shall not be included
as a liability (except that if the amount of such indebtedness outstanding at the time of sale of securities exceeds the amount
outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess
shall be included as a liability); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(C) Indebtedness that is secured by the person's primary
residence in excess of the estimated fair market value of the primary residence at the time of the sale of securities shall be
included as a liability;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(6) Any natural person who had an individual income in excess
of $200,000 in each of the two most recent years or joint income with that person's spouse in excess of $300,000 in each of those
years and has a reasonable expectation of reaching the same income level in the current year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(7) Any trust, with total assets in excess of $5,000,000, not
formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described
in &sect;230.506(b)(2)(ii); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(8) Any entity in which all of the equity owners are accredited
investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-6 MAT CTRCT
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 6.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TECHNOLOGY LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Technology License
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) dated as <FONT STYLE="background-color: white">of 25 August, 2017 (the &ldquo;<U>Effective
Date</U>&rdquo;), is by and between Life Science Biosensor Diagnostics Pty Ltd., an Australian proprietary limited company having
an address at Level 7, 222 Clarence Street, Sydney NSW 2000 Australia (&ldquo;<U>Licensor</U>&rdquo;) and Glucose Biosensor Systems
(Greater China) Holdings Inc <B>insert details of licensee</B>, a company having an registered office at Corporation Trust Centre,
1209 Orange St, City of Wilmington, County of New</FONT> Castle, Delaware 19801_ (&ldquo;<U>Licensee</U>&rdquo;) (each, a &ldquo;<U>Party</U>&rdquo;
and collectively the &ldquo;<U>Parties</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Licensor owns
Technology (as defined below) related to measuring or otherwise determining the amount or concentration of glucose in a bodily
fluid (e.g., saliva, blood) and to products (including, without limitation, meters, strips, and accessories), systems, methods,
processes, applications, and implementation for or of measuring or otherwise determining the amount or concentration of glucose
in a bodily fluid (e.g., saliva, blood) (individually and collectively, the &ldquo;<U>Glucose Sensor Technology</U>&rdquo;) and
owns Proprietary Rights (as defined below) in and to Glucose Sensor Technology (individually and collectively, the &ldquo;<U>Glucose
Sensor Proprietary Rights</U>,&rdquo; collectively with the Glucose Sensor Technology, the &ldquo;<U>Glucose Sensor IP</U>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Licensor wishes
to permit Licensee, and Licensee wishes to have the right, to use, market, offer, and sell products including or using Glucose
Sensor Technology as identified in <B><I>Schedule 1</I></B> that Licensee procured (but only if Licensee procured such products)
from an Authorized Supplier (as defined below) (the &ldquo;<U>Licensed Products</U>&rdquo;) in the Territory (as defined below)
under the Glucose Sensor Proprietary Rights owned by Licensor with legal effect in the Territory, including, without limitation,
the Proprietary Rights set forth in <B><I>Schedule 2</I></B> (the &ldquo;<U>Licensed Rights</U>&rdquo;), in accordance with the
terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, for
good and valuable consideration, and intending to be legally bound, Licensee and Licensor agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Definitions; Interpretation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">1.1</TD><TD STYLE="text-align: justify"><U>Definitions</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any entity or other legal or juridical person that, directly or indirectly, controls, or is controlled by, or is under common
control with, Licensor; whereby &ldquo;control&rdquo; of a person or Party means direct or indirect ownership of fifty percent
(50%) or more of the beneficial or record ownership of the outstanding shares or other ownership interests or the direct or indirect
power to designate fifty percent (50%) or more of directors, managers, or individuals exercising authority in its governance; provided
that, notwithstanding the foregoing, Licensee shall be deemed not to be an Affiliate of Licensor under or in connection with this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Anonymized
Database</U>&rdquo; means a production database collecting all Anonymized Demographic Information, and all Glucose Sensor Data
provided by Licensor to Licensee under Section 4.6, categorized under the different Anonymized Identifiers that is stored on a
cloud-based server or cloud based servers controlled by Licensor with a cloud server provider approved in advance in writing by
Licensor to Licensee, and any back-up database that may be continuously and simultaneously updated with such production database
and is located geographically separate from the production database, or any other server notified by Licensor to Licensee as the
server for the purposes of storing the production database.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Anonymized
Demographic Information</U>&rdquo; means, with regard to an End User, all demographic information, including, without limitation,
gender, age, race or ethnicity, disease information, other medical information, and eponymous data , of such End User, but excluding
any End User Identifiable Data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Anonymized
End User Data</U>&rdquo; means collectively with regard to a specific Anonymized Identifier such Anonymized Identifier, all Anonymized
Demographic Information under such Anonymized Identifier, and all Glucose Sensor Data under such Anonymized Identifier. The term
Anonymized End User Data does not include any End User Identifiable Data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Anonymized
Identifier</U>&rdquo; means a unique identifier given to an individual End User, which unique identifier has the only purpose of
distinguishing such individual End User from any other individual End User but does not disclose or make available to Licensor
the identity or any End User Data of such End User.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Authorized
Supplier</U>&rdquo; means, with regard to a Licensed Product, Licensor, any Affiliate, or any third party manufacturer and/or reseller
that Licensor has expressly identified or approved in advance in writing for the supply of such Licensed Product to Licensee, provided
that such a supplier shall cease being an Authorized Supplier upon Licensor&rsquo;s notifying Licensee thereof in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Change of
Control</U>&rdquo; means</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">in respect of the Licensee, means at any time following the allocation of securities pursuant to
the Licensee&rsquo;s initial public offering that (a) any legal or natural person, or any government or government agency, becomes
the legal or beneficial owner, directly or indirectly, of securities of Licensee representing thirty percent (30%) or more of (A)
the outstanding shares of common stock of Licensee or (B) the combined voting power of Licensee's then-outstanding securities;
(b) Licensee is party to a merger or consolidation, or series of related transactions, which results in the voting securities of
Licensee outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding or by being converted
into voting securities of the surviving or another entity) at least thirty percent (30%) of the combined voting power of the voting
securities of Licensee or such surviving or other entity outstanding immediately after such merger or consolidation; (c) the sale
or disposition of all or substantially all of Licensee&rsquo;s assets (or consummation of any transaction, or series of related
transactions, having similar effect); (d) there occurs a change in the composition of the board of directors or equivalent governing
body of Licensee without the prior consent of Licensor; (e) the dissolution or liquidation of Licensee; or (f) any transaction
or series of related transactions that has the substantial effect of any one or more of the foregoing; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">in respect of the Licensor, means that (a) any legal or natural person, or any government or government
agency, becomes the legal or beneficial owner, directly or indirectly, of securities of Licensor representing over fifty percent
(50%) or more of (A) the outstanding shares of common stock of Licensor or (B) the combined voting power of Licensor's then-outstanding
securities; (b) Licensor is party to a merger or consolidation, or series of related transactions, which results in the voting
securities of Licensor outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding
or by being converted into voting securities of the surviving or another entity) at over fifty percent (50%) of the combined voting
power of the voting securities of Licensor or such surviving or other entity outstanding immediately after such merger or consolidation;
(c) the sale or disposition of all or substantially all of Licensor&rsquo;s assets (or consummation of any transaction, or series
of related transactions, having similar effect); or (d) any transaction or series of related transactions that has the substantial
effect of any one or more of the foregoing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commercial
Unit</U>&rdquo; means, with regard to a Licensed Product, one (1) biosensor strip product unit at which such Licensed Product is
offered by Licensee to, or resale or provision to, individual end users of such Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Derivation</U>&rdquo;
means, with regard to any Technology, any modification, improvement, derivative work, derivation, adaptation, localization, translation,
transliteration, and/or compilation of any kind, directly or indirectly, to or of or from or based on or over such Technology.
A Derivation to any Technology that is a Derivation is also a Derivation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Distribution
Differential</U>&rdquo; means, for any period, the difference between the projected sales of Commercial Units agreed between the
parties and actual sales of Commercial Units during that period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>End User</U>&rdquo;
means, with regard to a Licensed Product, any individual who procures for use or uses any Commercial Unit of such Licensed Product.
For the avoidance of doubt, End User includes any subject who provides a bodily fluid for glucose assessment and performs such
glucose assessment using such provided bodily fluid and any individual who receives for glucose assessment a bodily fluid of another
and performs such glucose assessment using such received bodily fluid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>End User
Identifiable Data</U>&rdquo; means, with regard to an End User, any data and information that relates to the past, present, or
future physical or mental health or condition of such End User; the provision of health care to such End User; or the past, present,
or future payment for the provision of health care to such End User; in each case that identifies such End User or with respect
to which there is a reasonable basis to believe such data and information can be used to identify such End User including, without
limitation, the name, address, social security or similar government-issued number, and number of a passport or other government-issued
identification document of such End User.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>End User
Identifiable Database</U>&rdquo; means a production database collecting all End User Identifiable Data that is stored on a cloud-based
server or cloud based servers with a cloud server provider approved in advance in writing by Licensor to Licensee to which Licensee
shall for the Term have continuous password-protected and secure access, and any back-up database that may be continuously and
simultaneously updated with such production database and is located geographically separate from the production database, or any
other server notified by Licensor to Licensee as the server for the purposes of storing the production database.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Expiry Date
of the Patent</U>&rdquo; means the final date of the protection afforded to the patent portfolio directly associated with the development
of the Licensed Product, as advised in writing by Licensor to Licensee from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Glucose Sensor
Data</U>&rdquo; means, individually and collectively, any and all data, documentation, and information collected by any Licensed
Product that measures or otherwise determines the amount or concentration of glucose in a bodily fluid (e.g., saliva, blood) and
stores such values and other information and/or transmits such values and other information for storage, viewing, or processing
on a different instrument (including, without limitation, the blood glucose level, date, time, and other information from or related
to a specific measurement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Glucose Sensor
Data Destination</U>&rdquo; means a server outside the Territory as controlled by or for Licensor and as identified by Licensor
to Licensee from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Interference</U>&rdquo;
means, with regard to a Database, any event of: (i) any Malware having any effect on any data in such Database, on any data while
transmitted to or from such Database, or on any access to, or ability to access, such Database or any data therein, and/or (ii)
any invasion into or unauthorized or fraudulent access to, or interference with, such Database, any data in such Database, or any
data while transmitted to or from such Database.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>License Fee</U>&rdquo;
has the meaning set forth in <B><I>Schedule 4</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Licensed
Material</U>&rdquo; means any sales literature or other promotional documents, items, material, or things for use in connection
with promoting, marketing, offering for sale, and selling Licensed Products made available, supplied or provided by Licensor to
Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Licensed
Trademark</U>&rdquo; means any of the Marks set forth in <B><I>Schedule 3</I></B>, provided that: (i) if Licensor identifies use
of any such Mark only for a specific Licensed Product, such Mark is a Licensed Trademark only with regard to such Licensed Product;
and (ii) Licensor may at any time discontinue any such Mark as a Licensed Trademark, or replace any such Mark with a different
Mark, or modify any such Mark, or add a Mark as a Licensed Trademark, by written notice to Licensee, in which case, in accordance
with such written notice, such replaced or discontinued Mark shall cease to be a Licensed Trademark, such replacing or added Mark
shall become a Licensed Trademark, and such modified Mark shall be a Licensed Trademark only as so modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Licensee
Personnel</U>&rdquo; means any officer, director, employee, agent, and contractor of Licensee, including, without limitation, any
distributor, or any direct or indirect subdistributor of any distributor, of Commercial Units under agreement with Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Malware</U>&rdquo;
means, individually and collectively, any computer code or other mechanism of any kind designed to disrupt, disable or harm in
any manner the operation of any software or hardware or other business processes or to misuse, gain unauthorized access to or misappropriate
any business or personal information, including, without limitation, viruses, worms, Trojan horses, bombs, backdoors, clocks, hidden
keys, timers, traps or other disabling device code, or designs or routines that cause software or information to be erased, inoperable
or otherwise incapable of being used, either automatically or with passage of time or upon command.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Mark</U>&rdquo;
means any trademark, service mark, trade name, corporate name, business name, domain name, design, logos, slogans, trade dress,
and other designation of source or origin, and any common law right, registration, application for registration, extension, and
renewal thereof or related thereto, and all goodwill of the business symbolized by any of the foregoing or associated therewith,
any where in or throughout the world and under any law or legal system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestones
and Minimum Distribution Requirements</U>&rdquo; means, collectively, the commercialization milestones and other requirements set
forth in <B><I>Schedule 5</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&lsquo;<U>Net sales</U>&rsquo;
means the gross invoiced price for sales or other supplies of Licensed Products by the Licensee less only usual arms&rsquo; length
trade discounts and rebates actually given or allowed (such discounts and rebates not to exceed 5% of the gross invoiced price),
customs duties, transportation and insurance charges, and all taxes incurred on such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>New End User</U>&rdquo;
means, with regard to any Licensed Product and with regard to a specified point in time, any End User who has not previously, or
has not during the preceding twelve (12) months&rsquo; time, procured such Licensed Product from Licensee or any authorized distributor
of Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Royalty</U>&rdquo;
has the meaning set forth in <B><I>Schedule 4</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Projected
Net Sales&rdquo;</U> means a forecast for Net Sales on a rolling 5 year period, to be determined annually during the Term by agreement
in writing between the Licensor and the Licensee. In the event the Licensor and the Licensee cannot agree on the Projected Net
Sales in any year, the Projected Net Sales from the immediately preceding period will apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proprietary
Right</U>&rdquo; means any of the following, anywhere in or throughout the world and under any law or legal system: (i) any patent
and any patent application (including, without limitation, any utility and design patent and patent application, and any provisional,
continuation, continuation-in-part, divisional, reissue, reexamination, substitution, extension, and foreign, international and
other counterpart and equivalent of any patent and/or patent application), and any right in or to or arising from any utility model,
invention disclosure, patent disclosure, or invention (whether or not patentable), (ii) any copyright and any right similar thereto,
whether arising from statute, regulation, common or judicial law, treaty or otherwise, and any registration, application for registration,
and renewal thereof or related thereto, (iv) any mask work right, and any registration, application for registration, and renewal
thereof or related thereto, (v) any moral right, including, without limitation, rights of attribution and integrity, (vi) any data
base right and any right in or to or arising from any computer program (whether in source code, object code, or other form), algorithm,
data, website, webpage, web address, web presence, uniform resource locator, or digital property or information, (vii) any right
in or to or arising from any trade secret, any know-how, or any confidential information, (viii) any personality, likeness, publicity,
and privacy right, and (ix) any other intellectual or industrial property right, whether existing now or being recognized or created
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Technology</U>&rdquo;
means, individually and collectively, any material, item, document, documentation, technology, invention, creation, development,
discovery, reduction to practice, design, process, method, equipment, practice, work, know-how, show-how, software, source code,
object code, other code, data, database, device, product, prototype, specification, application, implementation, conception, idea,
and information of any kind, whether tangible or intangible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Term</U>&rdquo;
means the period commencing on the Effective Date and continuing until the termination, expiration, or cancellation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Termination
Date&rdquo;</U> means the date this Agreement is terminated or cancelled in accordance with clause 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Territory</U>&rdquo;
means <B>Mainland China, Hong Kong Vietnam and Bangladaesh.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interpretation</U>.
In this Agreement: (i) any reference to &ldquo;Section&rdquo; means any of the numbered sections in this Agreement; (ii) any reference
to &ldquo;Schedule&rdquo; means any of the numbered schedules appended after the signature page of this Agreement, which shall
be deemed to be a part of this Agreement; (iii) any reference to any provision of a statute shall be construed as a reference to
that provision as amended, re-enacted or extended at the relevant time; (iv) where this Agreement states that a Party &ldquo;shall&rdquo;
or &ldquo;will&rdquo; perform in some manner or otherwise act or omit to act, it means that such Party is legally obligated to
do so in accordance with this Agreement; (v) the principle <I>ejusdem generis</I> shall not apply to any provision in this Agreement;
(vi) the provisions of this Agreement shall not be interpreted against the drafter, and for purposes of any interpretation, both
Parties shall be deemed to be drafters of this Agreement; (vii) all Section headings and Schedule titles are intended solely for
the convenience of the Parties, and none will be deemed to affect the meaning or construction of any provision hereof; (viii) words
of any gender used in this Agreement are intended to include any other gender, and words in the singular number include the plural,
and vice versa, unless the context clearly indicates otherwise; (ix) all amounts in the agreement refer to amounts in United Sates
of America dollars; (x) specifying anything in this Agreement after the words &lsquo;include&rsquo; or &lsquo;for example&rsquo;
or similar expressions does not limit what else is included; and (xi) other parts of speech and grammatical forms of a word or
phrase defined in this Agreement have a corresponding meaning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Licenses</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Distribution
License</U>. Licensor hereby grants to Licensee a non-transferable, non-assignable, non-sublicenseable, royalty-bearing and fee-bearing,
limited license during the Term, in accordance with the terms and conditions of this Agreement under (1) the Licensed Rights and
(2) Licensor&rsquo;s ownership and legally enforceable rights in Glucose Sensor Data, solely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
act as the regulatory marketing authorisation holder (or similar designated position for the purposes of obtaining regulatory approval
in the Territory);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
promote, market, import into the Territory, offer, sell, distribute, and supply Licensed Products in the Territory, solely for
use in the Territory, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
provide reasonable customer support services to end users of the Licensed Products in the Territory on the use of the Licensed
Products,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
use the Licensed Products only for the purposes identified and permitted pursuant to the regulatory approval obtained in the Territory,
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
collect for and on behalf of Licensor, Glucose Sensor Data arising from use of Licensed Products in the Territory,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(the &ldquo;<U>Distribution License</U>&rdquo;).
No other right or license is granted by Licensor under this Agreement in or to any Proprietary Right or related to any Glucose
Sensor IP. Licensor has the right, but not the obligation, to agree to add or expand the Distribution License hereby granted, including,
but not limited to, by varying or adding to the Licensed Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exclusivity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Distribution License is granted as an exclusive license in the Territory unless and until Licensor terminates the exclusivity in
accordance with this Section 2.2. Notwithstanding the exclusivity of the Distribution License under the foregoing provision of
this Section 2.2, nothing in this Agreement shall prevent or prohibit Licensor or any Affiliate from performing or engaging in
any direct or indirect promotion, marketing, import, export, representation, offer, sale, resale, distribution, or supply outside
the Territory anywhere in any manner as decided by Licensor in its sole discretion, and Licensee shall have no right or claim in
connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Distribution License does not permit and the Licensee is prohibited from exploiting or seeking to exploit any rights in respect
of the Licensed Product outside of the Territory through any means, including digitally or online, where the End User is not physically
resident in the Territory. The Licensee must do all things necessary in turn to ensure that any distributors of Licensed Products
in the Territory do not exploit or seek to exploit any rights in respect of the Licensed Product outside of the agreed territorial
boundaries for that particular distributor. For the avoidance of doubt a breach of the obligations set out in the clause will be
a material breach for the purposes of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that Licensee fails to meet the Milestones and Minimum Distribution Requirements, Licensor may at its election require
the Licensee to pay in immediately available funds the Distribution Differential or immediately terminate the exclusivity of the
Distribution License or immediately terminate this Agreement in its entirety. Upon such termination of the exclusivity of the Distribution
License: (i) the exclusivity of the Distribution License will immediately end and the Distribution License shall be non-exclusive;
(ii) Licensor may, directly or indirectly, license any third party to promote, market, import, offer, sell, distribute, and supply
Licensed Products in the Territory, and (iii) Licensee shall otherwise continue to be subject to all terms, conditions and provisions
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Licensee fails to pay the Distribution Differential within 14 business days from notice in writing by the Licensor to do so,
the Licensor may either immediately terminate the exclusivity of the Distribution License or immediately terminate this Agreement
in its entirety in accordance with clause 2.2b. above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Trademark
and Promotional Material License</U>. Licensor hereby grants to Licensee a non-exclusive, non-transferable, non-assignable, non-sublicense
able, limited license during the Term to use the Licensed Trademarks, and to reproduce, use, and distribute (without any modification
or editing not approved in advance in writing) any exact copies of any Licensed Material, solely in the Territory and solely for
the purpose of reasonably promoting, marketing, offering, selling, and distributing the Licensed Products, all in accordance with
the terms and conditions of this Agreement (&ldquo;<U>Marketing License</U>&rdquo;). No other right or license is granted by Licensor
under this Agreement in or to any Licensed Trademark, any other Mark, or any Licensed Material. All use of the Licensed Trademarks
shall comply with any trademark usage guidelines that Licensor may provide to Licensee, as may be amended from time to time by
Licensor in its sole discretion with written notice to Licensee, and the provisions of this Section 2.3 and Section 2.4. Licensee
shall ensure that any Commercial Unit of a Licensed Product promoted and marketed under any Licensed Trademark, or with regard
to which any Licensed Trademark is used, meets the high quality of such Licensed Product made in accordance with Licensor&rsquo;s
specifications and requirements and has not been modified, altered, or degraded in any way. Licensee shall not use any Licensed
Trademark on or in connection with any Commercial Unit that does not meet such quality requirements. Licensee may not use any Licensed
Trademark in any way such that it is used as, or appears to be, conjoined with any other mark or name without Licensor&rsquo;s
express prior written consent and license and terms agreed to by Licensor in Licensor&rsquo;s sole discretion. Licensee shall use
each Licensed Trademark at all times with such notice (&reg; or &trade; as applicable) as directed by Licensor. Any Licensed Material
shall include a notice of Licensor&rsquo;s copyrights by using the symbol &copy;, followed by the name of Licensor (or such other
name as identified by Licensor to Licensee) and the year identified by Licensor. Licensee may not modify, change, alter, cover,
or obliterate in any way any such marking or notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations</U>.
Licensee shall not assign or transfer, or grant any sublicense or the right to sublicense under, the License, or agree or commit
to do so. Licensee does not have any license to, and Licensee shall not: (i) use, practice, or reproduce any Glucose Sensor Technology
(other than as part of and incidental to the marketing or promotion of any Licensed Product under the Distribution License), or
use, make, promote, market, offer, sell, resell, distribute, distribute, represent, or license any product or service including
or involving Glucose Sensor Technology or Glucose Sensor Proprietary Rights other than the Licensed Products under the Distribution
License; (ii) promote, market, import into the Territory, offer, sell, distribute, and supply Licensed Products outside, or for
use or resale outside, the Territory or to the extent Licensee knows or suspects that a third party buyer of Licensed Products
will promote, market, export, offer, sell, distribute, or supply such Licensed Products outside or for use or application outside
the Territory; (iii) promote, market, offer, sell, distribute, and supply Licensed Products for any use other than its intended
use measuring or determining blood glucose in humans from saliva; (iv) not reverse engineer, decompile, disassemble, modify, edit,
change, amend, customize, adapt, copy or reproduce (except as and to the extent expressly permitted in the License), or create
any Derivation of or to or from or based on any Licensed Product or any Glucose Sensor Technology; (v) without the prior written
consent of Licensor include any Licensed Product in, or combine any Licensed Product with, any product or any service other than
a Licensed Product; (vi) use any Licensed Trademark or any Licensed Material for any product or service other than a Licensed Product
during the Term under the Marketing License; (vii) use any Licensed Trademark or any Licensed Material outside the Territory; (viii)
do or omit to do anything that could adversely affect their validity or reputation or the reputation of Licensor or a Licensed
Product or a Licensed Trademark; and (ix) cause, induce, or permit any third party to do, or assist any third party with doing,
any of the foregoing, whether for the benefit of Licensee, such third party, and/or any other third party. Licensee must immediately
notify Licensor in writing if it becomes aware of a breach, or attempted breach, of any of the above obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Licensed
Products</U>. Licensor may require any change to any Licensed Product by any Authorized Supplier and may make any change to any
Licensed Material by Licensee. As of the effective time of such change, Licensee shall promote, market, import into the Territory,
offer, sell, distribute, and supply such Licensed Product, and all Commercial Units thereof, consistent with such change, and use
only Licensed Material with such change. Licensor shall not be liable in any way to Licensee for any such change or any costs,
expenses, damages, or liability arising therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringements</U>.
Licensee shall give written notice to Licensor of any infringement or attempted infringement of any intellectual property rights
in or to any Licensed Material that comes to Licensee&rsquo;s attention and shall cooperate reasonably with Licensor, at Licensor&rsquo;s
reasonable and necessary expense and reasonable request, in preventing and stopping any such infringement, but otherwise shall
not to take any action against any such infringer with respect to such infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Performance</U>.
Licensee shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promote,
market, import, offer, sell, distribute, and supply the Licensed Products, and all Commercial Units, on an arm&rsquo;s length basis
in accordance with all applicable law and the requirements set forth in <B><I>Schedule 6</I></B>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;monitor
and exercise all reasonable vigilance and meet all regulatory requirements in respect of quality control, sample control, distribution
quality and control and any adverse events in respect of the Licensed Products; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
shall be solely liable and responsible for all of its activities under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Without limitation,
Licensor shall not be liable for or obligated to make to Licensee, and Licensee shall not have any right or claim against Licensor
to, any fee, charge, compensation, reimbursement, or other payment of any kind in connection with any manufacturing, making, installing,
embedding, offering, selling, or other activity of Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Marketing
Approvals</U>. Licensee shall file for, prosecute the application for, and obtain a marketing approval for each of the Licensed
Products and all legal permits necessary for promoting, marketing, offering, or selling each Licensed Product (&ldquo;<U>Marketing
Approval</U>&rdquo;). Licensor agrees to provide reasonable information as necessary for obtaining the Marketing Approval for each
Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Fees and Royalties; Payment</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Royalties</U>. Licensee shall deliver to Licensor the reports, and pay to Licensor the License Fees and Royalties (individually
and collectively, the &ldquo;<U>Compensation</U>&rdquo;) as set forth in <B><I>Schedule 4</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment</U>.
Licensee shall pay all Compensation in readily available, indefeasible, unconditional funds, without any set-off or deduction,
in United States Dollar currency in such manner as directed by Licensor. Any amount of Compensation that is unpaid when it is due
shall accrue interest from the date it is due until Licensor&rsquo;s receipt of the payment of such amount at the rate of the lower
of (i) one-and-one-half percent (1.5%) per each full or partial calendar month or (ii) the highest enforceable rate of interest
under applicable law. All such interest shall be paid simultaneously with the payment of the unpaid amount on which such interest
accrued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax</U>.&nbsp;
Licensee shall bear or be liable or responsible for any sales, use, excise, value added, or other applicable taxes, tariffs or
duties, and none of which shall be included in or part of or deducted or withheld from any amount of any Compensation. In the event
that such taxes, tariffs or duties are assessed against Licensor, Licensee shall reimburse Licensor on demand for any such amounts
paid by Licensor. In the event that any such taxes, tariffs or duties are withheld from any payment to Licensor, Licensee shall
gross up the amount of such payment such that Licensor receives the full amount of such payment without any such withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Audit</U>.
Licensee will maintain financial records which are compliant with US generally accepted accounting principles (<B>GAAP</B>) regarding
all Compensation and data and information on which the calculation of Compensation in accordance with <B><I>Schedule 4</I></B>
is based for a period of not less than five (5) years after the end of the calendar year in which such Compensation accrued. Licensor
shall have the right, including through a certified public accountant, to audit and examine all such books and records upon providing
Licensee with reasonable notice. Licensee agrees to provide all reasonable assistance to Licensor and to provide access to all
personnel, employees and consultants and to premises at which books and records are retained for the purposes of the audit referred
to above, Licensor agrees to conduct any such audit during regular business hours. Any amount of Compensation due but not paid
shall be paid to Licensor immediately upon Licensee&rsquo;s having notice of such non-payment. In the event that an audit conducted
by an auditor discloses, with regard to any type of Compensation, an underpayment of any amount of such type of Compensation that
is five percent (5%) or more of the full amount of such type of Compensation owed and due during the period of time audited and
examined, Licensee shall pay all reasonable and necessary costs and expenses of such audit and examination. In the event that an
audit has been conducted during the Term pursuant to which Licensee has become liable to pay all reasonable and necessary costs
of the audit, all reasonable and necessary costs and expenses of all future audits conducted by Licensor during the Term will be
at the cost of Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Precedent</U>. The Parties agree that the amount or rate of any Royalty or other Compensation is based on the particular circumstances
of this transaction, shall not be deemed to be a precedent for any other transaction, whether between the Parties or of any third
party, or in connection with any rights or remedies asserted by Licensor, and shall not be deemed to be an indication of what constitutes
or may constitute, or be used in the determination of, a maximum reasonable royalty regarding any patent or other Proprietary Right
of Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Data</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Anonymized
End User Data</U>. Licensee shall: (i) promptly upon adding an individual as a New End User, establish an Anonymized Identifier
for such End User, (ii) promptly obtain as much of the Anonymized Demographic Information of such End User as may be lawfully and
reasonably collected for such End User and record same under such Anonymized Identifier, (iii) continuously cause all Glucose Sensor
Data for such End User to be automatically transmitted in real time under such Anonymized Identifier to the Glucose Sensor Data
Destination, with Licensee intercepting, storing, or capturing (but not modifying) any Glucose Sensor Data, and (iv) retain all
of the Anonymized Demographic Information of such End User and any Shared Glucose Sensor Data provided by Licensor to Licensee
under such Anonymized Identifier in a single cohesive database that is part of the Anonymized Database. Licensee shall ensure that
all Anonymized Demographic Information is at all times recorded, and all Glucose Sensor Data are at all times transmitted, one-hundred
percent completely and accurately under the correct Anonymized Identifier. Licensee shall within five (5) calendar days after each
calendar month, and at all other times upon request of Licensor, deliver, or provide access to, any Anonymized Demographic Information
collected during such calendar month, all in compliance with applicable law and as otherwise requested by Licensor, identified
by the Anonymized Identifier therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>End
User Identifiable Data</U>. Licensee shall obtain an express consent from any End User (in writing or such other form as required
by applicable law and clearly provable in the event of any dispute) for the collection, processing, storage, transmission, and
disclosure of all End User Identifiable Data and all Anonymized End User Data of such End User, including specifically, without
limitation, all transmission thereof to, and the use under this Agreement, by Licensor of all Anonymized End User Data and, in
the event of Section 8.3(b), all End User Identifiable Data, of such End User. Licensee shall ensure that the Anonymized Database
at no time, and no Anonymized End User Data at any time, links or reference to any End User Identifiable Data or the End User Identifiable
Database, or <I>vice versa</I>. In no event shall Licensee disclose, provide, or provide or permit access to any End User Identifiable
Data of any End User to any third party other than to such End User except to the extent required by applicable law or with the
written consent of the End User.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Databases</U>.
Licensee shall, on behalf of Licensor, establish and continuously maintain the Anonymized Database and the End User Identifiable
Database (each, a &ldquo;<U>Database</U>&rdquo;) at its sole responsibility, cost, and expense. Licensee shall establish each Database
such that it is at all times secured against any Interference and maintained in accordance with all applicable law, using state
of the art and continuously updated firewalls anti-Malware software and tools, highly secured access, and other measures as reasonable.
In the event of any Interference, Licensee shall promptly determine and notify Licensor of any impact of such Interference, and
perform any notification and other actions as required by applicable law. Licensee shall at all times keep the Anonymized Database
and the End User Identifiable Database completely digitally and physically separate without any links or cross-references between
both. Licensee shall ensure that no Anonymized End User Data or Anonymized Identifier is stored or introduced into the End User
Identifiable Database, and that no End User Identifiable Data is stored or introduced into the Anonymized Database.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Correlation
Database</U>. Licensee shall create and maintain a list, cross-references or other correlation of End Users or End User Identifiable
Data with any Anonymized End User Data allowing the correlation of each End User&rsquo;s End User Identifiable Data with the Anonymized
End User Data collected from such End User (the &ldquo;<U>Correlation Database</U>&rdquo;), provided that the Correlation Database
shall be maintained solely in a secure data base and server that is digitally and physically remote from the Databases and the
servers including either of the Databases. Licensee shall establish the Correlation Database such that it is at all times secured
against any Interference and maintained in accordance with all applicable law, using state of the art and continuously updated
firewalls anti-Malware software and tools, highly secured access, and other measures as reasonable. In the event of any Interference,
Licensee shall promptly determine and notify Licensor of any impact of such Interference, and perform any notification and other
actions as required by applicable law. In the event of any adverse event related to a Licensed Product or its use (including, without
limitation, a defect in a Licensed Product or a health or safety issue arising from its use) (&ldquo;<U>Adverse Event</U>&rdquo;),
Licensee shall promptly notify Licensor of such Adverse Event and resolve such Adverse Event in collaboration and coordination
with Licensor, including, without limitation, through use of the Correlation Database as necessary. Licensor shall have the right
to access the Correlation Database and the information thereon if it is necessary to address a serious Adverse Event or if required
or permitted by court order or governmental order in connection with an Adverse Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ownership</U>.
Notwithstanding, and without limiting, the obligations and liability of Licensee for all Anonymized Data and the Anonymized Database
as set forth in this Agreement, all Anonymized End User Data, and the Anonymized Database, shall be belong to, and be solely owned
by, Licensor from the time of their creation. Licensee hereby assigns, transfers, and conveys any and all rights, title, and interest
in and to any Anonymized End User Data effective at the time of the creation of such Anonymized Data and otherwise the earliest
legally recognized and enforceable point in time if different, and all rights, title, and interest in and to the Anonymized Data
Base and all Proprietary Rights in and to any Anonymized Data and all Proprietary Rights in and to the Anonymized Database. Licensee
shall own during the Term all rights, title, and interest in and to all End User Identifiable Data and the End User Database, subject
to the assignment, transfer, and conveyance and Licensor&rsquo;s rights thereto under Section 8.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Provision
of Glucose Sensor Data to Licensee</U>. Licensor shall provide, after receipt of Glucose Sensor Data under an Anonymized Identifier,
certain of such Glucose Sensor Data, as agreed with Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Provision
of all data relating to regulatory approval.</U> Licensee shall provide to Licensor a copy of all data, documents and material
provided to or received from any regulatory authority in the Territory (&ldquo;Regulatory Data&rdquo;). Licensee unconditionally
and irrevocable provides a royalty free license to the Licensor to use, modify and exploit the Regulatory Data or incorporate the
Regulatory Data into its own data, documents and material and in relation to which the Licensee will have no Proprietary Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Ownership and Reservation of Rights</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Rights</U>. As between Licensor on the one hand and Licensee and all Licensee Personnel on the other hand, Licensor solely owns
and shall solely retain all rights, title, and interest in and to any and all Glucose Sensor Technology, Anonymized End User Data,
Licensed Material, Licensed Trademarks, all Confidential Information of Licensor, any other Mark and any other Technology of Licensor
or any Affiliate, and all Derivations to or of or from or based on or including any Glucose Sensor Technology, Anonymized End User
Data, Licensed Material, Licensed Trademark, Licensor&rsquo;s Confidential Information, and/or such other Mark and such other Technology,
and all Proprietary Rights in and to any of the foregoing (including, without limitation, all Glucose Sensor Proprietary Rights),
including, without limitation, all rights and remedies for or against any misappropriation of any of the foregoing Technology or
any infringement or misappropriation of any such Proprietary Right, whether before, on, and/or after the Effective Date (collectively,
&ldquo;<U>Licensor Property</U>&rdquo;). All rights in and to any and all Licensor Property are expressly reserved. Licensor does
not, and shall not be deemed or held to make, have made, or have agreed to make, under or in connection with this Agreement or
any performance or activities under or related to this Agreement, any assignment, conveyance, transfer, grant, license (except
solely the License during the Term), or entitlement of any kind of or in or to any right, title, interest, lien, or encumbrance
of any kind in or to or under any Licensor Property. If and to the extent that Licensee or any Licensee Personnel owns, co-owns,
acquires, or is entitled to any right, title, interest, lien, or encumbrance of any kind in or to or covering any Licensor Property,
Licensee hereby irrevocably and unconditionally assigns, transfers, and conveys to Licensor, and Licensee shall cause that any
such Licensee Personnel irrevocably and unconditionally assign, transfer, and convey to Licensor, all of such right, title, interest,
lien, or encumbrance of any kind, all without having any right or claim to any royalty, fee, or other payment or value of any kind
against Licensor or any Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Protection</U>.
Licensor shall have the sole right to decide whether to, and if so, the right to solely control over, protecting any of the Glucose
Sensor IP, Licensed Trademarks, Licensed Material, and other Licensor Property, including, without limitation, any filing, prosecuting,
and abandoning any patent application, and obtaining, maintaining, and abandoning any patent, for any Glucose Sensor Technology
or other Technology, and any filing, prosecuting, and abandoning of any application, and obtaining, maintaining, and abandoning
any patent, for any Licensed Trademark, Licensed Material, or other Mark, work, or material, or to otherwise protect any Licensor
Property, in and/or outside the Territory. Licensee shall, upon and in accordance with Licensor&rsquo;s request, assist Licensee
with any such application, registration, patenting, or other protection or procedure. Licensee has no right to, and shall not:
(i) file or prosecute, any patent application, seek or obtain any patent, for or including any Glucose Sensor IP; (ii) file or
prosecute any application, or seek or obtain any registration, for any other Licensor Property; (iii) adopt or use as part of its
Mark, or apply for, seek, or obtain a registration in the Territory or anywhere else in the world of or for, (aa) any Licensed
Trademark or (bb) any other Mark of Licensor or (cc) any Affiliate or any Mark similar to a Licensed Trademark or such other Mark,
or (did) any translation or transliteration of any of the foregoing (all except solely if and to the extent such right is granted
expressly by Licensor in a written agreement with Licensee); (iv) claim any ownership or other right, title, or interest in or
to, or challenge the ownership or any right of Licensor or any Affiliate in or to, or challenge the validity or enforceability
of, any Licensor Property; and (v) cause, induce, or permit any third party to do, or assist any third party with doing, any of
the foregoing, whether for the benefit of Licensee, such third party, and/or any other third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringement
and Enforcement</U>. Licensee shall give written notice to Licensor of any infringement of any Licensed Right or misappropriation
of any Glucose Sensor Technology if, and promptly after, Licensee receives knowledge or suspicion thereof. Licensee shall cooperate
reasonably with Licensor in preventing and stopping any such infringement or misappropriation. Licensee shall not take any action
or undertake any enforcement of any Licensor Property against any third party, and shall not cause, induce, or permit any third
party to do, or assist any third party with doing, any of the foregoing, whether for the benefit of Licensee, such third party,
and/or any other third party. Any and all awards, revenues, proceeds, damages, and compensation arising from any enforcement of
any Licensor Property shall solely belong to Licensor, without any right or claim by Licensee to all or any part thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Further
Assurances</U>. Licensee shall take, and cause all Licensee Personnel to take, all such actions and execute all such documents
(including, without limitation, sign and execute any assignment, license, waiver, and other document, provide any testimony and
evidence, and give any other assistance) as and when requested by Licensor to give effect to and implement the sole ownership of
Licensor in and to any and all Licensor Property and/or assist Licensor with protecting and enforcing any of the Licensor Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Confidentiality and Non-Disclosure</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidential
Information</U>. The term &ldquo;<U>Confidential Information</U>&rdquo; means any data, documentation, material, and information
that is owned by a Party or is disclosed, provided, or made available by a Party (such Party, the &ldquo;<U>Disclosing Party</U>&rdquo;)
to, or directly or indirectly obtained from the Disclosing Party by, the other Party (the &ldquo;<U>Receiving Party</U>&rdquo;)
under or in connection with this Agreement, other than any data, documentation, material, and information that is Non-Confidential
Information. The term &ldquo;<U>Non-Confidential Information</U>&rdquo; means solely such information that, and to the extent it:
(i) was known publicly, or was known by the Receiving Party without obligation of confidentiality or non-disclosure, at the time
such Property was provided, disclosed, or made available or accessible by the Disclosing Party to, or obtained from the Disclosing
Party by, the Receiving Party; or (ii) becomes known publicly thereafter through no action or fault of the Receiving Party or any
of its employees, or (iii) is developed, created, discovered, or authored by the Receiving Party independently from this Agreement
and any performance hereunder and independently from, and without reference to, any Confidential Information or Technology of the
Disclosing Party, or acquired from a third party other than under a confidentiality and non-disclosure obligation; provided, however,
that any and all. Notwithstanding the foregoing, (i) all Anonymized End User Data, and all Glucose Sensor Technology (except for
any part of the Glucose Sensor Technology that is, and after it becomes, Non-Confidential Information), shall be conclusively deemed
to be Confidential Information solely of Licensor, and (ii) all End User Identifiable Data shall be deemed to be Confidential Information
of Licensee during the Term until delivery thereof to Licensor under Section 8.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted
Use</U>. The Receiving Party may use, copy, reproduce, and utilize any Confidential Information that is provided or made accessible
by the Disclosing Party to the Receiving Party as necessary for such Receiving Party to perform any obligations or other activities
of the Receiving Party, and to exercise any right that the Receiving Party is granted or has, in or under this Agreement (collectively,
&ldquo;<U>Permitted Use</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted
Disclosure</U>. The Receiving Party may disclose or make available any Confidential Information of the Disclosing Party to any
employee or contractor of such Receiving Party (and if the Receiving Party is Licensee, only any Licensee Personnel with, and to
the extent of, a need to know such Confidential Information) solely as necessary for any Permitted Use and if and while such employee
or contractor is subject to confidentiality and non-disclosure obligations (whether pursuant to a written agreement or written
policy) that are no less stringent than those in this Section 6 (such employee or contractor, a &ldquo;<U>Permitted Disclosee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prohibitions</U>.
Except solely to the extent expressly permitted under Section 6.2 and Section 6.3, the Receiving Party hereby agrees that it will
not, directly or indirectly, use, copy, reproduce, utilize, disclose, provide or reveal to, or permit or give access to, any third
party, or publish, disseminate, or distribute, any Confidential Information of the Disclosing Party, or any part thereof, in whatever
form or format.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Obligations</U>.
The Receiving Party shall (a) take the same precautions to protect the confidentiality of the Confidential Information as it takes
for its own Confidential Information, but in no event less than reasonable precautions and (b) cause any and all Persons to which
access to the Confidential Information is given by such Receiving Party to enter into non-disclosure and confidentially agreements
with the same terms set forth herein with regard to such Confidential Information. In the event that applicable law requires disclosure
of any Confidential Information, the disclosure of such Confidential Information shall be subject to the following provisions of
this Section 6.5. If&nbsp;the Receiving Party or any employee, agent or contractor is&nbsp;requested under, or required by, law
to disclose any Confidential Information of the Disclosing Party, the Receiving Party shall&nbsp;provide&nbsp;the Disclosing Party&nbsp;with
prompt notice of such request or requirement and reasonably assist&nbsp;the Disclosing Party with seeking an appropriate protective
order or other remedy as decided by the Disclosing Party. If such protective order or other remedy is not obtained, or to the extent
that the Disclosing Party waives compliance with the terms of this&nbsp;Agreement,&nbsp;the Receiving Party or any Permitted Disclosee
will disclose only such of the Confidential Information it is legally required to disclose and will use&nbsp;its best efforts to
ensure that all Confidential Information so disclosed will be accorded confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>This
Agreement</U>. This Agreement, and the terms hereof and thereof, shall be deemed to be Confidential Information of Licensor only,
provided that Licensee may disclose and use this Agreement: (i) in connection with receiving legal or financial advice from a
contractor of Licensee that is subject to a confidentiality obligation regarding this Agreement; (ii) any assertion or enforcement
of any right or remedy under or related to this Agreement; or (iii) if and to the extent required by law upon compliance with
Section 6.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>On
Request</U>. On the request of the Disclosing Party, the Receiving Party must: (i) cease all use of the Confidential Information
of the other party; (ii) destroy or delete all records and copies of the Confidential Information in its possession; (iii)return
to the other party all other Confidential Information of the other party in its possession (including all copies of the same);
and (iv) provide to the other party a written certificate confirming compliance with the requirements of this Section&nbsp;6.7,
provided that each party may retain one copy of the Confidential Information of the other party to the extent required by law or
for use solely in the event of a dispute arising out of this agreement. In complying with this clause, the Receiving Party shall
not be required to destroy any copies of the Confidential Information which are maintained in electronic form in back-up tapes,
servers, or other sources as a result of the Receiving Party&rsquo;s normal back-up procedures for electronic data, provided that
provided that such copies are: (v) collected under the Receiving Party&rsquo;s usual back-up processes; (vi) are not readily accessible
by the Receiving Party; and (vii) no attempt is made to recover such Confidential Information from the back-up tapes, servers or
other sources (except for legal or compliance purposes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B>Warranties; Liability</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties</U>. Each Party represents and warrants that it has the authority to enter into this Agreement, it is not a party
to any agreement of any kind that will or may prevent Licensee from entering into or performing its obligations under this Agreement,
and the execution, delivery and performance of this Agreement by such Party has been duly and properly authorized by all necessary
corporate actions, and this Agreement constitutes the valid and binding obligation of such Party. In addition, Licensee warrants
and represents that it will engage in any activities under this Agreement in a professional, good and workmanlike manner in compliance
with all applicable law and all good business and medical professional ethics in the Territory, that it will not, directly or indirectly,
claim ownership or co-ownership in or to, or challenge or contest Licensor&rsquo;s ownership or rights in or to, or the validity
or enforceability of, any Licensor Property, or assist or support any third party making such claim, challenge, or contest, that
it will perform all activities under this Agreement without disclosing, deliberately or inadvertently, any confidential information
of a third party or misappropriating or violating any third party&rsquo;s property or right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DISCLAIMER</U>.
WITH THE SOLE EXCEPTION OF A PARTY&rsquo;S WARRANTIES EXPRESSLY SET FORTH IN SECTION 7.1, SUCH PARTY DOES NOT MAKE ANY REPRESENTATION
OR WARRANTY OR CONDITION, AND SUCH PARTY HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES AND CONDITIONS OF ANY KIND, EXPRESS,
IMPLIED, AND STATUTORY. LICENSOR EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES AND CONDITIONS RELATED TO ANY LICENSED
PRODUCT, LICENSED TRADEMARK, LICENSED MATERIAL, LICENSED RIGHTS, GLUCOSE SENSOR TECHNOLOGY, AND LICENSOR PROPERTY, INCLUDING, WITHOUT
LIMITATION, ALL WARRANTIES AND REPRESENTATIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, TITLE, OR
WORKMANSHIP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>EXCLUSION
AND LIMITATION OF LIABILITY</U>. IN NO EVENT SHALL A PARTY BE LIABLE TO THE OTHER PARTY OR ANYBODY CLAIMING THROUGH THE OTHER PARTY
FOR ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, SPECIAL, OR LIQUIDATED DAMAGES OR LOSSES, INCLUDING, WITHOUT LIMITATION,
PROPERTY DAMAGE, DEATH, PHYSICAL OR PSYCHOLOGICAL HARM OR INJURY, LOST BUSINESS OR LOST PROFITS, OF ANY KIND UNDER OR IN CONNECTION
WITH THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, ANY SUCH DAMAGES THAT ARISE FROM ANY USE OF ANY LICENSED TECHNOLOGY. IF A PARTY
IS LIABLE FOR ANY DIRECT DAMAGES OR LOSSES UNDER THIS AGREEMENT, OR FOR ANY DAMAGES OR LOSSES THAT CANNOT BE VALIDLY EXCLUDED UNDER
THE FOREGOING PROVISION OF THIS SECTION 7.3, THE TOTAL AND AGGREGATE DAMAGES AND LOSSES FOR WHICH SUCH PARTY IS LIABLE UNDER THIS
AGREEMENT SHALL BE LIMITED IN THE AGGREGATE TO THE SUM OF THE ROYALTY PAID BY LICENSEE TO LICENSOR UNDER THIS AGREEMENT WITHIN
TWELVE (12) MONTHS PRIOR TO ASSERTING SUCH CLAIM FOR SUCH DAMAGES AND LOSSES, BUT IN NO EVENT MORE THAN THE AGGREGATE AND TOTAL
OF ALL ROYALTY AMOUNTS PAID BY DISTRIBUTOR TO LICENSOR UNDER THIS AGREEMENT. WITHOUT LIMITING THE FOREGOING, IN NO EVENT SHALL
LICENSOR HAVE ANY INDEMNITY, CONTRIBUTION, OR OTHER OBLIGATION OR LIABILITY WITH REGARD TO ANY OBLIGATION OR LIABILITY OF LICENSEE
OR ANY LICENSEE PERSONNEL, REGARDLESS OF THE LEGAL BASIS OF ANY SUCH OBLIGATION OR LIABILITY AND WHETHER OR NOT LICENSOR HAS BEEN
NOTIFIED OF THE RISK THEREOF. NOTWITHSTANDING THE FOREGOING PROVISIONS OF THIS SECTION 7.3, IN NO EVENT SHALL ANY LIABILITY OR
OBLIGATION OF LICENSEE (i) UNDER SECTIONS 4, 5, 6, 7.4, AND/OR 8.3, OR FOR ANY PERFORMANCE, OR FOR ANY BREACH OF OR DEFAULT UNDER
OR NON-PERFORMANCE OF, ANY OBLIGATION OR LIABILITY UNDER SECTIONS 4, 5, 6, 7.4, AND/OR 8.3, OR (ii) FOR INFRINGEMENT OF ANY PROPRIETARY
RIGHT, OR FOR MISAPPROPRIATION OF ANY TECHNOLOGY, OF LICENSOR OR A THIRD PARTY AFFILIATE OF LICENSOR, OR (iii) TO THE EXTENT LICENSEE&rsquo;S
LIABILITY MAY NOT BE EXCLUDED UNDER APPLICABLE LAW, OR (iv) FOR ANY COMPENSATION OR OTHER PAYMENT OWED TO LICENSOR UNDER THIS AGREEMENT,
BE EXCLUDED OR LIMITED UNDER THIS SECTION 7.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity</U>.
Licensee hereby agrees to defend, indemnify, and hold harmless Licensor, all Affiliates, and all officers, directors, employees,
and agents of Licensor or any Affiliate (collectively, the &ldquo;<U>Indemnitees</U>&rdquo;) from and against any claim, action,
suit, litigation, demand, allegation, arbitration, proceeding, judgment, order, damages, loss, liability, injury, costs, expenses
(including, without limitation, reasonable attorneys&rsquo; fees and witness and other defense costs), settlement, and other payment
obligation of any Indemnitee arising from or in connection with or related to: (i) any promotion, marketing, import, representation,
offer, sale, resale, distribution, or supply of any Licensed Product or any Commercial Unit or violation of this Agreement, (ii)
any activities of performance of, or any claims by, or any non-conformance or conduct of, any Licensee Personnel, (iii) any collection,
storage, processing, transmission, disclosure including unauthorized disclosure, or use of any Anonymized End User Data or any
End User Identifiable Data, including any data or security breach or Interference, or any Database, or any failure to comply with
any provision of Section 4 or any applicable law related to any data or information including, without limitation, any failure
to obtain all required consents and approvals for collection, storage, processing, transmission, disclosure, and use of any Anonymized
End User Data or any End User Identifiable Data as provided or contemplated under this Agreement, (iv) any direct or indirect infringement
or violation of any Proprietary Right of any third party resulting from, in connection with, or related to any activities of Licensee
or any Licensee Personnel, and/or (v) any negligence or willful misconduct or violation of any applicable law of Licensee or any
Licensee Personnel (regardless of any contributory or comparative negligence of any Indemnitee, but not for any damages to the
extent resulting from such contributory or comparative negligence of any Indemnitee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Savings
Clause</U>. Only in the event, and solely to the extent, that any part or provision of the foregoing provisions in this Section
7 is invalid or unenforceable in any particular state or jurisdiction, such part or provision shall be interpreted both to be valid
and enforceable and to conform to the greatest extent possible to the intent and purpose of such part or provision as set forth
in this Section 7 and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>Term; Termination</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement shall
commence on the Effective Date and continue, unless and until terminated earlier in accordance with Section 8.2, until the end
of the day immediately preceding the Expiry Date of the Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party may terminate this Agreement by providing the other Party with written notice of termination in the event: (i) of a material
breach of this Agreement by such other Party, which material breach shall be identified in such written notice, and which termination
shall become effective at the end of thirty (30) days of such written notice of termination unless such other Party fully cured
such material breach within such thirty (30) day period; or (ii) that such other Party discontinues its business operations, takes
steps to dissolve or cease to exist, admits its inability to pay its debts as they become due, files or is or becomes subject to
a petition in bankruptcy (or similar reorganization proceeding) or makes a general assignment for the benefit of its creditors,
or becomes subject to the appointment of a receiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
may terminate this Agreement: (i) in the event of a Change of Control in respect of the Licensee, by written notice effective as
of the date of such Change of Control, whether retroactive, contemporary, or prospective; or (ii) as set forth in Section 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
may terminate this Agreement in the event of a Change of Control in respect of the Licensor, by written notice effective as of
the date of such Change of Control, whether retroactive, contemporary, or prospective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect
of the End of the Term</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the expiration or termination or cancellation of this Agreement in any way, Licensee shall, and Licensee shall cause Licensee Personnel
to, (i) immediately cease any promotion, marketing, import, representation, offer, sale, resale, distribution, or supply of any
Licensed Product, use of any Licensed Trademarks and any Licensed Material, and any other licensed activities, (ii) pay all amounts
of Compensation owed and unpaid, (iii) return to Licensor (or, if and to the extent expressly requested by Licensor to Licensee,
irretrievably destroy or dispose of as directed by Licensor) all Licensed Products not sold (provided that Licensee shall deliver
any Licensed Product at that time already sold by Licensee), all Confidential Information of Licensor, all copies of any Licensed
Material, and any other Licensor Property in the direct or indirect possession or control of Licensee or any Licensee Personnel,
and (iv)&nbsp;irretrievably delete any copy or manifestation of any Confidential Information of Licensor and any Licensed Material
that may remain in the possession or control of Licensee or any Licensee Personnel after such return, destruction, or disposal.
Upon Licensor&rsquo;s request, Licensee shall certify to Licensor Licensee&rsquo;s full compliance with the terms of this Section
8.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the expiration or termination or cancellation of this Agreement in any way, Licensee shall promptly: (i) transfer to Licensor each
Database and the Correlation Database, together with all passwords and access information thereto, in an unencrypted, readable,
and formatable form with all data and information therein or related thereto (including, without limitation, all End User Identifiable
Data), keeping the Anonymized Database and its data strictly separate from the End User Identifiable Databased and its data, and
keeping each Database strictly separate from the Correlation Database, and (ii) following such successful transfer and receipt
by Licensor, following confirmation thereof by Licensor, irretrievably and finally delete all Anonymized End User Data, all Anonymized
Identifiers, all End User Identifiable Data, and all other data and information related to any End User or Anonymized Identifier,
in the possession or under the control of Licensee or any Licensee Personnel, and (iii) certify to Licensor Licensee&rsquo;s full
compliance with the terms of this Section 8.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the expiration or termination or cancellation of this Agreement in any way, Licensee shall promptly transfer all Marketing Approvals
to Licensor or a third party or third parties identified by Licensor to Licensee, and take any action necessary to legally effect
such transfer, at Licensee&rsquo;s risk, responsibility, cost, and expense. Licensee may not transfer, agree to transfer, promise,
or be committed in any way to transfer any Marketing Approval to any third party without Licensor&rsquo;s express prior written
consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination or cancellation of this Agreement by either party due to a Change in Control in respect of the Licensor, the Licensor
must pay the Licensee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) if the termination
or cancellation of this Agreement occurs no later than 5 calendar years prior to the Expiry Date of the Patent, the greater of
(A) the amount of the Projected Net Sales for the five (5) year period following the Termination Date or (B) five (5) times the
actual Net Sales achieved in the year immediately preceeding the Termination Date; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) if the termination
or cancellation of this Agreement occurs 5 calendar years prior to the Expiry Date of the Patent or later, (A) the greater of the
Projected Net Sales for the five (5) year period following the Termination Date multiplied by the number of years from the Termination
Date to the Patent Expiry Date divided by five (5) or (B) the actual Net Sales achieved in the year immediately preceeding the
termination or cancellation of the Agreement multiplied by the number of years from the Termination Date to the Patent Expiry Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
All provisions in Section 3 (with regard to any Compensation owed and unpaid), Section 4.5, Sections 4.1-4.4 and 4.6 (with regard
to any performance or non-performance prior to compliance with Section 8.3(b)), Section 5, Section 6 (other than Sections 6.2 and
6.3), Section 7, Section 8.3, and Section 9, and this Section 8.4, and Section 1 as relating to such surviving provisions, shall
survive the termination, cancellation or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Miscellaneous</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies;
Injunctive Relief</U>. Licensee recognizes that, in the event of any breach or anticipated breach of any provisions in Sections
2, 4, 5, 6, and/or 8.3 by Licensee, Licensor&rsquo;s right to damages may not be sufficient to avoid, prevent, or compensate Licensor
for any harm arising from such breach. Therefore, Licensee expressly agrees that Licensor is entitled to seek injunctive relief
or specific performance, without need or obligation to post any bond, to enforce any right, license, obligation, agreement, covenant,
term and condition in or under Sections 2, 4, 5, 6, and/or 8.3 against Licensee, in addition to any other rights and remedies available
to Licensor, including, without limitation, any damages, all as Licensor elects in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Relationship
of the Parties</U>. The Parties agree that they are independent contractors and will always represent themselves to any third parties
only as an independent contractor. The Parties are not, and nothing in this Agreement shall be interpreted that the Parties are,
partners, joint venturers, co-owners or otherwise participants in a joint or common undertaking. The employees or agents of one
Party are not, and shall not be construed to be, employees or agents of the other Party, and such other Party shall not be liable
for, have any obligations to, and may not be bound by such employees and agents of the first Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Law</U>. Each Party shall perform all activities and obligations under or in connection with this Agreement in accordance
with all applicable law. Each Party shall comply with all applicable trade, import and export laws, rules and regulations with
respect to any Licensed Product and Licensed Material and their use or deliverable. If requested by&nbsp;a Party, the other Party
agrees to sign written assurances and other export-related documents as may be required to comply with U.S. export regulations.
In addition, each Party specifically agrees to comply with all applicable anti-corruption law (including, without limitation, the
U.S. Foreign Corrupt Practices Act, as amended from time to time, the Bribery Act 2010 of the United Kingdom, and any other applicable
foreign or domestic anti-bribery and anti-corruption laws and regulations, and any laws intended to implement the OECD Convention
on Combating Bribery of Foreign Public Officials in International Business Transactions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>.
Licensee may not transfer this Agreement, or assign any right or delegate any responsibility or obligation of Licensee under this
Agreement, in whole or in part, without the prior written consent of Licensor. Any attempted transfer, assignment, or delegation
by Licensee in contravention of the foregoing shall be null and void. Licensor may transfer this Agreement, and assign any right
and delegate any responsibility or obligation of Licensor, at any time without consent or notice to Licensee. This Agreement shall
be binding upon and inure to the benefit of the permitted successors and assigns of the Parties. Nothing in this Agreement shall
prevent Licensor from, or limit Licensor in, assigning or transferring or granting any right (subject to Section 2.2) in or to
any Licensor Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement; Amendment; Waiver</U>. This Agreement constitutes the entire understanding and agreement between the Parties hereto
related to the subject matter hereof. Neither this Agreement nor any term or provision hereof may be waived, changed, discharged
or terminated except by an instrument in writing signed by the person against whom the enforcement of any waiver, change, discharge
or termination is sought. No modification, amendment, supplement to or waiver of any provision of this Agreement will be binding
upon the Parties unless made in a writing identifying the relevant provisions and signed by each Party through its authorized representative.
A failure of either Party to exercise any right provided for herein shall not be deemed to be a waiver of any right hereunder.
An transfer, assignment, or delegation permitted under Section 9.4 shall not constitute any modification, amendment, variation,
or extension under the immediately preceding sentence if this Agreement does not change as a result of such assignment (other than
the identity and contact information of the assignor to the assignee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. THE VALIDITY, ENFORCEABILITY, INTERPRETATION, AND PERFORMANCE OF THIS AGREEMENT SHALL BE GOVERNED BY UNITED STATES FEDERAL
LAWS, TO THE EXTENT APPLICABLE, AND THE LAWS OF THE STATE OF NEW YORK, UNITED STATES OF AMERICA, WITHOUT REGARD OF ANY CONFLICT
OF LAWS PROVISION THAT WOULD RESULT IN THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, AND THE TERMS OF THIS AGREEMENT SHALL
BE CONSTRUED AND INTERPRETED IN ACCORDANCE WITH SUCH LAWS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disputes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of any controversy or claim arising out of, relating to or in connection with the License, any provision of this Agreement,
or the rights or obligations of the Parties hereunder, the Parties shall try to settle their differences amicably between themselves.
Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and within
ten (10) days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations.
If such representatives are unable to resolve promptly such disputed matter, it shall be referred to the CEO (or equivalent) of
Licensor and to the CEO (or equivalent) of Licensee, for discussion and resolution. If such personnel are unable to resolve such
dispute within thirty (30) days of initiating such negotiations, unless otherwise agreed by the Parties, such dispute shall proceed
to mediation as provided under Section 9.7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a dispute arises out of or relates to this Agreement, or the breach thereof, and if the dispute cannot be settled through negotiation,
then the Parties agree to try in good faith to settle the dispute by non-binding mediation with a neutral mediator; <I>provided</I>,
<I>however</I>, that, in the case of a legal dispute, if such mediation has not occurred within sixty (60) days after a written
request for mediation by either Party, then either Party may proceed to resolution pursuant to Section 9.7(c). Each Party has the
right to pursue provisional relief from any court, such as attachment, preliminary injunction, replevin, etc. to avoid irreparable
harm, maintain the status quo, or preserve the subject matter of the dispute, even though mediation has not been commenced or completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
dispute of a legal nature arising out of or connected with the interpretation or enforcement of the legal duties, rights and obligations
under this Agreement, including without limitation, its validity, application or termination, that cannot be settled by negotiation
pursuant to Section 9.7(a) or mediation pursuant to Section 9.7(b) shall be referred to and finally resolved by arbitration by
the ICC International Court of Arbitration of the International Chamber of Commerce. The arbitration shall consist of a single
arbitrator mutually agreed by the Parties, or, in the absence of such agreement, the arbitration shall consist of a panel of three
(3) arbitrators who shall arbitrate the dispute, one to be selected by Licensor, one to be selected by Licensee, and the third
to be selected by mutual agreement of the first two (2) arbitrators so selected. Any arbitration shall take place in Sydney, Australia,
and any arbitration proceeding shall be conducted according to the laws selected under Section 9.6. The Parties shall conduct the
arbitration as expeditiously as possible. Within fifteen (15) days after the conclusion of the arbitration hearing, the arbitrators
shall issue a written award and statement of decision describing the essential findings and conclusions on which the award is based,
including the calculation of any damages awarded. The arbitrators shall not be authorized to reform, modify or materially amend
this Agreement or any provision hereof. The arbitrators shall be authorized to grant any temporary, preliminary or permanent equitable
remedy or relief that they determine to be just or equitable and within the scope of this Agreement, including an injunction or
order for specific performance. The award of the arbitrator shall be final and binding and may be enforced by any court having
jurisdiction. The Parties waive any right to appeal the arbitration award, to the extent a right to appeal may be lawfully waived.
Each Party retains the right to seek judicial assistance (i) to compel arbitration; (ii) to obtain interim measures of protection
pending or during arbitration; and (iii) to enforce any decision of the arbitrator, including the final award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the provisions of Sections 9.7(a) &ndash; 9.7(c), (i) Licensor may seek, obtain, and enforce any injunctive relief (including,
without imitation, for preliminary, emergency, temporary, permanent, or final injunction, specific performance, or other similar
relief under any applicable law) pursuant to Section 9.1, for any threatened or commenced infringement of any Proprietary Right
or misappropriation of any Technology, and/or for asserting any ownership in or to any Licensor Property; and (ii) Licensor may,
but shall not obligated to, proceed under Sections 9.7(a) &ndash; 9.7(c) with regard to any cross-claim or third-party claim or
other assertion of a claim by Licensor in a third party&rsquo;s legal proceeding against Licensor, Licensee, or both Parties.&nbsp;
With respect to any of the foregoing in this Section 9.7(d), and with regard to the enforcement of any arbitration award rendered
pursuant to Sections 9.7(a) &ndash; 9.7(c), each Party consents and submits to the non-exclusive jurisdiction of, waiving any objections
to personal jurisdiction in, competent state and federal courts in the State of New York, United States of America for any litigation
or proceeding, and to the venue of such litigation or proceeding in New York City (Borough of Manhattan), New York, United States
of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
proceedings under this Section 9.7 shall be conducted in the English language and all documents exchanged between the Parties and/or
submitted in the context of a proceeding under this Section 9.7 shall be in English or shall be accompanied with a certified English
translation of the original document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any provision of this Agreement is held to be invalid or unenforceable, the meaning of said provision will be construed, to
the extent feasible, so as to render the provision enforceable, and if no feasible interpretation shall save such provision, it
will be severed from the remainder of this Agreement, as appropriate. The remainder of this Agreement shall remain in full force
and effect unless the severed provision is essential and material to the rights or benefits received by either Party. In such event,
the Parties will use their best efforts to negotiate, in good faith, a substitute, valid and enforceable provision or agreement,
which most nearly effects the Parties&rsquo; intent in entering into this Agreement, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, demands, or other communications to be given or delivered to a Party under or by reason of a provision of this Agreement
shall be in writing and shall be deemed to have been given to such Party when: (i) delivered personally to such Party at, or sent
to such Party by reputable express courier service (charges prepaid) to, such Party&rsquo;s address set forth in the caption of
this Agreement or another address notified hereunder in writing at least thirty (30) days before such notice, demand, or other
communication by such Party to the other Party, addressed to the attention of (a) the CEO (or equivalent) if notice is to Licensee,
or (b) addressed to the attention of CEO (or equivalent) if notice is to Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be executed in one or more counterparts (any one of which may be by facsimile or PDF), all of which shall constitute
one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent.</U>
Any waiver or consent that may be provided by Licensor under this Agreement may be given or not given in Licensor&rsquo;s sole
discretion having regard to, amongst other things, without limitation, its own business interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><B>10.</B></TD><TD STYLE="text-align: justify"><B>Additional rights in relation to platform technology</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">In the event that the Licensor develops
intellectual property using a printable organic thin film transistor for the detection or measurement of indicators other than
glucose (<B>New Indicator IP</B>) and is seeking to license the use of the New Indicator IP in the Territory, the Licensor must
notify the Licensee in writing of the terms of the proposed New Indicator IP license. The Licensee shall have thirty (30) days
from the date of provision by the Licensor of a license agreement in relation to the New Indicator IP to exercise its right to
enter into the license agreement. In the event that the Licensee does not exercise its rights under this Section 10 to enter into
a license agreement in the Territory in respect of any New Indicator IP, Licensor may license the New Indicator IP to any party
in its discretion, without further reference to the Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
each Party has executed this Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LICENSOR:</B></FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LICENSEE:</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Life Science Biosensor Diagnostics Pty Ltd.</B></FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Glucose Biosensor Sensor Systems
(Greater China ) Holdings Inc </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/&nbsp;&nbsp;Spiro Sakiris</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Con Tsigounis</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jimena Hurtado</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Con Tsigounis</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Jimena Hurtado</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-align: justify; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">25 Aug 2017</FONT></TD>
    <TD STYLE="width: 15%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-align: justify; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">25 Aug_2017</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Schedule 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Licensed Products</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Glucose sensor strip</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Smartphone app or dedicated reading device</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule 1 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Schedule 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Licensed Rights</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As advised by the Licensor to the Licensee
from time to time in writing but includes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">1.</TD><TD STYLE="text-align: justify">The invention(s) described in PCT/AU2013/000207 and associated patent applications: Australian provisional patent application
2012900885; Chinese patent application 201380022888.2; US patent application 14/382927;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">2.</TD><TD STYLE="text-align: justify">The invention(s) described in the publication &lsquo;printable organic thin film transistors for glucose detection incorporating
inkjetprinting of the enzyme recognition element, and the invention(s) described in PCT/AU2016/050555 and associated patent applications:
PCT/AU2016/050555 and the National Phase applications it will ultimately produce, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">3.</TD><TD STYLE="text-align: justify">all project intellectual property within the field,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and any other rights in relation to such inventions
with respect to existing and future patents (including any divisions, continuations, continuations in part, renewals, reissues,
extensions, supplementary protection certificates, utility models and foreign equivalents) and rights with respect to existing
and future patent applications and patentable inventions in respect of glucose detection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule 2 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Schedule 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Licensed Trademarks</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common law trade mark &lsquo;Glucose Biosensor&rsquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such registered marks as advised in writing
by the Licensor to the Licensee from time to time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule 3 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Schedule 4</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>License Fees; Royalties</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><B>Licence fee payable as follows</B>:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">a.</TD><TD STYLE="text-align: justify">USD 1,000,000 within 14 days of attaining all required regulatory approvals in Mainland China</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">2.</TD><TD STYLE="text-align: justify"><B>Royalty Fee payable as follows</B>:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All royalties will be payable
quarterly from the Commencement Date and subject to provision of required reports and financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Fee payments include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.7pt; text-align: justify"></TD><TD STYLE="width: 18pt; text-align: justify">a.</TD><TD STYLE="text-align: justify">Royalty - 14% based on Net Sales of Commercial Units;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.7pt; text-align: justify"></TD><TD STYLE="width: 18pt; text-align: justify">b.</TD><TD STYLE="text-align: justify">Royalty &ndash; 14% based on Net Sales of an optional dedicated reading device;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.7pt; text-align: justify"></TD><TD STYLE="width: 18pt; text-align: justify">c.</TD><TD STYLE="text-align: justify">App license fee as advised by the Licensor to the Licensee in writing from time to time; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.7pt; text-align: justify"></TD><TD STYLE="width: 18pt; text-align: justify">d.</TD><TD STYLE="text-align: justify">App fee for services for patient education services as advised by the Licensor to the Licensee in writing from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule 4 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Schedule 5</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Milestones and Minimum Distribution
Requirements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Licensee must meet the
following milestones and Distribution Requirements, unless otherwise agreed in writing with the Licensor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">1.</TD><TD STYLE="text-align: justify">The Licensee must execute a Quality of Life clinical study prior to regulatory approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">2.</TD><TD STYLE="text-align: justify">The Licensee must obtain all required regulatory approvals in the Territory to allow the supply
and distribution of the Licensed Product within 24 month from the date of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">3.</TD><TD STYLE="text-align: justify">Within twenty four (24) month following receipt of all required regulatory approvals in the Territory
identified in paragraph 1 above, the Licensee must have placed orders with the Licensor (or Authorised Supplier) for a minimum
of 800 million Commercial Units.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">4.</TD><TD STYLE="text-align: justify">After twenty four (24) months following receipt of all required regulatory approvals in the Territory
identified in paragraph 1 above, the Licensee must have placed each year orders with the Licensor (or Authorized Supplier) for
the greater of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">a minimum of 800 million Commercial Units; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">an amount of Commercial Units that is equivalent to the average of all distributors&rsquo; of Licensed
Products sales in the previous 12 months multiplied by the Expected Market Growth (as defined below) plus 7%.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">5.</TD><TD STYLE="text-align: justify">Each year no later than 30 days prior to the anniversary of the Effective Date the parties agree
to meet in good faith to determine the expected market growth in the Territory for the following 12 month period of the Term in
respect of the traditional addressable blood glucose monitoring market in the Territory plus the then existing market for the Licensed
Product (<B>Expected Market Growth</B>). The Expected Market Growth will be based on &lsquo;off the shelf&rsquo; market research
as agreed between the parties. If the parties cannot agree on the Expected Market Growth for any period within 7 days prior to
the relevant anniversary of the Effective Date, either party may commission an independent third party to determine the Expected
Market Growth for the period. The parties agree to share the cost of any such third party report commissioned. The Expected Market
Growth either determined by agreement between the parties or reported by a commissioned third party will be applied annually at
the anniversary of the Effective Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">6.</TD><TD STYLE="text-align: justify">The total market share of the Licensee in the Territory must increase annually by 7% above the
Expected Market Growth as determined in paragraph 4 above, or as otherwise agreed between the parties in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">7.</TD><TD STYLE="text-align: justify">The Licensee must at least once each quarter order from the Licensor (or an Authorized Supplier)
Commercial Units in a minimum quantity equal to the estimated Commercial Units to be sold by the Licensee in the following quarter
based on the Expected Market Growth plus 7%.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">8.</TD><TD STYLE="text-align: justify">The Licensee must engage in a marketing campaign and ensure Share of Voice in the Territory must
be at 60% no later than 12 months following receipt of all required regulatory approvals in the Territory identified in paragraph
1 above. The Share of Voice will be determined by the Licensor acting reasonably and relying on a reputable third party report
as to the applicable Share of Voice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">9.</TD><TD STYLE="text-align: justify">The Licensee must convert all of their existing glucose monitoring sales to the biosensor strip
(Commercial Units) within 60 months from the Effective Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule 5 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Schedule 6</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Distribution Requirements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensee shall promote, market, import, offer, sell, distribute,
and supply the Licensed Products, and all Commercial Units, in accordance with all applicable law and the following requirements,
or as otherwise advised in writing by the Licensor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">1.</TD><TD STYLE="text-align: justify">All Licensed Products and Commercial Units will be supplied to each End User without the supply or inclusion of any other product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">2.</TD><TD STYLE="text-align: justify">All Licensed Products must be promoted and offered for use only in accordance with its regulatory approved use in the Territory
and in accordance with all relevant medical governance regulation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">3.</TD><TD STYLE="text-align: justify">The Licensed Products and Commercial Units must be supplied as provided to the Licensee by the Authorized Supplier or as otherwise
directed by the Licensor. The Licensee must not interfere with, re-arrange, add or subtract from the supplied packaging of the
Licensed Products and Commercial Units;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">4.</TD><TD STYLE="text-align: justify">The Licensed Products and Commercial Units must be supplied to distributors or End Users in packaging pre approved by the Licensee
which may not include any branding of the Licensee or any other third party;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">5.</TD><TD STYLE="text-align: justify">The Licensed Products and Commercial Units must be supplied to each End User in quantities as directed by the Licensor in writing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">6.</TD><TD STYLE="text-align: justify">Sufficient records must be collated and retained to allow all Licensed Products and Commercial Units to be recalled if required
by any government agency in the Territory or the Licensor; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">7.</TD><TD STYLE="text-align: justify">The Licensor must retain samples of each batch of the Licensed Products for a period of 7 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule 6 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-6 MAT CTRCT
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 6.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>VARIATION AGREEMENT TO TECHNOLOGY LICENCE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Variation Agreement
to the Technology License Agreement (this &ldquo;<U>Variation Agreement</U>&rdquo;) dated as 8 December 2017 (the &ldquo;<U>Effective
Date</U>&rdquo;), is by and between Life Science Biosensor Diagnostics Pty Ltd., an Australian proprietary limited company having
an address at Level 7, 222 Clarence Street, Sydney NSW 2000 Australia (&ldquo;<U>Licensor</U>&rdquo;) and <FONT STYLE="background-color: white">Glucose
Biosensor Systems (Greater China) Holdings Inc<B>.</B>, a company having an registered office at Corporation Trust Centre, 1209
Orange St, City of Wilmington, County of New</FONT> Castle, Delaware 19801 (&ldquo;<U>Licensee</U>&rdquo;) (each, a &ldquo;<U>Party</U>&rdquo;
and collectively the &ldquo;<U>Parties</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">WHEREAS, the parties
entered into the license agreement in respect of the Glucose Biosensor Technology dated 25 August 2017 (the &ldquo;Licence Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">WHEREAS, the parties
wish to amend the terms of the Licence Agreement on the terms and conditions set out in, and on and from the date of this Variation
Agreement. The parties acknowledge that the terms and conditions of the Licence Agreement, unless amended by this Variation Agreement,
remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW, THEREFORE, for good and valuable consideration,
and intending to be legally bound, Licensee and Licensor agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Definitions; Interpretation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">1.1</TD><TD STYLE="text-align: justify"><U>Definitions</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Any capitalised term set out
in this Variation Agreement has the meaning ascribed to that term in the Licence Agreement unless the context provides otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interpretation</U>.
In this Variation Agreement, clause 1.2 of the Licence Agreement is adopted and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Variation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">2.1</TD><TD STYLE="text-align: justify"><U>Clause 2.2 Exclusivity</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A new clause 2.2e.
is inserted to the Licence Agreement which provides:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt; text-align: justify"></TD><TD STYLE="width: 42.5pt; text-align: justify">&ldquo;e.</TD><TD STYLE="text-align: justify">The Licensor must (i) supply all Licensed Product as ordered by the Licensee in accordance with
this agreement, (ii) ensure that all Anonymized End User Data and End User Identifiable Data is accessible to the Licensee, and
(iii) ensure that all Licensed Product supplied to the Licensee will be of merchantable quality and in accordance with all laws
and regulations in the Territory.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">2.2</TD><TD STYLE="text-align: justify"><U>Clause 7 Warranties; Liability</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">A new sentence is included
at the conclusion of existing clause 7.1 is inserted to the Licence Agreement which provides:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&ldquo;The Licensor represents
and warrants to the Licensee that it is the legal and beneficial owner of all intellectual property rights in respect of the Licensed
Property and the exercise by the Licensee of its rights under this Licence Agreement in respect of the Licenced Product will not
violate any third party&rsquo;s property or right.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.3</TD><TD STYLE="text-align: justify"><U>New Clause 7.5A Licensor Indemnity</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A new clause 7.5A.
is inserted to the Licence Agreement which provides:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&ldquo;Licensor hereby agrees
to defend, indemnify, and hold harmless Licensee, all Affiliates, and all officers, directors, employees, and agents of Licensee
or any Affiliate (collectively, the &ldquo;<U>Licensee Indemnitees</U>&rdquo;) from and against any claim, action, suit, litigation,
demand, allegation, arbitration, proceeding, judgment, order, damages, loss, liability, injury, costs, expenses (including, without
limitation, reasonable attorneys&rsquo; fees and witness and other defense costs), settlement, and other payment obligation of
any Licensee Indemnitee arising from or in connection with or related to: (i) any third party claim that the exercise by the Licensee
of its rights under this Licence Agreement in respect of the Licenced Product is in violation of their property or rights, and
(ii) any Licensed Product regulatory or quality recall or any consumer or user claims or liability in relation to Licensed Product
(regardless of any contributory or comparative negligence of any Licensee Indemnitee, but not for any damages to the extent resulting
from such contributory or comparative negligence of any Licensee Indemnitee).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.35pt; text-indent: -42.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">2.4</TD><TD STYLE="text-align: justify"><U>Schedule 4 &ndash; License Fees; Royalties</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-indent: -5.65pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-indent: -5.65pt; text-align: justify">Paragraph 2, &lsquo;Royalty
Fee payable as follows&rsquo; of Schedule 4 is deleted in its entirety and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: -42.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt; text-align: justify"></TD><TD STYLE="width: 42.5pt; text-align: justify">&ldquo;2.</TD><TD STYLE="text-align: justify">Royalty Fee payable as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: -42.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: 0pt; text-align: justify">All royalties will be payable
quarterly from the Commencement Date and subject to provision of required reports and financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: -42.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: 0pt; text-align: justify">Fee payments include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 134.7pt; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 116.7pt; text-align: justify"></TD><TD STYLE="width: 18pt; text-align: justify">a.</TD><TD STYLE="text-align: justify">Royalty &ndash; 13% based on Net Sales of Commercial Units;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 134.7pt; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 116.7pt; text-align: justify"></TD><TD STYLE="width: 18pt; text-align: justify">b.</TD><TD STYLE="text-align: justify">Royalty &ndash; 13% based on Net Sales of an optional dedicated reading device;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 134.7pt; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 116.7pt; text-align: justify"></TD><TD STYLE="width: 18pt; text-align: justify">c.</TD><TD STYLE="text-align: justify">App License fee as advised by the Licensor to the Licensee in writing from time to time; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 134.7pt; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 116.7pt; text-align: justify"></TD><TD STYLE="width: 18pt; text-align: justify">d.</TD><TD STYLE="text-align: justify">App fee for services for patient support program and education as advised by the Licensor by the Licensee in writing from time
to time.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.35pt; text-indent: -42.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">2.5</TD><TD STYLE="text-align: justify"><U>Schedule 4 &ndash; License Fees; Royalties</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">A new paragraph 3, &lsquo;Milestone Payments&rsquo;
is inserted in Schedule 4 &ndash; License Fees; Royalties which provides:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120.5pt; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120.5pt; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 42.5pt">&ldquo;3.</TD><TD STYLE="text-align: justify"><B>Milestone Payments</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.35pt; text-indent: -42.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-indent: 0pt; text-align: justify">The following payments are due
on the meeting of each of the following milestones, as contributions towards the overall approval and commercialisation process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.35pt; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 70pt">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">a.</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 79%; font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    delivering a health economics study on the impact of diabetes in China</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">310,000</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">b.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSDB
    delivering finalised field prototype biosensor</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">670,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">c.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    defining final manufacture to scale methodology</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">660,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">d.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    delivering a global regulatory strategy plan</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">290,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">e.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;LSBD&nbsp;&nbsp;delivering
    commercial and medical affairs prelaunch strategy</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">f.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    delivering KOL development plan</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">198,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">g.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    delivering Publication Plan and strategy</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">137,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">h.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    delivering Validated Clinical Survey/Study&nbsp;&nbsp;for prescribers and patients</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">410,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">i.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    commencing scale manufacturing for performance testing</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">330,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">j.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance
    testing commencement</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">350,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">k.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance
    testing concluded</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">410,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">l.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory
    approval submission</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">600,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">m.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory
    review and approval</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">700,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">n.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    delivering applications to monitor readings on smart device</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">320,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">o.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    commencing development on cloud database</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">240,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">p.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    completing development on cloud database</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">320,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">q.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    completing artificial intelligence interface</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">r.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    delivering finalised product for sale.having the first batch of glucose biosensors ready for sale</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">310,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">s.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSBD
    delivering patient education and patient support programs</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">t.</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prelaunch
    delivery of initial calibrated&nbsp;&nbsp;batch for market</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">t.</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USD</B></FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,065,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.6</TD><TD STYLE="text-align: justify"><U>Schedule 5 Milestones and Minimum Distribution
Requirements</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">A new Section
B Licensor&rsquo;s Obligations. is inserted to the conclusion of Schedule of 5 the Licence Agreement which provides:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">&ldquo;<B>Section
B Licensor&rsquo;s Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">The Licensor
must, unless otherwise agreed in writing with the Licensee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt; text-align: justify"></TD><TD STYLE="width: 42.5pt; text-align: justify">10.</TD><TD STYLE="text-align: justify">provide to Licensee on request all required information associated with or necessary to obtain
regulatory approval in the Territory;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt; text-align: justify"></TD><TD STYLE="width: 42.5pt; text-align: justify">11.</TD><TD STYLE="text-align: justify">provide all reasonable assistance to the Licensee in meeting its obligations under this Schedule
5 Milestones and Minimum Distribution Requirements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 42.5pt">12.</TD><TD STYLE="text-align: justify">ensure that all Licensed Product is packaged in accordance with all regulatory requirements in
the Territory including in an accepted language in the Territory.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">2.7</TD><TD STYLE="text-align: justify"><U>Schedule 6 Distribution Requirements</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">A new sub-paragraph
8 is inserted to the conclusion of Schedule of 6 the Licence Agreement which provides:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt; text-align: justify"></TD><TD STYLE="width: 42.5pt; text-align: justify">&ldquo;8.</TD><TD STYLE="text-align: justify">The Licensor must, subject to regulatory requirements in the Territory, package all Licenced Product
in accordance with the reasonable written requirements of the Licensee.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">3.1</TD><TD STYLE="text-align: justify"><U>Entire Agreement; Amendment; Waiver</U>. This Variation Agreement and the Licence Agreement
constitutes the entire understanding and agreement between the Parties hereto related to the subject matter hereof. Neither this
Variation Agreement nor the Licence Agreement nor any term or provision hereof may be waived, changed, discharged or terminated
except by an instrument in writing signed by the person against whom the enforcement of any waiver, change, discharge or termination
is sought. No modification, amendment, supplement to or waiver of any provision of this Variation Agreement or the Licence Agreement
will be binding upon the Parties unless made in a writing identifying the relevant provisions and signed by each Party through
its authorized representative. A failure of either Party to exercise any right provided for herein shall not be deemed to be a
waiver of any right hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">3.2</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Variation Agreement may be executed in one or more counterparts (any
one of which may be by facsimile or PDF), all of which shall constitute one and the same agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt; text-align: justify"></TD><TD STYLE="width: 42.55pt; text-align: justify">3.3</TD><TD STYLE="text-align: justify"><U>Continuing agreement</U>. Other than varied herein the Licence Agreement continues in full force
and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
each Party has executed this Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENSOR:</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENSEE:</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Life Science Biosensor Diagnostics Pty Ltd.</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Glucose Biosensor Sensor Systems (Greater China) Holdings Inc</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-6 MAT CTRCT
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit 6.7</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[IQ3
LOGO]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>



<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">MASTER
SERVICES AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">IQ3CORP
LIMITED<BR>
ACN 160 238 282</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">AND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Client</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;[DATE
OF AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; border-bottom: Black 1pt solid">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">Page <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;BINDING
    AGREEMENT</FONT></TD>
    <TD STYLE="width: 10%; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;TERM
    OF MSA</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;&nbsp;&nbsp;PRICING</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&nbsp;&nbsp;&nbsp;COUNTERPARTS</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">SCHEDULE
    1 &ndash; PARTIES TO MSA</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">SCHEDULE
    2 &ndash; GENERAL TERMS AND CONDITIONS</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;DEFINITIONS
    AND INTERPRETATION</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1&nbsp;&nbsp;&nbsp;Definitions</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2&nbsp;&nbsp;&nbsp;Interpretation</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;APPOINTMENT
    OF IQ3CORP</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1&nbsp;&nbsp;&nbsp;Appointment
    of iQ3Corp</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2&nbsp;&nbsp;&nbsp;Limited
    Delegation</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3&nbsp;&nbsp;&nbsp;iQ3Corp
    Representatives</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;&nbsp;&nbsp;OBLIGATIONS
    OF IQ3CORP</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2&nbsp;&nbsp;&nbsp;Limitation
    of Service</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3&nbsp;&nbsp;&nbsp;Notification
    of conflicts</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&nbsp;&nbsp;&nbsp;OBLIGATIONS
    OF THE CLIENT</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1&nbsp;&nbsp;&nbsp;Client&rsquo;s
    obligations</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.&nbsp;&nbsp;&nbsp;PAYMENT
    OF FEES FOR SERVICES</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1&nbsp;&nbsp;&nbsp;Fees</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2&nbsp;&nbsp;&nbsp;Subject
    to:</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3&nbsp;&nbsp;&nbsp;Payment
    Withholding</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4&nbsp;&nbsp;&nbsp;Interest
    on Unpaid Fees</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5&nbsp;&nbsp;&nbsp;Out-Of-Pocket
    Expenses</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.&nbsp;&nbsp;&nbsp;GST</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.&nbsp;&nbsp;&nbsp;CONFIDENTIAL
    INFORMATION</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.&nbsp;&nbsp;&nbsp;INTELLECTUAL
    PROPERTY</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1&nbsp;&nbsp;&nbsp;Ownership
    of Intellectual Property in the Service deliverables</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2&nbsp;&nbsp;&nbsp;Licence
    to use the Intellectual Property pre-existing works</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.&nbsp;&nbsp;&nbsp;INDEMNITY
    AND LIABILITY</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.1&nbsp;&nbsp;&nbsp;Client
    indemnity</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2&nbsp;&nbsp;&nbsp;IQ3Corp&rsquo;s
    Indemnity</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.3&nbsp;&nbsp;&nbsp;No
    Consequential Loss</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4&nbsp;&nbsp;&nbsp;Limitation</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.&nbsp;&nbsp;&nbsp;INSURANCE</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.&nbsp;&nbsp;&nbsp;DISCLAIMER</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">Page <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.1&nbsp;&nbsp;&nbsp;Use
    of work</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.2&nbsp;&nbsp;&nbsp;Reliance
    on information</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.&nbsp;&nbsp;&nbsp;TERMINATION</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.1&nbsp;&nbsp;&nbsp;Termination
    for cause</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.2&nbsp;&nbsp;&nbsp;Termination
    without cause</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.3&nbsp;&nbsp;&nbsp;No
    Prejudice</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.&nbsp;&nbsp;&nbsp;DISPUTE
    RESOLUTION</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.1&nbsp;&nbsp;&nbsp;Notice
    of Dispute</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.2&nbsp;&nbsp;&nbsp;Dispute
    Resolution</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.3&nbsp;&nbsp;&nbsp;Compliance
    With This Clause Is Compulsory</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.&nbsp;&nbsp;&nbsp;NOTICES</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1&nbsp;&nbsp;&nbsp;Validity
    of notices</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2&nbsp;&nbsp;&nbsp;When
    notice given</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.&nbsp;&nbsp;&nbsp;GENERAL</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.1&nbsp;&nbsp;&nbsp;Entire
    Agreement</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.2&nbsp;&nbsp;&nbsp;Succession
    and assigns</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.3&nbsp;&nbsp;&nbsp;Publicity</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.4&nbsp;&nbsp;&nbsp;Jurisdiction</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.5&nbsp;&nbsp;&nbsp;Variations</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.6&nbsp;&nbsp;&nbsp;Assignment</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.7&nbsp;&nbsp;&nbsp;Waiver</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.8&nbsp;&nbsp;&nbsp;Cumulative
    rights</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.9&nbsp;&nbsp;&nbsp;Time
    is of the essence</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.10&nbsp;&nbsp;&nbsp;Consent</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.11&nbsp;&nbsp;&nbsp;Surviving
    indemnities</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.12&nbsp;&nbsp;&nbsp;Enforcement
    of indemnity</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.13&nbsp;&nbsp;&nbsp;Force
    Majeure</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.14&nbsp;&nbsp;&nbsp;Further
    assurances</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.15&nbsp;&nbsp;&nbsp;Counterparts</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">IQ3 MASTER SERVICES AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">PARTIES:</TD><TD>IQ3CORP LIMITED ACN 160 238 282<BR>
(&ldquo;<B>iQ3Corp</B>&rdquo;)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">and</TD><TD><B>The counterparty named in Schedule 1 </B><BR>
<B>(&ldquo;Client&rdquo;)</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">A.</TD><TD>iQ3Corp is a corporate advisory firm that provides strategic and financial advisory services to listed and unlisted corporate
clients in the life sciences industry.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">B.</TD><TD>The Client is a client of iQ3Corp.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">C.</TD><TD>The Client may from time to time appoint iQ3Corp to deliver Services to the Client through the issue of Service acqusition
orders in the form set out in Schedule 3 (each a <B>&ldquo;Service Acquisition Order&rdquo;</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>D.</B></TD><TD><B>1Q3Corp </B>shall perform the Services in accordance with the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPERATIVE PART</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD><B>BINDING AGREEMENT</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD>Upon iQ3Corp&rsquo;s acceptance of the Client&rsquo;s Service Acquisition Order:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>the terms and conditions set out in the Service Acquisition Order; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>this Master Services Agreement (<B>&ldquo;MSA&rdquo;</B>)<B>; </B>and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>the General Terms and Conditions attached to this MSA,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD>(together the &ldquo;Agreement&rdquo;) will be a binding agreement between the Client and iQ3Corp, and iQ3Corp shall be bound
to perform the Services in accordance with the Agreement. Any ambiguity or inconsistency between the documents forming the Agreement
shall be resolved and interpreted in the following order:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>the terms and conditions set out in the Service Acquisition Order;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>the MSA; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>the General Terms and Conditions attached to the MSA.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD>The effective date of the Agreement will be the date of the Service Acquisition Order. Each Service Acquisition Order shall
identify this MSA and must provide, in addition to the General Terms and Conditions detailed in this MSA, the following terms and
conditions:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>relevant date or period for delivery of any deliverables;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>price; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>detailed description of services to be performed.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD><B>TERM OF MSA</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD>This MSA shall commence when executed by the Client and iQ3Corp and shall continue until terminated by either party by notice
in writing and shall be given effect at a time when no Service Acquisition Order is then current.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD><B>PRICING</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD>Pricing for the provision of Services by iQ3Corp, as agreed between the parties, will be specified as set out in the Service
Acquisition Order.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD><B>COUNTERPARTS</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD>This Agreement may be executed in any number of counterparts, Each counterpart is an original but the counterparts together
are one and the same Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD>Any counterpart of this Agreement is deemed to have been duly executed if it is executed by a party and:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>sent by facsimile; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>sent in .pdf, .tif, or similar scanned format by electronic mail;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>sent by pre-paid mail; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>hand delivered,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">to all other parties at either the postal address,
facsimile number or email address specified for the parties at Schedule 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.3</TD><TD>A notice that complies with clause 4.2 is regarded as being delivered and received:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>in the case of hand delivery: on the date of delivery if delivered at or before 5pm, or on the following Business Day if delivered
after 5pm;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>in the case of registered post; 2 Business Days after the date of posting;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>in the case of ordinary post: 3 Business Days after the date of posting;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>in the case of facsimile transmission: on the receipt by the sender of a transmission report indicating successful transmission
of the facsimile; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD>in the case of electronic mail, on receipt by the recipient&rsquo;s email server if received at or before 5pm on a Business
Day, or on the following Business Day if received after 5pm.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXECUTED AS AN AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; padding-right: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SIGNED</B> for and on behalf of <B>IQ3CORP LIMITED ACN 160
        238 282</B> in accordance with Section 127 of the Corporations Act in the presence of:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 3%; padding-right: 5.75pt; font-size: 10pt">)<BR>
)<BR>
)<BR>
)<BR>
)</TD>
    <TD STYLE="width: 44%; padding-right: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name (print)<BR></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director/Secretary</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid"><BR></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name (print)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt"><B>SIGNED</B> for and on behalf of <B>Glucose Biosensor Systems (Greater China) Pty Ltd ACN 614 067 158</B> in accordance with Section 127 of the Corporations Act In the presence of:</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt">)<BR>
)<BR>
)<BR>
)<BR>
)</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">Director</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">Name (print)</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">Director/Secretary</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">Name (print)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 70%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Witness signature</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name (print)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">SCHEDULE 1 &ndash; PARTIES TO MSA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD ROWSPAN="4" STYLE="width: 25%; border: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black"><B>iQ3Corp</B></FONT></TD>
    <TD STYLE="text-align: left; width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; vertical-align: middle"><FONT STYLE="color: Black"><B>ACN:</B></FONT></TD>
    <TD STYLE="text-align: left; width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; vertical-align: middle"><FONT STYLE="color: Black">160
    238 282</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black"><B>Address:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black">Level
    6, 222 Clarence Street, Sydney NSW 2000</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; vertical-align: middle"><FONT STYLE="color: Black"><B>Email
    </B><BR>
    <B>Address:</B></FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; padding: 10 5.75pt; text-indent: 0; vertical-align: middle"><FONT STYLE="color: Black"><U>info@theiggroup.com.au</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black"><B>Facsimile
    number</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black">02
    8362 9547</FONT></TD></TR>
<TR>
    <TD ROWSPAN="5" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black"><B>Client</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black"><B>Entity:</B></FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; vertical-align: middle"><FONT STYLE="color: Black">Glucose
    Biosensor Systems (Greater China) Pty Ltd</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black"><B>ACN:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black">614
    067 159</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black"><B>Address:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black">Level
    7, 222 Clarence Street, Sydney NSW 2000</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; vertical-align: middle"><FONT STYLE="color: Black"><B>Email
    </B><BR>
    <B>Address:</B></FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; padding: 10 5.75pt; text-indent: 0; vertical-align: middle"><FONT STYLE="color: Black"><U>info@theiggroup.com.au</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black"><B>Facsimile
    number</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 10 5.75pt; text-indent: 0; text-align: left; vertical-align: middle"><FONT STYLE="color: Black">02
    8362 9547</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">SCHEDULE 2 &ndash; GENERAL TERMS AND CONDITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">1.</FONT></TD><TD STYLE="text-align: justify">DEFINITIONS AND INTERPRETATION</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">Definitions</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following words have these meanings in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>&ldquo;Agreement&rdquo; </B>shall bear the meaning set out <B>in clause 1.1 </B>of the Master
Services Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B>&ldquo;Business Day&rdquo; </B>means a day (other than a public holiday, a Saturday and a Sunday)
on which banks are generally open for business in Sydney, New South Wales.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B>&ldquo;Claim&rdquo; </B>means any claim, action, damage, loss, liability, cost, charge, expense,
outgoing or payment which the Client pays, suffers, incurs or is or may be liable for in connection with any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">bodily injury or death of any person;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">damage or destruction to any property (including the loss of use of such property);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any act or omission including but not limited to any unauthorised representation made or warranty
given by iQ3Corp;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">the relationship between the Client and iQ3Corp being deemed or assessed as a relationship other
than that of principal and independent contractor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">Intellectual Property; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">any breach of, or default under, this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><B>&ldquo;Client Representative&rdquo; </B>means the person(s) described in the Service Acquisition
Order or any person or persons replacing that person and confirmed as such in written notice delivered by the Client to iQ3Corp.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><B>&ldquo;Commencement Date&rdquo; </B>means the date described as such in the Service Acquisition
Order.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><B>&ldquo;iQ3Corp Representative&rdquo; </B>means the person described as such in the Service Acquisition
Order or any person or persons replacing that person and confirmed as such in written notice delivered by iQ3Corp to the Client.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><B>&ldquo;Confidential Information&rdquo; </B>means all confidential information of the Client
(or any other party) of which iQ3Corp, its officers or its employees become aware or generate on behalf of the Client both before
and after the entry of this Agreement including, but not limited to:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">trade secrets;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Intellectual Property;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">confidential know-how;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">information concerning the business, finances or customers of the Client including (without limitation)
products, service costs, prices, profits and sales, new business ideas, business strategies, product and service plans, marketing
plans and studies, forecasts, computer programs, databases, computer codes, software ideas, technologies, concepts and designs,
research projects and all information connected with research and development effort, actual and prospective customer lists, all
information relating to Intellectual Property, customer requirements, customer financial information, product design, and competitive
analyses;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">any information that is marked, or which iQ3Corp is told is, or which the Client in any manner
indicates is, confidential; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">any information that is inherently or can reasonably be regarded as confidential.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><B>&ldquo;Fees&rdquo; </B>means the fees for the Services as set out in the Service Acquisition
Order.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><B>&ldquo;GST&rdquo; </B>has the same meaning as in the GST Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify"><B>&ldquo;GST Act </B>means the A New Tax System (Goods and Services Tax) Act 1999 (Cth).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify"><B>&ldquo;Intellectual Property&rdquo; </B>includes but is not limited to inventions, ideas, discoveries
and improvements, whether patentable or unpatentable; copyright, patents, trademarks and designs; and any application or right
to apply for registration of any rights in connection with such intellectual property whether created before or after the entry
of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify"><B>&ldquo;Invoice&rdquo; </B>means an invoice which complies with all of the requirements detailed
in clause 5.3 of the General Terms and Conditions.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify"><B>&ldquo;Jurisdiction&rdquo; </B>means the location described as such in the Service Acquisition
Order.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify"><B>&ldquo;Master Services Agreement&rdquo; </B>means the agreement described as such and to which
these general terms and conditions are attached.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify"><B>&ldquo;Out-of-Pocket Expenses&rdquo; </B>means any expenses incurred by IQ3 in the performance
of the Services and includes but is not limited to travel and accommodation expenses, printing expenses, couriers and professional
fees in respect of any technical, legal, tax or accounting advice or assistance sought.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify"><B>&ldquo;Related Body Corporate&rdquo; </B>has the same meaning as in section 50 of the <I>Corporations
Act 2001 </I>(Cth).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify"><B>&ldquo;Representative&rdquo; </B>means the Client Representative and/or iQ3Corp Representative,
as appropriate in the context.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify"><B>&ldquo;Services&rdquo; </B>means the services as set out in the Service Acquisition Order.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify"><B>&ldquo;Service Acquisition Order&rdquo; </B>shall bear the same meaning set out in Recital C
of the Master Services Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify"><B>&ldquo;Term&rdquo; </B>means the term as set out in the Service Acquisition Order.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">Interpretation</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Unless the contrary intention appears, in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">headings are for convenience and do not affect interpretation;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">words importing the singular include the plural and vice versa;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">words importing a gender include any gender;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">a reference to a clause or schedule is a reference to a clause or schedule of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">a reference to a natural person includes any company, partnership, joint venture, association,
corporation or other body corporate and any governmental agency;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">a reference to any statute, regulation or any other type of legislation includes all statutes,
regulations and other types of legislation varying, consolidating or replacing them and a reference to a statute includes al! regulations
and other types of subordinate legislation issued under that statute;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">a reference to a party in a document includes that party&rsquo;s successors and permitted assigns;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">a reference to a thing includes a reference to a part of that thing;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an acknowledgement is deemed a representation and warranty by the party giving it;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">where the day on or by which any thing is to be done is not a Business Day that thing must be done
by the following Business Day;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">a reference to &ldquo;$&rdquo; or &ldquo;dollars&rdquo; is a reference to Australian dollars;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">a reference to any agency or body, if that agency or body ceases to exist or is reconstituted renamed
or replaced or has its powers or functions removed (&lsquo;defunct body&rsquo;) means the agency or body which performs most closely
the functions of the defunct body;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">where any party comprises two or more persons, any duty or obligation to be performed or observed
will bind them jointly and each of them severally and any reference to that party will be deemed to include a reference to any
one or more of those persons;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">a reference to a document includes the document as modified from time to time and any document
replacing it;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">if a provision of this Agreement is void or voidable or unenforceable or illegal but would not
be void or voidable or unenforceable or illegal if it were read down and it is capable of being read down, it must be read down
accordingly, or alternatively if it cannot be read down then it is deemed severed;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">to the extent there is any inconsistency between the clauses of this Agreement and any schedule,
annexure or other attachment to this Agreement, the clauses of this Agreement shall prevail to the extent of such inconsistency;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">no rule of construction applies to the disadvantage of a party because that party was responsible
for the preparation of this Agreement or any part of it.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">2.</FONT></TD><TD STYLE="text-align: justify">APPOINTMENT OF IQ3CORP</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">Appointment of iQ3Corp</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Client appoints iQ3Corp on an exclusive basis to provide the Services from the Commencement
Date for the Term, or until the Services are completed, on the terms and conditions of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The relationship between the Client and iQ3Corp <B>is </B>that of principal and independent professional
service provider. Nothing in this Agreement will be taken as constituting iQ3Corp as an employee or agent of the Client. 1Q3Corp
does not have any authority to bind the Client and must not hold itself out as having any authority except as expressly provided
under the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">Limited Delegation</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">During the course of this Agreement, the Services will be provided by the iQ3Corp Representatives
nominated in Services Acquisition Order.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">IQ3 reserves the right to substitute the iQ3Corp Representative during the course of providing
the Services if the needs of the business so require it.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">iQ3Corp may delegate the performance of the Services to any other person within its organisation
or a Related Body Corporate but must not, without the written consent of the Client, subcontract, assign or transfer its responsibility
to provide the Services.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify">iQ3Corp Representatives</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The iQ3Corp Representatives referred to in the Service
Acquisition Order will be determined by iQ3Corp upon acceptance of the Client&rsquo;s Service Acquisition Order. The iQ3Corp Representatives
will be primarily responsible for the provision of the Services, unless and until substituted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">3.</FONT></TD><TD STYLE="text-align: justify">OBLIGATIONS OF IQ3CORP</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">IQ3Corp must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">deliver the Services to the Client on time and as instructed by the Client Representative;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">perform the Services with the skill, care, competence and diligence expected of a professional
consultant experienced in providing services in the nature of the Services; perform the Services through suitably qualified, expert
and experienced personnel as is reasonably necessary;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">notify the Client if it becomes aware of any matter which may change the scope, or timing of delivery,
of the Services, such notification should include particulars of the relevant matter and recommendations on how any adverse effect
might be minimised;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">comply with all lawful and reasonable requests and directions of the Client;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">regularly consult with, and keep informed, the Client Representative of the performance of the
Services;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">co-operate fully and co-ordinate its performance of the Services with other consultants engaged
by the Client;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">hold all licences or qualifications required or necessary to lawfully provide the Services; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">not act for the Client or make representations, warranties, undertakings or assume obligations
for or on behalf of the Client without the prior consent of the Client&rsquo;s Representative.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify">Limitation of Service</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">iQ3Corp is not required to provide any services which
would not normally be expected of a professional corporate advisory services provider experienced in providing the same or similar
services, including without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">provision of legal advice; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any other requirement or service outside the scope of this Agreement, unless any change to the
Fees and the Services and any other relevant matters are agreed as a variation to this Agreement by the parties in writing.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify">Notification of conflicts</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If any conflict or potential conflict exists or is
likely to arise in the performance of its obligations under this Agreement, iQ3Corp must notify the Client as soon as possible
in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">4.</FONT></TD><TD STYLE="text-align: justify">OBLIGATIONS OF THE CLIENT</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">Client&rsquo;s obligations</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Client must ensure that it gives all reasonable
assistance and does all things reasonably necessary to enable iQ3Corp to deliver the Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">5.</FONT></TD><TD STYLE="text-align: justify">PAYMENT OF FEES FOR SERVICES</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">Fees</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Client must pay iQ3Corp for the Services in the manner outlined in the Service Acquisition
Order and this <B>clause 5.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Aside from the fees outlined in the Service Acquisition Order, the Client will not be liable for
any other cost, charge or expense for or relating to the Services or their delivery.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">Subject to:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the proper performance of the Services; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">iQ3Corp&rsquo;s provision to the Client of an Invoice,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">the Client must pay iQ3Corp all amounts invoiced to
it within one month of the Client&rsquo;s receipt of the given Invoice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">Payment Withholding</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Despite <B>clause 5.2, </B>if the Client:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">reasonably objects to all or any portion of any Invoice, and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">notifies iQ3Corp of that objection within fifteen days of the Invoice being issued, and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">gives valid reasons for the objection,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">the Client may, until the dispute is resolved, withhold
payment of that part of the Invoice objected to.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">Interest on Unpaid Fees</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If the Client fails to pay fees as required by this
<B>clause 5, </B>the Client must pay iQ3Corp interest on the daily outstanding fees balance, such interest to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">compound daily; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">be calculated each day using an interest rate equal to 2% above the Commonwealth Bank of Australia&rsquo;s
indicative lending rate on bank overdrafts over $100,000 for that day.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.5</TD><TD STYLE="text-align: justify">Out-Of-Pocket Expenses</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">IQ3Corp acknowledges that any out-of-pocket expenses
charged to the Client must be supported by appropriate documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">6.</FONT></TD><TD STYLE="text-align: justify">GST</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Unless otherwise stated, the fees payable by the Client to iQ3Corp under this Agreement are exclusive
of any GST.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If any GST is incurred, payable by or collectable from iQ3Corp in respect of services under this
Agreement, the Client shall pay or reimburse iQ3Corp for any GST paid or indemnify iQ3Corp for any GST payable. Where such GST
payment is due, iQ3Corp must promptly provide the Client with an invoice or receipt suitable for claiming GST in accordance with
the GST Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">7.</FONT></TD><TD STYLE="text-align: justify">CONFIDENTIAL INFORMATION</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">IQ3Corp:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">must not use the Client&rsquo;s Confidential Information other than for the purpose of providing
the Services;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">must not disclose the Confidential Information to any party unless the disclosure:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">is approved in writing by the Client;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">is required by law;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">is necessary for the implementation of the Services;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">is used for obtaining professional advice in relation to this Agreement; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">relates to information already in the public domain other than as a result of breach of confidentiality
by iQ3Corp or a person under similar confidentiality obligations; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">must ensure that its agents, officers, employees, consultants, and other representatives comply
with <B>subclauses 7(a) </B>and <B>7(b).</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">8.</FONT></TD><TD STYLE="text-align: justify">INTELLECTUAL PROPERTY</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.1</TD><TD STYLE="text-align: justify">Ownership of Intellectual Property in the Service deliverables</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">IQ3Corp assigns to the Client all existing and future
Intellectual Property rights in any material created, generated or contributed to by or on behalf of iQ3Corp specifically for the
Client in the delivery of the Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.2</TD><TD STYLE="text-align: justify">Licence to use the Intellectual Property pre-existing works</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Each party retains ownership of its pre-existing Intellectual
Property. To the extent necessary to enable the provision and receipt of the Services, each party provides the other party with
a nonexclusive licence to use its Intellectual Property. Any licence provided under this <B>clause 8.2 </B>will terminate on termination
or expiry of this Agreement for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">9.</FONT></TD><TD STYLE="text-align: justify">INDEMNITY AND LIABILITY</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify">Client indemnity</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Client indemnifies IQ3Corp against all claims,
demands, actions, liabilities, costs and expenses of any kind (including without limitation all legal costs on a solicitor/client
basis) arising from or in connection with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">!Q3Corp&rsquo;s provision of the Services in accordance with this Agreement including without limitation,
any public liability claims and all claims for which IQ3Corp is or becomes liable due to the valid and lawful exercise of its rights
and performance of its obligations under this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Client&rsquo;s negligence or misconduct; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any information provided by the Client to IQ3Corp upon which IQ3Corp relied in providing the Services.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.2</TD><TD STYLE="text-align: justify">IQ3Corp&rsquo;s Indemnity</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Except to the extent <B>clause 9.1 </B>applies, IQ3Corp
indemnifies the Client against all claims, demands, actions, liabilities, costs and expenses of any kind (including without limitation
all legal costs on a solicitor/client basis) arising from or in connection with IQ3Corp&rsquo;s gross negligence or material breach
of this Agreement. IQ3Corp&rsquo;s indemnity in this <B>clause 9.2 </B>is reduced proportionately to the extent that any act or
omission of the Client or its employees or agents contributed to the loss or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.3</TD><TD STYLE="text-align: justify">No Consequential Loss</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In any event, each party (the first party) shall not
be liable to the other (the second party) for any indirect, consequential, special, punitive, exemplary loss, liability or damages
of the second party or any third party arising from any act or omission of the first party under or in relation to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.4</TD><TD STYLE="text-align: justify">Limitation</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Despite anything else in this Agreement, the total
liability of IQ3Corp for all claims arising out of or in connection with this Agreement shall be limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">for liability in respect of breach of the Agreement, to the resupply of the relevant portion of
the Services or the payment of the cost of having the relevant portion of the Services provided by a third party (at the discretion
of IQ3Corp); and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">for all other liability not limited by <B>clause 9.4(a), </B>the parties agree to limit iQ3Corp&rsquo;s
liability to the aggregate fees IQ3Corp is entitled to receive under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">10.</FONT></TD><TD STYLE="text-align: justify">INSURANCE</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">10.1</TD><TD STYLE="text-align: justify">IQ3Corp must ensure that throughout the Term of this
Agreement, it is insured with a highly reputable insurance company with respect to professional indemnity insurance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">10.2</TD><TD STYLE="text-align: justify">iQ3Corp must provide the Client with a certificate of
currency within 14 days if requested.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">11.</FONT></TD><TD STYLE="text-align: justify">DISCLAIMER</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify">Use of work</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Unless IQ3Corp provides prior written consent to the
Client, which may be withheld at its sole discretion, any draft or final report prepared by IQ3Corp under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">must only be used for the Client&rsquo;s internal purposes;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">must not be reproduced (including on any website) in a manner that is accessible by the public
or a section of the public;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">must not be used in connection with any public offering; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Client must not refer to IQ3Corp in any public offering.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Where IQ3Corp provides consent to use such reports
or its name, the client will comply with any conditions or restrictions imposed by IQ3Corp on its use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.2</TD><TD STYLE="text-align: justify">Reliance on information</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The data, documentation, and assumptions used to prepare any analysis or reports from the Services
will be derived entirely from information supplied by the Client, prepared by IQ3Corp in the regular course of its business, and
other industry sources. All such information will not be independently verified by IQ3Corp for the purposes of this Agreement.
IQ3Corp will not be responsible for the accuracy of such data and information, and for any assumptions derived from such.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">lQ3Corp&rsquo;s performance will be based on IQ3Corp&rsquo;s professional evaluation of all such
available sources of information. The Client acknowledges and agrees that there may be differences between projected and actual
results because events and circumstances frequently do not occur as predicted, and those differences may be material. The Client
hereby releases IQ3Corp from any claims or liability arising from these differences.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Client is responsible for representations made to IQ3Corp about its plans and expectations
and for disclosure of material information that might affect the ultimate realisation of the conclusions, projections, estimates
and recommendations made by IQ3Corp. The final decision to implement any recommendations made by IQ3Corp rests with the Client.
The Client acknowledges that IQ3Corp&rsquo;s findings will constitute only one of the factors that the Client should consider in
its decision making process.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The parties understand and agree that neither IQ3Corp&rsquo;s fees nor the payment of those fees
by the Client is contingent upon the results, projections, findings, conclusions or recommendations provided by IQ3Corp.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">12.</FONT></TD><TD STYLE="text-align: justify">TERMINATION</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.1</TD><TD STYLE="text-align: justify">Termination for cause</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Either party (the first party) may immediately terminate
this Agreement by giving written notice to the other party (the second party) if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the second party materially breaches any aspect of this Agreement and fails to satisfactorily remedy
any such breach within 14 days of being notified by the first party;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the second party is or becomes bankrupt or insolvent or unable to pay its debts as and when they
fall due;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the second party enters into a scheme of arrangement or composition with its creditors or takes
advantage of any statute for the relief of insolvent or financially troubled debtors; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the second party is placed under management or administration or a receiver is appointed, or a
winding up order is made in respect of the second party.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.2</TD><TD STYLE="text-align: justify">Termination without cause</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Each party can terminate this Agreement by providing 30 days&rsquo; written notice to the other.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">In the event of termination without cause by the Client pursuant to this <B>clause 12.2 </B>prior
to the conclusion of the Service:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">iQ3Corp will be entitled to receive payment in full of any Out-of-pocket Expenses, including Out-of-Pocket
Expenses that have been incurred which have not yet been invoiced or paid; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">should the Client decide to obtain the Services contemplated in the Services Acquisition Order
within 12 months of the date of termination, then the Client <B>will </B>offer iQ3Corp the same role to that contemplated by the
Services Acquisition Order and on similar, and no worse, terms to those contemplated by this Agreement; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">should the Client not offer to re-appoint iQ3Corp under <B>clause 12.2(i&iacute;) </B>but nevertheless
the Services, or enter into an agreement to undertake the Services, within 12 months of the date of termination, then iQ3Corp will
be entitled to receive the Fees in full calculated as if iQ3Corp had been re-appointed in accordance with the terms of this Agreement,
not exceeding the amount they would have been entitled to had the Services been provided by iQ3Corp in full.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.3</TD><TD STYLE="text-align: justify">No Prejudice</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Termination of this Agreement will not prejudice any
right which a party may have, or but for the termination, may have had, against the other party for a breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">13.</FONT></TD><TD STYLE="text-align: justify">DISPUTE RESOLUTION</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify">Notice of Dispute</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If any dispute arises in relation to this Agreement
<B>(&ldquo;Dispute&rdquo;), </B>the party asserting that a Dispute has arisen must give the other party a written notice <B>(&ldquo;Dispute
Notice&rdquo;) </B>which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">says that it is a Dispute Notice issued under <B>clause 13.1 </B>of this Agreement, and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">sets out:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">each thing complained of;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the outcome sought by the party giving the Dispute Notice;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the things that the party giving the Dispute Notice thinks needs to be done in order to achieve
that outcome; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">the reasons that party thinks it should be entitled to that outcome.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.2</TD><TD STYLE="text-align: justify">Dispute Resolution</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">lf, within 7 days of a Dispute Notice being given (or within such further period as agreed in writing
by the parties), the parties have not agreed on:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the dispute resolution technique and procedures to be adopted in seeking to resolve the Dispute;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the timetable for all steps in those procedures; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the selection and compensation of all independent persons required for such technique, then the
parties must forthwith refer the dispute to the Australian Commercial Disputes Centre <B>(&ldquo;ACDC&rdquo;) </B>for mediation.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The mediation must be conducted in accordance with the ACDC Guidelines for Commercial Mediation
<B>(&ldquo;ACDC Guidelines&rdquo;) </B>which are operating at the time the matter is referred to the ACDC. The terms of the ACDC
Guidelines are incorporated into the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">During the course of any mediation each party must be represented by a person having authority
to agree to a resolution of the dispute.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.3</TD><TD STYLE="text-align: justify">Compliance With This Clause Is Compulsory</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Neither party to this Agreement may commence any court
proceedings in relation to the Dispute unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">it has firstly complied with this <B>clause 13, </B>and the Dispute has not been settled within
42 days of the delivery of the relevant Dispute Notice (or such other period as agreed to in writing by the parties); or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the relevant party seeks urgent interlocutory relief or seeks to enforce a payment due under this
Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">14.</FONT></TD><TD STYLE="text-align: justify">NOTICES</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.1</TD><TD STYLE="text-align: justify">Validity of notices</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A notice, consent or other communication under this
Agreement cannot be effective unless it is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in writing, signed by or on behalf of the party giving it;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">addressed to the postal address, facsimile number or email address specified for the recipient
in <B>Schedule 1 </B>(or as varied by any notice); and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">either:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">hand delivered to the recipient&rsquo;s address;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">sent by pre-paid mail (by airmail, if the addressee is overseas) to that party&rsquo;s address;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">sent by facsimile to the recipient&rsquo;s facsimile number; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">sent by electronic mail to the recipient&rsquo;s email address.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.2</TD><TD STYLE="text-align: justify">When notice given</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A notice, consent or other communication that complies
with this clause is regarded as given and received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in the case of hand delivery: on the date of delivery if delivered at or before 5pm, or on the
following Business Day if delivered after 5pm;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in the case of registered post: 2 Business Days after the date of posting;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">in the case of ordinary post: 3 Business Days after the date of posting (airmail being 5 Business
Days after posting);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">in the case of facsimile transmission: on the receipt by the sender of a transmission report indicating
successful transmission of the facsimile; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">in the case of electronic mail, on receipt by the recipient&rsquo;s email server if received at
or before 5pm on a Business Day, or on the following Business Day if received after 5pm.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">15.</FONT></TD><TD STYLE="text-align: justify">GENERAL</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.1</TD><TD STYLE="text-align: justify">Entire Agreement</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This Agreement is the entire agreement between the
parties and supersedes all previous agreements, representations and undertakings between the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.2</TD><TD STYLE="text-align: justify">Succession and assigns</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Agreement will be binding upon and will continue
for the benefit of the parties, and their respective successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.3</TD><TD STYLE="text-align: justify">Publicity</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Either party must:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">obtain the other&rsquo;s prior written consent before publicising its association or relationship
with the other or use the other&rsquo;s name, logo, or trademarks (including those of its Related Bodies Corporate); and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">comply with any conditions imposed by the other party on such publication or use.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Each party may publicise its association or relationship with the other if a legal or regulatory
requirement compels publicising that association or relationship in any regulatory document pertaining to the operation of the
Company including, but not limited to, investment prospectuses, annual company reports and other regulatory and market disclosures.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.4</TD><TD STYLE="text-align: justify">Jurisdiction</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This Agreement, its meaning and interpretation and
the relationship of the parties are to be governed by the laws of the Jurisdiction. The parties submit unconditionally to the jurisdiction
of the courts of the Jurisdiction and the courts hearing appeals from those courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.5</TD><TD STYLE="text-align: justify">Variations</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Any variation of this Agreement must be in writing
and executed by all parties to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.6</TD><TD STYLE="text-align: justify">Assignment</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">iQ3Corp may assign or transfer any of its rights or obligations under this Agreement to any of
its Related Bodies Corporate by giving written notice to all other parties to this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Subject to <B>clause 15.6(a), </B>neither party may assign or transfer any of its rights or obligations
under this Agreement without the prior written consent of the other.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.7</TD><TD STYLE="text-align: justify">Waiver</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A waiver on the part of either party of any term,
provision or condition of this Agreement shall not constitute a precedent or bind either party to a waiver of any succeeding breach
of the same or any other term, provision or condition of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.8</TD><TD STYLE="text-align: justify">Cumulative rights</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All remedies, rights, undertakings, obligations or
agreements of the parties arising by law, this Agreement or otherwise shall be cumulative and shall not limit any other right,
remedy, undertaking, obligation or agreement of such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.9</TD><TD STYLE="text-align: justify">Time is of the essence</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Time is of the essence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.10</TD><TD STYLE="text-align: justify">Consent</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Where consent of IQ3Corp or the Client is required
under this Agreement, such consent must be obtained from their respective Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.11</TD><TD STYLE="text-align: justify">Surviving indemnities</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Any provision of this Agreement which expressly or
by implication from its nature is intended to survive the termination or expiration of this Agreement and any rights arising on
termination or expiration shall survive. These clauses are continuing obligations, independent from the parties&rsquo; other obligations
under this Agreement, and continue after this Agreement ends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.12</TD><TD STYLE="text-align: justify">Enforcement of indemnity</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">It is not necessary for a party to incur expense or
make payment before enforcing a right of indemnity under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.13</TD><TD STYLE="text-align: justify">Force Majeure</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Despite any other provision of this Agreement, no party need act if it is impossible to act due
to Force Majeure.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The non-performing party must notify the other party promptly after it determines that it is unable
to act as a consequence of Force Majeure and must make reasonable efforts to avoid or remove the cause of non-performance.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">This clause does not apply to payments by one party to any other party where that payment or part
thereof accrues prior to a party giving notice under this clause.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.14</TD><TD STYLE="text-align: justify">Further assurances</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Each party must, at its own expense, do anything another
party reasonably asks (such as obtaining consents, signing and producing documents and getting documents completed and signed)
in order:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to bind the party and any other person intended to be bound under this Agreement; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">to enable the requesting party to exercise any rights granted under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.15</TD><TD STYLE="text-align: justify">Counterparts</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">This Agreement may be executed in any number of counterparts. Each counterpart is an original but
the counterparts together are one and the same Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Any counterpart of this Agreement is deemed to have been duly executed if it is executed by a party
and:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">sent by facsimile to all other parties; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">sent in .pdf, .tif or similar scanned format to all other parties; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">delivered by hand to the address specified for the parties in <B>Schedule 1</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><B>SCHEDULE 3 - SERVICE ACQUISITION ORDER</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD ROWSPAN="3" STYLE="width: 20%; border: Black 1pt solid; font-weight: bold">The Client</TD>
    <TD STYLE="vertical-align: top; width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Entity:</TD>
    <TD STYLE="vertical-align: top; width: 65%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-weight: normal">Glucose
    Biosensor Systems (Greater China) Ply Ltd</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">ACN:</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-weight: normal">(or
    Nominated Entity) 614 067 159</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Address:</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-weight: normal">Level
    7, 222 Clarence Street, Sydney NSW 2000</FONT></TD></TR>
<TR>
    <TD ROWSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold">IQ3Corp</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Entity:</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-weight: normal">iQ3Corp
    Ltd</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">ACN:</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-weight: normal">160
    238 282</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Address:</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-weight: normal">Level
    6, 222 Clarence Street, Sydney NSW 2000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; font-weight: bold">Commencement
    Date</TD>
    <TD STYLE="width: 80%; border-bottom: Black 1pt solid; font-weight: bold; border-right: Black 1pt solid"><FONT STYLE="font-weight: normal">01/08/2016</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold">Term</TD>
    <TD STYLE="font-weight: bold; border-right: Black 1pt solid"><FONT STYLE="font-weight: normal">From the Commencement date
    to Completion of project</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 20%; border: Black 1pt solid; font-weight: bold">Services</TD>
    <TD STYLE="vertical-align: top; width: 80%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.95pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Pre-lPO and Potential IPO Listing</U></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.95pt"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.25pt; text-indent: -18.25pt; color: #010101">A.&nbsp;&nbsp;&nbsp;&nbsp;Business
        Plan Preparation Assistance &amp; Review - $120,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.55pt; text-indent: -17.2pt">B.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: #020202">Qualifying
        Due Dilligence - $40,000</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.25pt; text-indent: -18.3pt"><FONT STYLE="color: #040404">C.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="color: #010101">Private
        Placement Capital Raising Support Services in jurisdiction </FONT>covered by Australian Financial Services License - $250,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt; text-indent: -17.7pt">D.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: #010101">Private
        Placement Capital Raising @ 8% of capital raised in </FONT><FONT STYLE="color: #020202">jurisdiction covered by financial
        services licence</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.35pt; text-indent: -17.95pt"><FONT STYLE="color: #010101">E.&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Preparation
        of Private Placement &amp; Public Offering Parameters &amp; Capital Modelling - $150,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: -17.85pt; color: #010101">F.&nbsp;&nbsp;&nbsp;&nbsp;Public
        Offering Project Management comprising of: Liaising with lawyers, Investigative Accountants, Regulators, Stock Exchange
        Representatives &amp; Management of the Prospectus Preparation Process and other out of scope work - per Hourly rates**
        below:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.7pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief
        Corporate Advisor - $800 per hour</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.7pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Head,
        Corporate Advisor- $550 per hour</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.7pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: #010101">Corporate
        Advisor - $400 per hour</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.1pt; color: #010101">&bull;&bull; Hourly rates
        are subject to review</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: -17.85pt">G.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: #010101">Public
        offering capital in jurisdiction covered by financial </FONT><FONT STYLE="color: #030303">services license - to be negotiated
        separately if applicable</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: -17.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: -17.85pt">H.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: #010101">Investor
        Relations Support Services - $20,000 per month from 1<SUP>st</SUP> July 2017 until close of offer</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 20%; border-top: #747474 1pt solid; border-right: #646767 1pt solid; border-bottom: #646464 1pt solid; border-left: #3F3F3F 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 80%; border-top: #747474 1pt solid; border-right: #3F3F3F 1pt solid; border-bottom: #646464 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">All amounts
        quoted are exclusive of Goods &amp; Services Tax (GST} , which will be added where appropriate . Amounts listed are fixed
        for a maximum of 90 days and subject to review by iQ3 thereafter.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The above fees
        are exclusive of fees payable to other service providers in the process such as legal, accounting , IT, prospectus layout,
        printing &amp; distribution.</P></TD></TR>
<TR>
    <TD STYLE="border-right: #646767 1pt solid; border-bottom: #777777 1pt solid; border-left: #3F3F3F 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>iQ3Corp's
    Representative</B></FONT></TD>
    <TD STYLE="border-right: #3F3F3F 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Accepted
for and on behalf of iQ3Corp Ltd by:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><IMG SRC="tv502124_ex6-7img1.jpg" ALT=""></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="border-right: #646767 1pt solid; border-bottom: #747777 1pt solid; border-left: #3F3F3F 1pt solid; padding-top: 0.05pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Client
    Representative</B></FONT></TD>
    <TD STYLE="border-top: #777777 1pt solid; border-right: #3F3F3F 1pt solid; border-bottom: #747777 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tv502124_ex6-7img2.jpg" ALT=""></P></TD></TR>
<TR>
    <TD STYLE="border-right: #646767 1pt solid; border-bottom: #747777 1pt solid; border-left: #3F3F3F 1pt solid; padding-top: 3.7pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="border-right: #3F3F3F 1pt solid; border-bottom: #747777 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">New
    South Wales</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-6 MAT CTRCT
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 6.10</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;<IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Technology Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Account Form</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This TECHNOLOGY SERVICES AGREEMENT, which consists of this account
form (the &ldquo;Account Form&rdquo;) and the associated Terms and Conditions (the &ldquo;Terms and Conditions&rdquo;) attached
hereto as Exhibit A, is made and entered into as of %%TODAY%% (the &ldquo;Effective Date&rdquo;) between %%ISSUER_NAME%% (collectively
referred to as &ldquo;Issuer&rdquo;, &ldquo;you&rdquo;, &ldquo;your&rdquo;) for its offering of securities entitled <FONT STYLE="background-color: yellow">&lt;offering
name&gt;</FONT> (&ldquo;Offering&rdquo;), and FundAmerica, LLC (&ldquo;FundAmerica&rdquo;, &ldquo;Technology Provider,&rdquo; &ldquo;we,&rdquo;
&ldquo;our,&rdquo; or &ldquo;us&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recitals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS</B>, FundAmerica is a technology firm providing engineering
and technology services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS,</B> FundAmerica has created, owns and maintains
proprietary tools and technology, negotiated third-party integrations, and has operational processes to provide certain back-end
tools, and technology, to persons conducting, managing and/or enabling technology-driven capital raises via offerings of debt and/or
equity securities, and for maintaining and managing investor data, reporting and communications (the &ldquo;Technology&rdquo;);
and,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS,</B> Issuer intends to use technology to engage in
and manage one or more equity and/or debt securities offerings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOW, THEREFORE,</B> in consideration of the mutual promises
and covenants contained herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties have agreed to execute this Technology Agreement (the &ldquo;Agreement&rdquo;) to memorialize the terms and conditions
for which FundAmerica will provide Technology to Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Technology
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FundAmerica will provide the Technology to Issuer, subject to
the Terms and Conditions contained in the attached Exhibit A. Such Technology include and are accessible via our Application Programming
Interface (the &ldquo;API&rdquo;) and our Invest Now technology (&ldquo;Invest Now&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer shall pay fees as indicated in Exhibit B below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Agreed as of the date first written above, by and between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">%%ISSUER_SIGNATURE%%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">%%TECHNOLOGIES_SIGNATURE%%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TECHNOLOGY SERVICES AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AND CONDITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS.
For purposes of this Agreement:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Agreement&rdquo;
means this Technology Agreement, which consists of the Account Form and this Exhibit A Terms and Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Issuer&rdquo;
means the company and any related party, subsidiary, agent, representative, administrator, successor in interest, or other person
or entity acting on behalf of or in place of the person or entity who is using (or enabling the use of) FundAmerica Technology
to aid in managing a raise of capital and who is identified on the Account Form as the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Materials&rdquo;
means all Issuer data, information, disclosures, advertising, works of authorship, inventions, drawings, logos, software code or
other communications related to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Account Form&rdquo;
means the Technology Agreement Account Form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Investor&rdquo;
or &ldquo;Subscriber&rdquo; means a person that commits to purchase equity or debt securities of an Issuer in an Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Offering&rdquo;
means Issuer&rsquo;s offering of debt or equity securities as it raises capital pursuant to SEC and/or state regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Person&rdquo;
means any individual, company, limited liability company, corporation, trust, estate, association, nominee or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Technology&rdquo;
has the meaning set forth in the Account Form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Term&rdquo;
has the meaning set forth in Section 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;User&rdquo;
means Issuer, its customers and any other person using the Technology in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Information&rdquo;
means any data or information, including personally identifiable information, provided by or relating to Users in connection with
any Offering, whether provided directly by User or Funding Platform in connection with the Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Invest Now&rdquo;
means FundAmerica&rsquo;s proprietary transaction engine technology to simplify engaging with the Technology, generally with &ldquo;plug
&amp; play&rdquo; access, both for posting data associated with an offering into our system (the &ldquo;Wizard&rdquo;) and for
investors to commit to an offering (the &ldquo;Button&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;API&rdquo;
means FundAmerica&rsquo;s Application Programming Interface, which is a set of code and programming rules which enable people to
connect their software to our systems. The API is secured with a &ldquo;key&rdquo; which triggers access, for that specific account,
to services and data access.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TECHNOLOGY AND
HOSTING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;API, Invest Now.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">API and Invest Now provide access to various Technology, which
may be selectively used at Issuer&rsquo;s option pursuant to FundAmerica policies in effect at the time of each desired use. Technology
may also be selectively enabled or disabled by FundAmerica, in our sole discretion, limiting which Technology, features and tools
Issuer has access to use, and at what fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor &amp; Cap
Table Management Technology, Data Access.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FundAmerica will provide Issuer with tools to manage its investors
(including changes and updates), communicate with investors, view its capitalization table, and access historical data. FundAmerica
provides these tools and access on a Software-as-a-service (&ldquo;SaaS&rdquo;) basis for an Issuer to manage its own Cap Table
and shareholder records. The Issuer agrees that is solely responsible for managing its Cap Table and shareholder records, and agrees
that FundAmerica SaaS technology that is being provided is only a tool to aid the Issuer to manage its shareholder records. The
Issuer acknowledges that the SaaS technology provided are not the services of a registered stock transfer agent, and that the Issuer
has the sole responsibility for determining whether a registered stock transfer agent is required for its securities offering(s).
The SaaS system can be used to access historical data on investors, the offering, and events. Issuers authorized administrators
will have access to the SaaS system, at Issuers sole discretion and responsibility. FundAmerica does not directly make changes
to investor data, nor does it issue certificates, enforce transfer restrictions or handle cash. SaaS services are provided for
the monthly and other fees detailed in Exhibit B of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hosting &amp; Management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At all times, the Technology shall be hosted, managed and maintained
by FundAmerica and our appointed third-party service providers. Our Technology are accessible via our API, and not by any separate
software installation. FundAmerica provides Technology to numerous other customers, including other issuers and funding platforms.
The Technology that FundAmerica provides are evolving and the Technology that we provide may change from time to time without prior
notice to you. FundAmerica may update, modify, change or otherwise alter the hosting location(s) and/or methodology, as well as
any or all features, functionality, user interface(s) located in Issuer&rsquo;s account on apps.fundamerica.com (the &ldquo;Control
Panel&rdquo;), business logic, policies, procedures, and/or the API and/or Invest Now from time to time at its sole discretion
and without notice. In addition, FundAmerica may stop (permanently or temporarily) providing the Technology (or any specific component(s)
or feature(s) of the Technology) to you or to users generally and may not provide you with prior notice. It is Issuer&rsquo;s express
will and consent that all data shall be stored in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Access.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FundAmerica will make the Technology available to Issuer and
Issuer&rsquo;s investors and other users (&ldquo;Users&rdquo;) in accordance with this Agreement and FundAmerica&rsquo;s rules,
policies, and Terms of Use then in effect. Issuer acknowledges that its use of the Technology are subject to this Agreement, including
all applicable terms of service, privacy policies and other policies that are then in. Issuer acknowledges that some of the Technology,
even though a la carte in the system, may be interdependent and not available except and unless combined with other Technology,
as determined in the sole and arbitrary discretion of FundAmerica, and that your terms, access to specific Services, and/or fees
may be different than those of other FundAmerica customers, and even different than those of other offerings you have conducted
using our Technology, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technology Restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer will not directly itself, and will not permit or authorize
third parties, including Issuer&rsquo;s Users, employees or agents to: (a) rent, lease, sublet, resell, convert, license, exploit,
use, modify, or otherwise permit unauthorized third parties to access or use any aspect of the API or Invest Now; (b) reverse engineer,
reverse assemble or otherwise attempt to discover the source code for the API or Invest Now; (c) circumvent or disable any security
or other technological features or measures of the API or Invest Now; (d) alter, modify, convert or attempt to, modify, convert
or otherwise manipulate the API or Invest Now, software or code; or (e) clone or otherwise copy, replicate or duplicate in any
fashion any part of the API or Invest Now design, workflow, features or methodology, all of which Issuer acknowledges are proprietary
intellectual property wholly owned by FundAmerica.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FundAmerica will provide Issuer with access to regular updates
via various web-accessible dashboards, various plug &amp; play web widgets, and/or via WebHooks functionality of the API, which
enables Issuer to pull data from our system directly into its servers and to get on-demand updates both for its own purposes and
so it can create reports and alert systems for its customers and other users with respect to all receipts of funds, deposits, disbursements
and other transactions for each open Escrow Account. When the Technology are used via the API, then FundAmerica shall not be obligated
to push or send reports or alerts to Issuer or any other person. When the Technology are engaged via Invest Now or via manual dashboard
tools then FundAmerica will send confirmations and alerts, generally on Issuer&rsquo;s behalf (meaning &ldquo;from&rdquo; you,
which you hereby unequivocally and unconditionally instruct, direct and authorize us to do in the form and format standard in our
system or as customized for you).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Data Privacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor data received by FundAmerica in conjunction with the
Technology shall only be used for the purposes of providing said Technology and as required by the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FundAmerica Duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FundAmerica will at all times manage the API, Invest Now, and
all related engineering functions, including application maintenance, upgrades, hosting and modifications. FundAmerica will provide
the API, Invest Now, and the Technology availability on an ongoing basis in exchange for Fees, (defined below) including technology,
upgrades, operating systems, databases and backups, SSL certificates, third-party service integrations, and related technology
licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuer&rsquo;s Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer warrants that it will operate its offering(s) in compliance
with all federal and state laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ethics, Reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer will use the Technology in compliance with all applicable
laws and regulations, and refrain from any conduct, use or misuse that may damage the reputation of FundAmerica or its subsidiaries
or affiliated entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Warranties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer will not make or publish any representations, warranties,
or guarantees on behalf of FundAmerica concerning FundAmerica&rsquo;s Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Content, Use, and
Protection Against Unauthorized Use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FundAmerica reserves the right to suspend or terminate any User
from using the API or Invest Now for any violation of the terms or intent of this Agreement, as determined by FundAmerica in its
sole discretion. Issuer is prohibited from using FundAmerica&rsquo;s API or Invest Now in any unlawful or unethical manner, or
in any manner that interferes with, disrupts, or disables the API or Invest Now or the networks or Technology on which the API
or Invest Now operates, or that is in any way a violation of the site Terms of Use of any federal or state laws, rules or regulations.
Issuer is solely responsible for the content of its postings, data and transmissions using the API or Invest Now, and any other
use of the API and Invest Now. Issuer will use its best efforts to prevent any unauthorized use of the API and Invest Now and immediately
notify FundAmerica in writing of any unauthorized use that comes to Issuer&rsquo;s attention. Issuer will take all steps reasonably
necessary to terminate the unauthorized use. Issuer hereby indemnifies and holds FundAmerica harmless for any and all violations
or breaches of this Section 3.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terms of Use, Privacy
Policy, Service Level Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as set forth in this Agreement, the Technology shall
be subject to the most current, then in effect, Terms of Use and Privacy Policy, as available via links at the bottom of the www.fundamerica.com
website. Furthermore, the Technology shall be available to Issuer in accordance with the Technology Level Agreement (the &ldquo;SLA&rdquo;)
as available via a link at the bottom of the www.fundamerica.com website. In the event of any conflict between any terms or provisions
of the website Terms of Use and the terms and provisions of this Agreement, the applicable terms and provisions of this Agreement
shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for the rights expressly granted in this Agreement, nothing
shall be construed or shall grant, convey, transfer, assign, or imply the conveyance of rights, claims, ownership or other claim
to any right or title to the technology, software, business processes or intellectual property of Issuer. Issuer will not acquire
any right, title, or interest in or to the API, Invest Now , or other software, technology, business processes, copyrights, trademarks,
or intellectual property of FundAmerica or its subsidiaries and affiliated entities by any reason, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) the execution and delivery of this Agreement, (b) the disclosure
of any information with respect to Invest Now or the API by FundAmerica either pursuant to this Agreement or prior or subsequent
to execution hereof, (c) Issuer&rsquo;s discovery of confidential information in the course of the commercial relationship contemplated
by this Agreement, or (d) any licensed or unlicensed use of FundAmerica&rsquo;s proprietary information, software, the API, Invest
Now , brand, or intellectual property and/or the creation or evolution of any derivative or new intellectual property, software,
information, arising from the use or misuse of the Technology. Rather, FundAmerica retains the sole and exclusive ownership of
all intellectual property and proprietary rights with respect to the API and software, Invest Now as well as business and technological
processes, including the sole and exclusive ownership to any improvements and derivative works of the API developed by Issuer or
any other person. Issuer hereby grants to FundAmerica a nonexclusive, worldwide, royalty free right and license to its copyrights,
intellectual property and proprietary rights strictly in connection with FundAmerica&rsquo;s development, integration, implementation,
hosting, marketing, advertising and operation of the Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FEES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees, Compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fees for the Technology provided under this Agreement are set
forth in Exhibit B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All Fees are incurred immediately at the time Technology are
ordered. Fees are generally payable via ACH debit to Issuer&rsquo;s bank account, in which case the parties agree that the definition
of &ldquo;investments&rdquo; in the &ldquo;ACH Debit Authorization Form&rdquo; is hereby expanded to include fees due hereunder.
Fees may at times also be payable out of escrow proceeds (paid to FundAmerica by the escrow agent before escrow agent sends funds
to Issuer), by credit card, or by company check or wire. No fee for any of our Technology is contingent upon the success or amount
of any investment in particular or the offering in general. No Fees are to be prorated for any partial periods, nor are they refundable
in whole or in part unless agreed to in writing by FundAmerica for the specific Technology for which any Fees were charged. Issuer
acknowledges and agrees that FundAmerica is no way is performing any duties of an underwriter, and is not in any way to be considered
a statutory underwriter as defined in the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each party to this Agreement shall be solely responsible for
their own federal and state taxes, and will pay their own taxes, duties, withholding taxes, and other governmental and/or regulatory
charges (collectively, the &ldquo;Taxes&rdquo;) resulting from or pursuant to its performance under this Agreement and as they
apply to its respective business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Late Charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any amount not paid by Issuer when due will be subject to finance
charges equal to one and one-half percent (1.5%) per month or the highest rate permitted by applicable law, whichever is greater,
determined and compounded daily from the date due until the date paid. Issuer will also reimburse all costs and expenses (including,
but not limited to, reasonable attorneys&rsquo; fees) incurred by FundAmerica or its subsidiaries and affiliated entities to collect
any amounts not paid when due. FundAmerica, may, at any time, in its sole and absolute discretion, suspend availability of the
Technology on any account which is late in payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MUTUAL WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mutual Warranties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each party to this Agreement represents and warrants to the
other that it has the right and authority to enter into this Agreement and to perform all of its respective obligations and undertakings.
Each party further represents and warrants that: (a) this Agreement has been duly executed and delivered and constitutes a valid
and binding agreement enforceable against such party in accordance with its terms; (b) no authorization or approval from any other
person is required in connection with such party&rsquo;s execution, delivery, or performance of this Agreement; and (c) the execution,
delivery, and performance of this Agreement does not violate the terms or conditions of any other agreement to which it is a party
or by which it is otherwise bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warranties by Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuer Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer hereby represents and warrants that the Issuer&rsquo;s
Offering and its Materials comply with all applicable laws, and will not infringe the copyright, trade secret, privacy, publicity,
or other rights of any third party. Issuer hereby indemnifies and holds FundAmerica harmless for any and all violations or breaches
of this Section 5.b.2. Issuer acknowledges that it is sharing its Issuer Materials with FundAmerica in order for us to provide
the Technology and perform under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Breach of Warranties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of any breach of any of Issuer&rsquo;s responsibilities
or warranties herein, in addition to any other remedies available at law or in equity, FundAmerica has the right to immediately,
in FundAmerica&rsquo;s sole discretion, suspend any related API features and/or Technology if deemed necessary by FundAmerica to
prevent or eliminate difficulties in the operation of Technology or harm to FundAmerica&rsquo;s reputation, or to prevent potential
litigation or other controversies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclaimer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, FUNDAMERICA
MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND WHETHER EXPRESS, IMPLIED (EITHER IN FACT OR BY OPERATION OF LAW). FUNDAMERICA EXPRESSLY
DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, QUALITY, ACCURACY, AND TITLE. FUNDAMERICA
DOES NOT WARRANT AGAINST INTERFERENCE WITH THE USE OF THE SERVICES OR SOFTWARE OR AGAINST INFRINGEMENT. FUNDAMERICA DOES NOT WARRANT
THAT THE SERVICES OR SOFTWARE ARE ERROR-FREE OR THAT OPERATION OF THE API, INVEST NOW OR THE SERVICE WILL BE SECURE OR UNINTERRUPTED.
FUNDAMERICA EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY ARISING OUT OF THE FLOW OF DATA AND DELAYS ON THE INTERNET. ISSUER WILL NOT
HAVE THE RIGHT TO MAKE OR PASS ON ANY REPRESENTATION OR WARRANTY ON BEHALF OF FUNDAMERICA TO ANY THIRD PARTY. ISSUER&rsquo;S ACCESS
TO AND USE OF THE SERVICES OR ANY API ARE AT ISSUER&rsquo;S OWN RISK. ISSUER UNDERSTANDS AND AGREES THAT THE SERVICES ARE PROVIDED
TO IT ON AN &ldquo;AS IS&rdquo; AND &ldquo;AS AVAILABLE&rdquo; BASIS. FUNDAMERICA EXPRESSLY DISCLAIMS LIABILITY TO ISSUER FOR ANY
DAMAGES RESULTING FROM ISSUER&rsquo;S RELIANCE ON OR USE OF THE SERVICES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warranties by FundAmerica</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FundAmerica Issuer hereby represents and warrants that the performance
of all of its oblgations and the provision of services pursuant to this agreement, including but not limited to the Technology
(including API and Invest Now), comply with all applicable laws, and will not infringe the copyright, trade secret, privacy, publicity,
or other rights of any third party. FundAmerica hereby indemnifies and holds Issuer harmless for any and all violations or breaches
of this Section 5.c. FundAmerica acknowledges that it is sharing the Technology with and providing services to the Issuer in return
for payment pursuant to this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LIMITATION OF
LIABILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclaimer of Consequential
Damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUER HEREBY ACKNOWLEDGES AND AGREES, NOTWITHSTANDING ANYTHING
TO THE CONTRARY CONTAINED IN THIS AGREEMENT, FUNDAMERICA WILL NOT, UNDER ANY CIRCUMSTANCES, BE LIABLE TO ISSUER FOR CONSEQUENTIAL,
INCIDENTAL, SPECIAL, OR EXEMPLARY DAMAGES ARISING OUT OF OR RELATED TO THE TRANSACTION CONTEMPLATED UNDER THIS AGREEMENT, INCLUDING
BUT NOT LIMITED TO, LOST PROFITS OR LOSS OF BUSINESS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer hereby agrees to indemnify, protect, defend and hold
harmless FUNDAMERICA and its officers, directors, members, shareholders, employees, agents, partners, vendors, successors and assigns
from and against any and all third party claims, demands, obligations, losses, liabilities, damages, regulatory investigations,
recoveries and deficiencies (including interest, penalties and reasonable attorneys&rsquo; fees, costs and expenses), which FUNDAMERICA
may suffer as a result of: (a) any breach of or material inaccuracy in the representations and warranties, or breach, non-fulfillment
or default in the performance of any of the conditions, covenants and agreements, of Issuer contained in this Agreement or in any
certificate or document delivered by Issuer or its agents pursuant to any of the provisions of this Agreement, or (b) any obligation
which is expressly the responsibility of Issuer under this Agreement, or (c) any other cost, claim or liability arising out of
or relating to operation or use of the license granted hereunder, or, (d) any breach, action or regulatory investigation arising
from Issuer&rsquo;s failure to comply with any state blue sky laws or other securities laws, and/or arising out of any alleged
misrepresentations, misstatements or omissions of material fact in the issuers&rsquo; offering memoranda, general solicitation,
advertisements and/or other offering documents. Issuer is required to immediately defend FundAmerica including the immediate payment
of all attorney fees, costs and expenses, upon commencement of any regulatory investigation arising or relating to Issuer&rsquo;s
offering and/or items in this Section 6.3(a) through (d) above. Any amount due under the aforesaid indemnity will be due and payable
by Issuer within thirty (30) days after demand thereof. Furthermore, Issuer shall protect, hold harmless and indemnify FundAmerica
and our officers, directors, members, shareholders, employees, agents, partners, vendors, successors and assigns from and against
any and all liability related to Issuer&rsquo;s business and business related operations and affairs, and use of the API, Invest
Now, the Technology or any breach of the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MUTUAL CONFIDENTIALITY
OF INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definition of Confidential
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As used herein, the &ldquo;Confidential Information&rdquo; means
all confidential and proprietary information of a party disclosed (&ldquo;Disclosing Party&rdquo;) to the other party (&ldquo;Receiving
Party&rdquo;), whether orally or in writing, that is designated as confidential or that reasonably should be understood to be confidential
given the nature of the information and the circumstances of disclosure, including the terms and conditions of this Agreement (including
pricing and other terms reflected in all Account forms hereunder), data, business and marketing plans, technology and technical
information, product designs, API designs, Invest Now , and business processes. Confidential Information shall not include any
information that: (i) is or becomes generally known to the public without breach of any obligation owed to Disclosing Party; (ii)
was known to Receiving Party prior to its disclosure by Disclosing Party without breach of any obligation owed toe Disclosing Party;
(iii) was independently developed by Receiving Party without breach of any obligation owed to Disclosing Party; or (iv) is received
from a third party without breach of any obligation owed to Disclosing Party. All intellectual property, work product, software,
code, and other proprietary information or work product of both parties to this Agreement is expressly agreed to be Confidential
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each party agrees to protect the confidentiality of the Confidential
Information of the other party in the same manner that it protects the confidentiality of its own proprietary and confidential
information of like kind, but in no event using less than reasonable care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Receiving Party discloses or uses or threatens to disclose
or use any of the Confidential Information of Disclosing Party in breach of the terms hereunder, Disclosing Party shall have the
right, in addition to any other remedies available in law and equity, to seek injunctive relief to enjoin such act, it being specifically
acknowledged by the parties that any other available remedies are inadequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TERM AND TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement shall become effective on the Effective Date
and shall continue for the duration of the Offering (the &ldquo;Initial Term&rdquo;) and for ongoing post-sale-of-securities data
access, reporting and investor &amp; cap table technology unless terminated earlier as provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Either party may terminate this Agreement upon thirty (30) days
written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon expiration or termination of this Agreement, (a) Issuer
will cease using the API, Invest Now, dashboard(s), and all associated Technology and FundAmerica will be relieved from any further
obligation to provide the Technology; (b) each party will retain all rights and claims arising hereunder prior to the effective
date of any expiration or termination; (c) the rights and obligations of the parties under Sections 3.2, 3.7, 3.8, 3.9, 3.12, 5,
6, 7, 8, and 9 will survive an expiration or termination; and (d) FundAmerica will continue to hold data and maintain records as
required by securities regulations and/or good business practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All notices permitted or required by this Agreement will be
via electronic mail (&ldquo;email&rdquo;), and will be deemed to have been delivered and received upon sending via any nationally
recognized and trusted SMTP delivery service. Notices shall be delivered to the addresses on record which, if to FundAmerica shall
be to support@fundamerica.com and if to Issuer shall be to the email address on file in their account on apps.fundamerica.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Implied License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as expressly provided in this Agreement, this Agreement
is not intended and will not be construed to confer upon either party any license rights to any patent, trademark, copyright, or
other intellectual property rights of either party hereto or any other rights of any kind not specifically conferred in this Agreement.
All right, title, and interest in and to the Technology are and will remain the exclusive property of FundAmerica.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any provision of this Agreement is for any reason found to
be ineffective, unenforceable, or illegal by any court having jurisdiction, such condition will not affect the validity or enforceability
of any of the remaining portions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independent Contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Performance by the parties under this Agreement will be as independent
contractors. This Agreement is not intended and shall not be construed as creating a joint venture or partnership, or as causing
either party to be treated as the agent of the other party for any purpose or in any sense whatsoever or to create any fiduciary
duty or relationship or any other obligations other than those expressly imposed by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limited License
of Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the term of this Agreement, Issuer has the option to
generally use FundAmerica&rsquo;s name, logo and trademarks on its website and other marketing materials so long as such use is
not construed in any way to imply that any securities offering or transaction is endorsed, recommended, or vetted by FundAmerica
or its subsidiaries or affiliated entities, or that Issuer is authorized to act as a securities agent or a representative of FundAmerica
or its subsidiaries or affiliated entities. Furthermore, it is agreed that FundAmerica, has the option to use the name and logo
of Issuer in publicly disclosing the existence of this business relationship subject to obtaining the prior written approval of
the Issuer in each instance of use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Legal, Tax or
Accounting Advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer agrees without reservation that FundAmerica is NOT providing
any legal, tax or accounting advice in any way, nor on any matter, regardless of the tone or content of any communication (oral,
written or otherwise). Issuer unconditionally agrees to rely solely on its own legal, tax and accounting professionals for any
such advice and on all matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Investment Advice
or Recommendations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer agrees that FundAmerica is not providing any investment
advice, nor do we make any recommendations to any issuer of, or investor in, any securities. Issuer agrees that it will only rely
on the advice of its attorneys, accountants and other professional advisors, including any registered broker-dealers acting as
an underwriter of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Electronic Signature
and Communications Notice and Consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Digital (&ldquo;electronic&rdquo;) signatures, often referred
to as an &ldquo;e-signature&rdquo;, enable paperless contracts and help speed up business transactions. The 2001 E-Sign Act was
meant to ease the adoption of electronic signatures. The mechanics of this Agreements&rsquo; electronic signature include your
signing this Agreement below by typing in your name, with the underlying software recording your IP address, your browser identification,
the timestamp, and a securities hash within an SSL encrypted environment. This electronically signed Agreement will be emailed
to Issuer and FundAmerica and will be stored on the Technology and accessible in the Control Panel. Each of Issuer and FundAmerica
hereby consent and agree that electronically signing this Agreement constitutes each party&rsquo;s signature, acceptance and agreement
as if actually signed by that party in writing. Further, all parties agree that no certification authority or other third party
verification is necessary to validate any electronic signature; and that the lack of such certification or third party verification
will not in any way affect the enforceability of your signature or resulting contract between Issuer and FundAmerica. Each party
understands and agrees that their e-signature executed in conjunction with the electronic submission of this Agreement shall be
legally binding. Each party agrees that their electronic signature is the legal equivalent of their manual signature on this Agreement
consents to be legally bound by this Agreement's terms and conditions. Furthermore, each of Issuer and FundAmerica hereby agree
that all current and future notices, confirmations and other communications regarding this Agreement specifically, and future communications
in general between the parties, may be made by email, sent to the email address of record as set forth in the Notices section above
or as otherwise from time to time changed or updated and disclosed to the other party, without necessity of confirmation of receipt,
delivery or reading, and such form of electronic communication is sufficient for all matters regarding the relationship between
the parties. If any such electronically-sent communication fails to be received for any reason, including but not limited to such
communications being diverted to the recipients&rsquo; spam filters by the recipients email service provider, or due to a recipients&rsquo;
change of address, or due to technology issues by the recipients&rsquo; service provider, the parties agree that the burden of
such failure to receive is on the recipient and not the sender, and that the sender is under no obligation to resend communications
via any other means, including but not limited to postal service or overnight courier, and that such communications shall for all
purposes, including legal and regulatory, be deemed to have been delivered and received. No physical, paper documents will be sent
to Issuer, and if you desire physical documents then you agree to be satisfied by directly and personally printing, at your own
expense, the electronically-sent communication(s) and maintaining such physical records in any manner or form that you desire.
Your Consent is Hereby Given: By signing this Agreement electronically, you explicitly agree to this Agreement and to receive documents
electronically, including your copy of this signed Agreement as well as ongoing disclosures, communications and notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No party may transfer or assign its rights and obligations under
this Agreement without the prior written consent of the other parties. Notwithstanding the foregoing, without the consent of the
other parties, any party may transfer or assign its rights and obligations hereunder in whole or in part (a) pursuant to any merger,
consolidation or otherwise by operation of law, and (b) to the successors and assigns of all or substantially all of the assets
of such assigning party, provided such entity shall be bound by the terms hereof. This Agreement will be binding upon and will
inure to the benefit of the proper successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Absolute Standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of the Technology are provided under a &ldquo;reasonability&rdquo;
standard. This means that no service may be held to an absolute or perfect standard. All services are provided &ldquo;as is&rdquo;
and in such a manner that they are reasonable, and not perfect or flawless. Issuer acknowledges this and agrees that this is fair
and acceptable, and that all applicable sections of this Agreement apply to this concept, including, but not limited to, Sections
3.8, 3.9, 3.10, and Sections 5 and 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Binding Arbitration,
Applicable Law and Venue, Attorneys Fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement is governed by, and will be interpreted and enforced
in accordance with the laws of the State of New York without regard to principles of conflict of laws. Any claim or dispute arising
under this Agreement may only be brought in arbitration, with venue in New York, New York pursuant to the rules of the American
Arbitration Association. Issuer and FundAmerica each consent to this method of dispute resolution, as well as jurisdiction, and
consent to this being a convenient forum for any such claim or dispute and waives any right it may have to object to either the
method or jurisdiction for such claim or dispute. In the event of any dispute among the parties, the prevailing party shall be
entitled to recover damages plus reasonable costs and attorney&rsquo;s fees and the decision of the arbitrator shall be final,
binding and enforceable in any court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts; Facsimile;
Email; Signatures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement may be executed in counterparts, each of which
will be deemed an original and all of which, taken together, will constitute one and the same instrument, binding on each signatory
thereto. This Agreement may be executed by signatures, electronically or otherwise, delivered by facsimile or email, and a copy
hereof that is properly executed and delivered by a party will be binding upon that party to the same extent as an original executed
version hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Force Majeure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No party will be liable for any default or delay in performance
of any of its obligations under this Agreement if such default or delay is caused, directly or indirectly, by fire, flood, earthquake
or other acts of God; labor disputes, strikes or lockouts; wars, rebellions or revolutions; riots or civil disorder; accidents
or unavoidable casualties; interruptions in transportation or communications facilities or delays in transit or communication;
supply shortages or the failure of any person to perform any commitment to such party related to this Agreement; or any other cause,
whether similar or dissimilar to those expressly enumerated in this Section, beyond such party&rsquo;s reasonable control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interpretation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each party to this Agreement has been represented by or had
adequate time to obtain the advice and input of independent legal counsel with respect to this Agreement and has contributed equally
to the drafting of this Agreement. Therefore, this Agreement shall not be construed against either party as the drafting party.
All pronouns and any variation thereof will be deemed to refer to the masculine and feminine, and to the singular or plural as
the identity of the person or persons may require for proper interpretation of this Agreement. And it is the express will of all
parties that this Agreement is written in English and uses the font styles and sizes contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Captions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The section headings in this Agreement are intended solely for
convenience of reference and shall be given no effect in the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are no third party beneficiaries to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement;
Amendments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement sets forth the entire understanding of the parties
concerning the subject matter hereof, and supersedes all prior or contemporaneous communications, representations or agreements
between the parties, whether oral or written, regarding the subject matter of this Agreement, and may not be modified or amended,
except by a written instrument executed after the effective date of this Agreement by the party sought to be charged by the amendment
or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SUBSTITUTE FORM
W-9- TAXPAYER IDENTIFICATION NUMBER CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 6109 of
the Internal Revenue Code requires us to provide you with our Taxpayer Identification Numbers (TIN).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Name: FundAmerica, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact: Accounting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: 2300 W. Sahara Ave., Suite 1170, Las Vegas, NV 89102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax ID Number (EIN): 81-3263611</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[X] We are exempt from backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under penalties of perjury, FundAmerica, LLC hereby certifies
that the number shown above is our correct taxpayer identification number, that we are not subject to backup withholding, and that
we are a U.S. person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-11 CONSENT
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: #000000"><B>Exhibit 11.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #000000"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: #000000">We consent to the inclusion in this
Offering Statement of Glucose Biosensor Systems (Greater China) Holdings, Inc. (the &ldquo;Company&rdquo;) on Form 1-A of our
report dated December 28, 2017, except for the effect of the stock split described in Note 1, as to which the date is June 7,
2018, with respect to our audit of the financial statements the Company as of June 30, 2017 and for the period from August 4,
2017 (inception) through June 30, 2017, which report appears in the Offering Circular, which is part of this Offering Statement.
We also consent to the reference to our Firm under the heading &quot;Experts&quot; in such Offering Circular.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000">/s/ BDO </FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">BDO East Coast Partnership</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Sydney, Australia</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>September 7, 2018</TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-12 OPN CNSL
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" TITLE="LetterHead" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-size: 10pt"><IMG SRC="tv502124_ex12-1img1.jpg" ALT=""></TD>
    <TD STYLE="width: 52%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Hughes Hubbard &amp; Reed LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">One Battery Park Plaza</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">New York, New York 10004-1482</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Telephone: +1 (212) 837 6000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Fax: +1 (212) 422 4726</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">hugheshubbard.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">September 11, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Glucose Biosensor Systems (Greater China)
Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">733 Third Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Floor 15</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Re:</TD><TD STYLE="text-align: justify">Glucose Biosensor Systems (Greater China) Holdings, Inc. (the &ldquo;<B>Company</B>&rdquo;) Offering
Statement on Form 1-A (the &ldquo;<B>Offering Statement</B>&rdquo;)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as special
United States counsel to the Company, a corporation incorporated under the laws of the State of Delaware, in connection with the
filing of the Offering Statement under Regulation A of the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;),
with the Securities and Exchange Commission relating to the proposed offering by the Company (the &ldquo;<B>Offering</B>&rdquo;)
of up to $25,000,000 in shares (the &ldquo;<B>Shares</B>&rdquo;) of common stock, par value $0.01, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of rendering
this opinion, we have examined originals or copies (certified or otherwise identified to our satisfaction) of :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Certificate of Incorporation, as originally filed on December 5, 2016 and as amended to date, as filed with the Secretary of State
of the State of Delaware;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Amended and Restated Bylaws of the Company in the form filed with the Securities and Exchange Commission; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resolutions
of the Board of Directors of the Company adopted by unanimous consent, including on August 12, 2017, October 30, 2017,
November 5, 2017 and December 26, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also examined
such other certificates of public officials, such certificates of executive officers of the Company and such other records, agreements,
documents and instruments as we have deemed relevant and necessary as a basis for the opinion hereafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In such examination,
we have assumed:&nbsp;(i) the genuineness of all signatures, (ii) the legal capacity of all natural persons, (iii) the authenticity
of all documents submitted to us as originals, (iv) the conformity to original documents of all documents submitted to us as certified,
conformed or other copies and the authenticity of the originals of such documents and (v) that all records and other information
made available to us by the Company on which we have relied are complete in all material respects.&nbsp; As to all questions of
fact material to this opinion, we have relied solely upon the above-referenced certificates or comparable documents and other documents
delivered pursuant thereto, have not performed or had performed any independent research of public records and have assumed that
certificates of or other comparable documents from public officials dated prior to the date hereof remain accurate as of the date
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing
and on such legal considerations as we deem relevant, we are of the opinion that the Shares, when issued and delivered against
payment therefor as described in the Offering Statement, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing opinion
is limited to the Delaware General Corporation Law, as currently in effect, and we do not express any opinion herein concerning
any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinion expressed
herein is rendered as of the date hereof and is based on existing law, which is subject to change.&nbsp; Where our opinion expressed
herein refers to events to occur at a future date, we have assumed that there will have been no changes in the relevant law or
facts between the date hereof and such future date.&nbsp; We do not undertake to advise you of any changes in the opinion expressed
herein from matters that may hereafter arise or be brought to our attention or to revise or supplement such opinion should the
present laws of any jurisdiction be changed by legislative action, judicial decision or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our opinion expressed
herein is limited to the matters expressly stated herein, and no opinion is implied or may be inferred beyond the matters expressly
stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to
the use of this letter as an exhibit to the Offering Statement and to any and all references to our firm in the offering circular
that is a part of the Offering Statement.&nbsp; In giving this consent, we do not admit that we are within the category of persons
whose consent is required under Section 7 of the Securities Act, or the rules and regulations of the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Hughes Hubbard &amp; Reed LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Hughes Hubbard &amp; Reed LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tv502124_ex12-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_ex12-1img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 8P"+ P$1  (1 0,1 ?_$ ,D   $$ P$!
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MG\M:7'4Q 702@^/I<@$;D62L S@/ZPN0FK;46=;5<-;2SCR2H< . ' #@!P
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M %5B9 '4RF*>KV.2\*QR61>6/K8KLY\D];V(YV(XJW%I0(U+> 30B'DXW!
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M;N#JQ3$@7Q.U=@:F@DG:&P#T]1Z139C1/3&S&@P:2[/S;E6)8QMIY.?.6>K
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M&]\CB<\9U^RK$8!Q2QIX7NSW$'EJ4)AD+D!ZUP)ZB*-(5&!,$64_";:&\O\
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MCKCQZ]/'@!TQ\.F.GPX!G@!TX < QTQ\>F.OX^G^7X^ 9X < . ' #@!P X
M< UC<Y]8O'A_O8SX_LY\>OAX?@Y7*JOK7@FEWY7A*7\9Y%Q1FY(37X2E)Y\^
MW^&/[;WF^.?A\TZ=?A\.GCSI]U?UN8R4GU!S\6R,<>;^%L.//9:98Z_0]M^I
MXM\S.'P9=DYS#.Q(< . ' #@!P X < . ' #@!P X < . ' -!3_ "F/UNOI
MX_5_6_7_ &>OZ/F_+RM<;\417FWX;Y_>,=7CIACOPXJ8\A7(_P#3[TO_ ,MO
M[1__ ,G?+\Q]W_I^]3K_ .%>?^#GTO\ TW)_O'V<_LL9<W^7_E<Q\1_HK)_U
/S[1?XCQ9_P"^_D9Y#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tv502124_ex6-7img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_ex6-7img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ =0%L P$1  (1 0,1 ?_$ )4  0 !! ,! 0
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M\1./V!O%,<I>/(>.1X#GT#_4< !R";Q Y1-QSX@8!'@/3G@!Y^.!5@,!@!$
M#D?0 P.,54P^)R '( ')@#U,/B4/S"'J8WH'WC@2!RB(  ^H\^GV\E'@0_R'
M KP(,/ <\"/X!\?AS@04Y3"( (<@ "(!Z\<_\X%6 P*#' G'/P' H!=(QO #
ME$_CY@3D/(2 (!Y<?=Y>F!6!^1XX_P!_^V!7@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@!P-<GU%)]6Q4C5'6&,=JISW:[<U0UD_10!9-P75\0]3M
MNVGHBF8HF:%J409HJ'/!RO/$?C@<^IGC*T]]]TN:\1D2E:%T-KK2X&9B/R4?
M;)R;=6UQ",P(F#=(\1 1[<BQ 'R(4Z8<<8&>TZFXD8>19Q;DC>0>,7:$<]\0
M5*S>K-E4V;XQ!*8#IM')BG$! 0'QP,.^@.W+;M_0Z;S8$J-@OVO-@;,T[=;(
M*#9N2S6#6UM>P8V!))JDBB0LG&$;J"!2@'D(^F!G%@,!@><MUF@Z96YJVV:6
M9P5=K<:]FIN8D%"HL8V,CFZCMX[=*&$ (DD@D;[>>> #UP-=<+6I_NY7G.S=
MTQMBH_7%9!_+ZHU1'SEBJ]GN#!DDZ^1V1M%]"N(R0;!(%1(\AXA,Y0;E,FJL
M!S\%P,R>NE<MU4TIJV O,RO/6F)HT"QFI1PNL\7=ND6A/;,N^<@5T]<)-C$(
M=93\ZQBB<P\B.!>[ XU#"!0X^)C 7GCGCD?4> ]1X# Q!Z?[.LVYZQLC:$X^
M<KP%BW3L>)UNQ42;IL6.OJ1-GI,2M'>VB1P)):0A'3I45CJ'%PJ?CQ()0 ,O
MP.41\>0$?S>@#SP)?B']0P*\#X\Z^1B8M]+N ,*,4T=2*OC\?99-E7*_(_#Q
M%!(W/^6:UDNV*-=_TPKY=-G=>K+>MA3<M/6>;WSN6046F'B[P\=$2M@0F*_"
MQPK*'^5B(R#?MB-FY/[:!>2E#.7;QO,?4GALG+Z%#_'Q]<V)P& P& P& P&
MP& P& P& P& P& P& P& P& P& P&!H3^H'V+MNHOJ%=?$Z#K63W#>*CU\OK
M^@TJ/2<N6S2[;3MS"EH3TLBR06<)-$(^.! 5A,BFD"P"HH0@B(!?&NLK=U+U
M9JC2,0X"S]N.X6R[!.7BS-3D74AK!/(+3VTMANE3B)#P6JH%1!E&E, )J+$1
M3#T,.!=GJJYGJGV"WCJ!MMN];?HNJ:-K9"UVC9,NC,OH_<EA<SDQ.1<5- F@
M1,@UTZ*SN/\ 4C$QD"@("8P8%K?I;[1U=%::EZY*;'H;*_[+[,=E+/#49Y;(
M-M;GB+S:-@;M4VM?6>EE7"IX^(*J4"I")DQ\@],#-;6W;O1FV-N7+2M%N:<]
M=Z0T?/9)-LP=A R*,5))P\V2M60R?Z79%J]+*D;2!6IU/E%Q\#^H#P%D]M]F
M-YS>[U="]4]=5:Z2^OG%-F-[WZ\/7+2ETN"LL@C[=3ABQ[E!Y+7YQ BH^42Y
M\&;<I1.0YCE+@;!D>?;)S\1#D?B'Q]?M]?A]^!KM[H*N-I[0ZQ]3B+G&M;5O
M$YL7;S9!P=N9_J33D<A/.ZXZ]L?)6,M=K=L6;E,0\5D"G3-R41*8-@Z3)LDQ
M1:)())-44$DD&Z*1$T$4TTP32221*0$DT2)@!0+X^(!Z<<8&"N]>W=GK&W6G
M6O0.N%=J[K+ 1=MN2BP.$J-IRD3,@2%A[)>7,>/SSU[)NU2JMXMD'S)F1#KB
M($ H&LF;@6^K'?.U2M"+7'>OX&1[3H;>L^BI+5,#-2 UB/M%4E$FTO?Y&?>M
M"R$;K!"'>-WQ7"B7OK>Z""0&4Y$N[K).$7CT9V'O6Q)/L%K/8]7KU9VQU_E(
MUC,MZK)2#^N6>$M544L57ML$K*(-Y!O'2!2J)&34 PIJ)"'EZ9S5:?H]L>J:
MH^F]JC:%MD$FM;J6K;+=[@\3**[CR1L%FEYGV4B"4SA^^D/--(/BNJ)>.1,
M"'P(W?/:NIVC3&UMF#1VNINP^S:MK>)T4A "SV#K5A?6CIY2[8M;2O%%;).&
M;LQ4F8TS9--HD81*</:-@;12.">) ,=,3CQ^4AOOY]0 W'W?A@6*WMMO7=)U
MKM5S9;3#MBUFE.5K-'MG(R<Y$,K2V<PT"X>0D45U,MD)>17!)!04? _J8!X
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M^/ZX$@' <<\_C@3@,!@../A@,!@,!@,"./4!Y]/NP)X_V^'X8#C[?M# @0Y
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M@<+*W ZC1IUPC]MZ\MZ2QQ%Z"NGKG9:X@S3Y*8PO)-E&-2MTC%\^5TR^/(@
MA;KZ3C.S;%@NP_;Z_ J%N[-[@DW,:@J*Y@B=?T$5X2M0S,RX!Y,8]\Z>HD,F
M/@<J(&#G[ V]%$>0#D./NX_YP.; XS!R8./3T^/^N!6 <!QSS^.!. P& P&
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/U_Q_L& P& P& P& P/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tv502124_ex6-7img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_ex6-7img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ =P'K P$1  (1 0,1 ?_$ +0  0 !! ,! 0
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M#6,2QN%6D$(J&4 H;]?S#R\_T#4N>T$"HJ30>9\/B44?G_)W#,=E>M81=WR
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M5@/6*_<;O#TA])1SQ!^S/(TAG825ITU*\;)J"W^7!$PIEW+T#6\?WGW?.?\
M<7$;H:%O'@TO((IK)0'0=.JAL<;=0353^(40VW -MMO+J'ET -N@:YUT49<9
M *N*MYJ\Q"FVW* B'AON/L'_  U5\3)"'2-!(\T!HK13 =OA#SZ[]0Z" !N'
M7;K^6H+' B-O^2=S74>04U"ZQ"TJL5V6L4W"5^&BY6W/&TC9Y)@P;M'\\_9-
M2,FCN7=(D*M(N&[,A4R'5$QBD+MOL.O5//-=1,AN"71P'\,5VZ_+50"NT]@>
M(@&^VP]1'\.H^737D$+7'W7M#9CN1X#S4U6O<J8MHN9:+8<;9)K<=;*3:F!X
MV>@I,IS-GC8QR*IB!TC)K(KH+IE434(8ITU"@8! 0UZ+>YN\;=,N[%Q:YM>O
MC^^JA:)Q?PPPEBE_$R4*PMEB>5X$@K9LA7VW9 ;UTJ ""!85C:)1_'1YFP"
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M,SHIN_'>28MD+RP#78#M-]*69IF;IHF$!2 1Z?2KJ*S[MP=J['W+;6\@CI)
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M*8LC\4&A'TFQJMCKCQJNQE<@1$W'JMGBKU5RLW==OI=J9>XFNEOKL]NQP6^
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M[4RC-LY.0#)ID,8!#NWVUZ#?W]Q9PVEV:LA! \J^"%;,UA4(([=1T14 P#T
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MCMU'5D0!WZAHBH8-PVWV]_\ ZZ(J 4  /,0\]NNB*[1$T1-$31$T1-$31$
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MBQL3!&UHII5H^IPZ$G0ZI4;C=>@4'5;7]3<N;);&;J)3,F$)7J["F@6K!NB
M@F1^\,_>NY0Y"[% "@W1[0_DZ].'#X&ND;"'$2.Y$NW'P^*%;/ -@ /9TZ=
M_B.H4*NB+&/<4=B[#OUV$=MOP]VB*\-]@W\?/;1%71$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT16$[MA$1W 1^'\-$5^B)HB".W4=$6$5-AWWZ;[>'^F_4=>>68,](^LD ?:G
MQ44N0&>WE(>P>,L=0I+OFZ]$<C5JHFL";.#B41!![>+@[,4R<56(914@B)MC
MN5=DT^HCK>X7M^UO9#D<E*8K*V(=)4_4*_0!U#MG'H#52'!QH-U%-S;(;BO+
M.*#3&LQRAYRYD.6<G6978IN2I.##Z4_=9</F&N*\0UD"#\LW$2J+E+VI)J*&
M$P=$^PNNYYY+^9_],[$A(UXAQ#&T!CMVFGNNE^DO!'MUY:THLC&T-2MX8$XN
M24);ASOR%LC3*_)"19"@C8&[([.EXN@W0BJ:E8M@#J"G&LFO=VN9)3=^_/N=
M02ATUJ,SWAC[RV.![.@_(]KL(#8R[W)Y7-W?(_?4Z\:T&REVRG.F $V -@*
M#^GXCUUR\ >QA,NLA/S6'JACE P#W!L/@/B ]-MNF_77H )%1OX=4HN'G[!%
M5R(>S<]*1L+#1J"CJ2E9AXA'1K%LB'>HX>O7)TV[9$A?]QQ  U$<5S>'V;)K
MS<$T #:G[%(7ESDGG3<\N,;=$\):K&6R IS26"Z\HL@>O&80I3B.:J*NF5-0
M.5"3RQ<$?3,"+9D"<>5;L!9QL/8;M<%V9CK"XCE[ON)A(_40L:7N>*_2:$<
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M-1K5D4?P*J$@QD9$J,:/<8[DY4SB!2'[@@U"A=DK[T%RL'$WGA=\.83BJWR
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M%;;K_+XXQPS81Y !2<R%8B%771[#'78ME!,']0QM3C(<G+@I^^<M*?>FD?!
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M>?IY&G > '@E0-EL8 VVZ?GK QI91HU;U/5157;!X[=?;K(H31$T1-$5HCY
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M@ %*[&F,JSBZ'^BUM!<Q7!_FI26DG*DA.SDB<H>M)3,FL(K/72FWGL0@="@
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ML?\ (/D&WZ:(J&'N#J.W3H;ITW]GEN.L,['21%C=RE::E>:&0<4YXA,_9*Y
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M+B.[?U9N,GRPG95FS%=JMH/88:4I][E2M7'4@:^:-%-3NO5WT2%3["E H
M4"E[0*!0 I *!>A0 .G3R#7RF-DK7N?*\O<XU->BL354*<I%.WN#^0-Q,'\O
MGX;>>LRA?40V^VP@8!W'< V /'PT15. @(&#RW[OX!HBM$PCT$?X:(LA #8!
MVZ]>OYCHBNT1-$31%:8VVX /7]OR\-$52CN "/[==$5=$6,Q@ZEV'?\ #I[?
M'1%CWVZ_ZZ(LA.X1$1'X1VV_]/+1%>8=@$0_;KHBP;[#W  ;^_\ TT19RCN
M"/CHBM$X .P[_H.VB*P^V_MWV]_[>&B*X@&$PF'P'P_@.B*_M+OW;!O[=$5=
M$31$T1-$31%38/8'Z:(JZ(FB+Y'+5-R*(J)HJ"@J59$52>IZ2I=R^H0.G:IZ
M9S  ^6^B+Z@Z!^W[_'<=$5=$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$U!-!5%U"Z6V I%:FKA:9-G"5FMQCZ8G)=^L5!LQC8]N9PY7.8YBE-VD*.P
M;[F-\(=1#41PW%_/%8V3'/N9WAH '3[U?"@U0"J\X<&P4GR5R#_YI9N9JUC'
M%1:2!^,&.[.8C=C6:D3O.[SG:HUZ"96]NMK9,%&9E=A81Y0[-A4$==ED[B+
MV;^TL*62Y&0L,SAK2AKP:[P\?^ZOQ/'ET6TEK)>N6[N:KE*--XZXWM7)HJ=R
M.BLYAKQEY-$3#(0V-@,BDXK]*<G_ **\V;9PY2$2M"@!A5#QRVUMV]P?=!LF
M7D;5K1ZFMJ/OGH1X>*JIAT.A53&M:AJ=2H..KE6@62;&'A(MN5!FQ;E#N-V]
M3*JJKG$3JJ*&.HJH(G.8QA$=<U--<WMQ^9NS^(*TH4^"[L!BCT#^'LU*A#_R
MC^7\0T14((; 'GUZ:(AR%.40'SZ;Z(HX\F^2-#XN8X/?;N+U\=V])"U>M1"1
MW,];K(X2.=C P[-%-1559?TQ$YP*())@)A >@:VV"P;^Y+P6,;VQ1T+G/<>(
M ;J?B3T'5"-%YG5WC#G3GL_2R-S#>SN/,4J./5J''Z&=.8Y$D(4B+IF_DBIJ
M'%Q)R!3=JSIZG\PD'PHIDZ#KZE+W/VYV#:_TKM*VCGRI'JNG@<F.&_$:U\*!
M5#2#KLO6W$^(,:83J#"D8JI<!1JLR(4R43 QZ+--942 !G;Y8H?,R#Y4 ^-9
M<QU3#XCKY+E<QG,_>F^S]R^[NJGB]Q^AM*<0-J?!7KI1;-V#RV#SZ!MU\Q_'
M6O:T,]+1H=RH60@EV\MP]OZ^/X:LBM$"F,.P .Y0#?;S 1$=_P M$60I0* =
M W#V!HBKN&_;Y^S]^B)L'L#] T14$Q2; /3?PV#]O;HBNT16@;<PE]GC^?Y:
M(KM$5/AW\M_RWT15Z 'L -$5I3@?<0\M$5=PW[?/V?OT18Q$"G#?IOX;?I_'
M1%E'W>.B*P!   #CN.W7IO\ X:(J"7?J&VP^'E_AHBO*&P &B*NB*@% .@!H
MB;AOV^?L_?HBKHB:(@CMU'1%A_F.(!Y@&P[#MOY_NT190Z  >[1%71$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T14-OMT_;\/?JKN6
MG'Q%?A75/BO*O[FT[(L:WAQM;:?;[!QQ;WU>R9Z&HO8-DYDV=<105HM+EW4[
M+0S)G6[/;5TC/EE%BI&00],P[G#7T#]/A&'9"6)_',F+C; -+C0_YKBT:BC*
MTHE1YT6UHAI<\O0IKAR%85O"&!6L='J1N*I*T0BHRT6D"*["0R+962[:NQL4
M='M*G&M7"J!DP*5102_".E][%8AS[3 M=>Y^8GWY2*F,]0!J?+4!>@D"$[[J
M<<,$.6-CRPYHT8@&* 1GTL$?IOT\"A\M\@9N8S86?I;=@D$2"&VVN<<)O<<Z
MX+C*3K7<+S<JC8KES"7M#8/'8 V#KM_';8-0E59U\A$!Z@ [".WY:)57")MM
MAW$.G7MV_P .G71*JA1^(/']!]@Z)59>X/8/_2/^6B5^*ZI/%JYW4$%D- $?
M?4C!6AF?IWS8S(ME=Q@_GOZP2?R@GZM_ZOI]WEOJS!<ECFVG*G4MKM7K3I\5
M-5V<GI@  '7\A'K^/MU@:QP<"]U7I7I0U5!'<1'80]P@(#TZ>&LJBJIO^VVB
ME7 .X@)@*7;< #V^/71154$0 2^F #MOT]OO#;?1*J\#&WZ@(!Y@ #_EOHE5
M7N+OX#O_ /J._P##?PT2OQ5@G-O\)3"'38!*8/W[:)56]P"8OJ (>.P"4=NG
MLW#KHE5E$P_[0'?\!#;W^&B U5A1V.(=1$ ^(1*/GX;]-%*R@/N'\PT16AV=
MP[;=WG[?T\=$5I^[<-M^T '?IX^/NT15)V@'38>O7MZ]?R]VB*HB ^ ;&]X!
MO^_KX:(K VW$5/'<.W?Q_(/QT19=^F_7].OZ:(L)Q^+SZ[>0].GG[-$60I@V
M -A_'M';Q_#1#HKM_P ?T'_+1$W]P_IJ:*:*G<'L-_TF_P M**#HK1$!W -P
M-Y#VCN [>\-0HK\4 1W#J;;WE'?P_#VZ)7XJ_N]P_P#2/^6B5JJ;AX" [>\!
MVT4JNX>P>GN']VBBJH(].F^_3R'_ "T2JLW/[_\ I_TVT5J*X##Y@;?V]H[:
M)16"H?<0*01#VB!@_P -$HLA3;^(" [=>@[?D.W710=%7?\ ']!T2J ._D(?
5CHBKHB:(FB)HB:(FB)HB:(FB+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tv502124_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Q0*1 P$1  (1 0,1 ?_$ -P   $$ @,! 0
M       &!P@)!0H" P0!"P$  00# 0$               ,$!08! @<("1
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M[E_Q-N+!W^\;O>,Z^RR?'J6(\I12N;1)QN6VE6Z5 C5M'?,VX+Z/=^'%N</
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M6:P_>YKG636"GKC+LSR*9N_.L9KKC[SAVW2A*$)J^\[UN._9S;AN<G7.0
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M?O#<?CIRF0J"W23]M)9.V[MD*4$A53X<?LI'?X*\@AY158W#KZ0ZI$@V4_W
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ML-5:]C[*\Y6XT26UJ1UZ]BBGI\.H(/QT D<*"JDW/&HZ<R^*'C'Y"1'XG-W
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M\Q\2\C<:V#;BD+1FF)W-(RXL*(*F;&9%17S I6Y[FGG ?7?TUE6*M<<:<I)
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MX>Y]*0=FY47D7&E<I\5MR_0$1.0>+78S!43LNU4$]5=;SL/_ )CVEN^SG62
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MP%@K[=^T*&_J-%8M7(I&^Q W'3T_#16:XK;;<2$N(0XD'N"5H2M(4.@4$J!
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M:<;\#Q9G)-]R7QSC.,9KF6597EU_53%Y%&O;:TA)M+<U+$QG':"80I$5(3\
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M'O?3QO\ II5[ ? :V\Z3&F@X5]T456UYU9K74N5<5L63Q%3@./\ )G,UZUW
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MZN'X<&6X&;2[7+EH:0)"TLMH[E;'M2DL-MP=V3MK;H,![YMO?DG.H4_$03S
MX5S[Z?=M?43&^BO:_;?;&XKA]V92&3,S,T'*D]&;]_E.@>Y]5)1T0IH>DV%8
MZJY=M*&OY-9R-;&=3,!RVAQ*@L<8BQJR1G%SDL6 J#C;<,ONUL;)*ZPF"/*+
M;GL)'SD(V4 PP^XOW64^4XG^7-HV4]09P0.E;?$>=AKY5%;7]9LW8-I[I7N"
M3&[@38-VQL7#;"586W"?((7T&(TZR26Z1K[I\Z<>@NX^=-V<#(./LFQ>P@"+
M];!RZIC-)=*W'%M*K+NMF3(%LVT\TI6[+P*>A(&^K!AY_P ZG5)&\<Y'!E*G
M[C8UV'MCN[([A:7$W79]QVCN"!5,R[A D;LC %/E9(BR3(+CK)/4%.O&O95<
M?8Y16D6TIV["N$1E;#=8Q8RS3D*04!?Z>ZXXTAQ&^X*=AOU(*NI>5;;BEFI.
M_IMZ_AM_R:*S7E<2-O0>A^'[-*( >-8J._,L$99E/ '%7:'6<_YNQJWNV1N>
M_#N)(TWE:\]U)Z%ARSQ>MCKWW'^\@'UTZA'1=E^(TOAQB?,C0ZE3U#R/C7NQ
M?STQCBGG+E&CNZ(7-%-R&KK[2VKW-KROE18*GTL1F75B+-CPVIY4XT5-*"U=
M%==M5K<]]@P,SY68>X+?E -=TV_Z7;KO6PIO6&P,SACT^/2Q7[+VJVSCWDG#
M.4L;B97@U_"OZ:7\OOQ5;/1'PD*<A6$1>S\&:R%#N;<"3\1N"#J1AGBR$$L+
M HPN/&N9[CMN?L^4V%N4;).I(.EK^SRI=Z6IG1HHHT44RODGCS66^.O/F*O(
M#C.3<+<I8^XV1N%HN,&O:]23OTZB1J6V&<XN^X62.,>7"W^C(I_13+<XQ-MV
M1$>#0./O4BOSQ?\ -_G?_P 8D?\ ZSW_ -[7M_\ RQA?J"O.O\9G\33S\0OO
MP.+\2JWBVE5= DP7.]M>S;T.ULXLQ*N[M ;[V.GHM'7?7S?^N(M]6]\/Z^6K
M#S#0Q$?D-?2SZ'^]])MB4<1AE?M6:4'\HI3SEO*1WA6Y;!0MY3P*V4M]SP(2
M$K7(8* >A!)V^&^N5WKJ1R6U%(NUFK2A2PX%+2%(1VMCM2 CN(/:4%M7M$?E
M['<;@==;!3?3C35IGZ3[*:>[F([W)*%H8=.P_>]P%"D)[P&W.JR%=VVX!'P]
M=/($<3*2#_(5O%N\^,+*-*:RQY#MZ)_M)W2A"5*6RESL25)V5O'5N$.H/[VY
M[O38:E4^+SM5GP>Z1&@$UJP#ODA0AM4*TD-MI0XON"BME0<4@!2U-KV25!+?
M50W)[2-^G1<"K/A]ZX,8/6R+IS-?6_(_C:,@J<D14;=H4E 3\J$D!1V^;N6I
M?=U^&QULJAOBIX_?>UA=9(]?,5A;?RSQ7L<A4-/.O9;[:V6$QXJFV6UJ<3W^
MZ\I03VAQ/3;U/PZZ<QPH5XCC5<W+Z@8D(O 5;3D:EGX$\'V'EEY0\-8EFM=]
M127^;43EC1LMJ$)%%6/F[NU6GR@S4(JH3I[5)#9_;J0PL57R8^G7WJX]WI]0
M\^;:L@1W2%D(M]EJ_1QAQX\2)&BPV6H\2*RW'BQV6TM,QXS" TPPRT@!#;3+
M2 E*0-@!J]D6-J\DDEB23<DFHT^1_%.-\F8AE&(Y76HL<-Y'QF[P;,(2V@M+
M]?>5K]<ZYVD%/O?3O%;:O5+K25#KL0MCLO52T.0^,W4@N35<7V]LYR>1Q-DO
MCOR9-7*Y@\0,SF<$9D_(4KZS(,4J&$3.),\'>>]V)EO'KL0I=ZA;T9SKOOJ3
MF9703(08_$<*WRX8X0"A'0WZ:2OF63X^<W^/GG)6H+&.8W:,^.ODLJ.@A$CA
M+E2WCLXQED]* 0XGC3D5V-)]Q0/M1Y;G4)WT1&\90?$> YFL1'KC,!X*/=\S
MX"K%+FFI\EIK?';R)&N,>R.IL*2XA+V>B6=+=0G8$^,O^RXQ,@RE)W^*5;CX
M::N"00.((O\ ?2:"T@ZM-:K_ /M?9A;<)W'+_@WF]C(EY#XDYC]%@LZ<M2Y6
M5>,_([SU[Q;=M+<(7)1C0D.5KZANEI3+:-_AI?-_>PJ8O> M>VM*92L91)8]
M%K7J]$$* ((4" 00=P01N""-^A&HBXO;G3>ONBBC111HHHT44:**-%%&BBO%
M9=@KK N;^V(4KOV]>SV'.[;;KOVZWCOUK;C<5JWPGV5!'[6G=_Z>?B5W?N_X
M0TGL>F_TADSC""]O_$$3L[M^O=OOUU<?J)__ !ON?C\TU_;87_+4#VK_ /P[
MA_\ 8C]-J:_[KGGG#\*^!/T_$+BJ8\@N9C8X?P]!G/L 8^1&2G)N4;..\M"#
M48% E)=:2OY)5H]%8V4E;G;-_2GL&;OON1,>86V:!@\[G0$7NL=_%[&_,(&(
MUM>/[T[FC[;VEI4-\^4%8QQ-^;6\%OI^T0.%ZU"O&7@',?*[F;"/'CBVW>FY
M#F\Z=<9UGZY*+I[#,,9EIG<B<I9),+K@DW+RYRDQ ^L*GW,QEO?YB1[N[Y[N
MVCZ<=GOEQ]%XT].&-2/><BRJ+</L^%03P6O-O;FQYW=>^K _5[S=4C&^B\23
M?^1) YUOZ<-\18'P)Q;@O#?&-*W08'QWCL'&L<K$$..IB0T$NS)T@)0J;;6L
MQQR5,DJ'?)EO..K^99U\TMUW/-WK<9MUW%S)FSR%W/F>0\ !8*.0 '*O7&%A
MX^WXD>%BKTX\:A5'D/TGB3S.M(WROCNR_%KR5BL)[GI/ /,<=E/7YG7N.\C;
M;3T!/5:AIYVPP7N3;V/ 9T!__52F^] ML^6HXG&E_P"HU:/.:YE(9\;L-L*I
MWOE4F*<?V#2$_*H-QJRG:64D$_/VJV_KUQ3O6+_ZUW=%XC<\J_M]>2OHI].&
MAQ^T-DDD]Z"79,(J?$?+IH?8=*S'"/DJN[@J4U8%N;#0RF4P\^4N-*0LI4>U
M:@KJ1T_#5<,4J"Z<:F,M<7U&"JMF;C5@O$W/KDPM0WIJ'%N/N,MH<6I?:CN>
M^8=CJNQ04>A(Z _CHBR9H[+(2Q'C41N.Q)/$)E &O*I0UUW69$RM;LE =3NA
M06^A25!*UC=2SV;J<(W!/3M'[=+NF/FV=^*Z:57<J"?!O\NI9& Y<#2RP'E/
M/N%+867'N4&'"D+#MAC%BA<_%+G91[A(KO>;#$ET;I^HC%IY).^ZO0OL'<LO
M9V#XQ,D);53K8#D*K>\]I[1W5A.N=$J9@2RR@6:_G_-P-6@<6>;O%F<PZJ!D
MRI.#9G,<3#>HYZ5RJZ1)VV#]1=)2W&DQ)"TD-H<#4@*/:4$[$WW;^X=OSE$4
MC>GDMJ5;E?S\/"O/W</T\W_86+*GJX MTR*+W%N%N-QS^^GHY5Y^XZXBP1[.
MLCMFWXJR[&IJF$M!MK^V0@J15P8SJFUMN@[%Y;@2B.WNI>PV!LL<#.W1<: &
M_EXU1Q$Q<IH''(Z?GK3=\D_,[R%^XURKR9QYP/.30<,W&:<=< \O\_U3A-;5
M8YE>3M4=UP)P#)<9<9NLUM(M].?O;\!QJ%&864%)6V=:$6)%^!J1D]3$P&N
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M9+TM0>6V3W%PC2&?'V_&F'M&_0S8^WQ.9(7AT*N5-O5(XFYM?76H[N$?3?\
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M%);0$DI /<2=]AI>'-5Q8'G2$NW/"O2^IX_HK9*^PIPDS-Y[SOD]V.I4#CC
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M,&;0BD%'1(.K36HH_;YY*RC)N&+7AKE&8N3S?XHY?8>/G)ZI"S]5=-XDVW_
M&<]J]G'(F;X&N'+2Z=PX\EWJ2#I?(3HZ73X7%S6LQ:_4FM-;YQM#QUYAX \_
M*>.ZS5X)<Q.!O)@0VRHVO ')UFQ"J\BL4HV#JN,LX=CS&W%;EMF01N$CH804
M(T;Z$\*4ZWECZ.8UJ\'CZ]9N\?C*;D-2C%:90B2PX'694)YL.U\QAT$AUF1&
M(*5#HH#<:B\F(13D?BI#AI2ZTC11HHHT44:**-%%&BBC113=\O9"UB/$_)^5
MON!IC&..\UR%]U1V2TS2XU9V3CA)Z (1&).GVV0')W+'QEU:2>-?])@/TTWS
M)!#B2RG@L;'[E)J/?V\,>>Q7P0\/:22V6I,?QPX@E2&B"%-R+7"*:V?0H'KW
M)=G$']NIOOB<9'>.Z2KJISY@/8)&7]%1W;L9BV'#0\?EH_RJ#^FGIY#\?.!N
M7+6'>\J\*\4<F7==7BIK[?/^/<3S"R@50DO3!6PIV0U-A)BP/JY#COM-J2W[
MBRK;<DZB<+>]YVV(P[=EY./"S=16.1T!-K7(4@$V%K^%/<C;\#+<29<$4L@%
M@716('&P)!TKNXZX%X-X@FV5GQ/PWQ9QC8W,5B#;S^/^/\4PZ;:0HSRI$>'8
MRL>J:Y^;%8?65H;<4I"5DD#?6,[>=WW-%CW+*R,B-3=1)([@$Z$@,38^8K./
M@8.&Q;$ABB9A8E$521X&P%Z=G4;3NDCR!CPRW \VQ120H9-B.28\4D=P4+JF
MFUI24]=P1)]-.L&?Y7-AR?\ 9RHW^BP/Z*1R8O6QY(?UT9?O!%?G7\.8-SOY
M3LTWC-P-A5SF>?"HQ_';J2S'?3CN#0ZZ5$II60YS=*;^AH*&O?AD.NNJ[UE/
M:TE;A2DUKZ@;)*OU0WS%C'N/N,T@/+IE;U0?M#BO5787?&U[5](MAW'<9QTI
MM$4877J,D8]-D''4%#4\_([[&'+'B1Q_;\SR/,_BQV2Q3,AO#;/#,GHYN:YO
M[#2ABV)O1;.V7+7.>0H-R'(J0VC\U]#;?<I,!G;!\KC--/.J(H^_[Z3[=^K#
M;]N";9C;?,W5)\=R0@\6'"Q/'7V7JJ"FY^SCA^WCUG(U1;XY<!2RR9C3IA6+
M*Y""J36V".^-+;&ZOF;4KMVV(!Z:JRQ0-=U<%.&M=MCW,I(GKH;.OV \O94\
ML)\Q*:?4(L&;R.V6'T/R&RZ&G ULX=U?. 0KM^"1UTE)BO%JNBFIO$R,220+
M,%$9^VII\3\X2,OJZ^PF1IDZ-);2\R5)#"'FE[J:5&<<"0M!0L=4@@ZT0"(]
M9))J/W[%PGZH<( 0D<0+:U*2H2G*'&X[L>%!AR$H3(,HR)OT[?<-EN-1T;$M
M@ CJ"".G72T0?.D$,=P;WOX?;5!W1I<#&:"5#)[MPO&_D!4H.1_!VM\LO'>Z
MXHL_(?D> [>U"Z:ERS"WH$>SQJ(Z[',VCARIT29>LU]O!8,.9L\V]].Z2CM6
ME)UU#;,7(Q8$>.;U%(UO>_D!Y5YS[FWC"R,Q<+/V^**$M[SC1]. TT\:KRS9
MOB+[;&$>-W$_)]&SB=1Q9D>5Y3CG&_'U=(O,GY*S:JIY5#@&&\;TC85:9GE>
M:95G+$AE:^YPK:7(DK0AMQ0>(T@N#XU4-[3;SA-'M9]./A:_5^4\ZD?X_P#C
MCR;R5R93^8OF?6P4\Q0HTH< >/<6:B[P3Q%Q2V;*5I0XE(@Y5Y!Y!!6@7^1%
M!^A),*![;2%*4LA)&M4*9HH8Q%%:]M=+:UD.;O(/DCE+DFZ\1O#FSB-<GU"8
MS7D'Y#OP6KO!_%+'K9KW$5T9E>]?F/D1D$%952X_W*:JPH3K'M;2AIS>DHXR
M(O4E&O+SJ7'CIXZ\<^.O'D#CWCVLG,5")TW(+[(+^8[=9KR-FENOZC(>0>0L
MDE;V&3Y?DDTEZ5+?4?@TVEME#;:2LL[3(%<64<KU(UKN3LI)V(].T;!.WIML
M?E T7-K#A6I8,PCX6 ^ZFPL^(Z@V,K(,&N;?C/([!PR+.9BPAJHKR3N27\BP
M^P;=Q^UD+5U5(2VQ+5Z>[J&GV>-ICDX;'&S"W47C^%[:(CQGW2!Q8CC]M<ZW
M/Z:;:-P;>>V,B7:-]D?U))L:PCF(/NIDXK#T9UYLQ D\) >'R,CGBJ2EIUGB
MS-D@D":U*R3!)RT D(]V"N+E-?[NW578ZE._H/36BR]RXQ(CBQ\B3@NI4-^T
MPO[MSKTWTX7-,(X?JYLT)CG&S;HDDA]\?,8\LAO[JJO3,JZZ]/6;<V"#K;G(
M>Y^GA+,#&^)L:2K=#EA:Y)E.4K;! _,8JZVEQ]MY:0>@7*0-_76AF[EUCA@5
M'&A8L"M^?2>8OPI;,;ZUY-X<"#MS:@="\\\^X,/$B''$"26Y*TT:WT-ZX0>'
M$VEA$N^5,JLN3K.ODM3*RFFPX]'Q_2S6?F9EUV$P%.Q)TR.K^[?LGISR".Y)
M2K68-GGFD$^[SF0@@]"CW3;6QOH1XC6],-M^DV-FY\>]?47/R>X]UBD5T2>.
M''P(W4W'IX$*=! (T.3).]N!6GG=)4>X]2=@3_0-D_T; ;?AJ< 8ZOTZ< H"
MJ/8*ZZJHB=$21Q)?X8E]-/\ 1!M7F7TV)]/C_IZ;G6U;'A4:;E]-SSY;R>\*
MB<;\4U==W;[I8N>1[Z9;S]@K=*7&:3"X!)Z'M?Z^HTY5K1D-QJ;V")BC.O!C
M8'CQYV\*=GP2RNA>O<S1*4VUD&<2)]W5/.*2E4NL@6LMMV"W\Q[GFFE(="1Z
MMH5_U3IB<N)Y!#>S^%6K=-NR$V],X+^[63I;ROP/WU9SI6JY2.FYYC<*6N&J
M6Y(<:7[;ZX;"Y#+#@]4+=1\JEI^(1W%/QVT5NL;-[:4T&?$LHS<R"^W(CNC=
M#C9Z=/5*@0%(6/BD@$:*U((-CQJ.GF;?LXKXB>4>3/N>VBB\>.:+(*WV_,C\
M<Y&ME/\ WE.A('Q).I[M6$Y/<^W0#4OG0#[Y5J+WJ00[/ERG\.-(?N0UG_%J
M@=Q3QD\=,7?1[;^.<$\1T+Z-NTH>J, Q^O=21\"'(YWTEW%,,GN#.R!PDS)F
M_P!*1C^FE-JC,6UXT1XKCQC[D KRY)XF>+69WUME67^-W ^59/?3'+&\R/).
M),"O+VYGNI0AR;:6]G02I\^4M#:4EQUQ:NU(&^P&LP=R=Q8L*XV-GYD>.@LJ
MK-(JJ/ *&  \@*Q)M.U32&6;&@>5C<DQH23XDD7-.7@/&G'7%-$K%^+\"PSC
MG&ESY-HO'L$QBEQ*D79S$LHEV*JJAA0(*ITI$=L./%'N+"$@DA(V89N?G;C-
M\QN$TL\_2!U2.SM8<!=B387-APISCXV-B1^EBQI'%>]E4*+GG8 "]+;32EZQ
M-]4LWU'<T<G;Z>YJ;&I?W&X]FQAO0W=Q\1V/'2L,IAF29?B1@P^PWK21!)&T
M9X,"/O%J_+=B8DY0V\G!&FG!8P\IOJ>QCG\I3,RMMI]7(^7X^P\R$]Q .X U
MCZP9"8/?&Y@ =,TYE'LF190?N>NI?27$;=>TMJ;B(,8HPY=43-&;^?N^VKV?
M%'B*+48]7*=B[O\ M,N2B5;$N;'M4D#J2>T]1Z'7$(8SERM,> .E=RRI!AXX
MB0=)(UMI5L''M$PRU'2ZR4I"0I#C2%N-?+NE?>E ) 0!N1T)V]=7';<;I4%A
MI:N=[SE,P/23U=0UI[N]N,T2B0I;2FCW=B7$I:<; *0DJ4">[N_U:F#[J^[5
M5=7D8$?$3K37WUH5..MH<<3WC=TD;= "A))!/<2".NHZ61G4ACH*M.W8X N_
M'2F]GK2MHCO)42=U'\">A Z'KOJ)90S7-7'"-FNWP@4/T1N<71CP20YR?F^&
M<6M=%!Q=%+M$Y%G;WQ5[?\'TLU"MOATU:>WXG1/44 H2=37)/J3N*R1_*1M9
M1;\M3YM&[(PW#2_3(FH6E334@!$=2$]V\<J"%^UW= " 3L.GKJT6 -APKACD
MEM=#7.J7:.0657+,=FQ[G@^F*26"A+RTL+1NX[M[C !([CL2=%:Z\0;-R-85
MB?#JWK&O<42^FRDOPX,9EV1+D1YP1.06&6TJ*VP](<'?T;200HC;32.0PQ-&
M5)))-ZL69M^3GHF1(%"!0+]0\!K7J3:2$+C_ %M5)A1Y3[<9$A4F)(]EY]79
M&3,:CN+,=+[A" H%82M0"MM]]:+G78!HI ">.FGY:1_@H=7;&R890BDZ=0)L
M. TXFLZ D ]W:1Z_ CX;=?VZD&C4V5R K?\ 34&K]*K,%ZR7*]',^.GD+FOC
MT=E]I3$EAI]EP J9D,H>:<&X/SM.H6VK8CXC^C6N5%CSJ!/''(!PU%ZTRL#'
MR\==ORT2;;5OTI)'J.KX@";_ /MKN;2A*4H 2A"$I0A"0$H0E/1"$)&P2A ]
M .@&M(PD:]$:!$\O_96T6.L&-'CXL<<&# .A(D6VAUZM-.5K<=:[.P?B?Z-]
M;WO6=:Z3Z'^@_P#)HHK'O;G< $J/:D >NZE; #]NYUN=4 ''JK8V]+[:K$YW
MSF1B?A+YJ<S0UN"UYCY!Y'H,6>:)+CV,\?UD?A;%U1U$A9C//T4J8@__ )V_
MQUOFSB*&;ETH #X>Z.%= [&PQE[IM^,P'O27-QQ]XVO?\E_LK7.XBR Q7**N
M4M2?I*:MBQD['\],.&TSV %)*%(2CX=-<4SR)&,C?$237T6V5&QX70$W72_L
MJY#A"[;:JFI .P7%6%M[$@N+24+"TK':E*@=)X>0H4H!93Q\Z@=^A9Y!*VK@
M\:M@^TBQ8P(W,<"&9",-;R!V32Q/S/HHBYEF^MMN$%'L0TL_4$!('RI!]-M6
M'L1)EBR!U'Y$261>2^SG^6O-_P#S#2X.3ON#+%T_Q!\8M*W N>5P-/N JZ/7
M0*\\4:**8GRCR1O#?&CR&RUUSVF\8X.Y9R!3FX3VBGP*_G@@G;914P /B20-
M3';V.<K?\'%&IDS(5_TI%'Z:8;K*(-LR9C^""0_<I-:"?^1G//\ X4[_ /QE
M_P#N]>T/\WX?ZP^^O/W\!R/"K$_.GCM.#^??EWCBVRTS?YKB/+M4LA24.5W)
MV!T<VRDMI2DJ4@9;4V3:EI2H!Q*M]^IU\_OK%&KX7;F_ $F?;)<,GPDQ,A^D
M$_\ 931_97OGZ 9J1X^^;(Q_>P[I%D(/V,J!;GV>I"]SXU'YJDBJV[X:SNE&
MY]H*;2HJ"NQ2VU+0LKV(&Y[B#ON-<6Z@-#7?#COU<K7KU)PY#Z4N(0V$[?.U
M*2M3H2.J>U)]Y+ZMO3M!["=]AL3HZQRXUO\ +K79!XWK9;C:O97&["$K]R,E
MAI*UGO <+OMJ:*B.BO:6"=QW?#6/4?QH..@%Z=K%^!:=\H?D$!T#N#/:A<=;
M("]P0_\ WKO;U1VCION?E]!7D.@K1[0CK07-.HGA3'HS)<#?U*6F$%"0PEN,
M%._EI676$@;=[1"0!N0GN)(&VMP7_%6BY3CBHI/W_'F/TZ7W'/;!:9DH2GV$
MI'<E"F6  \.C/>07%'=92G8?'632Z2-."U@ *AWFE"U^JN/(:+H3WO%1;*NZ
M0Z2I'8I1W*1TV"@00/PT_P 0%4]0\.JU1F;[Q4#BV@]HUK9V^R[Q8O"O%JUS
M:5%+%AREGEO9-.+0$*=H\90G':Y:"DJ!9=L&)KB0GY1W]-=4[>A5,(2D>\S'
M[A7FGZBYJY&_C&4W2! /*YU-OR5<"-P.O[?^74Y7/EN!KQK[HK-09\W/'6H\
MA>&N2.*K1P5\?DO&94"KN4#\_&<\K"W:89E$1W8JCRZ;(8426A:=E#VE[>NE
M<65AQX4K#(Z,%/ FU1S\(N;[GGKQYQ:_S-H0N6L&G6_$7-U,KY7Z?EOC.7_#
M>5>ZPO\ ,;:NU1FK-@JZ+9E@@G3V4*Q5S_9L:SD_NY@I\:CYS>Z/%KSIX;\C
M$*^@XH\KX59XO\[+2?;KZSDV 9%CP+G\_JEIMV:1(H7GU['VU-C?TTO&2Z&)
MOB_#]E8 ZSTCC4_N4>-<8Y?XXSWBC.X:9V)<BXI>8;D49:0I8K[R$[!<?:!2
M4IEP5K2\TKIV.MI5\-(MUHPZ>(.OLH1A&QZO"U1L^UAR]E'^&MQP!RC-6]RY
MXGYE,\<>2')7RR+NIQY/N<49XCO/>[#RS!S$4AWT6MMWJ3K;.C#@2I]MZPZ$
M#JY$U<5J*I.C111HHHT44:**-%%&BBH-?<LRR9B7@CY/O52U)N\GXQLN,,?2
M@[.O9#S!+@\5T+# ]5//6N8M)2!N=_AJW]@XRY/>.WK)_91Y E;^C #,WY$-
M07<TQAV'**_&\10>V2T8_*U2ZP/%8F"X/AN$UX2(&'8ICN*P@@=J!$QZHAU,
M8(3\$AF(G8?AJLYF2V9F2Y;_ !RR,Y]K,6/YZF((A! D"_"B!1]@M2KTVI6C
M111HHHT45K:^!/&7"G@+DGW#_(?-+N5,S")Y3\L\(8KQ]5][-O*HV;.KY'Q6
MHJX+KR6["?EE/E%;*1(*$QX$%HJ)W+FK%]1CCXV\8_=3L N?M6+*?%G6(02?
M;UQ&]/\ LJ3=>Y-GB[!Q(U*X.XY ZB- DDAE2YY +)]M12YAY Y>\H^29?(_
M*7>F,VIQK#\.B.O_ ,/8+2ET+36U;#FP?G/(;29DQ:0]+=W4KM0$(3YSW7<I
M]WDZ\@WBO[HUL!RY_GKV5VAVIM7:6-Z..Q;(8#K<D$L;:VL  M^%N5,5R3Q+
MBN781E%+FV*5F15%=!?LD5]BQNE C=Z'W85B/;D5LP(&Z5MK0>\>OIO'8O4A
MT&@-7MIH)RL4YM%;C4$.)_"S :C-F,O@?Q-88Z][:Z;"<BDL2F&I!677GI;K
M2$O6,1GY?8;> ).Y7W'IJ5GSY)H@AL"*C_1A@RF>-BT'+E5IN+XL*VL_4%H]
MJ2AQF&J&AHH?896I2?9C-M@MM-,M #?IL=@-OAI JYX$*'IE/&EYLTXL;EP&
MA(TT^T5*3"U5Z(4=* IIAM" F.$K2M*O^N\5_.XI2CU)WU:\'&AP@$%R;V)]
MM<PW7)R<K+]93K8Z>/E4I.'^81QID\:>5I542E)A6L(NA*3'?(:$Q &X;D12
M=P=NJ=P=3N!DOB3^\0822+>VN>=S;%'NN([A?WX'4/:-?RBXIW?(KCG@W*N1
M.-?*_,<'J,@Y1X>J+#$,)S&4'K&7A^,YU80/U2TI*]YQ5:W<MR&FTIGI9^M9
MBO/(:<2%J!G,MUZ5>,V!KBS[5D3L^#'JZ'J /$_R%5]\Q>1?(7DAR7D?B9X0
MY(BNGXXN-!\F_+J#'8ML0\=ZRP8#K^!\:.N=]9F_DA=U[A3&C)]R'C2%_53?
MS4H9UM%=TOR%5J3&>&=QF!5*: <-?*IO^/7CUQGXX<<47%_%N/*I,3IW),]]
MZ;)>M,DRW);-8E7^:YSD4M2['*,QR>P*Y$^PE*6\^ZK8=J$H0G>F4TDLS :+
M&.%2 &RE)"CLD=.@_=0G<] /B$^GXZ*R6) !Y5&')N8^5<)4R]:\0V<^G2S:
M,2[826%)<R!>3L-T\" UCSM\\BG&)/E:)<AE)ES@ED!MS=*RL4Z]/RM5N1*]
M_(:FSQ==E*S9,13ZX]O -7@2Y NLBEV%7W_IM(ZU%6MEV2TR2>UL@+6VE913
ME4M[39%"BV-#:0K:',C-S([L)]+I<C...M(<+1['V@76'$$.(2I+C:TD!25
M:E5;C60Q'#C:WL!XV\+\[<:S:5=?B.T[$$$$;_L]1\=9 "J%711P%:*JH.E
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MB?X'- OQS%(A[975/S,:G[!A1ZV%#KHC8:B0(L>%%:&P#<>*RAAAL  #9#:
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M"QBJFP)L1"PVY(8<2RX=]FWP.^,X>WYMFWTI)VZ[#II*56:,JNK$:4[VJ:#
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M '+']H[+6"H !;+D]T*MM11 K1Q68&PX4^N*8Q!JH,)2&4)^8-1RU\SBE+!
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M_IZCI_3UUDDCD36;CQ%?._KUVV_I_P!!K!9OU6K3K'58E;>VN7=\>FWX[_\
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M -IO:L[)CC.(]^A0+'\EJ3W;;X&ROG(M>HZ@<?&F=Y@Y@XTX1Q2VRC.<HC9
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M@7YCVUP3ZQX>))V1AYN2@7>H\GHZC;J>,7U]AXU?5J_UY<HT45P6OL Z;DD
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M/[1_GI;U7F=Y-5_MAZ[Q*[0#L19XI#;*SMT[UU;U>K?^C;KJ27O3>ND I"2
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M*]TCM*NH4@'9(;[NHW&VV_35?Q\9FLIUJ3WG.B#,N@4&E886X4V&.T]PV!(
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M+U'T:**KL\O^7<\S#),=\)O':\>JN>N:*:1:9_G]8E$O_+1X[N2359?RY8+
M]F+F^1A3M-A<192N3;NJE;AB$Z=7?M;;,/&QW[NWU VS8CVBC.GS63:Z0CQC
M71YV'!!T\7%5W><R>65=CVUK;A.MW<?W,/!I#^T?AC'-M>"FIG\2<58-P=QG
M@_$/&E*SCV"<>8[78QC54THN*8KZYD-^_+D* =G6<]\KD2Y+F[LJ4ZXZX2M:
MB:MN>Y9F[[A-N>>Y?,GD+N?,\@.0'!0-   -!4SAXD&#BQX>,O3!&H51Y#\Y
M/$GF=:<33&G-&BBC111HHIO>5^*\!YOXXS'B7E'&X&6X!GM'+Q_)Z"Q1W1YL
M"6 0MMQ)2]$GPI"$/Q9+2D/1I+3;K2DN(2H/MMW'-VC/BW+;I#%FPN&1AR(_
M(01HP.A!((()IOEXF/G8SXF4H?'D6S \Q^@CB"-0=1K7YNOW4_M@\J?;[YDD
M0(R)60\*Y@_8V'%/)*F>Q%] 969+F,W[J$?1U^=XY'6D2V![0F- 2V![:UH9
MZ)GX^+ON"_=';R]"#7,Q5)OC2'^]C'$XLAX'^Y8]#>[TFH[:MRGP9U[?WDAY
M#ICSFW[Y1^!S_MT&A_VB^\-;BH \1<]<G<6Y- R3"[7(\1M:Y3)5=XW9V%-:
M10P?E>BRZR5%EH6HIZCO[3^'PU5NM1[S@,#XZ\:L[J67I%7W^.?\P7YB<1M,
MUN8W5?SYC<3Z9(A<EU*F<A0R[MW-M9K2_06KSJ4#Y52TS2#Z[CIIO/MN/(.O
MX03RIL^//IZ>IJ^KQY_F"O%#DV-$B\OXUF'!UT\EA+LIT(SO$PXYL%+_ %*C
MCL7\5 4>H=K2$@CYSZED=HEZ2^.0RCCR/E_+2DS'*FDHL:N$XJ\D.!N<(K,K
MB/ES <^#R/<^CH,EKI%PRC8$F51.O-74,@'J'8Z"/PU&M')&>F06(HM3VZUK
M%&BBC111HHHT44$;C8^A]?VC\/Z]%%5?_<]\;87(_@[Y!U^/M3)61T>._P"(
M=&PLH>0E_"I[61S8S$=+0[BY2QI;:">Y0*AMJ,W?'.1@L@)!77[O^FK=V-NA
MVON?%F)]QY!&=>3D?I K14P//[+CFV%I%4"8\A#CC)4@^\WT'O-MJ04+6$*V
M4-MBD_ZN53X<.0I675D)(\_(U[9QV*QNER$8_D\JLZXN\Y\7DL,1)_T4*6DL
M=R%QV6"M2 $@@_*I/56HQ"T9*2(O2.&@^VF<FRQY +8\CG]8$GCY:U,.G\GL
M4M([;C;]<0M*5ALEE:4KV [@VK='=UZ[#?3I)TMJHX^ J#R-@GZ]';AXFO3+
MYSIY!*TR(B!T2"A2$ [;$'MW[4CIZ#24K!VN.'Y*>8VUO#$$8DL"=;UA'^<H
M/<H)F-A)^7N[NU6X!ZH[2!U ]-)>N4]T7L*5.UHQNP!8_>:2EES-.GRJFIQJ
MIN\RRS*+B)B^#X-BZ!*RC.,OL4J-;C=!%)]M+KO:7)4IW:+6PD.2I*D--DZL
MG9_96[=_;NVWP.N-MD">KDY+7$6/"#K(Y'$GA'&#U2/95'$BE=_=X;'].-B&
M?FH9]SG<ICXZV]2:4C1%\%'%W^%%N3R!V)/ ?PSD>-.+76?\I2ZO*O)GEN-6
M/\GY17]\BGQ&CK@X]CG#?'CTD?41L#PGZA?>[LAVYLUO3Y *G&D,]YWG<=N^
M5Q^W.W(V@[5P 1"C?'*Y_M,F<CXIIB+GB$3IC70:^.(_XCG9\^_[]()M_P P
M@R,/A11\$,5^$<8T'-FN[:G2P?5=IY1HHHT44:**-%%&BBC111HHHT44ROD'
MP'Q_Y+<59%Q+R/$F*IKDPK"IO::4JLRO",NI)3=EBF>X1>M RL>S+$;IAJ9
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M-9;<8T*7\M:MI"$ERCQF?'82H'O:?O+&(VXM0^"TQ:PI_H41JC=OQIZZS\5
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MR7R&=<3MK$L<C,E!]&%>2CG+,W]W"EW8^"^\.3?5GOWMKZ5X"?. 9G=N0/\
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M:FG2PU(U]E;\_P#+:<%R<"\">4.4EQ%,WWD3S&UCU(XI'YS^.X>W'QJN+2B
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M5&$/9UEDE*F@%E84>T]I*P/7UUM3D\*ZT93 FS6<8KOJ8DB"T"N5("]EC8I
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M:/\ .S_EV_A[V'/TK_&S^#?U7][K_"/ZW_\ ,GZA[G[GZ5_O/=^[UU:>V/\
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8%4E1HHHT44:**-%%&BBC111HHHT45__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tv502124_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $G ?0# 2(  A$! Q$!_\0
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M_!13]M_3;B2YB_:)\6732-N,6H:-X)N(%. -L:0^%K5D7C@&1CZDU](?#_\
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M\W\DKM_),FHJ))5<[>C8S@D'CCT^HXJ6DFGJOR:_-+[]@[:-75]4T[/R:3_
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M&A3R^DN:E6JV]^ISTI6A*QXMY[DRJX#A?B#'8+)>#,/D^=\=^*=;%5_889<
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MK]@T9X.0/,"L#_>QQG K[P_X*KI:)^W%\3/LH 9_#'PXDOP !_Q-'\+P"\+
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MGC;XD>(F;3? ?@C3X86NM0N=<UJ026DU[:6\;!=#M)6NYPT<L]S81EVC^O\
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MQTL"5)3'_":?":$NR@J6 /PA4L"P)!.20,YS7]$M94J%89B'9CEV))V\9*A
M2> O<@C@<^E?-YEPY3S3%RQ,\XX@P$I4^7ERW,OJN&IJG=W5#ZM5O*7-J^9M
M\O3<_8N!_&G,. ,AI9%A/#WPBXH=/%UL53S'C?@#!<3Y]B*E=4XQPSS/&YE0
MITL'0Y+JE]3=HSDG4:21_.CXH^%G_!:O0/#NL:SXO_:'\)Z/X7TS3[R[\1:E
MXC\?_!VTT"TTB&W<:@^L3WWPA6T734MW87GFL8FB+Q;P[#'YZ?L)>%OVC/%/
M[5OA^[_9YUF"WUW1=>M]3^(WC33K)4^'</@*?5O-\17&OP6%G8:3>^'_ !1:
MQ7\7A#2A96EU=73V^J:.NGF)+A?NW]K+XB?M1_M\_M/:[^Q;\/?#>N?#;X:>
M!->GC\4V7B"VFL[._P!-T?4&B3XH?$.:-!+)X6E>*2?P#X6M)KJ/7KV*W>6*
M]NGM)]-_;;]FC]FSX<_LL?"^Q^&WP]T\964ZCXE\1WBB;6O&?B:2&'[3XAUN
M261[EYYHXTM["Q:ZFL])TZW@T^V_<0,[_GF7\/QXDX@A+!9EQ#7R[(,8X2S+
M.JU55ZM>A4C''8;+)SPF$JTL/5DHPKU6ZM.M&\H.FK)_V1Q%XV4O"CP>S##<
M4\)^"<_$3QDX<HU</P/X?\'Y1@.'^'.#,?"<\'Q#XBU<OS/,\LS;,YRG*MPQ
MPS]4AF%&O3G7GF%"DL50QGU!8J%M8PH95W2LBNVYE1II&16/7*H0N#EEQM8D
M@DVZJ6,8AM88U 54#  %F !=C]YB2>O7H>HP,"K=?LSC"/NTDE3C[M-)62IQ
MT@DM;)144E=Z)'^:B;:3<IR;6LJD%3J2?652FG)4YR>LH*34)-Q3=KLHHHH&
M,E_U;_3Z5_.U_P %T?"\DD7[-OQ M;&X-FE[\1O NJZ@R,$CO[RQ\/>+?#&F
MLI!'GW%AI?C:ZB!.=EA<CD*QK^B2;B)^0/E/)[>]?GK_ ,%(?@7<_'S]DOXA
MZ'IUH;_Q7X$ET[XJ^!88(M]PVO>#H+V+4+6",2(6FU7PGJ?B?04;+-$=2658
M9B!"_P ]Q=EU3->%\YP-%7Q-;"3^K*^]:FX5K.-O>7+2DFKJR=]=C]J^CEQ=
M@^!O'+PZXAS/$+"91#.GE><8ER<%0RSB+!8[AG$8KG6D%E]?.\!F-:4TX?5<
M-B(RY4^=?QP*=I8$<;MO'.",C/4E@3T(SD<Y-)*=\4B@E2\<B!AU4E2-P[Y&
M<@CD8SVIJ,DD<;1L'0QH8\#:53YHU1L\DIY?+-AC+YB%=JK([7=57DXR7 7!
MSS$74X.7(*@M\BMC!X/%?R-*?-#FI*]2DG&HFN://AU*$_=TTY\/)-7UUC?4
M_P"@R$XJ4*F*K4HT:\J59XQJU""K>RJNG42E=RJQG[EI)VK4TE=)O]HOCI^U
M/XZ_9?\ A3^Q;X?^%_@7X,-:^-?V//AEX^UNY\7?#/0/$6IW7B34-&TZ'4+P
M:E-%'<;;R0[[D2L_F>?*X8.J;.-_:DU9O%OQ[_X)K>/[K1/"^AZ]\0O"OP#\
M4^)(_">@V/A[3;K5[_XZ1L\@L=/BCA*0HZPPLP><11J))G145?'/V^U9O ?_
M  3^8"4R1_L)_#"W9/*F"I+;P6L-P@?RC\T$L4<:HP5F1]Q 9 K^F_'LH?B)
M_P $I' N D?PQ_9\5RT#AD,'QO25E; (1XTAE=XV99/+164-DX_6JN-Q\ZV=
MX6=7$O!8-<&T\OH_V?%1H1Q>99+6J\EJ"?,W[L;-<L'*,E+=?POP]D7#V49;
MX;<597EV%P_%.>Y-])W"\1YERYW4S',Z&'X3\;.;"9S]<SK&X?,_88K*,)_9
M^&E@*52E7I4Z-!QJ-->4?M/EO^'F'Q#V#YA^TKX15.QW)JOAT(,>BE55<?P#
MT)!^S? >/^'P'[5?! 3P_P#&EB<<'=\'-#R%/<C&2.V17QA^TX=W_!3#X@;$
MGDQ^TOX7,ACAFD$;+K/AY5Q(%*D,PG7>=H1(=QSN(7[+\#R*O_!7S]K,-'=*
MB^&?C/(9C;N(L-\&]%W[) "C#8H,1#$R-\F%(-++X2GCZB<<0[<>X9W^J34F
MG1XJBKNRYHJ_NOS5K\P^,?;_ .H^4PG[&I/$_0AQ6&4U*4IT\'3XE\#J-*A:
MFX*.*IPJ57' R3J04I5FG&2/D#_@EF=O[8'AW(/_ "3;XWC&,DX\!:CC@9Z@
M\<]>.>M?GDG^J1>^U/\ V3MUQ\IP>F<CL<?H3_P2W9E_:^T%S'*G_%M_C@</
M!-&=B> ]08L ZCGY K+NX9D4$[B:_/900 C JZ!%>,_?C8#'ER9Y#@J5=2 5
MQ@\G%?&X^,Z7#N53]C62CG>=U%5JPE3BY1S?"UK.FTFDIX.BKW2E%SLU>\?Z
M/R2:J>-_BQAYU,+*B_#SPNC.=#$J4^:.*XZI-482E.=>"6+KKVL.:+J1Y8V=
M":E,' 'T ^G8=>WX\>_-1S-)L;R59IBCI$H&6:5U*1JJYY+.5 !ZDC&:>JYR
M3QR!VP 6 R/Q..HZ<\5]$?LC_!J\_:!_:+^%/POM8'FLM7\1P:QXH<1EDL/!
MWADOJWB*\NF$D0162R%A -Z;Y+I2"758G\#"8-YABL)E^%O)XBOA\)=O6]2K
M3IW32TVO>ST5]KGWW$W$.!X<X=SWBS-<1'#Y;DF69IG6*:BXUI0RO"XC,)JD
MF])2J8:C&,+-^^Z5^:2E'^Q#]DWP?-X _9D^!?A"XM9;.ZT?X7>$(KVTG#I<
M6U[>Z1#J-_;SJX!2:*[OY4E1N4D#(?N\_1\ Q$H.3@ <\8P!Q@],&LF'RH+9
M(K=/+MH((X(8]Q)2*+;$BX/ PJ!5ZY51T/ UX3E,_P"TWYYK^S,-3>'P]+#6
MTH4,)3ZWO"A"&M_*'KJ[^?\ S99QFU?/<[SG.L3)2Q&=9IF6>XCE5H*MG&9Y
MGC:BA&[Y::EBI1A&\K**]YDM%%%;' 0NA+AL9&%!S[,20..^>_\ (&OS[_;M
M\#?MN^,-$^',7[&GC.R\&:M9>(-;N/B#)=:UX:TAM2T>2S@318XI?$?A?Q/
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M_P!LKXH?L7_'WXX? OX*?\%"O^"P;^(?A_X(^#FN^.?C)X&OOVD_BC\/-4^
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M^(? VK2VMMH5Z_AFTBA:POM0\PT+]CW]O?XA-\7_ -BO5?V4-=^%WPB\9_\
M!9[XE?\ !0+4_P!L3X@?$[X1ZSX*;X"^'_VKK#X[^$],^%/@#P3XW\2?%+_A
M9_C]?#^@6FE:3XJ\-^%M-TO0M9\37>KWUGJ$(TH '[,_M6_\%4/V2/V,OB[I
M_P $OCAKWQ8L_&DOPM@^./B"Y\!? OXN_$[PSX"^#W]N>(O#5_\ $SXC>)/
M?A/Q%I'@GP?H>I>'/$%[XBU3Q'=6MAH>DZ8VJ:A<I:Q11W7T)J7[7WP TKX@
M?LS?#&Z^)>ES>+OVR-!\;^*OV;K?3X[O4=.^)/AGP1X/T/QWKFMZ?JMO']AM
M+ >%?$6B:KI,UY>VC:PEZD=C$+E)[>/\IOVR?^"<GQ=_;$_X*8>)/&.M?$KX
MZ_ ;]D7Q?_P3ETO]GGXI>+?A!XE^%-C8?&^X\1?'GXA2^.?V=/%MIXLM?%7B
M[0M/\0?#KQ=]K?Q5X7\.^';ZUN-:A.A^-$UBS-O:?%/[6/[!_P#P4Q\2_M,>
M./VA/V6_@=\)=!^&G["NE_LH_"[]@_X8_%#QA;R?&?QE\/\ ]F2]E\4_$"Y^
M &LZ5XYU'P3\.]/^/-OKMW\*O$\WQANM&UWQGX4\)>%AJ]CI+Z7:K* ?JQ\0
MO^"W7[&7PL^->O\ [/'BOPW^V!+\5O#_ (D\>>&4T'PW^Q/^TSXLB\4GX:^)
MV\(>+O$W@2_T#X;ZE;>.O!=EK!M2GB_PK+J_A^>TU32KF#4)8-1LI)[/C3_@
MM1^P_P"#;'P%??VK\??%=Y\2OB)^TA\,_"OA7X;?LQ_''XC>-M2\3?LGZYX9
M\-?'6W?P?X1\):KK^G:9X/UOQMH$*Z[=:>NF7\,TTEG++%8W-S'O^/?@[\8_
M&/\ P5'_ &$OVD=*^&'B/2O@UX"_9 _:D\'_ !&UK4]8\&V[?#OQQ\5=7^"V
MN>$O ^MZ-;^*[K4[[5)8?"VLV<TOA*R\1>'["?2U0ZLMG]GG/X%>-/\ @GE^
MW'X9\5?LQ>+KC]E+]L#Q=HWP[_:K_P""TGCCQ98?L?\ [6_PP_9H^->@^$?V
MJ_C9\'O$WP$\1:9\4K7XU>!+D^%/'>B>'?$NIZMX2TWQ&EV\5NZ>*M&MY19V
MUZ ?TL^#/^"AW[,?C75-5\.6OC'Q3X:\=Z-^RZ/VR-0^&7Q"^'/CSP%\1+7]
MG^35M8TB]\;_ /"!>*]%T7Q//=:%J^A'3M>\+FUCU[09];T"&^@4:]HSW_RO
MXK_X+N_L*>"KWX;6.HVW[5FMCXQ^"_AIX_\ A3JO@_\ 8X_:*\9:%\1M!^+/
MP>\,?'7PK#X*USPW\/\ 4M*\2ZW;_#OQ58ZEXF\/:+<WFK>$KZRUW1]>M;._
MT'5!%\)_M(?\$_OVJ?VV?VLOB'^TSI_PS\?_ +(OQ F_X)G?#OPG^S_\0/&W
MC7X>>++[P#^T8/&OQETKXC_L[_%.U\$?$3Q';^//!?Q%^%GC/^QOB5/<VVL^
M"+FVO] \5Z?K3>-/"&D);>]?#W]D;]IKP_\ "?\ X-U?"]_\)]:M]8_8PT'P
M-IW[4EK%XC\#"/X1SZ)^Q;J'PKU'^UIAXL2#Q.D?CFY7P^I\"/XL:X=Y;J)'
ML"UP0#]XOA[XVTCXE> _!?Q$T"U\06.A^.O"V@>+]'LO%GAO6_!WBBTTOQ%I
M=KJUC;^(O"7B2RTWQ#X9UN&VNXH]4T'7-/L=6TF]6:QU"TM[J"6)2NO4A@&'
M0@'GKSV/OZT4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !44TGE)NX/.#G/ P2S< YV@%B.X! YQ4M07#[(P=RKE
MU^\2"0,NP4@$!RJMM)PN>IH _*/]IO\ X*?Z_P#"/XZ>/_V=/V=?V,_CU^VY
M\3O@A\,]'^+7[0MA\%M1\#^'M-^$7AKQ5IVH:UX)\/2WWCS6-)D\<?$_QIH>
MDWNM>'?AKX,M=4\2ZCI[Z<]K!/+J$40\W^.G_!9KPW\(?'/QTN-#_90_:!^*
MW[*W[*GQ#TWX2_M4?MA^!9O P\ _!OQV8])N?'%K:^!=:UNU^(7Q!T3X26'B
M/P]>?$KQ-X2T.^T?PZ;R^B=KI-(NY&YW]H/]DO\ X*:?#']K+]IK]I7_ ()L
M_$']CQM,_;)^'7P\T[XM>#?VP7^+NB7/PL^-/P;\$S_#?X;_ !3^$^N?"OP/
M\0K+Q9I=_P"&KS3'\3>!O&NF:9I*:KX5MIK274$\0WYT?PCXO_\ !,?]O[6H
M/VO?V2_A!\9/V3;/]@3]OWXO>+/B_P#&7QIXW\-?&6']J?X06OQHB\.1_M#?
M#WX.>$]$M=4^$_BO1?%4OAI[[P/XC\=>/]#UGPY%X[URWN=/U1O#&D:IJP!]
MU?&?_@JG\ _@7XN_;4\'Z]:>(-7G_8C_ &1? 7[8'BB\TS4]#>V\?> OB(OC
M8:/X:\)K<W8N8M?LW\,Z#;RRZA;QV-W_ ,)QX::)[JYF7[+\P?'?_@N3X;^#
M7BCXCS6?['WQP^*WP(^!7P,_9@_:._:"_:"^'_C;X7)I'PK^%/[4]I?7_@75
MH?!GB'Q+I/B+QO=6,.BZTUWIO@][ZYG70]2U"V2U2*WE?P?XE?\ !#;Q)\?_
M -HKXF_&#XM>(/AIHGAKXR_M.:7I/Q3\ Z#X@\3>([CXD_\ !-KX3? 7X+Z5
M\%_V?O$MYJWPZT2.V\;7/[2G[-7P6\?>/_"NE:Q>>"M#\/\ B'XA:GX;^)/B
M'4G.C^*V_LF_\$'-+N/B_9_%;_@I)X#_ &<_VA6\ _LO_L<?!#X4Z1X2\=_%
M_P 3^&K'Q3^S5+\2--\0:[XZ\$>)_!_PT\'^,O"_B#1[WX9KIVD^+K+QQ ^H
M>']9:XT+38Y8KC40#]A/A%^VEX8^+=]^W+:6/@?Q/I$W[#WQB\6?"'Q8E]J6
MCSIX^U3PS\)?"/Q?DUGPO%%/+'96=]I?BFPTVSAU\M>6UU;W$FZWM61$^=T_
MX*U_ ;2_@W_P38^-'B_PWXO\)V__  4TU_X8>&OAUX?FNM,N[[X90?%+0+2_
MTSQ'X]U.,_V?'X9T?Q#KG@'P/>:Q:K;VIUOQGHUQ(2LY0?,_A?\ 9+_X*E?!
M_P#:)_;GF^$]O_P3[UW]E7]MS]I'Q1\7M?O_ (B_$7]IRQ_:'\,>&?%WPG\$
M_"6_LM(T7P]\$K[X:6NN6NG^$EUC3[6ZU+6-/:\U![2[UBZMA!)#\>Z]_P $
M'OVQOBK\)OA[\+/'?[7'A;X+Z9^SU_P3!^"7[%'P6M?@7(GCS2OB-\4- MM/
M^(_QD\9_%F[^*'[/=MKGPR\$3_&SPC\)M)\!ZA\*M7OOB'JO@_X5Z;X^EN_
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M8(''<  ^H%+M7KM&?7 I:* $P/0=CT'4=#^';THP.#@9'0X'';CTX 'X4M%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIJ%RRG[Z_+\_MY=D&:9DHNC@ZE-.[_?R]E&UFTG.44O.Z5GHDW='Y?Q;XO\
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M+AZE7#<29[AL5[#$XC$TX1G/*,KQN'JPJX##TZ=1.OF]&M"G.K#$83VR=*M
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MFCQAV_L?7;61Q?VD;F-?-MI7!NK.=-RW%O)&Q;>I4>^B1&Q@_>&1P0<8SR"
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MHDCO?MPN&L[FZBBOK:(F_BLQI-X&M_@:,A@65MRDD!@"H(5W7.UOF'3 W8)
M#8 (%>UE>.JXS"OV]*M2J0E'F52#C'FL_@DW[R:>FF]T_>BS\XXRX=PO#F;+
M"93Q%@.)\AJ?6)Y7FN Y'.%159PQF19A3C"G5PN(X>G!86G7Q%-+-H?[30J5
M8.XP1LC"1',<L;K-!,&=6M;J)@]M=6[1%76:*55E.,!I " *_HT_96^*K_&+
MX)^$/%EY-%+XCM8[KPMXL5<;H_$/AZ3[)>W,BA0(Y=5M6LM9DCW,%348EY*,
M:_G0<E5+ 9*X8 =6*D,%'N<8'N17ZD_\$RO%MRM_\5/ ;M(;.XM-)\7VBM("
MB74=S<>'KV=(RQ*W-_;Q6EQ<3 'S(;>SW$>6!7A<99?3Q64U,2DO;8*4:EWI
M:A*2C.S5[M5)1ERZ)J-VUL?K?T:>)\1DOB%3R>524LOXDPL\!4PK_A2S2G"O
MB<JQ$DY)+DGA,32G4M)TX3BU&7-9?L#;A &53G&S=VY*#G\1@YJQ5.TC5 Y4
MDEBF[)R,K&JC'''R@9]35ROR5N]G=NZB[O?X4?Z(JS2:^TE.7^.:4ZEO+VDI
MV[JVBV11112&%%%5#),H.YD^4LS$+GY<G:H]3C@GVXIJ+=[6T_'TT_RW1,I*
M*3LY-RC&,(ZSDY.WNIM*RWDVU9:ENBL:#6;&XU"XTN&]M)-2M(4GN]/CN;>2
M\M(I0OE/=6R2&>W#Y!0RQJKA@58G &GO;'')X &!GKS[?X]CZEI)VE%PENHS
M7+)Q>TENG&2NXM-II-A&<*G-[.=.JH5)TJCI5*=14ZE.RG3J.$Y*,X.24XM\
MT6TI13=B:BFKG:-W)[D# Z^F3_.G4BOQ\ULPHHHH 9(<1L>N 3CUKQOXZ_$F
M'X1_"OQO\09Q%)+X>T:9]+MI252[UN[9+#1[5@""PN-3NK6 J&4L9>"I()]C
MF)6*1E&2%) QG)'..W7ZU^6W_!3'QA=6G@3X9^#(6E2/Q)XNU7Q!?2(RK'<V
M/@[2Q;P6<T(!,D<NK>*=-U.(YVQW.B(Y#,$QZF3X%9CF6"P;C%^UQ$;.3T]U
M.;Z.VD;)VZ]'8^%\2>):G"' _%'$-%<U; Y6J6&B]HXK,*\<!AZB?,M8U<1%
MR:NXQ@IVDE9?D%=W]]JM_?ZIJ=RUYJ.IWM[J.H7CY\R\OKZZFO+N[F+?,9[B
M>X>67)VC>B1X5<" KN&W^]A?S(!SR./7) QU(IJDDL2!R%)P, _+C/UP!D]Z
M)!E''^RW\C^OH><'L:_<XQC32A#2--*"_P"W$H[>L';RMW/\I%4JU*\J^(JR
MQ%:KBJE>M5F[2JU*F*E6J7D^;3FG."DU+W5&3BU[I]=?"[X7?!23]GSQ'\:_
MBQ)X[EN[;Q[-X$TZV\(7MG:V:73Z1#<Z6\UE+I=U<B,SS[=1F^W['5"P7RV9
M)/;/ MM\<KG]DGX9I^SB-?MM7N?&_CP^,Y?!\MO;:@8(1>Q6$M])-*WEW4S1
M::H\L(S?(RQJ<$^-6B'_ (8!\1R99G_X:0TY-I#R"1;?1K2.)#&O#-LB0!L'
M#88XYKRGP9X0_:!TN3PWI?@*+X@Z*WQ*L=0UKPQ8^&-8ET^+Q1:Z(8IM1N8H
M+?6].MU:&U: 3"Y :3[5'(F S9^05.6)6,KU\71E'"YOB53PN94:F)R]Q]ER
MOVM"%2G)<D9RJQ<6^6<5.5HIM?N6#S&AD57A.-#AK-:E'-_"S 2Q^=\'55AN
M**N;\3\0XBI&IB<PA2J/%2P]/)\MR?"RPN"P_/AZDZ<E"BVH_0ND>#?^"AND
MW:7UFWQFCN6^R--]J\41W]K(6=#<K<6=Y<M#/SN/"J@'0[1SN?'/2_A5JO[6
M]QI7Q>B\3QP^(/ 7PNTW4YO!!M;/5Y/B+K-II^DQR:])+%J2'S=.:RM-1*6\
M:Q6<5O(58QF1O/?^%8_MVQ@.T'QY3(S(#XTU91NSNPZV^MW,>Y>Y68_,"< \
M#QJ]\!_$?P)\6_A]'\4]%US1_$FO^-?!NLM-XFE;4]5U98_%>EZ:-0FO(YIG
MDF:U3R[N2:50PC4.4V&KA1P]6=25#,,BP^(I8#,*U*.0X>OAJ]=0HT^>E6G.
MK53M%)T*=DW-S?,D=&;8K%X+!9-E6-X5\2L;A%Q[PIC,RJ>*TZ^8Y0\+3GF&
M#IX&:Y*=&GA,SJYO3IU)1S*G.I]3H)X:LZ*HE7X[^ ]&^&/Q?\<^ O#DVHSZ
M%X:U=+:PFU2\CO[]Q=Z?:3S1W=U%!9Q226[QJL82T7"2\OQ\WD]?1/[7LT<O
M[2GQ8EB:.5!K=DD4D+PR1QJNEVV5#)R6NF!D^5G0?9RLI20(&^<-S9Z\<]@.
M_ /?ISD$<\>]?09<L0LMRZ>(IUE*M@<-6<ZD5=QJPDXRFU*5N91<M=4FKI-\
MJ_)>+J-&EQ7Q/A<OHS>%P?$?$&#P]&G*E..'PV'SO-(THTH1=/V.!@JDHX*$
MG4G'#PBY3FIPLC%LL5;8XSL8#)5E)*/]%;:WKGW)KZV_8I^+4OPH^.6CP37'
MD>%_B"B>#->M'E86@FN)I9O#&K.A?;]NTC5V-M#)@AK'Q%X@1P96LFB^2PNX
M [OQY[$^_KU'\^<O2XGL);>]MG=;FSN(+NV>,[72XM)DN(&5ADJXDC4J_5&
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M>767M;?4#!9ZQ"(6=%O1&6\SX1^.H?\ X7=\6VEV^:WQ!\3[RHP2%OV500.
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M>MEU',,KJ.O6P'UO+81=/'8.K[6&)II/V=#$<\::I2I1C**E3NY<]W%)6?\
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M)<OP6\-KIFNKK?COQIKES>^+=QT^5+2PT>"YC\U#<D1Q74H9PT$D\@.8\O\
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MNPHHHH CEW"-R@!<*=H/0GMFOC;]MSX8W'Q+^ /B>*SLS=ZQX*U'3O'N@11
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M/MG@FO2?B5\8OB)\6=0M+[QSK8O8=.CFBT?1K*SATG2-,,V$!L='M%CMK4O
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MEO<P"YTC6+<JFH^']<M][V&KV,A(V26LP1FC.8[F,O!,#$Y!_GE^+_P=\<?
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M*?@[JWPZT#XL^';OX@^%+;6_AGKGQ>MK6]^%.C^/-,FU5+SPGJ?Q*M+ZRN?
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MK#QAX>O+/6_#%WI=G=0:_I5Y:WVEO=6US#(_N_B/XI?#'P=XM^'O@#Q9X_\
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M98X8D>1@IEZMONW^9HKV5[)VUY5:-^O*GJE?9=%8^_J*\+T?]I_]F[Q#X?\
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MB3XF?%GX<?%G2%_;?_;L_P""47_!47PUX.D^'/C#5+'X"_"O5OV@/B7\,9O
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MJW4442PJ%4D@*BY)))"+M!+,2Q.T 9))P!S4M !1110 4444 %%%% !1110
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M!X9FM[R3P4/"P=]-M=7\UK/R3X\?L^6/["'[9'[ ?@7X@?%#XE_#KP'\*O\
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M'_#;Q1XKMT\5^+/&,S]?\2?"'QB_:K\4?MD?&+XY_ W_ (+7Z7^RY?\ B?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tv502124_img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_img03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Y (B P$1  (1 0,1 ?_$ /8  0 !! (# 0
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MRQ7]<GC>H'_>WAS_ (;S7_(&E=Z?-Q?\:?\ U4\O[LOZW??[+%?UR>-Z@?\
M>WAS_AO-?\@:5WI\W%_QI_\ 53R_NR_K=]_LL5_7*!GJ5J\PAXAW\N4V7'9&
MBFFJ($XIC63R8ZM(%^<H88\$$;-$LX@6@RH( N)S@8$]^T!-L&H=OP[G^S,W
MUB+$6?/'S>492_VVT]MH;2M*^A;(_=-9T,'7#&'9TFZ7;C]WO/)%_'8-M_\
M=9>>I@E=+S>7S\E!3FI6@JM9$PB!3" ;B "(!]X@'0/ZHZP$OKD*$Z\%./E)
M/S='H'&_#-(E'T3AQ]@>B97[(95>-C\DY$O2;YW>K=9%&AT@L,G!3:!H=!-P
M*@1R3($R%()AWEVX9I;2RL<7:.+<6;..;PU EEDJ9'NI[1:[P"M>4-H*+7CH
M]C<?N'<VZ]^;@ACGWW'N2\QU90V1]C96A8VSMH X'R8YHB+IY9RF=TO,XN %
M.CX8X(QOR&RU'US+V3S5*#6?1T0SKT8LN[R/?YB3:21V,;5P79OFC&*AVL2H
MO(R#D1(V2*DD0AC+%$OCM;#V&;R38,G<>5"2&AHUED<0:!FA #0*N<> H -5
M<>O74?=?2_9,N5V/B!>Y%L;Y'32 -L;**-T8?)<4<QSY)72!D$+-9'%[W. 8
M0:-D^/363O658#%63JAD6H8XQ=/9H;7!+XG''EJ1#(L'2L,\BC,%5XC(#).2
M(@\CU1!!%RF</&[=M4LF$;)>7,..N(I[:"W=.'ZBL;:'E(IX9!6CFG0$'57Z
MTZGS6>W<-DMY8B^Q6<RN8AQ3K4^6\1W<I>T2MDYP);)YC+XIF^-T9:?+K51O
M2661'N0770,/:/<@LJB?W1[BCW)'(;<INH=>@]=6($C4$A95?'&\<LC6N'I
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M[,RK2#!U*A,YJR[1L-5ET*,C(1C8(]A9+\T</3>+XA&2:IDR*J 1,Y%>X3%
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MJS;"'CTRF1Q[25)]LV;,T$FK1N@U;($!-%NV230013+T*1))(I4TR%#V
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M>9\3?#'-RLF:WP\Y: !)WBMDW$]TY5\<HRB<;J?A^70R2=ZXLE?R!DFUO7S
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ME1:V4(H^]O7CV8(M&#QS/B9XC0-0XMR=PL45E'E=8X[-.0H]R64K=);MG#;
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M]Z6XL9TO=#QA=L"9UQG=;_9Z]38,8<U7R37E+!9I1K#QB"CI@]KLXDU4?NR
M93R!Q(41,(=-=_/<[P]B[^[-<PN8:T"W!\.("ZF;P[.4H$BU(&L(JIA[PK,&
M*DA(E!;8!.7QY)/H&VPEUTD[%0/[E9?(V)KI@:WS6?N,\*M*(3#D\SG3CK'F
M2:PV5VY0#S]YQTV.9-A6<VL&I!4,!/#:64B8(.0!R*2XPR^QEUA[E^:P#.8.
M/-<6PT;,.V2(<&3@:]@EX.\5"MA-J;WP/4;"V_3'JY<"&2!@BQ&<?5TN.=\B
MTOG"KY\4]WA%>:2Q)\R(F+GC4JL7Y.I68Z+7\C8^F4IRK6-H+ADZ*FHW=-5T
M5#MW\3+,%P(ZBIN(?)*-GC1<I%FSA,Z9R@8HZD./R%IE+-E]9.Y[>05!X$=A
M!'$.::AP.H((*P[O#:&X-B;BN=J[G@-OF+1_*]M0YK@0',DC>*MDBE80^*1A
M+)&.:YI(*K_5:HTFB)HB:(FB)HB:(FB*F;G<JMCRJ6"\7>=CJS4JM%NIJP3T
MJN#=A&1K),5%W"Z@@)C#L':1,@&454,4A"F.8I1I[JZM[*V?=W;VQVT;2YSC
MH !V_P#34\!JKO@<#F-T9FVV]MZVEN\W>3-BAAC',^21YH&@?A))#6@%SB&@
MD0HIM#M7+VP0^8LZP,A7,%0L@VG<&<>)U$4%K&=L8%XC+V=(D^Z;^8= !7$'
M6UP.UB$C%6=$4>&_"BEK9W&YIVY3+L<S#L<'6]L[Y5/9FN!VN/&.(Z,&KJNX
M; 9W<F&Z'XR?8O3FYBNNHUQ$Z'+YN$U$ =I+C,1(-61-U9=WS*27+@60ED \
M<_             #8  /8 !]@!J9K6@FNIXKSHB:(FB)HB:(FB)HB:(FB)HB
M:(K1YFPG1<Z55.LW1H[2<1C]"=J-M@G9XBYT&UL??B[;2["W#SD'/1JP )3D
M$4UB;I+$41.=,ULRN)L\O;^[W8/,T\S'M/*^-XX/C<-6N'Q'@002%-]A=0=Q
M].LR<O@'L,4T9AN;:9HDM;RW?I);74#O#+"\:$'Q--'QN8]K7")'$LQ./5PL
M/&7+,>@WR[;IBPY"KV;7"KAP'*YB*PKR-GD9>16<O$,HU-BHDA*P*BQR-&A"
M+L %D(@E&]MD82Z?@,DT#)RN=(V<U/O@[7EQJ1*P4#XZZ"A9X.&;>M8=U/P5
MKU<V5*YVR+&""RGQ(#6_9Q]*,MV1,#6NQ]R\.?;7@:#)(71W)%P*OR)ZFZU;
M31$T1-$31$T1-$31%UDS#1%CB9*!GXN/FX.89.8V6B)5H@_C9./>)&0=,GS)
MTFJW=-7")Q*=,Y3%,4=A#7G+%%/&Z&9K7PN!!:14$'B"#H055V%_?8J]BR6,
MFEM\A!(V2.6-Q9)&]IJU['M(<US2*@@@@K #RK]%Y5T_D[GQ/FX]B@Y46=K8
M?N+]9NR:J'-WBWI5O6!R+=L(FV3928"1( V!V4G:0N&=Q=*RY[KK;CV@'7R7
MF@'HC?K0=S7\/G=B^F'1G[_+(K:' ]:;>621@#1D[5@<YP&G-=6PY>9WSI;?
M5W; 35QPQ9&XN\CL2NEFN0\(Y*KP(J'3&0^5I*8@EO#'8QVMB@$I6"=)?<8C
M@P;:Q9?;?SF-<6WMI.RG;R%S?@<VK3\:WVVKU@Z5[VA;-M?<.)NBX \GO$<4
MPKV.@F,<S3Z"P*T32L6A^X*T8U>S/G9S 0K5G7IETY,<=MB%;H,E%A,._0-M
MQU;&V]P]W*R.0N[@UQ/Q *;S9?#V\1FN+RTCA KS.GB:VG?S%X%/A4O<.>G?
MR]S6[:%@\03U0@W)DQ4MF3D5J)!MVZA@*+HC>70"Q29"AUV9L' C^CVZDV+V
M1N;*N'DVKXH3\N7Z-H'?1WB/\%I6#]]_>BZ'; @><CG+:^R+*TMK B\F<X?)
M+HCY$9],LS MA;A?Z8^*>+;EA?;4\2RIF=!,#-K0_8%:URG*JI]JY*1!+'<'
M;/-CF(,DY.H\.3^U@W*8Z8YKVKL#';><V\N3[QE1P>11K/Z-NM#^4:N[N74+
MY@]?/O=;SZQ12;;PT9PVP7'Q6['\T]T =#=S -YFZ B",-B!]OS2&N&3C4_6
MHJ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(H_\ (O-BF&*8P-7(9.X96O\ -MJ+
MAS'X+B@I;[Y*I*G:%>J$'Q657KS1%62F7O0C2.;*&$P'%,#67.98XJU;Y#/-
MR,SQ'!'\^0\*]S&BKGN^2T'MHLF=+.G[-^YZ496X-CLO&6[KS*7M*BVLXR [
ME!T?<3.+8+6+C)/(P4Y0XCY<>,&)X9K,HO/3/SME?($F%NS%DITW!-]=KHX1
M*F8S8AP[XVIUQL ,(2-)VHL(](I2E\0RAC\X3$#%6[C,_P W)3NYYY3QD>>[
MN8T>&-O!K1WU)=4.HC]_YB%F.M_J_9.,A]VQ=@TU9:6K34<Q_G+F=WTUW.:N
MFF<23RA@;>"Y7"MX_JMBN]RF6%=J=3AI"PV.=E%RMF$3#1+91[(/G2IM^U-N
MV1,;8-S&'8H (B :N[GM8TN>:- JL;PPRW$S8(&ETKS0 <23P "U,,JY]R/Z
MC&:'=UF$Y*O<?*;*+ML(8_,=1,SIH!CH#?+*V42!$ULGDQ[]C&.#%J<K<GL5
M,IC'.9.3*7?N\;B(65H!W]Y6U&QMHV^TL9[_ 'P!RLK03H*MJ*T'J4LL>T"/
MJC41\))OV-AW!0PI@50I![03,'3<J@AOM[=>5E"(!Y\NI XJ]Y7*OR$C86$T
M)I2GX5'/F-@+)W+O 5\X_P",;)6JG9<KOH6%2GK4,F6"+6:6_0O-F:NCP[1\
M_(:26B8]D4Q4CE*9R F#;4OVO!)-<OO'CZ.NGJHL3]7\A'9X:#%LH974<=>&
MI'#X%KUSOH^>J=QXBLA,*%C>L9,JV0Z<\I]M2QK?HE\YF([Q2NV#UBT>OZ;;
MF,I#R*)5T 0]Q38R+A)=!0Z1IH9!70:+ #[J T87&HIK18?LE<2.36'5ERY1
MP'EVB WW ZUEQY9H]@':'4Q93X<I%*$VZ]Q5A*(==]</>TB@.JJO>(JZG15?
M&/>%5EJ5'@+3"YVQ#D"$BDHR]7FKK5S)E:N,P8X^9FU*;-2-<DZZ1+< *W9N
M#E[ '<!-L(^:\H@[Q&-X<2>!THN$_P",7'&_P49)8]Y*XQ)9'SN3"0H^;863
MQO(QS,'KA*&.A;"Q4E6W[QTU*07)?&031,(F VP@4/,OH:478NN&#FE #?1J
MK>2'ILY@DSSZ54H\1>UH*%AK$Z##^1:AD0[N&G74LS8.HEI6YN77D%06A7 K
M-B) Z13(!SI 4Q1'@OJ*=B]#=QM%7%U/4H>7/CI.TN>DJS8FT]4[)%+%1?U^
MVP3F*EF2AR%53!RU7(U<)%43.4Q3"GVG((&*(@(#KI55#9HWM#HR3^!6\=8I
MLB'<9#R;P@ 8=T7'88  0#<4URI[!N(==_MUW:QCA4NH5ZLF:#1^C>]97O0F
MXZ3&5O58XDQ$W#N @Z3=G^6IT5D.]K\/Q= R5K2$Z@"=,2#+LFI?_M!KLV/Q
M 5[56Q2L$3R#70K]<+ +,Z>.F<NM_;[5+3MF4';813D9)9-B([AU#X:U1V^S
M;763VB.Y6QQYG55YSD[RB&_:([>\ =0V'?I[.NO-=5 ')3-SQ#R9(\A*VBJ7
M 629MDCR:J;5$XLZ38WZB$=%\CZ^R1 2-42JBDTN2210!PT%.1$IE6ZQC0W(
M,.V;]V;MQ_X+</'O3!PC<: 7+1V#@)P.(H_BTK9;:%Q'UPVC%TNS#@>IF(MW
M' 7+B.:\@8'/DP<SSJYU.:3&.<?!)S6H(9*P"?;=P@[01=-5D7+9RBFX;N&Z
MA%D'""Q"J(K(K)F,FJBJF8#%,41 P" @.VIBUP< YI!:14$=JULEBDAD=#,U
MS)F.+7-<""T@T((.H(.A!U!7VURNB:(FB)HB:(FB)HBQ_1K?\Z.6CV&1(#OB
ME@JW+M*G%G$%(K/N:JL],A(6^12ZHRV,L5RR)FT6D/>VE)U)5R;Q$FJ)1A<;
M?M5DO/?KMRSEHP=EQ.PZO/?%"=&#@^0%VH:%LS=R_P"0>R1B[4\G6?<=B'7,
M@TDPV*N&U9;,/&._R,9#[API);VCF0CE?,\C(#J:+69-$31$T18!/4)]3GE=
M7^7D'Z<7IN88J&4^4;R@ER!D*Y9)<BWI>,("28I2,68C964@XU=XA%.6[MPZ
M?.A:I^=:MTT'"RPE(15#Z;'J;\C<L\F<I^GSZ@&&:QAKE]BJG-KW&2-$>'<T
MG)=2($5YUZR0&3G&[62!I,MGZ"S-XLR>-3J]I&ZC<R1B+.UHB:(FB)HBZ^6E
MHR!BI.<FG[2*AH6/>RTM*/UTVK&-C(YLH\?OWKE4Q4F[1FU1.HH<P@4A"B(C
ML&B+65MG[T;Q;B+[.H5#C=R+R-@.L6EO5YSD57HN+;5<JKA;PD)&/@Y 4E#M
M9 A3+,47KU@^>(@4Q$ $P%T1;&.'<NX\SYBVAYGQ/9&=NQQDJM1MLJ%B8@H5
M&2AY1$%43'06*FX9O&Y^Y%PW5*19LX3.DH4IR&*!%<G1%9C.V$Z[G>BJU27>
M/J_.1D@TLU OD&8J-HQS?88QEZ[<ZT['M,B_BW0[*)"().VIU6ZH"DJ<-6K,
M8F#,69MI263-<'QR-]N*1OLO:>\'B.#A5IT)4]Z<]0,ITXW$W-6,<=UCIHG6
M][9S:V]]9RZ3VL[>UDC?9=3FBD#)64>QI5&<:\R6'(,79\>Y49L8//V')%K5
M\JPC$AD(R8%RW%Q6<EU-)0 .K2<C12?G68^UJN"[0_OMS;TN!RD][')99$!F
M9M7!DS1P=459*S_9RCQ-[C5IU:K_ -6-AXO;-Y9[GV:^2YZ:9Z)UQCI7FLD7
M*[EN+"Y(T%W8R'RI?UC#'.WPRBDFM7]8C31$T1-$31$T1-$31$T1-$7@"E 1
M$  !-L)A   3" ; (C]NP:+FI.AX!>=%PFB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB]%%")$.JJ<B::9#****& A$R$ 3'.<YA I2%*&XB/0 UP2 *G@NS6N
M>X,8"7DT &I)/  =Z@KQ[;J<@LJ6GEQ.)&<5%L$UBSC''N W098VCI$S6ZY3
M;HG( $E,N66.$&R^Q5"P#%L4!$JY]XE@P<SD9-S3:VPYH;0=@B!I),/3,X:'
MCY;6CM*V(ZI2-Z:;.LNA^.(;FGF+([@>/:??/8'6F.<1QCQL#P9&:M-Y-*:5
MC;2<ZRR+9%1991)!%%,ZJJJIR))(I)%$ZBJBAQ*1--,A1$QA$   W'4M)IQX
M=ZUU-:AK15Y- .\K6DYQ<RI7F;;)SCKAV3!/C=$/VS&[V1HF4ZN:)>*D4G*K
M5@\ 3"ECB+?-">%X>QI5<GB&'P 3*: [BS\DCSC[ 5%:.<.WT>I;!=/MAQXR
M-NX,ZT&\I6.-WR.YWYQ]/!=KB['$7789I&QK--FV:)E*?PB@DFBF4I2[AVD#
M<=@ZATWU8[&R:V3S'@<_;^ZIQ?Y.9SBXFLG&A7<Y+L)("N6:19,G<DSJ]?G+
M-(I,NWS 1<"P.Z>NA.H9-)%(FP!WG, %$P &XB #<7,?.3!'5S.T#73X%VBN
MX+&-N0O'<DA- TT%2:D 5]2O)A*+\68@5';(S=2LXJK[N3;"(F.WLF3Y LY*
MMC*B4O>NSBJLV3[N@@53[ '61\9"+*QCBB\-6ZT_=JM6NH&6ERF6E>\Z%U&Z
M\&U_?JHQX\PYRWB>4<):[%(6E"E-+9EZ6R=>'V9T;#CS*-%GG#M/$E+JN$W#
M5=U29*HQIF/OMRQB<>Z:.SG6D0>E$E6H:&!C>70D#BLA-KD9"&A%G+&NR=M-
MX[5%>$B_*&7.R57*5\\!!^LD@Z*P:]RG@%[E5S "9 W-N#EIK14W'11*N/&W
MAAR):KJY,XPXSL7B.9=B\DKAB:(K\LV<PZ[!J^\Q-M&L?+-E!6DB@D?Q@$XD
M4]GAFUT>2."Y;X35NA6/&]^AGZ6V8&!IFCL;)C('S<SMO(8URJ[&.02.N#4J
MYJ_>/F9N@D5T<$^T2I!WB!>@B&O,G6I5='<2@5YO$H*9!_=DE8I=>3X_<O96
M%=I&4.T:Y I"K9PB?8Q/!&S4&:;+D,)#=HF\AOL/LZB \(,D]WADC;R%8[<W
M^@GZF,5)O+"*-+Y N?+MD#3<%E8KVS/&D>V3:,$#-<BE@)-0K5FB1)%(%5 3
M(4I"]  --%[LR$%*/:0.R@7;<7:I8N!%"S75.4? SENPM.7ZO8J#8<MUJGU2
MZUF,H<I'B@RCHRLVJJ3==:23"24.Z/)(2@*K )2[%*F77#&.?)[5&47$\@NX
MN6W=RANIKI7T:J2G[L[B,ZV?N4>:W#-RDCB3!Z5'@UW[<R+AM8<JV4C<A52*
M !T'I8.JK=X>T 5'[]552TU'$*\1,YK)GD@&4T'[FJWQ\.\E<)3$# U-A;$H
M9_ P["&,WL3->!1=+QC5)HNHR=.Q48+$451,8I?&[Q =]M6:WRUE=2NB#N69
MIU#O"/@)H#\"D&1V7N;&,9+-;\T,C0X%OB-"*BH&HT[PI3LGS.1;)O&#ML]:
M+!W).6BZ3ENJ'VBFLB8Z9P ?N'5P]/8HP]CXW%D@+7CB"*?C7$FXB-GXF2A9
MABUE(B6CWL9*QCU!-RRDXR0;*-'\<\05 4UFCUJJ9-0A@$IB&$!UTDCCFC=#
M*T.B>TM<#J""*$$=Q&B][*]N\=>0Y''R/AO[>5DD4C"6O9(QP<Q[7#4.:X @
MC@0H<\69*3Q3:KOP_M;YX^-BY@SN.#)N3657>V?CW/O%6<'%KNE@$[V7Q-.)
MJ5]V<3=QFA6"@A^*(C%MO/DQMS-MBY)=[N ^W<=2^V<:-%>UT+OHW>CD/:L\
M=8;:TWKA<=UTPL;(AF)'6N7BC :VWS4+ Z:0-&C8\E$1>Q"E!(;E@/@HIMZE
MBU^31$T1-$31$T10\Y96^RRC>D<;,:2KB(R7R&?2<(ZL$><H/L=X@@T$'&5\
MB)F[@%K(-(9VG%Q)S=O=+R: D'=,VHQN2ZGD;#@;!Q;?WQ+2X<8H6ZS2^@AI
M#&?EN'<LZ=%<'B;.7(=6-VPMGVGM>..5L+QX+W)RDMQUD?G,=*UUQ<@5I;02
M BCPI-4BEUG'%/K-"ID2V@JI4(2.KU?B69 (@QBXMLFU:I /ZRJHII]RBAA$
MZJ@F.<1,81&_VEI;V-K'9VK0RVB8&M:.P 4'_6>TZE8CW#G\ONK.W>Y,_.^Y
MS5]</FFD<:E\DCBYQ] J:-:-&M :T  !53JH5G31$T1-$6L'ZR'&;/\ Q&S5
M9/6TX;92JE0N^-\715/Y#X^OT4>8A;O32.H:G1S^(0\,6KPRC16.0>,55&:A
M3,$';9T18ADS$5;>C+Q%SEEG*#[UDN8>4:OD',G*'#T,QQ)5:5&*1L#CW&$Z
ME&*MSOB>$W:H2IX6&:M&K%OYA-HW.NHLY<.5S"F1;(VB)HB:(FB*T>?\6$SE
M@K,V%U)9> )EK%=_QL,XV[Q7A_G>JRM;"33*0Q#J"Q&2\7M 0[P+MOUT1:#3
M*_>H=Q(PED']W[><3L<6O)_(&9L"=&MS25:JR-IJ-]?N)20MD(JHZ0K$PV\*
MJN%XZ7DEV;B$0:'(NB*C1("$6Z;Z8W%"Q<).#6 >-MRFVL_=*)6I%W<WL<NH
MYAT+7;K%,7&>B(-=4B9UH>#D)T[-NJ)2^.1#Q>TO?V@13TT1-$4).5L))XQF
M*IS#H[%RYG<.M%H?,,)&D4.XO_':3=INKDQ5;)?[NF,<. "QQ(CU(9LZ1#<'
M(AJ)[CBDQ\L>Y[0$S6HY9VCC);$U>*=KHC]*SU.'REL'T8R%INZPO>A>X9&,
MQN=>)<9+(0&V>;C:6VKPX^Q%?-_L-S30B2&0ZQ J9<1+1L]$QD[#/6\G#S4>
MREHF1:* LTD(V1;)/&+UJJ7W56[MJL10A@Z&*8!U*8I(YHVS1$.B>T$$<""*
M@CT$+ U]97>-O9L=?QNAOK>5\<C'"CF2,<6O8X=CFN!!'80NPUW5*FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(H@<S;'-J8ZK
M^%J9(+1M\Y*W&.PU"R#,Q@>P%9F&SN4RA;T0( J$^6<;Q<DH10-A3=*(;#N(
M:C.Z9YC8LQ5JXMO+^40-(XM8X$RO_@1!QKV$A9QZ"XO',W3==0,_$V7;>TK"
M3*2L=[$UQ$YL>/MC70^\7TD#2T^U&V3L!4G:K6(2D5> J-98(Q==J\+%UZ!C
M&I>U!A#P[)".C6:) #]5!HW(7].V_MU(+>"&T@9:P-#8(V!K0.QK10#X@L09
MC+Y#/Y>ZSN7E=-E+VXDGFD=Q?+*\O>X^DN<2L ?J3\]G&3)NP</>.$]YELBN
MM!YOO\(ON5<P"*<AC6N2;<W85N42BG-N4S;GV,S((!XXZCF?S+(6&T@)\VFO
M=3N![^]91Z<;%]] SV5J(6N^C:>/YU/Q#X5'WCWA!&G0C!$[5/O(DD4%$B 0
MA.PI?=3+L!"II@&P '36/;/F\PN(XN*S;D982SDC]D #53$<D1C(PC9 O8IV
M&3.H AL/3<=QVW-MOJ\-)C8:BIHHRR%\LSI7:@#0>I?*^XO7B^)LE*R9U6]C
MY+Y4Q=C"!0,D0RQ<='N;.<G&H$4 3II62(K3YTN8H=PMDD>NPCO+\+CS!;"5
MX FE</B6.]TY]N0W*RQMG\V/LF%SNXR 4T[^6M.SM5W<2(D=M[Q92A^%8K]-
M(L3!T T13465&C@3V';P!6KSA0NW3\41#VZE36E@Y3Q"P-E)GS7CR_L<:>HD
ME6\YI7/,V-^*^;[UQXKQ;-F6M4EW(4B*&--.* \!TT1D)1M!% QIQY!0ZKAZ
MBT #>.H@!1*8-RCV"\&>R%C,](3D=RPSG9,UQ&9+??<O8DK==ILI5,L9*Q:T
MQ;8&.2I=94+;CA@W8(H-Y^)B&P"J"O:(HBF40[ 5 FO5[PX47$D<;65;QJLV
MLO*LHIJHYDG#9JS3*@5PZ?*F3:)^:6*T;D4,":QA%==0" ';MUZ]->#FD\%3
MJGC4"E.I%W.GJT0A-.FX1[]^BR20<KI(OD90@+&0*DDN?SZ"2X*F**@G(7<>
MFP>1%#1<JF%\4U5&7E99.2LK&2FW8R$DHC99!,%E%3+"IMN<IFR:B:O84.X/
M"*4GA]HEWUPBX&;#Y)98DR4\P]'-)3*[2EV!QCR.>BQ*W?6M%BH>+; ,H=*,
M,Z55#9N5T8C4SCL!8P)"<=$44N&4ER'E$+DWS \R_*U)M7<=? IG.U)K5!R"
MMDAS%R1\K1$=&U8C%"7H,8Y\B#1TLT1(1\=TDT4<-"I* 0Z#F/!7%5E(JC5W
ME!DUA&1[%2>R74L:,E&31K'G?DQI36(NW*RC5%(SPZ%PN3TICG[S;H=FX?9X
MY*?W;'3S]K&T^$C13[IGA'Y[.V.+832:;G(.C>1KO$#Q[M%9.K6%K*13)F@J
MDNNX!(BPF*!S*+]H'-N?^R/TV[1$>FL9-D\P<\GZ1SM%NIF<=[G+()(S[NR(
M4/8 !3_IZ%FOX:QLO&8_F$7S=VUCU)M)2,2<I+(I^,,<@$H+4BY2#X'F.T!$
MH=HG =O8.IWA&3LM")RXDOTYNZ@_ M.=XRVTN8>ZU+2RFM.^I_"I@![-7A10
M"@HH3<R&;BBM,=<I81!0\SQPM*4O:RM2=SF8P=<C-:WF*%5*4AA72C(=1O/(
M@;<$W,.4P!N.HINAALV0;BA'TMC)5].+K=]&S-^!M)!W%BV Z#SQ[CNLKT<R
M+@,?NNR,=MS'PQ9>UYI\9*#70R2A]F^GM,NB#HIIM7+=ZV;O&BZ3EH[02<M7
M*!RJ(N&ZZ9545T5"B)5$E4S@8I@Z" [ZE37->T.::M(J#WA8$FAEMY703M+)
MF.+7-(H6N!H01V$$4(7WURO--$31$T1-$4(^,)!RUDS-_*=^ N(^S3[K"F&%
M5.XR;7#^)YA]&2DO&F,( 5#(&3"2<@<P!^*W:M.H@4-1/;X^LK^[W$_5DCS!
M!Z(87$%P_I)>=WI :M@^KSALK:6WNC=MX;JTMFY7*@<79/(Q,DCBD]-E8>[P
M@?)?)/I4E3<U+%KXFB)HB:(FB+7"]7;E-RCJ?*:N\:\.Y<AL78U_)C=^0]K9
M/,/XQRP>\VB#R,M68Z!G&>4H.Q1*%<;LXXBI2(-R*"N83F,;8@%O>#Q4>6FF
MBE>Y@CA<\4 -2*:&O8L7]4]_7O3[&X^^LK>*Y?>Y.*U<)'.:&MD#B7MY>+A3
M0'18LZ#SJ]2M2/Q3#17-YU6X>T</I/D*C$P/&?C;'1=>DX?Y43:TV&CFE%09
M-ZWV6$X 8"%5("10*'4=7N':MM+Y59I!YED9^#=".7P^K7CQ6+\CU]S5E[_R
M8ZT=[GN5F,%9)/%&[SJRFG!X\L>$>'4^A1%Y2^LYZL''^E<8K3"\QQL;C/6(
MF^2)EI+8$P2T0KS]9M7UQBXH[*E>(Z9%&:. '6_$V3+]XZLF6Q4>.@M)HWN<
M;B'G(( Y3IH*=FO:LH]/=_7N],MN#'7=O% S#9,VK',<YQE:#(.=_-H'> :-
MTU*AU_\ ,:^L!_G/0O\ D1PQ_P RM619/5SL1^NAZYV>+@6@XDS@SNEN-%24
MY\&887P4U5+%1)4C/WBCB2J;-HFFB*Z9  R@&.HH4I0$P@&JNRL;O(3^[V;#
M)-0F@IP'$ZT"L&Y=TX#9^,^N=RW++3&"1L?.X.(YWUY6T:'.)-">%  2: +J
M[1Z]'K@TNK05ULF=F<17;,YDVD!(O<(X0%)^^AE%DG[4[9.HF=-SI*ME V5*
MGW@0PE$0#?5D@RV.N<A/BH)6NR%M3S6:U97OJ*'70T)H>*RAENG^\<'M#$[^
MRMA+#M#.!QL;DEA9<!H)):&N+V@M!<TO:WG:"6U 7Z(/#[)]GS;Q0XU9BNHL
M#7'*6"<4W^U'BVOD8U2Q6VD0DY-*L&7>H#-HK(O5#)I 8P)E$"@(@&K@H<M<
M/F#_ /ZA> ?_ *DF?_\ &.1>B+;)T1-$31%QW;1J_:N6+UNB[9/6ZS1VT<I$
M6;NFKA,R+ANNBH!DU45DCB4Q3 (&*(@/375S6O:6/ +"*$'@0>(*]8)IK:9E
MQ;N<RXC<'-<TD.:YIJUP(U!! ((U!4,N'BSG'PY8XL2JZJJW'BW(HT!1RJ*K
MA]@O(*3FSXL."IS=[@*REYZOF, ;%^#E >HZBVV"ZR]YV[(36QE^CKQ-O)5\
M/KY?%'_ 6>NND<6YAA>LEDUHCW18DW@:*-9E[(MM\@*#1OGGR;T#M]Y)&@4U
M=2M8 31$T1-$31$T1-$5JLMYQQ)@BNC:LNW^N42&,)R-59IZ!'LFLF!1.UA8
MAN5>7FWA0, BBT064 !W$-NNK=DLOC</![QDYHX8NSF.I]#6CQ./H )4SV3T
M\WOU'RGU-L?&762O]"X1,JR,'@Z65U(HF_E2/:WTK%'D/UP,$0+Q9GC?%V1L
MC$2,<@2LFM$T.(<"4P@"C4'PS4X*)P#<!68HFV']76.;[JUAX7%MA;SS@=II
M&T^JO,[XVA;G[7__ !Z=1\E V?=>8Q6*<X ^7&)+R5OH=R>5#4?DS/'I5HF?
MKNM?,%^(<97A6@B/>9CE5LJZ*&_02)N:*@BH(!]@G)N/VAJV-ZP-YO'CSR^B
M85_#&IO/_P#CCE\H^Z[N89_R\<X-^-MX2/B/J4N\.>L!Q,R8[9Q%M>V?#$T[
M,1(AL@1S<]8,NH8I")A;8!U*1S-,1'^VOB,DP#VB&I-B^INV[]PBN3):RG]8
M!R?QVD@>MW*%A#??W&NM6TH'WV$CL\_8,!)]R>X7%!V^[3-C>X_DPF5W<%E$
MBI6+G8YE,0DDPF(B2;I/(Z4BGC>0CG[18H'1=,GS119LZ;JE'<ITS&*8/8.L
M@QR1S1B6)S71.%00001W@C0A:?7EE>8ZZDL<A%+!?1.+7QR-<Q['#BU[' .:
MX=H(!"Y^NZIDT1-PWVWZA[0^T-_9_7VT1-$31$T1-$31%T\]88"JQ#R?M$Y#
MUN"CBI'D)N>DF4/$,2++I-43O)*06;LVI57*Y$RB<Y0,<Y2AU$ T1=QHB:(F
MB)HBA4T(;)7.>?=J *\'QDPM%0<>D<0\)#)&>I%27F7B(>P'3''=.8H[_K%3
MDS![#]8JS^W[O>\ZPX^T#1_2W!YG'UB)C1ZG>E9\N2-J?=TMK=GAR.[L_),\
MCBZPP[!%$P_DOO;J9W<70#M;I!'UJ?4#E>*^)XC">)I<\=G?.L>\;-IID<2/
M\>X]\?X7+VAF<#%,A/S;LYF,6?H*9B.%RB!T2"-XR5\VQM^9_M.J%C+9N";F
M,DUUP";1KAIWGC0^CO6&S@MC!.#K+-Q)-RK2CTY';IXX 7"ZBRYS*G%0Z@B)
MU3&$1,([B(CN(B([ZQ,'R7MPYU21S56TLXALK-D4(Y0UM*#AP696O0:(,VH
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M+XYOXE<9N2B]8=YYP9C3*K^E$>HU.4N%7CI.7K[*4%L:6BHN7,D22:PDP+)
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M3(\%K@1I0J:VL/-[0H3Q518IC$WMQH+!-( 0@VM^R$_,0H !WZR,91H-5;M
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MY6%5OD-&7> CBC]I(V.L!&Y?LV2#5?N.SBL,W<6]N*6W.'L'<R1HD:/@#J?
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M3H"N@O-)QS!X^J-@K.2VMOM,ZZL#:S5-&(<QZE;9L%G"48_.JX,*@EDT$R'
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MUZZ)^1CFR2_E:K:(>5E3%,BD50"I0J3DX[#^J4?LU#=_V#)]IW?E,'/&&OT
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MVD[N]!*QVA!SBK%S5<I>B;OP']C>I@;8=FI3 &WMBM]_;MTV=D-8K.)]R_\
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MK)_-J3=PEL(+(5T&T?4BG X=Q3&8'.0=MC:D^+Z>;8Q;Q*(3/,.#ICST/YM
MS^2L&;[^^+UUWU;OL'9-F)QD@(='CH_=BYI[#/S/N:4T($P![0LAJ**+9%)N
MW220;H))HH((IE21112*!$DDDB 4B:29"@!2@   !L&IL &@-:*-"U>DDDED
M=+*XNE<222:DDZDDG4DG4D\5]=<KHFB)HB:(FB)HB:(FB)HB:(FB)HB:(@@
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M7BLI.*_4:X#YQ;0K+$G-;!DE*$\JF#"PW")KEEDR"* *(O(NZC6)07JB1#%
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MQ/('.49@ZGM9!**<W#(5OE$JCB;&D4H0)[(E\D$SC&PK$H[^4BF92BZE)!0
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M=A6P3PF]7EA?I6%Q9RC3AJK:)-9",K^68U,D749R06,5%JQN,:)A;U22>K&
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M 0="%<64P9R3KJ:AV*>/<@(I@)@(PD7U6E' $#< !&234C/'. ;  JE+N/M
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MMJX-JVM?(>#);'U,)#HJ]\3@/R2L[LZT8G><3;+K=AH\[*&AHREL]MEFF :
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M.HEFD[LSQDW<JNTFI^T"FW[@VZCJ]XO 9'+P27-IY(@B<UKG22,C +@2!5Y
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M,I ,)S.G<_'MVY2 7WNX5E"[;==6"U:Y]U$QGMF5@'K+@ LNYZ>&UP-_<W!
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M1WK!E]TOV9TUZW;".R+:XM#?SY=EP#=WEPV5L6/+XP67$\K1RN)(+0#7B=%
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MO/(5YY'UT%'$8Q2DQ/*GV<JD78SF59R0K7*BO\?_ % %%N&%&RAP[DJ3R Y
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M/G)/I\22;./C(F4N%(R76<$UJ0O_ )LQI!"!M,2G@MJY:MP1=M/'>F\0#D2
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MOXWF_#\CY?X!TW\CX'7P=$60ZS?T>WYFB_./Y._SB>'1O#^9OHQ^8_;ST?\
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D:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tv502124_img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ XP"8 P$1  (1 0,1 ?_$ -D  0 " @(# 0$
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M6MALV9.<DT]E2&'#$,P;SYTPX8AF# '#$,P8 X8AF# '#$,P8#$K^@? >^&
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MQ&3.6 ;$9,Y8!L1DSE@&QR#BXRS]KP+0=)9GN1U:WO04;NV\6$X"F@-8">/
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M&I#*T @'"22'!LEOI*R53";DWHL6^D[-R5G6=;4I$DY=$S$5:DFB A2%Q1"
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M 8 P!@(LKC]#-5OT>7P]X9Y@,>W9_H&IC^3</VW-L!.C & , 8 P!@# & ,
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9G;>[?N!_+ON5J/\ "/ OV5LM;9=VY@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tv502124_img06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_img06.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Y0#; P$1  (1 0,1 ?_$ ,$   $$ @,!
M      < !@@)! 4" PH! 0 !!0$! 0$              @,$!08!!P@)$  "
M 0,# P$&! ,%!04##0 ! @,1! 4 (08Q$@<305%A(A0(<8$R%9$6":&QP5(C
MT>%",Q?Q8D,D&%,T5/!R@F-S)35%)C9&6!D1  $# @0$! ,&!0(& @,   $
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M44 :;>0<EJXHVQ1")H  Y)K%10[#H?9\/PTT7!N:42!FL1U/7:E/\= ((J$
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MKAC\'8JQK7U<"M#*YJ5KTJ#TI^6GV^X>:$U,W012?'<_E0:DKC_:4 N42_J
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MT[#*16C,@8GWZGQ&"U:61"@XJB[FC=NY8\&L\3JMX4/.@P* 7G*UO+*[FO\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tv502124_img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv502124_img07.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *P!L P$1  (1 0,1 ?_$ ,L   (#  ,
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M95[#MB-/HG$A*'##0A24$ZE*, 7JB[QVWG4R]:;2U$PVB(X1[Y)B4CG!(&L
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M 'T<P$]%SII+:XQ(/20JX1B-.KU:RK5O5TVXIR5:<P+;)Q)PW=)!-Z;CB$(
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MZQ-N =%+;0,2 (A"$]% )4M<2I1@4U,US.]4&R;Q%-R4B.S:2=)4H\NLF\Z
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%?_1M_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H /<# 2(  A$! Q$!_\0
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MY NDWY]-N<YH U**1F"*68@*!DDG@"LR#Q#HNH326ECK%A<W(4_N8;E'?IZ
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MTG3]).E6FG6T6GD,#;",>60W7*]#FL:Q^&O@S3=134+3P]91W*-O1]I8*WJ
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KI110I26S!Q3W1<F\(>';B]-Y+H]FUR<?O/+ / VCI[<4444<\NX<J['_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
